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Mapping and Phenotyping Genes in the DeI(13)Svea36H Region of 
Mouse Chromosome 13 
Abstract
Del(13)Svea36H (also known as Del36H) is a 12.7Mb gene-rich region that has 
been deleted in mouse chromosome 13. It contains numerous disease loci as well as 
showing conserved synteny to two regions of human chromosome 6p which can be 
missing in some deletion syndromes. The mouse deletion causes homozygous 
embryonic lethality but is hemizygously viable. It has therefore been used as a tool 
to screen for lethal recessive mutations that could help to identify developmental 
genes that are responsible for the symptoms of the associated human diseases
A Physical map of the region was constructed in order to facilitate the mapping of 
mutations arising from the lethal screen. Eleven lethal lines have been mapped to 
varying degrees of accuracy, including one lethal mutation that exhibited circulation 
defects which localised to Sox4.
The forkhead transcription factor Foxf2 was considered a potential candidate for 
embryonic lethal mutations within the interval. To complement the lethal recessive 
screen, an attempt was made to identify an allelic series of mutations in the gene. 
ENU mutagenised mouse archives were screened for novel Foxf2 mutations. Three 
potential functional mutations were discovered - two coding mutations (Foxf2m74R 
and Foxf2Y4U¥), and a splice site mutation.
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Foxf2wll4R heterozygotes exhibited thinning of the iris stroma, alongside hypoplasia 
of the trabecular meshwork and canal of Schlemm and a reduction in the irido­
corneal angle. Homozygote eyes at El 8.5 show no signs of the developing ciliary 
body which were seen in wildtype littermates.
Homozygote carriers survive for several days, significantly longer than the 18hr 
survival time observed in the knockout, suggesting a hypomorphic mutation. In 
contrast to Foxfl knockouts, homozygotes for the W174R mutation do not possess a 
cleft palate or malformed tongue.
xvi
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Mapping and Phenotyping Genes in the Del(13)Svea36H Region of 
Mouse Chromosome 13 
Chapter 1: Introduction
1.1 Deletions
Large chromosomal deletions can occur in the human population and commonly 
result in mental retardation, morphological malformations or restricted growth when 
the aberration is inherited [1-3], or cancer in the case of deletions in somatic cells 
[4]. Deletions are one of several forms of gross chromosomal anomaly, others 
include trisomy, inversion, duplications and translocation mutations [5]. An 
estimated 20-50% of all human conceptions carry such chromosomal abnormalities, 
although a much lower 0.6% of live births carry them [6].
Macrodeletions have traditionally been regarded as those deletions which can be 
visualised cytogenetically by light microscope with giemsa staining, whereas 
microdeletions were those deletions which could not be detected with this method. 
This distinction however, has since become less relevant with the advent of 
techniques such as FISH (Fluorescent In-Situ Hybridisation) and more recently with 
the higher throughput array-CGH (Comparative Genomic Hybridisation) [7]. The 
more appropriate term is perhaps “Contiguous Deletion Syndrome” which was 
coined by Ballabio [7] to describe deletions which spanned at least 2 genes and 
produced a defined clinical phenotype. This group of diseases could be considered a 
subset of the “Contiguous Gene Syndromes” that Schmickel conceptualised [8] or
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“segmental aneusomy syndromes” [9] which also include the inversions, 
duplications and translocations of fragments containing several genes.
The phenotypes which are observed in carriers of these deletions are likely to be 
caused by the reduction in gene dosage of those genes within the region for which 
dosage is critical for normal function [10].
Large chromosomal deletions which are not associated with a detectable clinical 
phenotype have been detected in the human population [11]. However, it is possible 
that effects may have gone undetected due to the absence of a relevant 
environmental challenge.
1.2 Mechanisms of Deletion Formation
A lot can be learned about the mechanisms of deletion and other chromosomal 
rearrangements by the comparative analysis of closely related species such as 
chimpanzee and man [12-15]. There are two mechanisms which are thought to cause 
the majority of known deletions. These are: -  1) Non Allelic Homologous 
Recombination (NAHR) and 2)Non Homologous End Joining (NHEJ) [16]. 
Recombination driven by either of these mechanisms can result in the formation of a 
deletion when two different alleles on the same chromosome recombine during 
meiosis with the resultant loss of the region between the two alleles.
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NAHR is the predominant mechanism for deletion and duplication syndromes [16, 
17] whereby alleles with high levels of sequence identity, usually Low Copy 
Repeats (LCRs), are the substrate for erroneous recombination[18, 19]. Several other 
chromosomal features have also been implicated in the process however, and in 
particular other repeat elements such as a-satellites, transposons and chi-sites [16]
Those deletions which are thought to be caused by non homologous end joining 
(NHEJ) tend to have widely scattered breakpoints compared to those formed by the 
tightly clustered rearrangements seen in NAHR [16]. NHEJ is well documented in 
tumourogenesis but its involvement in hereditary deletions is not as apparent as is 
NAHR.
1.3 Mouse Deletions - Tools for Recessive Phenotype Screens
Mouse deletion mutants can model human deletion syndromes. There has been 
significant rearrangement during the evolution of both organisms, so large deleted 
regions are rarely contiguously syntenic, but large regions of synteny are present.
Deletions can be induced at various sites across the mouse genome, without 
destroying the viability of the hemizygous deletion carriers [20]. These carriers often 
demonstrate a range of developmental problems but are able to carry the deletion 
and survive and breed (albeit often with a reduced viability) [20,21]. These mice 
represent an excellent opportunity for regional screens to identify novel recessive
3
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mutations, and thus the potential for a greater understanding of the functionality of 
genes within these regions.
X-ray induced deletions and ENU have been effectively combined in a powerful 
mutation discovery approach which was first used on mice by Eugene Rinchik[22]. 
He was inspired by the success of similar methods that employed ethyl 
methanesulfonate (EMS) to identify novel genes in drosophila [23].
This breeding strategy utilised the female FI progeny of ENU mutagenised 
BALB/cRl males that were homozygous for the recessive albino mutation (c/c). 
These were crossed to a male carrier of an X-ray induced deletion on chromosome 7 
[22]. Hemizygous Lethal mutations were identified by a birth ratio of fewer than 
1:30 albino coated offspring from individual females. Rinchik suggested that this 
approach could be applied to a region in order to obtain saturation mutagenesis i.e.: 
at least one mutation in every gene in the deleted region.
In their review of phenotype based mutagenesis Screens, Schimenti and Bucan 
highlight several advantages of the regional deletion based recessive screen over the 
whole-genome alternative [24]:
1. The whole genome recessive screens require 3 mating stages instead of the 
two stages that are used in deletion screens for recessive mutations.
2. In the third stage of the whole genome screen, only 12.5% of the progeny are 
likely to be homozygous for any given mutation, in contrast to the 25% of
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progeny likely to be hemizygote mutation carriers following the final stage 
of deletion screens. This is because only 50% of the parental mice in the final 
mating stage will be mutation carriers during the whole-genome method (see 
figure 1.1).
3. The backcrosses required for the whole genome approach also means that if 
several mutations are present, the results of phenotype analysis are likely to 
be confused.
4. The use of visible markers within deleted regions means that lines carrying 
lethal recessive mutations can be easily identified by the absence of the 
visible trait. The whole-genome method is unlikely to detect these highly 
informative mutations.
5. This technique also allows the detection of recessive alleles which are 
effectively already “pre-mapped” to a deleted region.
Although a large chromosomal region is “targeted” in deletion screens, this method 
does not have the inherent bias of gene-targeted approaches because no assumptions 
are made about which genes within the region are likely to disrupt normal function.
In addition to their use as a tool for the identification of recessive mutations, mouse 
deletions can also model chromosome anomalies in humans [25]. They have the 
potential to increase the depth of knowledge about the genes responsible for the 
human phenotype and how the genes’ displacement effects the genetic interaction 
between genes within the region. Deletions also provide a unique opportunity to
5
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analyse the cumulative effect from altered expression levels of more than one gene 
within a region when closely linked genes are involved in the same biological 
process [26].
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Figure 1.1: Whole Genome & Deletion Mutagenesis Screens
Schemes representing the whole genome and Deletion based mutagenesis recessive screens. Both 
approaches involve the initial exposure to GO mice with ENU which induces mutations (represented 
by “m” in A & B, and by in C). The G1 offspring are then mated to wildtypes to generate G2 
litters which are either intercrossed with siblings (A) or backcrossed to their fathers (B). Mutagenised 
individuals in the regional screen (C) are crossed with animals that contain a dominant visible marker 
(M) to produce mutation (*) carriers that are subsequently crossed with carriers of a large 
chromosomal aberration such as an inversion or deletion. The absence o f the visible marker in the 
progeny from this cross suggests the possible presence of a lethal recessive mutation. Diagram 
adapted from Schimenti and Buchan [24].
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1.4 Alternative Methods of Deletion Induction: Targeted Deletions
One shared characteristic of ENU and X-ray mutagenesis is that both systems cause 
random mutations within the genome; the experimenter has no control over the 
region affected. An alternative technique which was pioneered by Ramirez-Solis & 
colleagues, has utilised a Cre-lox system to induce specific mutations within any 
region of interest in the genome of mouse ES cells.
Ramirez et al described an approach for creating deletions whereby loxP sites were 
inserted into the flanking regions of an intended deletion site in embryonic stem 
cells. Cre recombinase induces recombination between these sites [27]. Different 
types of cis- chromosomal rearrangement (i.e. deletion, inversion, duplication) are 
dependent on loxP orientation. These recognition sequences contain an 8bp 
asymmetric sequence at their centre which confers directionality. Deletions are 
likely to form when the two loxP recognition sites are aligned in the same direction 
and on the same chromosome. This is because when two such sites align, a loop 
forms between the two sites and this is subsequently removed from the chromosome 
on recombination (figure 6.2).
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Figure 1.2: Cre-lox system for Mutation Induction
The Cre-lox system can be used to form deletions provided that the loxP sites are oriented in the same 
direction and are on the same chromosome. Cre recombinase induces recombination between the 
loxP sites. The features labelled “1-2” and “3-9” represent exons of Hprt (Hypoxanthine 
phosphoribosyl transferase ). This is a gene which allows the breakdown of hypoxanthine and 
therefore allows survival in HAT media. It is only viable when the exons are correctly positioned in 
relation to each other, which only occurs following recombination between the lox sites, they 
therefore provide a system o f positive selection for recombination. The unidirectional nature of the 
LoxP sites means that their orientation can affect the type of chromosomal rearrangement which they 
induce and other alignments would instead result in inversions, duplications or translocations. PGK is 
a promoter element, puro and neo are resistance genes that are required for gene targeting of the Hprt 
cassettes. This image was adapted from Ramirez-Solis et al [27]
The Cre-lox system has also been used to induce targeted point mutations [28], so 
can also produce the full range of different allelic forms. This approach though, 
requires the screening of a large number of embryos and there is an inherent bias in 
any targeted approach because of the assumptions that must be made about which 
regions, genes, domains and nucleotides are important enough to target.
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The Trans-allelic targeted meiotic recombination (TAMERE) strategy has since 
been used to modify this method. Mice which carry different loxP loci can be 
crossed with each other to facilitate either deletions or other chromosomal 
rearrangements [29]. The availability of these mice would reduce the number of 
electroporation and selection stages for the insertion of novel loxP sites in individual 
crelox chromosome rearrangement experiments [29].
1.5 The Specific Locus Mutagenesis Test ((SLM) and Mouse Mutagens
William Russell designed the specific locus mutagenesis (SLM) test to determine the 
heritable gene mutation rate caused by radiation in germ cells [30]. However, this 
technique had much further implications and formed the basis of experiments which 
led to the discovery of several hundred “specific locus mutations” at Oak Ridge 
National Laboratory in the USA and at the Medical Research Council at Harwell 
[31]. These mutations later formed a crucial framework for the genetic mapping of 
the mouse.
This test utilised a mouse (The T-stock mouse) which harboured seven recessive 
mutations that produced distinctive visible traits. These loci were: nonagouti (a) on 
chromosome 2, the brown (b) allele of Tyrpl on chromosome 4, the chinchilla (Cch) 
allele of Tyr on chromosome 7, the dilute (d) allele of Myo5a on chromosome 9, 
pink-eyed (p) on chromosome 7, the piebald-spotting (s) allele of EdnrB on 
chromosome 14 and the short-ear (se) allele of BMP5 on chromosome 9.
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Wildtype males were X-ray irradiated before crossing with T-stock females. 
Mutations which disrupted the wildtype allele at any of the seven specific loci 
resulted in a failure to complement the recessive allele so that the visible traits were 
expressed thereby identifying mutation carriers.
Russell noted that the mutations discovered with this approach frequently 
mutagenised both the d and se loci and he suggested that these individuals may carry 
large mutations which spanned the region between the loci [30]. This theory was 
given greater credence by the construction of a more detailed linkage map between d 
and se which charted the relative positions of 8-9 independent functional units [32] 
and it has since become clear that many of the X-ray induced mutations arising from 
the SLM strategy were large chromosomal inversions, deletions or translocations 
which affected multiple genes[33] [34].
10
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1.6 Genetic & Physical Mapping
The Mouse genome sequencing project was initiated in 1996 to complement the 
human sequence. It provided an opportunity to improve previous mouse mapping 
data. Sequence would facilitate physical positioning of all previously identified loci 
and allow the precise determination of physical distances between them.
By 1996, a dense mouse genetic map of 6580 polymorphic SSLP markers had been 
developed [35]. The known mouse genome rapidly expanded with the use of 
sequence tagged sites (STS), radiation-hybrid panels[36], and YAC libraries[37]
As human genome sequencing began in the early nineties, YACs (Yeast Artificial 
Chromosomes) made up the most comprehensive of the human and mouse physical 
maps [38]. By 1995 various genome-wide STS-based human maps were completed, 
including a genetic map, a YAC map, and an integrated YAC-RH genetic map. 
These maps provided a framework for positioning additional loci [39]. However 
YACs have several associated disadvantages. Deletions and rearrangements within 
YAC sequences are frequent, they are prone to a high rate of chimaerism, and DNA 
extraction from the yeast host can be problematic [40].
Because of these problems, alternative systems were identified for the cloning, 
mapping and sequencing of the genome. For example, PI bacteriophage derived
11
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plasmids: PACs [41], and BACs (Bacterial Artificial Chromosomes)- a vector 
system which utilises the innate F-factor conjugation plasmid of E. coli [42].
Although PACs are much more stable than YACs, they only have a maximum insert 
size of 100kb[42]. One disadvantage of BACs is that there is no positive selection 
for recombinants, meaning that identification of recombinant clones is required by 
colony hybridisation[41]. On balance though, when the hierarchical approach has 
been used for large scale physical mapping, BACs have been considered the best 
option due to both their large insert size and relative stability [43].
There were two strategies for sequencing the human genome: The whole genome 
shotgun approach that was championed by Craig Venter of Celera, breaks the entire 
genome into sequenceable fragments[44]. For a time, the publicly funded 
sequencing centres were in direct competition with Celera but had already decided 
upon a method known as hierarchical shotgun sequencing, in which the genome is 
first broken into overlapping large-insert clones[45]
The whole genome shotgunning approach is the simpler of the two, and gave rapid 
early coverage, but genomes with highly repetitive sequences can be 
problematic [43]. Hierarchical shotgun overcomes this problem because it is a 
localised assembly method - the number of repeat copies in each assembly is 
reduced and it is possible to compare large regions of overlap between the clones. A
12
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combination of both approaches was decided upon for sequencing of the mouse 
genome [43].
It is vital that sequence-ready maps should contain contigs (several clones that 
contain overlapping sequence) which are of sufficient depth that the clones can be 
validated by several other overlapping clones [40]. This helps to reduce the chance 
of including sequence from clones which have undergone rearrangement which 
would incorporate incorrect sequence data into the construct.
13
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1.7 N-Ethyl-N-nitrosourea (ENU)
Another major contribution to mouse genetics by William Russell, in addition to the 
SLM test, was the discovery of the potent mutagenic effect of Ethylnitrosourea 
(ENU) in mice [46].
Russell had observed that in contrast to SLM tests with X-rays, tests with ENU did 
not produce mutations which occurred at both the se and d loci simultaneously -  he 
therefore suggested that ENU may cause mutations within individual genes rather 
than large multi locus regions [46]. Stronger evidence for this arose when the 
peptide sequence of haemoglobin a-chain 5 in an ENU mutagenised DBA/2 mouse 
was shown to carry a single amino acid substitution (His-Leu) which suggested an 
A-T point transversion in the gene [47].
ENU is an alkylating agent which forms ethyl free radicals that can bond to 
nucleobases and cause point mutations in DNA[48,49]. It preferentially reacts with 
AT base pairs [50] and since the discovery of the first ENU induced point mutation, 
the majority of reported mutations in mouse have been AT-TA or AT-GC base pair 
transitions [48, 51]
These point mutations do not necessarily knockout the total functionality of a gene 
as is often the case with mutations caused by other mutagens or gene traps[52]. 
Instead, a range of different effects can be observed in genes mutagenised at a single 
base. Hypomorphs, which result from reduced gene dosage or protein activity are the
14
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most common ENU induced allele [51]. These are followed by the null alleles that 
other less specific mutagens tend to cause. ENU can also result in hypermorphic 
mutations that indicate an increase of gene dosage or protein activity; neomorphs 
where a protein has acquired a novel function; and antimorphic alleles which are 
dominant negative effects that can be caused by competitive inhibition of normal 
protein function [51] [53] [48].
This range of different allelic forms that can be caused by point mutations can 
potentially provide vastly more information about the activity of a gene and its 
product than a knockout (null allele) alone could provide[49]. Null alleles certainly 
can give a very useful window of insight into the role of a gene when its not 
functionally redundant, but a detailed analysis of protein function and of interaction 
with other factors is not possible without other allelic forms.
The potential for ENU was highlighted to the scientific community with the 
discovery of the clock gene thanks to the presence of an ENU induced circadian 
rhythm mutation on mouse chromosome 5 [54]. The excitement surrounding this 
insight into such a complex and what had been up to then, little understood 
molecular system provided the impetus for an explosion of ENU mutagenesis 
experiments during the 1990s and into the new millennium.
Two large scale genome wide ENU mutagenesis screens for dominant mutations 
were independently initiated by Steve Brown at Harwell [55] and Rudi Balling at the
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Institute of Experimental Genetics in Neuherberg, Germany [56]. A systematic 
phenotyping approach was taken; following general observations of each animal 
screened, a wide range of tests were performed to optimise the potential detection of 
any morphological, biochemical or behavioural mutants.
1.8 Phenotyping
Mouse mutations are of limited use without a detailed characterisation of the 
phenotype of the carrier. The ultimate aim of mouse mutagenesis is the linkage of 
genetic factors with physical or behavioural traits, and for this to be realised accurate 
phenotyping is essential. SHIRPA is a comprehensive and standardised series of 
tests designed to highlight a wide range of behavioural, physiological, and metabolic 
mouse phenotypes [57]. It has been used both for both phenotype screens in the 
high-throughput analysis of large numbers of individuals which have been subjected 
to random mutagenesis [58], and genotype screens when the phenotype of mice with 
a mutation in a known gene is interrogated [59].
There are many factors which could potentially obscure a real association between a 
mutation and a mouse abnormality. The common inbred strains are known to vary 
extensively in various phenotype tests, a phenomenon which is being explored with 
the mouse phenome project [60, 61](http://www.jax.org/phenome). The behavioural 
traits which are detected by SHIRPA, often show significant differences between the 
common inbred strains, including learning and memory [62], locomotor activity 
[63], and anxiety [64]. This suggests that a mixed background could mask potential
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behavioural phenotypes. Repeated backcrossing to a selected strain can minimise 
these effects, but even following multiple backcrosses of over 10 generations, large 
regions that are undisturbed by recombination can flank the gene of interest, and 
frequently contain in excess of 300 genes [65].
In addition to these genetic considerations, a wide range of environmental factors 
can drastically affect results, particularly in behavioural screens. Noise, light, diet 
[66], cage environment [67], husbandry techniques, experimenter [68] and 
pathogenic environment are all factors which are likely to vary between mouse 
facilities.
Differences in experimental protocols can also have an important influence on the 
results obtained. The Eumorphia project (http://www.eumorphia.org) was initiated to 
try to standardise working practices so that results between laboratories can be 
reliably and directly compared. A hierarchical phenotyping platform is under 
ongoing development which consists of a set of standard operating procedures 
(SOPs) that are intended as a reference point for robust phenotyping protocols for 
the mouse community [69]. Following validation studies, many of the tests are now 
consistent between centres, but others still require the elimination of variables which 
prevent reliable data comparisons [70].
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1.9 Deletion Syndromes of Human Chromosome 6p
Deletions o f sections o f chromosome 6p in humans are rare. In 2004, Mirza et al 
counted 43 cases in the medical literature [2], since then at least 11 new cases have 
been reported [2, 71-77]. It therefore seems that these syndromes may have 
previously been under-reported, but with improved cytogenetic techniques the 
frequency o f small deletion detection is increasing [78].
Davies and colleagues were the first to note that there are two distinct groups of 6p 
deletion syndrome: 6p25 deletions, which is the 6p region at which deletion 
frequencies are highest, and variable interstitial deletions between 6p22-24 [2, 79, 
80].
Clinical findings from the 6p25 region, the most frequently deleted region o f the 6p 
syndromes, include corneal opacity, malformation o f various structures of the ocular 
anterior chamber, hypertelorism (widely spaced eyes), ptosis (drooping eyelids), 
optic nerve abnormalities, hydrocephalus, Dandy-Walker malformation, heart 
defects, deafness and mental retardation [2, 73].
The symptoms o f the interstitial syndromes have included orofacial clefting, short 
neck, clinodactyly (curved fingers), syndactyly (fusion o f fingers), and brain, heart 
and kidney defects [2, 79].
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Although these deletions can provide a wealth of evidence relating to the function of 
genes in the deleted regions, direct comparisons of phenotype with deletion span can 
be misleading because of other factors affecting phenotype such as the environment 
of the womb during gestation, parental origin and mutations in other genes with 
related function. This has been noted as a particular source of difficulty in the 
characterisation of the 6p25 associated eye phenotypes which have highly variable 
penetrance levels [2].
There has been a concerted effort to characterise the correlation between map 
positions of various 6p25 deletions and the associated eye phenotype. This interest 
has been primarily fuelled by the phenotypic link to the well characterised Foxcl 
mouse mutant, congenital hydrocephalus (ch) and the Foxcl knockout [81]. These 
mutants die with hydrocephalus, skeletal abnormalities and Axenfeld Rieger 
anomaly which involves malformations of the anterior segment of the eye that can 
lead to glaucoma.
1.10 The Del(13)Svea36H Deletion
Del(13)Svea36H is a deleted region of mouse chromosome 13 [82] with conserved 
synteny to human chromosome 6p21.3- 6p23 and 6p25[21]. The deletion can be 
detected cytogenetically and was initially estimated to result in the removal of 
approximately 12% of the chromosome at G-bands 13A2-13A3.2 [82]. Subsequent 
cytogenetic analysis however, which reviewed the deleted interval in 9 animals, 
suggested an expanded interval at G-bands 13A3-13A5 and was 20.1% of the
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chromosome [21]. This is quoted as equating to 25.6Mb with the most accurate 
estimation of chromosome 13 size at that time (corrected to 24.18Mb with the more 
reliable chromosome 13 size taken from the Ensembl v50 sequence assembly).
The later estimate was given greater credence by high resolution genetic mapping 
with the EUCIB (European Collaborative Interspecific Backcross) resource [83] that 
indicated a similar size of 12.5cM, equating to 26.5Mb (corrected to 25.03Mb with 
Ensembl v50). However, following the precise localisation of the end-points of the 
deleted region (J. Raggoussis, personal communication) and attainment of the 
completed sequence for this region, a more reliable size estimate of 12.7 Mb has 
been made. This figure is closer to the initial cytogenetic size estimate o f-12% of 
the chromosome which would have equated to -1 5.28Mb with the earlier whole- 
chromosome size estimate (or corrected to -14.43Mb with chromosome size data 
from Ensembl v50).
There is a high density of genes in the Del36H region -  with 201 known genes [84]. 
This has led to speculation that the Del36H region may have undergone high 
frequencies of recombination during its evolution, which would have encouraged 
gene duplication [84]. Regional Features that increased recombination rates during 
evolution are likely to affect size estimations determined by genetic mapping, 
because inter-loci distances are calculated by recombination frequencies with these 
methods.
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1.11 The different Gene Families Within the Del 36 region
A detailed annotation of the Del36 region was carried out using manual annotation 
and comparative sequence analysis [84]. The high gene density of the region is 
largely due to the expansion of three gene families: The prolactins, the serpins and 
the vomeronasal receptors. There has also been an expansion of a butyrophilin 
cluster on human 6p, in which seven butyrophilin genes in the human region are 
represented in the syntenic del36H region by only two butyrophilin mouse genes. 
Several histone gene clusters are present which can also be found on the syntenic 
human 6p region.
1.11.1 Vomeronasal receptors
This family of chemo-sensory proteins are thought to mediate the response of the 
vomeronasal organ to chemical stimuli [85]. In humans the vomeronasal organ 
regresses during foetal development, although this is not the case in mice [86]. This 
is reflected in the wide disparity in the size of this gene family between these two 
species and there has been a significant vomeronasal expansion in Del36H when 
compared with the human syntenic regions [84].
1.11.2 Prolactins
The prolactin family of genes have undergone species specific gene duplication at an 
extraordinary scale -  there is only one member of the family in human chromosome 
6p, but 26 active genes in the syntenic region of the mouse Del36H region, including
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three pseudogenes [84], Wiemers et al predicted that there were 26 fully functional 
genes [87] but Mallon pointed out that three of four of the genes predicted by 
Wiemers on the basis of cDNA and EST data had not been mapped and may be the 
result of sequence or copy-number polymorphism in the region which may have 
appeared as individual genes due to the use of multiple mouse strains [84].
Prolactins are expressed in the uterus, placenta and anterior pituitary. They are 
responsible for the regulation of maternal-foetal interactions during pregnancy and 
the induction of milk production after birth [87].
1.11.3 Butyrophilins
Butyrophilins are members of the immunoglobulin superfamily. They are associated 
with the membranes of lipid droplets in milk and are involved in the regulation of 
droplet secretion. The malformed lipid droplets in Btnlal mouse knockouts suggest 
that they are also important for the integrity of the membrane structure of these 
droplets [88]. 50% of the pups that suckled from Btnlal(-/-) mothers died within 20 
days of their birth.
1.11.4 Serpins
The term serpin is an abbreviation of “serine protease inhibitor”. Many serpins are 
active protease inhibitors, but the term has been applied on a structural rather than a 
functional basis, and some of them do not demonstrate any enzyme inhibiting 
activity [89]. All of the serpins in the human syntenic region to del36H however, are 
from the ovalbumin (ov)-like serpin clade, and are either cysteine or serine protease
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inhibitors [89, 90]. Ov-serpins are frequently involved in tumour development, 
inflammation and apoptosis control. Many of the ov-serpins that are present in the 
Del36 region have localised expression in the placenta, although there are also a 
number with more widespread expression patterns in other, varied organs and two 
with apparently ubiquitous expression in adults [90].
1.11.5 Transcription Factors
Transcription factors are a large and diverse group of genes that code for proteins 
which either repress or facilitate the activation of DNA transcription. They have 
modular structures and the large majority contain a DNA binding domain. Some of 
the basal transcription factors do not bind to DNA but contribute to the pre-initiation 
complex that interacts with RNA polymerase II. Another common feature of 
transcription factors are trans-activating domains which contain binding sites for 
attachment to other proteins such as transcription co-regulators.
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1.12 Forkhead Transcription Factors
Forkhead box (Fox) transcription factors were named after the spiked ectopic head 
structures that formed in association with the diminished guts of mutagenised 
Drosophila embryos [91]. A domain within the causative forkhead (fkh) gene was 
identified that had high levels of sequence homology to Hepatocyte Nuclear Factor 3 
factor (HNF-3), suggesting that they may be members of a larger family of 
transcription factors [92].
The known forkhead family, members of which all contain this highly conserved 
DNA binding domain, has greatly expanded since the discovery of these first 
members and there are currently 42 known Fox genes in humans, 16 in drosophila 
and at least 4 in yeast [93]. The presence of the family in yeast is evidence which 
supports the hypothesis that fungi and animals form an evolutionary supergroup - 
the opisthokonts, and are linked by a more recent ancestry than are other eukaryotes 
[94]. The apparent correlation between the complexity of an organism and the 
number of Fox genes it carries led Carlson to suggest that increasing complexity of 
body plan may drive the expansion of the Fox gene family [94].
1.12.1 Structure of Forkhead Genes
The first forkhead protein analysed to be structurally characterised by X-ray 
crystallography was rat HNF-3 (now known as FoxA3) [95]. The phrase “winged 
helix” was used to describe the helix-tum-helix structure of the forkhead DNA
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binding domain. This consists of three clustered helices on an antiparallel beta-sheet 
structure which forms the base of two extended loops or “wings”. Subsequent NMR 
analysis of other forkhead proteins suggested an additional alpha helix in these 
molecules[96, 97] but it was later realised that the predicted presence or absence of 
these structures was probably due to differences in interpretation rather than 
sequence variation [98]
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Image A = structural prediction o f how the structural features o f the Foxa3 protein may fit into the 
helical form o f its DNA binding sequence. This image was taken from Cirillo et al, 2007 [99]. Image 
B = The envisaged alignment o f HNF3 (now known as Foxa3) on DNA when the DNA is wrapped 
around histones as chromatin. This image was taken from Cirillo et al, 1999[100].
1.12.2 Forkhead Protein - Chromatin Interaction
Cirillo and colleagues found that unlike many other transcription factors, the FoxA 
proteins bind with greater affinity to DNA wrapped around histones as chromatin 
than they do to free DNA [100]. Recent data suggests that the wing-like structures of 
the protein are important for keeping the protein on one side of the DNA helix, 
allowing space on the other side for the histones or other transcription factors [99].
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A domain at the C terminal end of the Fox A proteins is thought to bind to histones 3 
and 4 within the nucleosome. Cirillo believes that this binding combined with the 
strong affinity of the forkhead domain to the specific DNA site, is probably the 
beginning of a process which sees the opening of the chromatin structure to allow 
access to the DNA [101].
Much of the work investigating the chromatin -  forkhead interaction has been 
carried out with the structurally well characterised FoxA proteins, but Carlsson and 
Mahlapuu suggested that a common theme uniting forkhead genes may be the 
mechanisms by which they interact with chromatin [94]. This could well be the case 
as the DNA binding domain is highly conserved throughout the forkhead family. 
However FoxA -  footprinting experiments showed that the C terminal domain was 
important for binding to histones 3 and 4 of the nucleosome to facilitate the 
chromatin opening and therefore access to the DNA. Other transcription factors that 
require access to chromatin would also probably need histone binding regions, but 
sequence outside the forkhead domain is highly variable between forkhead genes 
and the C terminal region studied was thought to be unique [101]. The exact method 
of chromatin entry is therefore likely to vary somewhat between the different 
members of the forkhead family.
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1.12.3 Forkhead Gene Function
Despite the highly conserved forkhead domain, forkhead transcription factors are an 
extraordinarily diverse group of genes with key roles in the development, 
homeostasis, stress response and cell cycle control of a wide range of tissue types. 
Many of these genes also have a broad pattern of expression individually and 
mutations within them often cause highly pleiotropic effects.
Some forkhead transcription factors can act as key modulators of the cell cycle. 
Foxml is responsible for the upregulation of CDC25A, a phosphatase which 
activates the transition from phase G1 into S phase [102] and without Foxml, 
mitosis does not occur. It also down-regulates p21CIP1 and p27kip, which are 
molecules that function as inhibitors of the cell cycle shift [102].
p21cn>1 is regulated by Foxkl in myogenic stem cells [103] [104] and by Foxgl in 
cortical progenitors [105]. The FoxO clade also functions to regulate cell cycle arrest 
by the regulation of p27kip [106,107].
Fox genes in the developing Embryo
Foxa2 is a key component of the pathways that form the node and the notochord. 
Without it, severe defects in gastrulation, neural tube patterning and gut 
morphogenesis cause early embryonic lethality [108]. Foxa2 also contributes to the 
correct functioning of the foregut endoderm, in combination with Foxal. Many other
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tissues of endodermal origin such as liver, pacreas, lungs and prostate also require 
Foxal and 2 for normal development. Glucose metabolism can also be affected in 
FoxA mutants due to the abnormal functioning of the liver, pancreas and adipose 
tissue [109].
Fox genes are essential for correct skeletal formation. Foxcl deficiency causes skull 
and thoracic defects [110]. In addition, mesenchymal cells fail to differentiate into 
cartilage, even with the addition of BMP2 or TGFB1 [81]. Foxcl is expressed in the 
paraxial mesoderm at early gastrulation, and then subsequently in the presomitic 
mesoderm and the first branchial arch [111].
Fox gene expression is very tightly localised during the formation of the branchial 
arches. Foxc2, Foxdl, Foxd2, Foxfl and Foxf2 expression is lost from a range of 
facial primordia when hedgehog responsiveness is incapacitated in neural crest cells 
[112]. These forkhead genes have also been reported to be induced by Shh in 
somites and foregut [113-116].
Initiation of forkhead gene expression by hedgehog transcription factors is a 
common theme in the literature and it is possible that the forkhead susceptibility to 
the effects of hedgehog proteins may be a common feature of the entire gene family.
Forkhead gene induction by Sonic hedgehog is necessary for aortic arch 
development, and is also required for expression of Foxa2 and Foxc2 in the
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pharyngeal endoderm and head mesenchyme [117]. Foxa2 expression in the 
notochord and the floorplate of the neural tube is maintained by a positive feedback 
loop with sonic hedgehog. Sonic hedgehog also interacts with Foxal and Foxa2 in 
the branching morphogenesis of the mammalian lung [118].
Fox genes in the heart
Deficiency of Foxpl can result in Atrial Septal defect, defective myocardial 
proliferation and abnormal outflow tract septation [119]. The forkhead genes Foxcl 
and Foxc2 are also involved in the regulation of cardiac outflow tract septation in 
association with the known cardiac regulator Tbx [117, 120]. Foxpl, Foxcl, and 
Foxc2 are expressed in the cardiac neural crest [117, 119-121]. Foxn4 regulates tbx5 
which controls the development of the AV boundary [122]
Lung
Foxpl and Foxp2 repress the mouse CC10 promoter and, to a lesser extent, the 
human surfactant protein C promoter -  thus implicating them in the regulation of 
epithelial lung gene transcriptionf 121]
Glucose Tolerance
The FoxO and FoxA clades play fundamental roles in the appropriate formation of 
pancreatic islet cells and liver. They are also involved in the regulation of many 
metabolic genes such as are present in the hepatic gluconeogenesis pathway -  which 
is important in the prevention of hypoglycemia during fasting [123].
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Foxo proteins regulate the entry of cells into the G1 cell cycle and are critical for cell 
survival and proliferation. Foxol, Foxo3a, and Foxo4 contain three phosphorylation 
sites for insulin activated protein kinase pathways [123].
Even closely related forkhead genes can have apparently completely divergent 
functions. There is mounting evidence that Foxp2 is critical for the correct 
development of speech and language, following the discovery of a family in which a 
single amino acid change (R553H) co-segregated with severe verbal communication 
difficulties in otherwise intellectually normal individuals [124]. The closely related 
Foxp3 though functions as a lineage specification factor in regulatory T cells, and is 
important in the maintenance of self-tolerance [125]. There does not appear to be 
any overlap in the function of these two genes despite a whole protein sequence 
homology of 54% and a forkhead domain homology of 75% (Ensembl v50).
The variety of tissues and processes in which forkhead genes are involved (See table 
1.1) would suggest that the expansion of this family was more indicative of a useful 
general transcriptional mechanism than of any property that makes them useful for 
the development, maintenance or activity of specific tissues.
The eye though, is the system in which most Fox related human disorders have been 
identified to date [126]. It is a delicately balanced system and seems to be prone to 
suffering effects from alterations in Fox gene dosage [10,127-129].
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The anterior segment of the eye, which is formed by a complex process of 
interactions between ectodermal, neuroectodermal, and neural crest cells appears at 
particular risk of such alterations. Disturbances in the balance of this process can 
result in glaucoma, cataract, leucoma, or other visual defects.
Forkhead mutations in human disease were first identified in association with 
FOXC1 (previously known as FKHL7) in patients with Axenfeld-Rieger syndrome 
and glaucoma hypoplasia [130, 131].
This discovery was followed by the discovery of a number of other mutations in 
various forkhead genes that also resulted in eye disorders. Mouse Foxe3 is expressed 
in the lens epithelium following a wider distribution in the developing lens. The 
dysgenetic lens (dyl) allele of Foxe3 prevents DNA binding. The phenotype is 
equivalent to Peters’ anomaly in humans and includes central corneal opacity, lens 
and iris hypoplasia, keratolenticular adhesion, absence of secondary lens fibres and 
severe cataracts. Foxe3 is essential for the proliferation of the lens epithelium and 
also acts to prevent apoptosis and inappropriate differentiation of its precursor cells. 
In addition to defects of the anterior segment that are reminiscent of those seen in 
FOXC1 mutations, some FOXC2 mutations cause abnormal eye-lash growth that 
can result in damage to the cornea [132], FOXL2 mutations cause eye lid 
abnormalities in occasional association with ovarian disorders [133]
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Gene Vertebrate Mutant/Disease Phenotypes
FoxAl
Growth retardation, hypoglycaemia & reduced glucagon production in mouse null mutants 
[134].
FoxA2
Mouse null - absent node & notochord; foregut development severely impaired [108]. 
Hypoglycaemia with conditional null Foxa2 mutations in the pancreas [135].
FoxA3
Mouse null - inefficient glucose transport from hepatic cells and hypoglycaemia during 
fasting [136]
FoxBl Mouse null - growth retardation. Failure to nurture pups. CNS Defects [137]
FoxCl
Mouse null - hydrocephalus, skeletal, ocular, renal & cardiovascular defects [81,110,138]. 
Human missense, frameshift, deletion and protein truncation mutations - anterior eye segment 
defects, glaucoma & Axenfeld-Rieger anomaly [131, 139].
FoxC2
Mouse null - skeletal, cardiovascular, lymphatic & ocular defects in mice [120, 140]. Human 
missense & frameshift mutations - lymphedema & distichiasis syndrome, ptosis, ocular 
anterior segment anomalies & cleft palate [132, 138].
FoxDl Mouse null - Renal failure[141]
FoxD2 Mouse null - Partially penetrant renal anomalies [142].
FoxD3,
Mouse null - loss of epiblast cells, expansion of proximal extraembryonic tissues, and an 
ectopic anterior visceral endoderm [143,144].
FoxD4,
Human point mutation - Cardiomyopathy, obsessive-compulsive disorder, and suicidality co-segregated 
with aFOXD4 mutation in a single 3 generation family [145]
FoxD5
(FoxD4Ll), Xenopus null- Immature neural cell fate; Inhibition of neural differentiation [146].
FoxD6
(FoxD4L3), N
FoxEl
Mouse null - Cleft palate & Aberrant thyroid development in mice [147], Human missense - 
as in mouse abnormalities alongside Choanal atresia [148].
FoxE2, Described by Ensembl as a synonym of FoxEl
FoxE3
Mouse null - fusion of the lens, cornea and iris. Cataract formation [149, 150]. Human 
frameshift mutation - Eye anterior segment dysgenesis & cataracts [151].
FoxFl
Mouse null - absence o f vasculature in the allantois or yolk sack. Also lung and foregut 
malformations and defects in cell adhesion [116,152].
FoxF2
Mouse null - cleft palate and malformed tongue [153]; megacolon, colorectal muscle 
hypoplasia & agangliosis [154]. Human insertion mutation - glaucoma [155]
FoxGl Mouse null - cerebral hemispheres of the brain are smaller than wildtypes [156].
FoxHl
Mouse null - the node, notochord, prechordal mesoderm and definitive endoderm all fail to 
develop [157, 158],
Foxll Mouse null - Inner ear malformations: Deafness & balance problems [159].
FoxJl Mouse null - Ciliogenesis defects and left-right asymmetry in mice [160].
FoxJ2, Human - Foxj2 is upregulated during heart failure [161].
FoxJ3,
Mouse null - reduced post-natal growth. Decreased fat and type I muscle fibres but increase 
in type Ila/b muscle fibres. Inefficient muscle regeneration following injury. Increased 
myoblast proliferation rates. [162].
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Gene Vertebrate Mutant/Disease Phenotypes (Continued)
FoxKl
Mouse null - restricted growth. Defect in the proliferation and differentiation of myogenic 
stem cells [163].
FoxK2,
Human Embryonic Kidney (HEK-293), mouse fibroblast (NIH3T3) and mouse pituitary 
(NtT20) cells - apoptosis in proliferating cells. Overexpression prevents apoptosis [164].
FoxLl
Mouse null - structural abnormalities o f the stomach & intestine. Uncontrolled epithelial cell 
proliferation [165]. Increased propensity to tumour formation [166].
FoxL2
Human missense, frameshift mutations & protein truncation & extension mutations: 
Blepharophimosis, Ptosis, Epicanthus, Ovarian failure (BPES syndrome). [133,167] [167]
FoxMl
Mouse null - Polyploidy in cardiomyocytes and hepatocytes [168]. Cardiovascular defects 
[169]. Failure to enter mitosis [170]. Overexpression of mouse Foxml accelerates the 
development, proliferation and growth of prostate tumours [171].
FoxNl
Mouse null - thymus fails to develop, hairless [172]. Human protein truncation mutation - T 
cell deficiency. Alopecia. Malformed nails [173, 174].
FoxN2 N
FoxN3 Human oral squamous cell carcinoma cells - reduced FOXN3 expression [175].
FoxN4,
Mouse null - early postnatal lethality or noticeable body size reduction. Fewer amacrine and 
horizontal cells in the retina [176].
FoxN5
(FoxRl), N
FoxN6
(FoxR2), N
FoxOl
Mouse null - defective angiogenesis [177]. Mouse Foxol HaploinsufFiciency restricts the 
probability o f insulin resistance. Overexpression of mutant Foxol in mouse liver and 
pancreas can cause diabetes [178]. Human chromosomal deletion of FOXOl - common in
(FoxOlA), prostate cancer.
Fox03
(Fox03A,
FOX02,
F0X 06), Mouse null - Abnormal ovary development. Early female infertility [179],
Fox04 No obvious phenotype in knockout mice [179]or known human diseases.
FoxPl,
Mouse null - severe defect in early B cell development [180]. Foxpl+/- mouse heterozygous 
mutation compounded with Foxp2 null: Severity o f Foxp2-/- lung phenotype is worsened. 
Oesophageal muscle development is disrupted [181].
FoxP2
Human point mutations & chromosomal translocations - speech and language disorder [124], 
Mouse null - Defects in lung alveolarisation. Lung defect severity is increased by the 
additional presence of a single Foxpl null allele ( Foxp2-/-;Foxpl+/-). Oesophageal muscle 
development is also disrupted in Foxp2-/-;Foxpl+/- embryos [181].
FoxP3
Mouse frameshift mutation. - overproliferation of CD4+CD8- T lymphocytes [182]. Human 
deletion mutations cause immune dysregulation, polyendocrinopathy and enteropathy (IPEX 
syndrome) [183].
FoxP4, N
FoxQl Mouse intragenic deletion mutation - defect in hair differentiation [184].
T a b l e  1 . 1 :  P h e n o t y p e s  o f  m u t a t i o n s  i n  v e r t e b r a t e  f o r k h e a d - b o x  g e n e s .
List o f Phenotypes associated with vertebrate forkhead genes. Phenotypes listed are primarily sourced 
from induced mouse mutations and human disease symptoms.
N = No data available. Genes in brackets = Fox named synonyms.
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1.13 The Forkhead Cluster Within the Del36 Region
There are 8 clusters of forkhead genes that have been identified within the human 
genome [126]. One such cluster contains the genes FOXC1, FOXF2 and FOXQ1 
and is located at 6p25 in humans and the del36H region of chromosome 13 in 
mouse. A paralogous cluster is located at human 16q24 (mouse chromosome 8) 
containing FOXC2 and FOXF1 in place of their close paralogues FOXC1 and 
FOXF2. There is no direct FOXQ1 paralogue but a forkhead gene from a different 
clade, FOXL1, is present.
Mazet and co-workers have carried out comparative analysis of these genes in 
different bilaterian groups. FoxF, FoxC, FoxQ and FoxL are all represented singly in 
amphioxus on one tightly linked cluster. Mazet et al were therefore able to construct 
a potential model for the evolution of this cluster before the divergence of the 
bilaterians [185]. They suggest that the replication of two closely linked genes and 
maintenance of their relative positions suggests that the paralogues are the result of a 
block duplication event in early vertebrates. The loss of one FoxQ gene at one locus 
and one FoxL gene at the other, perhaps caused by their redundancy, could explain 
the formation that can now be seen in mouse and human.
Expression studies by Mazet showed that during the development of the endo- 
mesoderm these genes were expressed sequentially [186], and the order of 
expression is matched by the physical positions of the genes on the chromosome, a 
pattern reminiscent to that of hox clusters in somite differentiation [187]. Mazet
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makes the convincing argument that this pattern in endomesoderm formation could 
be a selective force for the maintenance of the cluster, and may explain its 
persistence in most bilateral organisms.
Many of the phenotypes associated with deletions of chromosome 6p25 have been 
attributed to FOXC1 because many of the phenotypes associated with the deletion 
syndrome were detected as equivalent phenotypes in Foxcl knockout mice [81].
1.14 The Del36H Eye Phenotype
The Eyes of Del36H mice were analysed following the initial observation that they 
had a “gummy” appearance [82]. Ruth Arkell and co-workers later noted that the 
eyes were open at birth and 40% of carriers had irregularly shaped pupils in one or 
both eyes. Older mice had opaque eyes which were severely scarred and frequently 
infected. The “gummy” appearance of eyes was described as secondary to the eyes 
being open at birth [21].
Mutations in several forkhead genes cause a wide spectrum of eye disorders [126]. A 
forkhead cluster is present in the Del36H region that includes the gene Foxcl which 
has a strong association with defects of the ocular anterior chamber [81]. Foxf2 -  a 
neighbour of Foxcl and also a member of the cluster, is expressed in the eye from 
-day 13 of mouse embryonic development [188]. These are therefore immediate 
candidates for the analysis of the eye defect in the Del36H mutants.
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Another potential factor that may contribute to the Del36H eye phenotype is that 
prolactins, of which there are a large number in the deleted region [84], have been 
shown to inhibit angiogenesis in the retinas of rats [189]. It is possible that 
overproliferation of blood vessel cells could result in malformation of the eye(s).
1.15 Foxcl & The Eye
The mouse Foxcl null homozygote mutation causes death at birth and the mice 
suffer from hydrocephalus and a range of skeletal abnormalities. In the anterior 
segment of the eye, a range of morphological anomalies were present including iris 
hypoplasia, malformed eyelids and incorrectly aligned corneal cells [81].
Mice that were heterozygous for the mutation possessed a disorganised and 
undifferentiated trabecular meshwork, irregular pupils, iris hypoplasia, small or 
absent Schlemms canal, and a displaced Schwalbes line [138].
In vivo cell fate mapping has since demonstrated that neural crest cells are present 
from day E10 in the optic cup and lens vesicle of healthy wildtype mice [190]. 
Coordinated interactions between the neural ectoderm and periocular mesenchyme 
are necessary for the formation of the highly specialised structures of the ocular 
anterior chamber. TGFP2 activates the expression of Foxcl and Pitx2 which are 
critical for the differentiation and proliferation of neural crest cells.
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The neural crest cells eventually develop to form the iris stroma, ciliary body, 
trabecular meshwork, choroid and primary vitreous of the mature eye [190]. It 
therefore seems likely that the Foxcl mutations are affecting the developing eye by 
interference with the correct differentiation, proliferation or activity of these cells.
The abnormal structures in the anterior segment of Foxcl null mutants possess 
insufficient levels of extracellular matrix (ECM). The ECM that was present was not 
the characteristically organised beam structure that is typical of this component of 
the anterior segment, but was instead disorganised and with reduced levels of 
collagen and elastic tissues. However despite these abnormalities -  which affect the 
eye drainage system, most of the mice did not have increased intraocular pressure.
ECM of structures in other systems such as the sternocostal cartilages, sternum and 
kidneys are also disrupted in Foxcl mutants, and Smith suggested that this may 
indicate that Foxcl has a role in the regulation of the synthesis or organisation of 
ECM. He suggested that the similar phenotype seen in Foxc2 individuals could also 
indicate a role in this pathway.
Collagen is a key constituent of the ECM. Coll8al knockout mice, which cannot 
produce type 18 collagen, have an abnormal ciliary body and iris [191]. Type 8 
collagen is also important in eye development and when the two subunits are 
disrupted, there is a decreased proliferation of endothelial cells which leads to a 
thinning of the cornea and Descemet’s membrane [192]. These studies indicate that
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collagen levels are important for the correct development of the anterior segment. 
Collagen should perhaps therefore be considered a likely downstream target of 
transcription factors that are associated with eye malformations.
Douglas Gould and colleagues have predicted a set of potential genetic pathways of 
iridocorneal angle development which centres on the conversion of tyrosine to 
dihydroxyphenylalanine (L-Dopa) [193]. Gould et al believe that this molecule is 
likely to be important in the process because it is a precursor to catecholamines 
which are developmental regulators [194]; and because it can be linked to known 
pathways for many of the genes involved in angle formation such as PAX6,
LMX1B, PITX2 and 3 and for Bmp4, Tgfb2 which demonstrate similar phenotypes 
to Foxcl and Foxc2. Foxcl can also be linked to this pathway since the recent 
finding that PITX2 binds to and inhibits the activity of the FOXC1 protein [127].
1.16 Evidence of at least one other glaucoma locus at 6p25
There have been several previous reports of additional glaucoma loci within the 
6p25 region. A paper published shortly after glaucoma was first linked to Foxcl 
[130], mentioned four glaucoma patients whose condition was linked to 6p25 but in 
whom mutations were absent from the coding region of Foxcl [131]. In two of these 
cases, Foxcl was also excluded by familial recombination mapping.
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Gould highlighted another patient with an unbalanced translocation between 6p25 
and 4pl4 [80], in which the breakpoint was between two markers that surrounded 
FOXF2 but was distal of FOXCl. This raised the possibility that FOXF2 may have 
been monosomic and FOXC1 disomic in this individual. However the heterozygous 
marker (D6S967), which lies between the two genes, is significantly closer to 
FOXF2 than was the hemizygous marker (D6S942) (see table 1.2).
Locus
Ensembl.v50 Position
Zygosity
Start End
D6S942 765305 765544 Hemizygous
Foxf2 1335068 1340831 -
D6S967 1428847 1428985 Heterozygous
Foxcl 1555680 1559126 -
Table 1.2: Markers used by Gould et al to Characterise a 6p Translocation
Updated Positions of markers that were used by Gould [80] to characterise a 6p unbalanced 
translocation which had a breakpoint distal to Foxcl that resulted in loss of the 6p terminus.
In addition to these findings, Davies reported the case of a patient with a 6p 
interstitial deletion that was at least 1200kb proximal of Foxcl [195], and contained 
neither the FOXC1 or FOXF2 genes. This data suggests that if Foxf2 is a glaucoma 
locus there may also be a third locus in the 6p25 region, although as Kleinjan 
suggests, the expression of Foxcl may have been altered in this case by the 
disruption of a regulatory element [196].
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1.17 FOXF2 Associated Glaucoma?
Cheryl Gregory-Evans, Helena Vieira and colleagues identified a poly-glycine 
expansion in the FOXF2 gene of a family o f glaucoma sufferers [155]. A 3bp 
insertion mutation (Gly302-306ins3bp) in the second sub-region o f the AD2 
transactivation domain o f FOXF2, has been implicated in a glaucoma which was 
present in six generations of a family [155] who develop symptoms in their 5th to 6th 
decade (C. Gregory Evans, personal communication). Glaucoma is an eye disorder 
which is characterised by damage to the optic nerve and retinal nerve fibres as a 
result o f an increased intraocular pressure.
Pilocarpines are commonly used as a topical treatment for glaucoma [197], they can 
be used to stimulate the ciliary muscle to increase fluid drainage thereby reducing 
pressure in the eye, thus preventing optic nerve damage. However, individuals that 
harbour the FOXF2 mutation do not respond to pilocarpine treatment (C. Gregory 
Evans, personal communication) - implying that there may be a ciliary muscle 
abnormality.
The family also suffer from iris hypoplasia which involves thinning and patchiness 
o f the iris stroma, (see figure 1.4). In combination, these symptoms would suggest 
generic problems with the development o f the anterior segment o f the eye.
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F i g u r e  1 . 4 :  T r a n s i l l u m i n a t i o n  D e f e c t  o f  t h e  h u m a n  e y e
(supplied by C. Gregory-Evans): A healthy human eye has an outwardly visible thick, white iris 
stroma, whereas the stroma o f the affected patient is thinned and patchy.
Foxf2 heterozygous knockout mice exhibited anterior chamber anomalies that 
shared many properties with human irido-goniodysgenesis [155]. These included a 
narrowing of the irido-comeal angle and defects in the trabecular meshwork and 
canal of Schlemm. This is a phenotype resulting from the aberrant migration of the 
neural crest cells that form the anterior segment of the eye [190].
Foxf2 was shown to be expressed in the neural crest cells in this region (figure 1.5). 
Each structure which is involved with fluid drainage from the eye is formed by these 
neural crest cells and therefore any defect in their migration is likely to impact upon 
the drainage of aqueous humour and thus also on intraocular pressure.
t*
F i g u r e  1 . 5 :  P e r i o c u l a r  m e s e n c h y m e  i n  a  m o u s e  e y e  a t  E 1 2 . 5
An in-situ o f Foxf2 in mouse eye development at E12.5. Purple staining is located at the level o f the 
periocular mesenchyme (that contains migrating neural crest cells). Cells migrate forward in the 
direction of the arrow, (in-situ hybridisations performed by, and picture supplied by H. Vieira & C. 
Gregory-Evans)
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Genes that contribute to ocular anterior segment dysgenesis (ASD)[193] often either 
effect the activity or migration of neural crest cells or they have roles in the 
developing lens. Lens genes are thought to contribute to ASD because the lens 
controls many of the processes required during the formation of the anterior 
segment[198,199]
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1.18 Aims of the Project
The initial aim of this project was to facilitate the sequencing of the Del36H region 
by fine mapping, and to contribute towards the characterisation of the region’s 
genes. The most immediate benefit of constructing a fine map of the Del36H region 
was the accuracy with which it could subsequently be used for positional cloning of 
mutations from the lethal recessive screen -  an experiment for the functional 
characterisation of the genes in the region.
Regional phenotype screens are designed to uncover novel mutations within known 
chromosomal rearrangement intervals, eliminating the requirement for a preliminary 
mapping stage following confirmation of the existence of a mutation. However, 
Del36H is large at 12.7Mb and gene rich (~200 genes), so mutations that are 
discovered will require further localisation before the sequencing of candidate genes 
can begin. In order to facilitate this process, the region will need to be searched for 
novel polymorphic markers. These are then to be utilised to genotype recombinant 
individuals arising from the screen.
One of the most striking overlaps between the phenotype of the Del36H mouse and 
patients presenting with 6p deletion syndromes are the Axenfeld-Rieger anomalies 
and the equivalent mouse eye defects. FOXC1 is a known locus for Axenfeld-Rieger 
anomaly in humans and anterior eye defects in mice [81,200] but various studies 
reported another potential locus in 6p25 [80,131]. The Del36H mouse presents an 
ideal opportunity to study this phenotype in greater detail.
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The potential involvement of another gene that is physically close and closely 
related to FOXC1 has recently been highlighted: H. Vieira and C. Gregory-Evans 
discovered a FOXF2 poly glycine expansion in a family of glaucoma sufferers [155]. 
This has provided the incentive to undergo a search for novel mutant alleles of Foxf2 
in the Harwell ENU mouse mutagenesis archives [201, 202]. Mouse mutant carriers 
of a Foxf2 mutation with a glaucomatous phenotype would provide strong 
supporting evidence to further implicate FOXF2 as a key genetic factor in heritable 
glaucoma.
A wide range of organs and tissues are affected by the 6p deletion syndromes, and 
Forkhead genes are often highly pleiotropic. There is therefore an incentive to 
thoroughly examine as many potential phenotypes of Foxf2 mutants as possible. The 
use of a broad phenotyping platform for the analysis of physiological, behavioural 
and metabolic abnormalities is necessary to achieve this goal.
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Antibodies
Anti-Digoxigenin-AP Fab fragments (Roche)
Anti-Rabbit IgG (whole molecule)-Peroxidase (Sigma)
FOXF2 Antibody 1: Rabbit Anti-Human FOXF2 Polyclonal Antibody. 5mg/ml. 
(Abeam®)
FOXF2 Antibody 2: Mouse Anti-Human FOXF2 Polyclonal Antibody, 
Unconjugated serum (Abnova® Corporation)
2.1.2 Competent Cells
XLl-Blue Supercompetent Cells (Stratagene)
JM109 competent cells (Stratagene)
2.1.3 Enzymes
Amplitaq Gold™ - 2.5u/pl - (Applied Biosystems)
BigDye ® v3.1 (Applied Biosystems)
DNA Polymerase I, Large (Klenow) Fragment -  5000u/ml - (New England 
Biolabs)
Klenow -  lu/pl -  (Amersham Life Sciences)
Pfu Turbo® DNA Polymerase -  2.5u/pl - (Stratagene)
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Positive Control Placental Alkaline Phosphatase (BD Biosciences)
O.lmg/ml
Thermoprime Plus DNA Polymerase 2.5u/pl - (ABgene)
Restriction enzymes. All restriction enzymes were purchased from New England 
Biolabs:
Sfc I, Bsr I, Dde I, SnaB I, Mlu I, Bgl II, Hind III, Kpn I, Dpn I, Sal I, 
Xba I, BamHI 
Sensiscript™ (Qiagen)
Superscript™ (GibcoBRL)
T4 DNA Ligase - 400u/ml (New England Biolabs)
2.1.4 Film
Hyperfilm ECL Chemiluminescence Film (Amersham Biosciences)
Scientific Imaging Film (Kodak)
2.1.5 Kits
DC Protein Assay kit (Bio-Rad)
DIG DNA Labelling Kit (Roche)
DIG Wash and Block Buffer Set (Roche)
DNeasy® 96 Tissue Kit (Qiagen)
ECL™ Western Blotting Analysis System (GE Healthcare)
EndoFree® Plasmid Maxi kit (Qiagen)
Great EscApe™ SEAP Detection Kit (BD Biosciences)
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MightyLight™ RIuc Assay Kit (Novagen, Merck)
Multiplex PCR Kit (Qiagen)
Nucbuster Protein Extraction kit (Novagen, Merck)
Proteoextract™ Subcellular Proteome Extraction kit (Calbiochem)
Qiaquick® Gel extraction kit (Qiagen)
Qiaquick® PCR purification kit (Qiagen)
Wizard® Plus SV Miniprep (Promega)
2.1.6 Membranes
Hybond N+ (GE Healthcare)
0.45 pm nitrocellulose/Filter Paper Sandwich (Invitrogen)
2.1.7 Plasmids 
pE G FP-C l (Clontech)
pEVRFO & FOXF2(Gly302-306ins3bp) insert. A mutant FOXF2 (Gly302- 
306ins3bp) expression construct was supplied by Cheryl Gregory Evans. This was 
initially constructed by Marika Hellqvist and co-workers [203] who inserted a 
truncated FOXF2 cDNA sequence (missing 39 amino acids from the 5’ end) into a 
pEVRFO plasmid [204]. The Gly302-306 insertion was induced with site directed 
mutagenesis by H.Vieira [155].
pGEM-T Easy (supplied with the pGEM-T Easy Cloning System, Promega) 
pIRES2-EGFP (Clontech)
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pMLuc-3 CMV Positive Control (Merck -  Novagen) 
pTAL-SEAP (Clontech).
2.1.8 Radiolabelled nucleotides 
[ot-32P]-dCTP (Amersham)
2.1.9 Stock DNA
lkb DNA size marker ladder (GibcoBRL)
lOOng/ jj.1. In ration of 1:4 0rangeG:dH20 
Lambda DNA at 500jag/ml (New England Biolabs) 
Mouse Cotl DNA - 1 mg/ml - (Invitrogen)
Salmon Sperm DNA (lOmg/ml)
2.1.10 Precast Gels
Criterion™ Precast Gel. 5%TBE. (Biorad)
NativePAGE™ Precast Gel. 4-16% Bis-Tris (Invitrogen) 
NuPAGE™ Precast Gel. 4-16% Bis-Tris (Invitrogen)
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2.1.11 Solutions
Laboratory grade reagents and distilled water (dH20) were used to make up 
solutions. Autoclaving of these solutions, where stated, was carried out at a 
temperature of 120°C and a pressure of 38 PSI for 20 minutes.
Acetonitrile (Fisher)
Ampicillin Stock
50mg/ml ampicillin (sodium salt, Sigma). -20°C 
Betaine (Sigma)
5M stock
BigDye Reaction buffer (5X) (Applied Biosystems)
400mM Tris-HCl; pH9.0, lOmM MgCl2 
BSA (100X ) (New England Biolabs) 
lOmg/ml
Buffer IV (ABgene)
Chloramphenicol Stock
34mg/ml chloramphenicol dissolved in EtOH. -20°C.
Church-Gilbert Hybridisation Solution
ImM EDTA, 500mMNa2HP04 (pH 7.2), 7% (w/v) SDS, 1% (w/v) BSA 
Cryopreservation Media 
10%DMSO in Foetal Bovine Serum 
CSPD Chemiluminescent substrate (Roche)
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Deoxyribonucleotide Triphosphates (10X)
2.5mM dATP, dCTP, dGTP, dTTP (Boehringer Mannheim and Biogene). Stored at 
4°C
DEPC H20
0.1% (v/v) Diethyl pyrocarbonate (DEPC) in dH20
lml DEPC in 11 ddH20. Parafilm on lid and incubated lhr @ 37°C -  then
autoclaved.
Dimethyl sulphoxide (Sigma)
EMSA Binding buffer (4X)
400 mM KC1, 80 mM HEPES, 2 mM DTT, 0.8 mM EDTA, 80% glycerol, pH 8. 
HotstarTaq reaction buffer (10X) (Qiagen)-15mM MgCl2, KC1, Tris-HCl, 
(NH4)2S04; pH8.7
Dulbecco’s minimal essential medium (DMEM)
IX DMEM + Glutamax with 4.5g/l glucose, without pyruvate (Gibco).
Dulbecco's Phosphate Buffered Saline (DPBS)
1XDPBS (Gibco)
EDTA (Ethylenediaminetetra-acetic acid)
0.5M EDTA at pH8.0. Autoclaved.
Ethidium bromide 
lOmg/ml. 4°C in dark.
Foetal Bovine Serum (Gibco)
Glycerol (80%)
Genejuice® (Novagen)
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Growth Media for Cell Culture
10% Foetal Bovine Serum (FBS) & 1% Penicillin-Streptomycin solution in DMEM 
Hepes buffer (5X) 
lOOmM Hepes (Sigma)
HepG2 (Abeam®)
Human hepatocellular liver carcinoma cell line whole cell lysate 
Hi-Di™ Formamide (Applied Biosystems)
Isopropylthiogalactosidase (IPTG)
24mg/ml. Filter sterilized. 4°C 
Karnovsky fixative (50%)
2.5% glutaraldehyde, 2% paraformaldehyde, 0.05M sodium cacodylate (pH 7.4) 
Loading buffer 6X (Merck -  Novagen)
Loading buffer for Gel based sequencing
5:1 deionised formamide: 25mM EDTA with 50mg/ml blue dextran. -20°C 
Loading buffer for SSCP Gel Electrophoresis
95% (v/v) formamide, lOmM EDTA (pH7.5), l%bromophenol blue, 1% (w/v) 
xylene cyanole.
Luria’s Broth (LB) and LB agar mix
10g/l Bacto-tryptone, 5g/l Bacto yeast extract, 5g/l Sodium chloride (Difco 
Laboratories Ltd)
For LB agar mix: 1.5% agar was added (Difco Laboratories Ltd). 4°C
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Magnesium Chloride
MgCl2 (Applied Biosystems)
25mM at -20°C
Neutral Buffered Formaldehyde 10% (Surgipath Europe Ltd)
Formaldehyde 3.8 -  4.0% (w/v) [205]
NZY+ broth
10g/l NZ amine (casein hydrolysate), 5g/l yeast extract, 5g/l NaCl. pH 7.5. 
Autoclaved. Filter sterilised additives: 12.5ml of 1M MgCl2, 12.5ml of 1M MgSC>4, 
and 20ml of 20% (w/v) glucose.
Orange G: Loading buffer for agarose electrophoresis.
0.25mg/ml Orange G (sigma) in 30% (v/v) glycerol 
PCR Reaction buffer II (Applied Biosystems)
Penicillin -  Streptomycin solution -10,000u/ml penicillin & lOmg/ml streptomycin 
in 0.9% NaCl (Sigma)
Pfu DNA polymerase reaction buffer (Stratagene)
Phospate Buffered Saline (PBS)
0.8% (w/v) NaCl, 0.02% (w/v) KC1, 0.115%(w/v) Na2HP04, 0.02% (w/v) KH2P04. 
Autoclaved
Phospate Buffered Saline -  Tween (PBS-T)
0.8% (w/v) NaCl, 0.02% (w/v) KC1, 0.115%(w/v) Na2HP04, 0.02% (w/v) KH2P 04. 
Autoclaved. 0.1% Tween.
Paraformaldehyde (Sigma)
(4%) in PBS or DPBS
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Proteinase K (Sigma)
lOmg/ml in lOmM CaCl2. -20°C 
Q Solution (Qiagen)
Restore™ Western blot stripping buffer (Pierce)
RT Buffer (Invitrogen)
200 mM Tris-HCl, pH 8.4, 500 mM KC1 
Sodium Acetate
3M NaOAc (pH5.2. adjusted with glacial acetic acid)
Sodium Dodecyl Sulphate (SDS) -  (stock)
10% (w/v) in H20
Standard Saline Citrate (SSC) -  (20Xstock)
3M NaCl, 0.3MNa3citrate.2H2O (pH7.0 adjusted with 1MHC1) 
Tail Buffer
500mM Tris Buffer, lOOmM EDTA, lOOmMNaCl,, 1% (w/v) SDS 
Tris-acetate EDTA Electrophoresis buffer (TAE)
40mM Tris-acetate, ImM disodium EDTA (pH8.0)
Tris-borate EDTA Electrophoresis buffer (TBE)
89mM Tris, 89mM boric acid, 2mM EDTA 
Tris Buffered Saline -  Tween (TBS)
0.8% (w/v) N aCl, 0.02M Tris HC1 (pH 7.6).
Tris Buffered Saline -  Tween (TBS-T)
0.8% (w/v) N aCl, 0.02M Tris HC1, 0.1% Tween (pH 7.6).
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Tris EDTA (TE)
lOmM Tris-HCl(pH8.0), ImM EDTA. Autoclaved.
Triethylammonium acetate (TEAA) - (Transgenomics)
Tris-HCl
Stock solutions of 1M Tris base in dTEO. Adjusted to desired pH with HC1. 
Autoclaved.
Trypsin Solution (Gibco-BRL)
(2.5%)
Vectashield® Mounting Medium with DAPI (Vector Laboratories) 
Wave buffer A
0.1M Triethylammonium acetate (TEAA)
Wave buffer B
0.1M TEAA, 25% Acetonitrile
Wave buffer C
4.5% Acetonitrile
Wave buffer D
75% Acetonitrile
X-Gal
40mg/ml 5-bromo-4-chloro-3-indolyl-P-D-galactosidase (X-Gal) made in 
dimethylformamide (DMF). -20°C. Kept in the dark.
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2.2 Methods
2.2.1 Plasmid Preparation using the Promega Wizard Plus SV Miniprep
6 ml of LB supplemented with lOOpg/ml ampicillin, was inoculated with the 
bacterial plasmid, and incubated overnight at 37°C. Glycerol stocks were then 
prepared for each culture by adding 250 pi of 80% Glycerol to 750 pi of culture, 
then mixing and storing the stock at -70°C. The remaining culture was then used for 
extraction of the plasmid as described by the manufacturer. DNA was stored at - 
20°C
2.2.2 Preparation of Mouse Genomic DNA 
Method 1: For DNA extraction from tail tips and whole organs
The tail tip was cut 1cm from the end and added to 400 pi Tail buffer. 5-15pl of 
proteinase K solution (lOmg/ml) was added to the sample. The amount of proteinase 
K added depended on the thickness of the tissue to be digested. Samples were 
shaken vigorously overnight at 55°C.
After the overnight digestion, 200pl saturated NaCl was added to each sample. The 
mixture was then gently inverted until it became homogeneously viscous and white. 
Samples were then centrifuged for 20 minutes at 10,000g. 400pl of supernatant was 
transferred into a fresh microfuge tube and added to 800pl 95% Ethanol. The tube 
was then inverted ten times before centrifuging at 10,000g for 1 minute. The 
supernatant was removed by pipette and lOOpl 70% ethanol was added to the pellet.
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The tube was re-centrifuged at 10,000g for 1 minute and the supernatant removed by 
pipette before allowing the pellets to air dry at 25°C for 30 minutes. DNA was 
resuspended in ddFbO and quantified as described in 2.2.3. DNA samples were 
stored at 4°C until used, then archived at -20°C.
Method 2: For DNA extraction from ear-clips and toe-clips and embryonic tail 
tips
The tissue was added to 500 pi Tail buffer. 2.5pl of proteinase K solution (lOmg/ml) 
was added and samples were shaken vigorously overnight at 55°C. Following 
digestion, the sample was inverted repeatedly until it became a homogenous 
mixture, then centrifuged at 10,000g for 2 minutes. The supernatant was then 
transferred to a clean microfuge tube, and 500 pi isopropanol was added and mixed 
with the sample by repeated inversion. The sample was then centrifuged for 10 
minutes at 10,000g.
The supernatant was then removed by pipette, before allowing the pellets to air dry 
at 25°C for 30 minutes. DNA was resuspended in dT^O and quantified as described 
in 2.2.3. DNA samples were stored at 4°C for use within 3 months, then archived at - 
20°C
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2.2.3 Quantification of DNA Concentration 
Spectrophotometry
DNA concentrations for low numbers of samples (fewer than 10), were determined 
by spectrophotometry using a Beckman DU640B spectrophotometer. DNA samples 
were added to water in UV cuvettes, mixed by pipetting, and placed in the 
spectrophotometer. Absorption was measured at 260nm and 280nm. Samples with a 
260/280nm ratio below 1.8 potentially contained impurities in the solution so were 
repurified. The concentration of DNA was calculated using the absorption 
coefficient of 1 OD26o=50pg/ml of double stranded DNA.
For high numbers of samples (10 or more), a Spectramax 190 spectrophotometer 
(Molecular Devices) was used to measure DNA concentrations. DNA samples were 
diluted with dF^O and mixed in 96-well, clear flat-bottomed plates (Coming). 
Analysis was carried out using SOFTmax® PRO 3.0 alias software (Molecular 
Devices), as described in the manufacturers instructions. Absorption was measured 
at 260nm and 280nm, impurity levels were calculated as with the Beckman DU640B 
spectrophotometer.
2.2.4 Oligonucleotide Primer Design and Synthesis
Oligonucleotide primers were designed using the Primer3 programme at the 
Whitehead institute website (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi), or through the local network. Primers for routine 
PCR were designed with a GC content of between 30 and 70%. Repeat sequences
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and single base runs of more than 4 bases in length were avoided. Most primers were 
approximately 20bp in length, with annealing temperatures of at least 50°C.
Oligonucleotide primers were either ordered from external sources (MWG-Biotech, 
Genset, Sigma-Genosys), or were synthesized in house (by J.King) on a Beckman 
Oligo 1000M DNA synthesizer. Following Oligonucleotide synthesis, the base- and 
phosphorous protecting groups were removed to ensure the oligonucleotide was 
biologically active. The ultrafast Cleavage and Deprotection kit (Beckman) was used 
for the purpose, following the manufacturers instructions. Oligonucleotides were 
then passed through a NAP-5 column, and eluted in 1ml dF^O. The concentration 
was determined by measuring the absorbency of a diluted aliquot at 260nm on a 
spectrophotometer, and assuming that for single stranded oligonucleotides, 10D unit 
is equivalent to 20 pg/ml.
2.2.5 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) was developed by Kary Mullis [206] and is 
used to exponentially replicate DNA at regions of interest. This process involves 
alternating temperatures to allow DNA melting, primer annealing, and DNA 
polymerase facilitated elongation of a novel complementary strand formed from 
dNTPs (Deoxynucleoside triphosphates).
PCR was performed on a MJ Research PTC-225 DNA engine tetrad thermo-cycler. 
They ranged from 10-100 pi in volume and were carried out in microtitre plates.
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Each individual PCR contained 1 X PCR buffer, 0.2uM of each primer, 0.2-0.25mM 
dNTPs, 0.2-1 unit(s) of taq5 and 5-50ng of template DNA. The yield of some 
reactions increased with the addition of either betaine ( at a final concentration of 
1M-1.5M), or Qiagen’s Q solution (at a final percentage of 10% (v/v)). The plates 
were sealed with Easy Peel (ABgene), and placed on the thermocycler. One of the 
following programmes were then used, with the heated lid switched on:
Conditions for PCR were as follows: 200 uM dNTPs, 2.5mM MgC12, 0.2uM 
forward and reverse primer, 0.45 U Applied Biosystems AmpliTaq Gold, and 0.025 
U Pfu Turbo polymerase and IX Ampli Taq Gold buffer. Reaction volumes were 
prepared in bulk and transferred into individual 96-well microtitre plate wells 
containing DNA pools (final volume 25-50 pi).
Programme 1 Standard PCR
(Genetic mapping, PCR screening, RT-PCR, multiplex PCR) with ABgene taq 
95°C (15 minutes)1
35 cycles of 95°C (30 seconds), 55°C2 (35 seconds), 72°C (45 seconds3)
75°C (5 minutes)
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Programme 2 Touchdown PCR
(PCR screening, Novel Marker Detection) with Hotstar taq, taq gold or Pfu Turbo 
polymerase.
95°C (15 minutes)1
9 cycles of 95°C (05 seconds), 55°C2 (20 seconds) with a decrease of 1°C per 
cycle,72°C (45 seconds3)
35 cycles of 95°C (05 seconds), 55°C2 (20 seconds), 72°C (45 seconds3)
Programme 3 DHPLC PCR
(Amplification of products for DHPLC analysis) with 0.45 U Taq Gold, 0.025 U Pfu 
Turbo polymerase and IX Ampli Taq Gold buffer:
95°C (10 minutes)1
13 cycles of 94°C (20 seconds), 67°C4 (1 minute) - with a decrease of 0.5°C 
per cycle, 72°C(1 minute)
19 cycles of 94°C for 20 sec, 60°C2 (1 minute), 72°C (1 minute)
72°C (5 minutes)
15°C hold.
Following amplification, heteroduplexes were formed with the following cycle 
conditions:
95°C for 4 min
45 cycles of 93.5°C for 1 min with a reduction of 1.5°C per cycle 
25°C hold.
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Programme 4 Site Directed Mutagenesis
(Mutagenesis of plasmids at specified loci) with Pfu Turbo polymerase.
95°C (3 minutes)1
12-16 cycles of 95°C (30 seconds),
58°C2 (1 minute),
72°C (6 minutes and 30 seconds3)
'HotStarTaq, AmpliTaq gold and Pfu Turbo DNA polymerases require an activation step. 2The 
annealing temperature was changed depending on the Tm o f the primers used in the reaction (ranging 
between 55 and 68°C). 3The extension time was changed depending on the expected size o f PCR 
product (ranging from 10 seconds to 2 minutes).4The initial annealing temperature for DHPLC 
product amplification should be 7°C higher than the annealing temperature for the second round of 
cycles.5DHPLC PCRs contained 0.45 U Applied Biosystems AmpliTaq Gold, and 0.025 U Pfu Turbo 
polymerase with IX Ampli Taq Gold buffer
2.2.6 PCR Product purification
Primers, nucleotides, polymerases and salts were removed from PCR products, when 
necessary, using a Qiagen Qiaquick PCR purification kit. The DNA was eluted by 
adding 30 pi of dt^O to the centre of the column and leaving to stand for 5 minutes 
before centrifuging the sample at 10,000g for 5 minutes. DNA concentration was 
determined as described in section 2.2.3.
2.2.7 Agarose Gel Electrophoresis of Nucleic Acids
Agarose gel electrophoresis was used to fractionate DNA using 1 X TBE buffer. 
PCR products were analysed on 0.8% - 2% agarose, depending on their size.
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Agarose was added to IX TAE buffer and heated in a microwave until boiling, this 
was then mixed and allowed to cool before adding 0.5 pg/ml ethidium bromide. The 
molten agarose was set in a gel plate with a 16 or 20-tooth comb on a flat surface.
The gel was immersed in 1XTAE buffer; 0.5pg/ml ethidium bromide in an 
electrophoresis tank and the DNA samples, containing Orange G dye loaded into the 
wells, lkb DNA ladder (Gibco-BRL) was used as a size standard.
Gels were electrophoresed at 50-150 V. The products were visualised under ultra­
violet light (312nm) and photographed using Alphalmager2000 software for the 
visualisation of BAC DNA and novel marker detection, or Alphalmager2200v5.5 for 
all subsequent gels.
2.2.8 Extraction of DNA from Agarose Gels
A scalpel was used to excise DNA fragments from agarose gels. These samples were 
weighed, and the DNA extracted with a Qiaquick Gel Extraction kit (Qiagen). The 
DNA was eluted by adding 30 pi of dH20  to the centre of the column and leaving to 
stand for 1 minutes before centrifuging the sample at 10,000g for 10 minutes. DNA 
was stored at -20°C.
2.2.9 Random Oligonucleotide Radiolabelling of DNA probes
A Megaprime labelling kit (Amersham) was used to label probes. Approximately 
50ng DNA, in a total volume of 25 pi, was heated at 95°C with 5 pi labelling 
primers (random nonamer primers in dH20). These were then placed immediately on
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ice for 5 minutes. The following constituents were then added: 10 pi labelling buffer 
(dATP, dGTP, dTTP in Tris/HCl pH 7.5; 2-mercaptoethanol and MgCk), and 2 pi (2 
units) Klenow polymerase and 30-50 pCi [a-32P]-dCTP (Amersham). The reaction 
mixture was incubated at 37°C for one hour.
Nick columns (Pharmacia) were used to separate unincorporated nucleotides from 
the radiolabelled probe. The volume of the probe was increased to 100 pi with 
dH20. After mixing, the probe was loaded onto a previously equilibrated Nick 
column (as described in the manufacturers instructions). Two volumes of 400pl 
dH2 0  were added to the centre of the column and collected in two separate tubes. 
The second tube contained the radiolabelled probe.
Overgo End-Fill Method
All overgos used in this project were designed by Matthew Cadman. Overgos are 
overlapping oligonucleotides which can be used to amplify short sequence 
fragments. The overgos made to probe the RPCI-23 library were designed from the 
flanking sequence of known dl3Mit STS markers.
A lOpl mixture of the forward and reverse overgos at lOpM were heated to 80°C for 
5 minutes, then at 37°C for 10 minutes. 2pl of this mixture was then added to lpl of 
klenow buffer, 3pl of a dA, dG and dT mixture (at lOOpM), 1 pi klenow (2u/pl), 2pl 
H20  and 1(.il dCTP-32P.
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The reagents were mixed and incubated at room temperature for 1 hour before 
stopping the reaction with lpl of 0.5M EDTA. The volume was made up to lOOpl 
with ddTEO then loaded onto previously equilibrated Nick columns (as described in 
the manufacturers instructions). Two volumes of 400pl dT^O were added to the 
centre of the column and collected in two separate tubes. The second tube contained 
the radiolabelled probe. The probe was then denatured at 95°C for 5 minutes, placed 
on ice for 5 minutes, then added to the hybridisation buffer. Hybridisation was 
carried out as described under “Hybridisation of probes”, but overgo probes were 
incubated overnight at 47°C and washed twice with 2XSSC/0.1%SDS for 15 
minutes.
Blocking of Repeats in Probe with Mouse Cot-1
Mouse Cot-1 DNA (Invitrogen) was concentrated from 1 mg/ml to lOmg/ml by 
ethanol precipitation. 25 pi lOmg/ml mouse Cot-1 DNA, 125 pi 20XSSC, and 5 pi 
20%SDS were added to 400pl purified probe. This mixture was then heated to 95°C 
for 5 minutes in order to denature the DNA, then incubated at 65°C for 20 minutes 
before commencing with hybridisation
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Hybridisation of Probes
BAC membranes were wetted with 0.2 X SSC before pre-hybridisation for 4-24 
hours with Church Gilbert buffer at 65°C in rotating Hybridisation tubes. Each tube 
contained up to 4 BAC membranes, each membrane separated by a layer of gauze. 
The prehybridisation solution was then discarded. The radiolabelled probe was 
denatured at 95°C for 5 minutes before adding it to 25-40ml of prewarmed Church- 
Gilbert solution at 65°C. This mix was then added to the tube containing the 
membrane(s) and hybridised at 65°C for 14-20 hours. After hybridisation, the 
membranes were washed at 2 X SSC/0.1% SDS. Following this step, wash 
conditions were specific to each probe. IXSSC/O.5% SDS and 0.5XSSC/0.5% SDS 
were used as necessary. Each wash was at 65°C for 30 minutes, the membranes were 
separated and incubated on shaking incubators when stringent washes were required. 
Membranes were wrapped in Saran wrap (Dow), and exposed to X-ray film in 
cassettes with intensifying screens at -70°C, from 5 hours to 1 week. The X-ray film 
was fixed and developed using the X-ograph Compact X4.
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Genomic Library Screening by Hybridisation
2.2.10 RPCI23 Mouse BAC library.
The RPCI23 BAC library was constructed by K. Osoegawa, M. Tateno and P. de 
Jong (Roswell Park Cancer Institute, Buffalo), and was provided by the MRC 
HGMP-RC for members of the Mouse sequencing consortium, kidney and/or brain 
genomic DNA was extracted from Female C57BL/6J mice, then partially digested 
with EcoRI and EcoRI methylase. DNA was cloned into the pBACe3.6 vector at the 
EcoRI sites after size selection, and the ligation product transformed into DH10B 
cells. Clones averaged approximately 197kb in size. Clones were gridded onto 
22.3cm2 Hybond-N+ membranes at a coverage of 18,864 clones in duplicate, per 
membrane. 10 membranes were used for the complete library of approximately 
170,000 clones, representing an 11.2-fold coverage of the mouse genome[207]
Primary Identification of Genomic Clones by Hybridisation.
STSs, cDNA probes and overgos and were used for genomic library screens. Pre­
hybridisation, hybridisation and washing temperatures were 65°C with cDNA 
probes, and 47°C with overgo probes.
Either random priming or the overgo end-fill method (section 2.2.9) were used to 
label the probes. Any repetitive elements within the probes were blocked with 
mouse Cot-1 DNA. Overgo probes were pooled in batches of up to eight probes
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together for genomic library screening. Hybridisation of the libraries was carried out 
as in section 2.2.9
Co-ordinates of positive clones were then determined according to the library 
manufacturers’ instructions. Positive clones were ordered from the HGMP-RC for 
further characterisation (i.e.: secondary hybridisation and BAC-end sequencing).
2.2.11 BAC DNA Vector storage
BAC clones could be stored for up to one month in a host bacterial strain, at 4°C on 
LB agar plates containing the appropriate antibiotic. They could be stored 
indefinitely in 15% (v/v) glycerol at -70°C.
2.2.12 Restriction Enzyme Digestion of DNA
Restriction enzymes were used to digest DNA according to the conditions 
recommended by the manufacturer. DNA was typically digested in IX restriction 
buffer and 1 enzyme unit/pg DNA (see table 2.1 for details of specific enzymes). 
Samples were incubated at the appropriate temperature for 1 to 16 hours before 
loading onto an agarose gel for electrophoresis as described in section 2.2.7.
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List of Restriction Endonucleases
Enzyme 5'-3' Restriction site Reaction
tem perature
(°C)
BSA? Buffer
Sfc I 5’-CAT Pu Py A G -3 ’ 37 Y NEB4
Bsr I 5’-A C T G G N A-3’ 65 N NEB3
Dde I 5’-CAT N  A G -3 ’ 37 N NEB3
SnaB I 5’-T A CAG T A 37 Y NEB4
M lu l 5’-AAC G C G T 37 N NEB3
Bgl II 5’-AAG A T C T 37 N NEB3
Hind III 5’-AAA G C T T 37 N NEB2
K pnl 5’-G G T A CAC 37 Y NEB2
Dpn I 5’-G A*AT C-3’ 37 N -
S ail 5’-GAT C G  A C -3 ’ 37 Y NEB3
X bal 5’-TAC T A G  A-3’ 37 Y NEB2
Bam HI 5’-GAGATCC -3’ 37 Y NEB3
* = Methy ated base only
A = Position o f cut on 5’-3’ strand 
Table 2.1: Restriction Enzymes used.
Xbal and BamHI were used for double digests as were Bglll and M lul and the enzymes H indlll and 
KpnI. All enzymes in double digests were in buffers that allowed 100% efficiency, with the exception 
o f Kpnl which is 75% efficient in NEB2. Dpnl was added directly to site directed mutagenesis PCR 
mixtures, following amplification o f  the respective target vectors.
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2.2.13 Single Stranded Conformational Polymorphism (SSCP) Assays 
Based on a method previously described [208]. SSCP gels were made using the 
following reagents: 1XTBE, 18% (v/v) acrylamide, 0.5% (v/v) bisacrylamide, 0.12% 
(w/v) ammonium persulfate (APS), 0.0004% TEMED (NNN’N* 
Tetramethylethyldiamine). Two glass gel plates, with spacers separating each pane, 
were aligned and gel mix was poured between them. A comb of 50 or 100 wells was 
inserted, and left for 1 hour at room temperature. Once set, the gel was clamped to a 
vertical electrophoresis tank containing 1XTBE buffer. DNA samples, containing
4 pi SSCP loading dye, were denatured at 95°C for 5 minutes, and placed 
immediately on ice. The samples were loaded into the wells. Electrophoresis was 
carried out at 36-38V for 8-16 hours at 4°C.
Following electrophoresis, the gel was removed from between the plates and placed 
in 10% ethanol, 0.5% acetic acid for 5 minutes, to fix the DNA. The gel was then 
stained with 0.1% (w/v) silver nitrate for 15 minutes. The gel was rinsed with dT^O, 
and then developed in 1.5% (w/v) sodium hydroxide, 0.12% (v/v) formaldehyde 
until the bands were visible.
2.2.14 Novel Polymorphic marker Identification 
DNA Preparation for Novel Marker Identification
Tail tips of 0.2-0.5mm were removed from mice of the following inbred strains:
B ALB/c, C3H/HeH, 101, C57BL/6, 3H1 (a C3H /101 mosaic strain), Satin mice
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(Foxql hair colour mutants on a 3H1 background). Tails were also taken from 
CAST/Ei and SPRET/Ei mice. DNA was extracted from this tissue as described in 
section 2.2.2.
Novel Microsatellite Identification
Sequence from individual clones were analysed by Joseph Weekes, Ann-Marie 
Mallon and Richard McKeone, using RepeatMasker (A.F.A. Smit and P. Green, 
unpubl.) (http://repeatmasker.genome.washington.edu/), to mask repeats from the 
sequence. The associated output file was then used to identify the positions of 
microsatellites (dinucleotides, trinucleotides, tetranucleotides and pentanucleotides). 
The microsatellite sequence and flanking regions were then screened with ePCR 
(http://www.ncbi.nlm.nih.gov/sutils/e-pcr/) to determine whether microsatellites at 
these loci had previously been identified and tested. If a sequence was not 
recognised by the database, primers were designed using sequence that flanked the 
microsatellite.
These primers were then used to amplify the microsatellite regions from the DNA of 
each o f the mouse strains previously described, as described in section 2.2.5. 
Amplified DNA was then loaded onto agarose gels as described in section 2.2.7 and 
SSCP gels as described in section 2.2.13, and the band patterns were analysed for 
polymorhisms between strains.
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Novel SNP Identification
Sequence from individual clones was analysed using PIPmaker 
(http://pipmaker.bx.psu.edu/pipmaker/) and also RepeatMasker. Regions within the 
deleted interval, with low sequence identity between mouse and rat and without 
repeats, were selected at random for SNP discovery. The selected sequences were 
used to design primers as described in section 2.2.4.
These primers were then used to amplify the selected regions from the DNA of each 
of the mouse strains previously described. Amplified DNA was loaded onto agarose 
gels (section 2.2.7) and SSCP gels. SSCP gels were prepared as described in section
2.2.13 with the following modifications to the protocol: Gels were prepared with and 
without 20mM Hepes incorporated into the gel mixture and buffer. Both types of gel 
were run at temperatures of 20°C and 4°C. This method has been previously 
described as improving the sensitivity of SSCP to conformational changes of DNA 
fragments [209].
2.2.15 Production of the Genotyping NED size standard
The NED size standard was produced in conjunction with Alison Hough, using the 
method of Lorraine Southam. Lambda DNA was added to a PCR that contained the 
forward primer and the appropriate reverse primer listed on table 2.3. Each PCR was 
carried out as described in section 2.2.5. Products above lOObp were gel purified as 
described in section 2.2.8. 30 pi of each purified product was then added to 60 pi of 
each unpurified product and 280 pi ddH2 0 .
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Primers Used In The Production Of The NED Labelled Genotyping Size 
Standard
Primer Direction
Product
Size Primer Sequence
70bp 5-GTG AGA GAT AGA CTT TCT CCG TG
80bp 5-CCC GGA ATT TGT GAG AGATA
90bp 5'-GTT TAC CAG TCC CGG AAT TT
lOObp 5’-ACA GCG CCA TGT TTA CCA G-3’
120bp 5’-GGA AAC AAT CGG CGA AAC GTA-3’
140bp 5’-CGG GAA CGG ATA ACC TCA C-3’
160bp 5’-ATT CAG AGG TGG AGC CGC-3’
180bp 5’-CTT GAC ATA TCC CGG CGT A-3’
Unlabelled 
REVERSE primer 
(20pmol/pl)
190bp 5’-CAT GCT TCG GCT TGA CAT AT-3’
200bp 5’-GGA TTC ACT TCA TGC TTC GG-3’
220bp 5’-GGC GAC GCA GGG TCA TCT G-3’
235bp 5’-GAT CTT CAT CCG GCA GGC-3’
260bp 5’-TAA GCC GGG TCC GCC AGA-3’
281bp 5’-ATG ATG ATG CGA CGG CGG-3’
300bp 5’-TTC GTC ACG CAT GTT CTG CAT-3’
320bp 5’-ACC TGA GCA ATG GCC AGC-3’
340bp 5’-AAA CTG CCT GCA TCT CTT CG-3’
360bp 5’-TTT GCC CTT AAG CAC GGC-3’
380bp 5’-GCT TCA CCG GTC ATG GTG-3’
400bp 5’-CCA CCT CAA CCG GAT CGA-3’
NED labelled 
FORWARD primer 
(17.7 pmol/pl)
- 5’-GAT CCG CTG TTT CTG CTG-3’
T a b l e  2 . 2  P r i m e r s  u s e d  f o r  t h e  N E D  s i z e  s t a n d a r d  u s e d  f o r  g e n o t y p i n g
Primers for the amplification of Lambda DNA that were used to produce a NED labelled size 
standard for genotyping
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2.2.16 Genotyping
PCR products that demonstrated polymorphism between the test strains in section
2.2.14 were selected and sized by Ghazala Mirza of the Wellcome Trust Centre for 
Human Genetics. ROX, HEX and FAM Fluorescent dye labels were selected for 
these primer pairs by Ghazala Mirza, and products of a similar size (alleles with a 
size difference of less than 20bp) were labelled with different dyes in order to 
differentiate the products on analysis.
Tail tips of 0.2-0.5mm were removed from mice, by an animal technician in 
accordance with home office regulations. Tissue was stored at -20°C until processed. 
The DNA was extracted using a DNeasy® 96 Tissue Kit (Qiagen), using the 
protocol described by the manufacturer. Extracted DNA was then quantified using 
the Spectramax 190 spectrophotometer as described in section 2.2.3. DNA was 
diluted to give a working stock of 5ng/pl.
Amplification of pooled products for genotyping was carried out by PCR using 
Multiplex PCR kits (Qiagen) with an MJ Research PTC-225 DNA engine tetrad 
thermo-cycler. Reactions were carried out in microtiter plates in volumes of 12-15 
pi. Each reaction contained 6pl of multiplex mastermix, 2-6 primer pairs (forward 
and reverse primers) at individual concentrations of 0.15 - 0.25 pmol/pl), and 
10%(v/v) Q solution when amplifying primer sets which showed improved PCR 
efficiency in its presence.
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Each plate of reactions was pooled in the following ratio: ROX products: 4 jj.1; HEX 
products: 3 pi; FAM products: 0.8 -  1.5 pi. 1 pi of this pooled mix was then added 
to 10 pi of formamide: NED size standard mix (50pl NED size standard - as shown 
in figure 2.2, in lOOOpl formamide). The pooled samples were then loaded onto an 
ABI Prism 3130XL Genetic Analyzer (Applied Biosystems) according to the 
manufacturers instructions, using dye set D. Genescan® Analysis software version
3.1 (Applied Biosystems) was used for analysis of the raw data and calculation of 
the peak sizes for each dye used. This data was then downloaded into Genotyper 
(Applied Biosystems), which was set to identify specific alleles from peak size 
information.
Allelic size determination was repeated at Harwell and appropriate adjustments were 
made to the primer sequence in order to differentiate the products with the available 
equipment.
Dye
colour
Marker 
multiplex pool
Number
of
products
Volume added to 
Final Pool (pi)
Green
HexA 4 3
HexB 2 3
Blue
FAMA 4 1.5
FAMB 4 0.8
Red R O X 2 4
T a b l e  2 . 3  D y e  l a b e l s  a n d  v o l u m e s  u s e d
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2.2.17 Ligation
When non-complementary sticky-ends underwent ligation, an initial end-filling 
stage was required before ligation could commence. DNA Polymerase I (Klenow) 
was added to the DNA, in the presence of 33 uM dNTPs and IX NEB buffer2. 
Klenow was added at a concentration of lu/pg of DNA. The reaction mixture was 
incubated at 25°C for 15 minutes, and stopped by the addition of EDTA to a final 
concentration of lOmM, and heating at 75°C for 20 minutes. End-filled products 
were then purified as described in section 2.2.6 or 2.2.7.
Ligations using T4 DNA ligase were performed in order to anneal blunt ends and 
sticky ends with their respective complementary sticky ends. In addition to the 
subject DNA, reactions typically contained IX T4 DNA ligase buffer, and T4 DNA 
ligase in excess of 1 unit per 200 ng of template DNA. Reactions were incubated 
overnight at 16°C. Reactions were inactivated by heating the mix at 65°C for 10 
minutes, then stored at -20°C until required
2.2.18 Transformation 
Transformation using XL-1 blue supercompetent cells.
0.8 pi of p-mercaptoethanol was added to 50 pi of XL-1 blue supercompetent cells 
in an ice-cold sterile microfuge tube. The cells were then incubated on ice for 10 
minutes, gently flicking the tube every 2 minutes to mix the cells. 1-5 pi of the 
plasmid DNA or ligation reaction was then added to the cells, depending on 
concentration of the plasmid. The tube was mixed by gentle flicking before placing
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it on ice and incubating for 30 minutes, then heat-shocked for 45 seconds at 42°C. 
The sample was then immediately put on ice for 2 minutes, before adding 500pl 
NZY+ broth. The sample was shaken at 220rpm for 1 hour at 37°C. The reaction 
mix was then spread onto 2 LB plates containing lOOpg/ml ampicillin. These were 
incubated overnight at 37°C to grow visible colonies.
Confirmation of Transformants by Sequencing
Colonies were picked, using a sterile loop and prepared for wizard SV+ preparation 
as described in section 2.2.1. After completion of plasmid purification, plasmids 
were screened by restriction digestion (section 2.2.12) or sequencing (section 
2.2.19).
2.2.19 Sequencing
All sequencing was performed with the dideoxynucleotide chain-termination 
method [210]. This technique utilizes labelled dideoxynucleotide triphospates 
(ddNTPs), unlabelled deoxyribonucleoside triphosphates (dNTPs), DNA template, 
an oligonucleotide primer and klenow, a DNA polymerase enzyme. The ddNTP 
molecules cannot form a phosphodiester bond with adjacent deoxynucleotides and 
they therefore terminate DNA chain elongation during polymerisation of the 
unlabelled dNTPs. Fragments are formed that begin at the primer sequence and 
terminate at any one of the potential nucleotides downstream of the primer. Each of 
the nucleotides downstream of the primer are represented as terminating ddNTPs of
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differently sized fragments. Sequence is determined by analysis of the labelling 
signal produced by the terminating ddNTPs of size-ordered fragments.
The ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit was 
used to sequence all DNA templates using the appropriate primers.
Method 1
Template DNA was quantified by agarose gel electrophoresis (section 2.2.7) to 
determine the concentration and quality of the samples. Sequencing reactions were 
set up following the protocol of Dr. B. Roe, using one-twentieth the amount of ABI- 
recommended BigDye Terminator sequencing reaction mix
(http://www.genome.ou.edu/big_dyes_plasmid.html). BigDye terminator sequencing 
reaction mix was diluted 1:2 with 5 X BigDye reaction buffer. A master mix was 
made for the total number of samples, containing the following components for each 
reaction: 2 pi BigDye diluted mix, 1 pi 10 mM primer, lOOng template DNA (up to 
4 pi) in a 7 pi reaction volume, with the remaining volume made up with dfbO. 
Cycle sequencing was performed on a MJ Research PTC-225 DNA engine tetrad, 
using the following conditions:
100 cycles of 95°C (10 seconds); 50°C (5 seconds); 60°C (4 minutes)
The sequence reactions were purified to remove unincorporated dye terminators 
from the samples, which can interfere with base calling. To each sequence reaction,
1 pi sodium acetate (pH4.6) and 18 pi 100% ethanol were added, transferred to a 0.2
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ml tube and mixed by flicking the tube. The samples were placed on ice for 15 
minutes before centrifugation at 10,000g for 30 minutes. The supernatant was 
discarded and the pellet washed with 100 pi 70% ethanol, and centrifuged for 5 
minutes at 10,000g. The ethanol was removed and the pellet left to air dry for 5 
minutes. The pellet was resuspended in 2 pi of loading buffer for ABI sequencing 
reactions, and the sample stored at -20°C prior to loading on the gel.
- Preparation of Denaturing Polyacrylamide Gel
The gel apparatus was set up, with two 36cm plates placed in a manifold, separated 
by 0.2mm spacers. The gel mix was made up fresh each time, with the following 
reagents: 18g urea, 25ml MilliQ water and 5.7ml 19:1 40% acrylamide:bis- 
acrylamide (BIORAD). The mix was stirred with Amberlite resin for 5 minutes to 
dissolve the urea. The solution was then degassed for 15 minutes. 27ml of gel mix 
were added to 3ml 10 X TBE (BDH), to which 150 pi 10% APS and 21 pi TEMED 
were added and mixed gently. The solution was poured between the glass plates 
using a 50ml syringe, tapping the plates continuously to avoid trapping air bubbles. 
The gel was left to polymerise at room temperature for a minimum of 2 hours.
- Electrophoresis on the ABI PRISM 377 Automated Sequencer
A Filter Set E matrix (instrument) file was made previously from the ABI PRISM 
dRhodamine matrix standards, according to the manufacturers instructions. The 
samples to be sequenced were denatured at 95°C for 5 minutes, and placed directly 
on ice prior to loading. Between 1.5 and 2.5 pi of sample was loaded into each well
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of the polyacrylamide gel. Electrophoresis was carried out using run module “Seq 
Run 36E-1200”, which was configured to read 36cm well-to-read gels, with 1200 
scans per hour. Typically, electrophoresis was carried out for 7 hours. Data was 
collected and analysed by ABI PRISM DNA Sequencing Analysis Software, version
3.2
Method 2
2 pi BigDye v3.1 was used undiluted, and added to 2.5pl template DNA and 0.5pl 
primer at 20pmol/pl. Cycle sequencing was performed on a MJ Research PTC-225 
DNA engine tetrad, using the following conditions:
100 cycles of 95°C (10 seconds); 50°C (5 seconds); 60°C (4 minutes)
In order to remove unincorporated dye terminators from the samples and to 
precipitate the purified product, the samples were treated with 15pl dTEO, 2pl of 3M 
sodium acetate and 50pl of 95% ethanol. The reaction plate was sealed, gently 
shaken, and left in darkness at room temperature for 15 minutes. The samples were 
then centrifuged at 3000rpm for 45 minutes at 4°C. Following this, the plate was 
inverted onto a paper-towel and centrifuged at 1960rpm for 1 minute to remove the 
supernatant. The samples were stored at -20°C until sequencing.
Sequencing using the ABI Prism 3130XL Genetic Analyzer
No polyacrylamide gel was required for this machine. All sequencing that was 
carried out on the ABI Prism 3130XL was performed by Deb Brooker, Anne
79
Richard McKeone PhD Thesis
Southwell and Zuzanna Lalanne, as described in the manufacturers instructions. The 
matrix used was Pop4, the run length (length of capillaries) was 36cm and the dye 
set, Z. Software used for the analysis of sequence data was Sequencing Analysis 3.7 
(Applied Biosystems).
2.2.20 Total RNA Extraction from Mouse Eye and Lung Tissues
Mice were sacrificed and tissues were removed from the mouse. These tissues were 
immediately snap-frozen in liquid nitrogen and stored at -70°C. RNA was extracted 
from mouse tissue using a Qiagen RNeasy Mini Kit for mouse eyes and a Qiagen 
RNeasy Midi Kit for mouse lungs, according to the manufacturers instructions. A 
maximum o f250 mg of mouse tissue was processed at a time. Homogenisation was 
carried out using an IKA Labortechnik T25 basic homogeniser. The concentration of 
the total RNA was determined by spectrophotometry (section 2.2.3), given that an 
OD reading of 1 is equivalent to 40pg/ml RNA. The ratio of absorbance reading at 
260nm and 280 nm (A260/A280) gave an indication of the purity of RNA. Pure RNA 
has an A260/A280 ratio of 1.9-2.1 in lOmM Tris-HCl, pH7.5.
Additional RNA Quantification and quality control
An RNA 6000 Nano assay chip (Agilent technologies) was used in conjunction with 
an Agilent 2100 Bioanalyzer in order to determine concentration and quality of RNA 
samples, as described in the manufacturers instructions. Quality checks involved 
ensuring that peaks for 28S and 18S ribosomal bands were present, and that the 28S 
band was approximately twice the strength of the 18S band.
80
Richard McKeone PhD Thesis
2.2.21 First Strand cDNA Preparation
First strand cDNA was prepared from 200ng-lpg of poly A+ mRNA with lpl of 
oligonucleotide (either Oligo-dT at 50uM, gene specific primer at 2pM or random 
hexamers at 50ng/pl), 2.5pl of dNTPs at lOmM, 9.6pl Trehalose at 1.2M and DEPC 
H20 to make the reaction volume up to 25pi. The sample was incubated at 65°C for 
5 minutes, and then placed on ice for 2 minutes. 5pi DDT at 0.1M, 5 pi of 10X RT 
buffer, lOpl MgC12 at 25mM, lpl RNase Out at lOu/pl and 200 units (1 pi) 
SUPERSCRIPT Reverse Transcriptase (GibcoBRL) were added and made up to 
50pl with DEPC H20 before mixing and incubating at 55°C-65°C for 1 hour 
(preceded by a 5 minute incubation at 25°C when random hexamers were used). The 
reaction was inactivated by heating the mixture to 70°C for 15 minutes. cDNAs were 
stored at -20°C. Negative control reactions were also prepared as described above, 
but without the inclusion of reverse transcriptase.
2.2.22 Reverse Transcriptase PCR (RT-PCR)
5 pi of cDNA was used in RT-PCR assays. A 50 pi RT-PCR contained 1 X Pfu 
buffer (Stratagene), 0.3mM dNTPs, 0.4uM forward and reverse primers and 2.5 U 
Pfu Turbo (Stratagene). Genomic DNA and water controls were also included for 
each primer pair assayed. PCR conditions were as stated in programme 2 (section 
2.2.5), with an annealing temperature of 55°C, and an extension time of 45 seconds. 
RT-PCR products were electrophoresed through an agarose matrix.
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2.2.23 Bioinformatics
Manipulation of raw sequence was performed using ContigExpress, and DNA tools 
(http://biology.semo.edu/cgi-bin/dnatools.pl). Repetitive elements were identified 
through RepeatMasker, and were masked from the sequence for further analysis. 
Sequence similarity searches were performed against the various public databases 
using the BLAST suite of tools, through the National Center for Biotechnology 
Information (NCBI). ContigExpress was used for comparative analysis of sequence 
chromatograms. S.A.M was used by Mathew Cadman in the construction of the 
Del36H BAC contig.
A range of protein prediction programmes were utilized. PIX was hosted by the 
Human Genome Mapping Project Resource Centre (HGMP-RC) at 
www.hgmp.mrc.ac.uk/, which is no longer operational. Both nnpredict and NORSp 
were accessed via the PredictProtein-Meta portal
(http://www.predictprotein.org/meta.php). Amino acid sequence comparisons of 
FOX genes were performed with the SIM alignment tool 
(http://expasy.org/tools/sim-prot.html). A database of protein structures was 
accessed to identify the structural characteristics of homologous regions in proteins 
related to F0XF2 (http://molvis.sdsc.edu/protexpl/fmtdoor.htm).
Pairwise alignment of sequences was performed through the BLAST algorithm at 
NCBI. This site allows two sequences to be compared for the identification of 
regions of sequence similarity. Genomic sequences were also compared with
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Pipmaker (http://pipmaker.bx.psu.edu/pipmaker/), which enabled the identification 
of non-conserved regions between two or more genomes.
2.2.24 FI DNA and sperm archive
Two archives of DNA with parallel sperm archives were constructed at MRC 
Harwell by R. Cox, A. Hough (nee Hughill), D. Quwailid and co-workers [201,
202]. ENU mutagenised BALB/c males were crossed with C3H/HeH females and 
the DNA and sperm from male FI offspring of this cross were archived.
The GSK-archive DNA consists of two sections of tail, whereas the new Harwell 
archive comprises whole tail, liver, kidney, spleen, and heart tissue. DNA for the 
GSK archive was extracted by A. Hough and DNA for the MRC archive was 
extracted by D Quwailid using Qiagen DNeasy 96 tissue kits. Test PCRs were 
performed on each DNA sample with primers from exon 2 of the Resistin gene 
(Retn), and these products visualised on an agarose gel as a further quality check. 
Sperm freezing was carried out as described by Nakagata and Takeshim a [211] 
with modifications (Thornton et al. 1999) [212].
2.2.25 Denaturing High-Performance Liquid Chromatography (DHPLC).
Mutation detection was performed using a Transgenomic Wave machine that utilises 
DHPLC. The system was run according to the manufacturers instructions 
(Transgenomic). Primers for PCR amplification were designed in the introns at least
83
Richard McKeone PhD Thesis
30bp from the splice sites of each exon (to allow for subsequent sequencing of the 
splice sites themselves) and with an optimal fragment length between 150 and 
500bp.
DNA from four individuals were pooled using 12.5ng of each DNA giving a total of 
50ng in the PCR. Sequence analysis was performed as described in section 2.2.19. 
Recovery by in vitro fertilisation was onto a C3H/HeH genetic background.
2.2.26 Pyrosequencer
SNP detection with the pyrosequencer required biotinylation of the forward primer. 
The reverse primer was left unlabelled. A sequencing primer was also designed by 
Zuzanna Lalanne, using software at the website.
http://primerdesign.pyrosequencing.com/jsp/TemplateInput.jsp. Samples underwent 
PCR as described in 2.2.5 using the biotinylated forward and unlabelled reverse 
primers. Either Debra Brooker, Anne Southwell or Zuzanna Lalanne then loaded 
20pl of the reaction mixture into a PSQ HS 96A instrument (Biotage) as described 
in the manufacturers instructions.
2.2.27 Mouse Necropsies
Eye Extractions for Histological Analysis
Eyes were enucleated from each mouse and fixed in 50% Kamovsky’s medium for 
45 minutes. This was followed by 3 X 30 minute washes in PBS before being stored
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in PBS at 4°C until embedding and sectioning at Imperial College by the histology 
team there.
Lung Extractions for Histological Analysis
Once the lungs were removed, they were placed immediately in Neutral Buffered 
Formaldehyde and stored at 4°C until embedding.
Head Extractions For Palate Histological Analysis
After decapitation, heads were placed immediately in Neutral Buffered 
Formaldehyde and stored at 4°C until embedding.
Head Extractions For Eye Analysis
4% paraformaldehyde in PBS was heated to 65°C and mixed until the 
paraformaldehyde dissolved, then stored on ice. After decapitation, embryo heads 
were placed immediately into 10 ml of ice-cold fixative and left overnight at 4°C.
Following fixation, a series of 30 minute washes were performed in lOmls of 
solution, whilst gently shaking the sample. The wash steps were carried out as 
follows:
2 x 10 ml washes in PBS; 1 x 10ml 1:1 (v/v) PBS-ethanol mix; 2 x 10 ml 70% 
ethanol; 1 x 10ml 85% ethanol; 1 x 10ml 95% ethanol; 2 x 10 ml 100% ethanol.
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The embryos were stored at 4°C in 100% ethanol until embedding at Imperial 
College.
Embedding and haematoxylin and eosin Staining
Embedding of mouse tissue in Paraffin wax and the subsequent haematoxylin and 
eosin staining was performed by the MRC MGU Histology unit for palate and lung 
analysis. Embedding was performed with a Shandom Embedding centre as 
recommended by the manufacturer. Haematoxylin and Eosin staining was carried 
out using a Shandon Varistain 24 device, according to the manufacturers 
instructions. Sections were taken using a Microm HM320.
2.2.28 Mouse Behavioural Studies
Mouse behavioural primary screening tests were carried out by the MRC Harwell 
Phenotyping core on a cohort of 32 littermate mice; 8 Foxf2 W-R mutant 
heterozygote females, 8 Foxf2 W-R mutant heterozygote males, 8 Foxf2 wildtype 
females, 8 Foxf2 wildtype males.
Protocols for the modified SHIRPA, Grip strength test, Y-maze test and swim test 
that were all performed on these individuals are all described in detail in the mouse 
phenotyping database, Empress (http://empress.har.mrc.ac.uk/browser/).
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Light-Dark box: Mice were acclimatised for 5 minutes in individual cages attached 
to the Light-Dark box before they were allowed to explore the Truscan Light-Dark 
box arena (Coulboum Instruments). The following parameters were automatically 
measured by the associated computer system: Latency, number of moves, time spent 
moving, velocity, distance covered, time spent in the light area, time spent in the 
dark area, number of times the light area was entered, vertical plane entries (rearing), 
central area entries in the light region, central area entries in the dark region.
Acoustic Startle & Pre-Pulse Inhibition
Startle box tests, which included “startle” and “prepulse inhibition” 
programmes were carried out as described in the Empress phenotyping document 
10_005 (http://empress.har.mrc.ac.uk/browser/). Each test format incorporated 
pulses in a pseudorandom order, with the intervening period between each pulse not 
exceeding 25 seconds. PPI-1 and Startle-1 were used for primary screening, 
secondary screening was performed using all 4 of the programmes described below:
Startle 1
A 5 minute period of acclimatisation was followed by 10ms pulses at 1 lOdB and at a 
frequency of either 12kHz, 20kHz or white noise. Mice were subjected to each pulse 
frequency a total of 5 times.
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PPI1
Mice were subjected to 10ms white noise pulses at 1 lOdB which were preceded by 
10ms pre-pulses of 90dB at either 12 kHz or 20 kHz. The pre-pulse was 90ms before 
the white noise pulse for each trial. There were 15 trials for each of the pre-pulse 
frequencies, and a further 18 trials that did not incorporate a pre-pulse
Startle 2
Mouse movement was measured 10 times with white noise 40ms pulses at 65dB to 
determine background motion levels. White noise 40ms pulses at 1 lOdB were then 
used to test the mice 10 times with a delay of 20-30 seconds between trials.
PPI2
Responses of mice to 10ms white noise at 70dB, 80dB, 85dB, 90dB and 1 lOdB were 
tested 10 times for each volume. PPI trials incorporating further 10ms white noise 
pre-pulses at these volumes were performed 10 times at each volume, with a 40ms 
delay before 1 lOdB white noise pulses lasting 40ms in each trial.
2.2.29 Mouse Metabolic Phenotype Studies
There was a reduction in numbers of the cohort for this aspect of the study: 4 Foxf2 
W-R mutant heterozygote females, 5 Foxf2 W-R mutant heterozygote males, 7 
wildtype females and 8 wildtype males were tested.
Richard McKeone PhD Thesis
An Olympus AU400 Clinical Chemistry Analyser (Olympus Diagnostics, UK) and 
associated reagents were used by Tertius Hough for the Harwell Phenotyping Core. 
Mouse phlebotomy was carried out as described in Hough et al, 2002[213].
Metabolites tested with the Olympus AU400
- Sodium
- Potassium
- Chloride
- Urea
- Creatinine
- Total Calcium
- Phosphate
- Alkaline phosphatase (ALP)
- Alanine transaminase (ALT)
- Aspartate transaminase (AST)
- Total Protein
- Albumin
- Total Cholesterol
- High density lipoprotein cholesterol (HDL cholesterol)
- Triglycerides
- Glucose
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The MRC Harwell Phenotyping Core also carried out Urinalysis and IPGTT (Intra- 
peritoneal Glucose Tolerance Test) as described at 
http://empress.har.mrc.ac.uk/EMPReSS/servlet/EMPReSS.Frameset.
2.2.30 Plasmid Preparation 
Site Directed Mutagenesis
Primers were designed to a target region within a plasmid containing the gene of 
interest as described in the literature for the Quickchange® Site Directed 
Mutagenesis Kit. Forward and reverse primers included the required mutation in 
their approximate centre and were complementary to each other, spanning 25-40 
bases and with a melting temperature (Tm) of greater than 78°C.
The supplied FOXF2 expression plasmid was used to transform XI-1 Blue 
supercompetent cells (section 2.2.18) and subsequently harvested from these cells. 
PCR with the mutagenesis primers was performed to amplify the entire plasmid as 
described in section 2.2.5 programme 4, although the V410F mutagenesis primers 
required an annealing temperature o f ~67°C. Each 50pl reaction mixture contained 
5pl o f plasmid at 20ng/pl, 125ng of each mutagenesis primer, lp l Pfu Turbo 
polymerase, 4pl dNTPs at 1.25mM, 5pl pfu buffer (10X) and 67.75pmol betaine. 
Following thermal cycling, ten units o f Dpnl (0.5pl) was added to each reaction, 
mixed by pipette and incubated for 4 hours at 37°C.
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XI-1 Blue supercompetent cells were then transformed with this mixture, and the 
plasmid extracted and screened by sequencing as described in section 2.2.18.
Empty pEVRFO
A double digest of the FOXF2-pEVRFO construct (500ng) was performed with 10 
units of BamHI and 10 units of Xbal in order to remove the FOXF2 insert. After gel 
purification of the linearised plasmid, 1 unit of klenow was added to 200ng of the 
linearised pEVRFO plasmid with dNTPs at 33uM in a 50pl reaction to allow blunt 
ended ligation as described in section 2.2.17. Following EDTA reaction termination, 
the product was purified with a Qiaquick PCR extraction kit.
4ng of this purified product was then added to a ligation reaction with 200 units of 
T4 ligase. Other conditions were as described in section 2.2.17.
These ligation products were used to transform XL 1-Blue supercompetent cells. 
Single colonies were selected for harvesting, and were prepared using Wizard 
miniprep kits (as described in section 2.2.1), before screening the plasmids by direct 
sequencing with pEVRFO primers that amplify the insertion site:
CCCTGAAAACTTTGCCCCCTCC and GGGGGATCTTGGTGGCGTG.
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Reporter Vector Construction 
Oligonucleotide Multimerization
Two semi complementary oligonucleotides were designed that incorporated the 
human FOXF2 binding sequence that was determined by Pierrou and colleagues 
[205]. At the 5’ end of each of these primers was a restriction sequence also present 
within the multiple cloning site of ptal-SEAP. The oligonucleotide containing the 
binding sequence as described by Pierrou carried an Mlul restriction sequence at the 
5’ end and the oligonucleotide which contained the reverse complement of the 
previously described binding sequence carried a Bglll site. Both oligonucleotides 
were synthesised with a phosphate group at their 5’ ends.
1. CGCGTCCAAACGTAAACAATCCGA (Bold = Mlul site. Underlined =
FOXF2 binding site).
2. GATCTCGGATTGTTTACGTTTGGA (Bold = Bglll site. Underlined = FOXF2 
binding site complementary sequence)
A 20pl ligation reaction mixture was set up for multimerisation of the 
oligonucleotides. The reaction contained 2pl of the 10X ligation buffer, 8 units of T4 
ligase, 150pmol of each multimerization oligonucleotide and was performed as 
described in section 2.2.17.
Reactions were incubated overnight at 16°C. They were inactivated by heating the 
mix at 65°C for 10 minutes and were then run on a 2% agarose gel (section 2.2.7)
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from which DNA was extracted and purified (section 2.2.8) from band sizes 
consisting of multimers of X5, X7 and X9 double stranded oligonucleotide lengths 
(124,172 and 220 bp respectively).
Meanwhile, the reporter vector pTAL-SEAP was linearised with a double digest of 
Bglll and Mlul before purification with a PCR purification kit.
The purified product was ligated to the oligonucleotide multimers with T4-ligase as 
described in section 2.2.17. The ligation product was used to transform XL 1-Blue 
supercompetent cells as described in section 2.2.18. Colony PCR was performed on 
the resulting colonies with primers designed from either side of the pTAL-SEAP 
multiple cloning site (Forward: CAAAATAGGCTGTCCCCAGT; Reverse: 
CCTCCTCAACTGGGATGATG). Reaction conditions were as described in section 
2.2.5, standard PCR but pipette tips were jabbed onto XLl-Blue colonies to remove 
a fraction of the colony for a DNA template. These pipette tips were twisted several 
times in order to mix the template into the reaction mixture before their disposal and 
the commencement of thermal cycling.
Long Oligonucleotides (~100bp) that contained multiple FOXF2 binding sites and 
therefore did not require multimerisation were also used for ligations of Mlul/Bglll 
linearised pTAL-SEAP vector. In common with the multimerisation primers, these 
oligonucleotides were synthesised with phosphate groups at their 5’ ends. 0.064pmol 
of linearised pTAL-SEAP vector (20ng) was added to ligation reactions with 3X,
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3 OX and 300X this molarity of the multiple binding site oligonucleotides, and 
1.6u/pl of T4 ligase. Screening conditions were as described for the multimerisation 
oligonucleotides.
Mlul Multiple binding site oligonucleotide:
CGCGTTTCCAAACGTAAACAATCCTTCCAAACGTAAACAATCCTTCCAA 
ACGT AAAC AATCCTT CC AAACGT AAAC AAT CCTT CC AAACGT AAAC AAT 
CCA
Bglll Multiple binding site oligonucleotide:
G ATCTGG ATT GTTT ACGTTT GGAAGG ATT GTTT ACGTTT GG A AGG ATT GT 
TT ACGTTT GG AAGG ATT GTTT ACGTTT GG A AGG ATT GTTT ACGTTT GG AA 
A
(Bold = Restriction sequence, underlined = FOXF2 binding sequence)
2.2.31 Probe Dig Labelling
The two multimerisation primers in section 2.2.30 which contained the human 
FOXF2 binding sequence were also utilised for the EMSA.
The oligonucleotide that included a Bglll site and complementary sequence to the 
binding sequence described by Pierrou [205]
(GAT CTCGG ATT GTTT ACGTTT GG A") was labelled with digoxigenin-ddUTP
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(Dig) in accordance with the protocol described in the Dig Oligonucleotide 3’ -  End 
Labelling Kit (Roche). Determination of labelling efficiency was performed as 
described in the manufacturer’s instructions.
This oligonucleotide and its unlabelled semi-complementary counterpart 
(CGCGTCCAAACGTAAACAATCCGA) were then mixed at 50 fmol/pl, and 
incubated at 95°C for 10 minutes before cooling to 25°C to allow formation of the 
double stranded probe.
2.2.32 Cell Culture Techniques
Cos-7 cells were initially provided at passage number 7 (P7) by Richard Gale and 
Jane Baker.
Trypsinisation of Cells
Cos-7 cells were incubated at 37°C in T-75 flasks until a surface coverage o f-80% 
was obtained. Cell growth media was extracted before washing the culture twice 
with fresh DPBS. 1.5mls trypsin/EDTA was added to the cells (2.5mls for T-175 
flasks) and the flask was rocked from side to side until all the cells had contact with 
the trypsin solution. The cells were then incubated at 37°C for 7 minutes before 
lOmls of fresh, pre-warmed media was added and mixed by pipette until the cell 
suspension was homogeneous.
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Cos7 Cell Passage
Cell cultures were typically split upon reaching a surface coverage of -80% to allow 
continued survival and for culture expansion when required. Following 
trypsinisation, a fraction of cell suspension was added to a new flask(s), depending 
on experimental requirements and based on the assumption that the cells 
approximately double their surface coverage during a 24 hour period.
Fresh pre-warmed growth medium was added to make the final volume in T-75 
flasks up to 20mls and T-175 flasks up to 30mls, before incubating at 37°C.
Cryopreservation of Cells
Cells were trypsinised and 2 X 4.5mls of cell suspension was distributed into 2 X 
15ml falcon tubes. These were centrifuged at 167 RCF (Relative centrifugal force) 
for 5 minutes before disposing of the supernatant
Both pellets were re-suspended and combined in 4mls of cryopreservation media 
(10%DMSO in Foetal Bovine Serum). This suspension was distributed into 4 X 1ml 
cryovial tubes. The cells were then placed in an isopropanol filled cryopreservation 
container, and stored at -70°C for 1 day before transferring the cryovials into liquid 
nitrogen for long-term storage.
Reviving Frozen Cos-7 Cell Stocks
Cryovials containing frozen Cos-7 cell stocks were removed from liquid nitrogen 
storage and thawed out at 25°C for 3 minutes, followed by 2 minutes at 37°C. The
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thawed cell suspension was then added to 20mls of pre-warmed growth media. The 
media was then rocked from side to side in order to evenly distribute the cells before 
incubating at 37°C.
2.2.32a Optimisation of Transfection Conditions
Glass cover-slips were sterilised by immersion in 95% alcohol for 5 minutes. They 
were then allowed to air-dry within a Laminar air-flow hood for 10 minutes before 
placing them into 9.6cm2 cell culture wells (Nunc).
Cos-7 Cells were trypsinised and diluted with fresh, pre-warmed (37°C) growth 
media to 1.75 X 105/ml before adding 1ml of this cell suspension to each well. The 
cells were mixed by rocking the wells from side to side, and incubated at 37°C for 
24 hours.
Transfections of Cos-7 Cells were set up with the following reagent ratios, with the 
EGFP plasmid at 250ng/pl:
1
3 pi genejuice, lpig EGFP 
1.5pl genejuice, lpgEGFP
6pl genejuice, lpg EGFP
3jnl gnejuice, Opg EGFP 
3pi genejuice, 2pg EGFP
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The genejuice was added to 97pl serum free DMEM media before vortexing then 
incubating the mixture at room temperature for 5 minutes. EGFP vector was then 
mixed into the media by gently pipetting up and down. Following a 15 minute 
incubation at room temperature, this transfection complex was dripped evenly across 
the media surface and the flask then rocked from side to side to allow an even 
distribution.
After 24 hours, the coverslips were washed with DPBS then the cells were fixed 
with 4% paraformaldehyde in FBS whilst shaking at 4°C for 20 minutes. The cells 
were washed twice with DPBS and placed on an orbital shaker at 4°C for 10 
minutes. Coverslips were then placed on slides with 20pl vectashield & DAPI 
(Vector Laboratories). These were stored in the dark at 4°C until analysis of GFP 
transfection ratios with an Axioplan 2 microscope.
Blue filters were used to capture images of the DAPI stained cells (all cells) and 
green filters to visualise the GFP transfected cells. Photographs of 3 random fields of 
view at a magnification of X200 were taken for each coverslip with both the blue 
and green filters.
2.2.33 Transactivation Assay
Glass cover-slips were sterilised by immersion in 95% alcohol for 5 minutes. They 
were then allowed to air-dry within a Laminar air-flow hood for 10 minutes before 
placing them into 9.6cm2 cell culture wells (Nunc).
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Cos-7 Cells were trypsinised as described in section 2.2.32 and diluted with fresh, 
pre-warmed (37°C) growth media to 1.75 X 105/ml before adding 1ml of this cell 
suspension to each well. The cells were mixed by rocking the wells from side to side, 
and incubated at 37°C for 24 hours.
Transfections of Cos-7 Cells were set up using the genejuice manufacturer’s 
instructions with the following reagent quantities:
97pl serum free media
4pl pooled vector DNA at a total concentration of 250ng/pl (450ng expression 
vector, 450ng pTAL SEAP (either with or without the FOXF2 binding site), lOOng 
pEGFP-Cl Transfection control.
3 pi genejuice.
50pl growth media was extracted from just beneath the surface at 24,48 and 72 
hours after transfection of the cells. This was then centrifuged at 12,000 ref for 10 
seconds before aliquoting 2 X 18 pi of the supernatant into separate tubes and storing 
at -20°C until analysis. A Great Esc Ape™ SEAP Detection Kit was used for the 
determination of secreted alkaline phosphatase quantities in these media samples as 
described in section 2.2.34
The coverslips were then treated and analysed as described in section 2.2.32a.
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2.2.34 Reporter Activity Quantification
50pl growth media was extracted from just beneath the surface. This media was 
centrifuged at 12,000 ref for 10 seconds before aliquoting 2 X 1 8j j l1 of the 
supernatant into separate tubes and stored at -20°C until analysis by either the Great 
EscAPe SEAP Chemiluminescence Detection Kit or the MightyLight™ Rluc Assay 
kit, depending on the transfection control used.
Secreted Alkaline Phosphotase (SEAP) Quantification
Levels of SEAP were quantified using a Great EscAPe SEAP Chemiluminescence 
Detection Kit. Samples were subjected to the procedure described in the 
manufacturers instructions, alongside a positive control placental alkaline 
phosphatase (BD Biosciences) at concentrations of 1000,000 pg/ml; 200,000 pg/ml; 
40,000 pg/ml; 8,000 pg/ml; 1,600 pg/ml; 320 pg/ml; 64 pg/ml; and 12 pg/ml. The 
luminescence of the standards and samples was detected at 20 and 40 minutes after 
the addition of CSPD with a Luminoskan Ascent luminometer (Thermo Scientific).
Luciferase Quantification
Samples which had been transfected with the pMluc-3 CMV vector as a transfection 
control required the detection of luciferase levels within the media. The 
MightyLight™ Rluc Assay kit was used as described in the manufacturers 
instructions in the Sample preparation -  Culture Medium section and Assay 
procedure section.
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2.2.35 EMSA 
Protein Extraction
Cell cultures were trypsinised and resuspended as described in section 2.2.32. A 
haemocytometer was used to estimate cell density
The volume of media equivalent to 5.25 X106 cells was added to each T175 flask, 
for an estimated cell count of 1.5 XI07 at vector transfection, 24 hours after seeding.
Transfections were performed as described in section 2.2.32, with the following 
reagent volumes:
Genejuice: 56pl
Total Vector: 70pl at 250ng/pl (17.5pg)
Expression Vector: 63pl at 250ng/pl
pTAL-SEAP or pMLuc-3 CMV Transfection control vector: 7pi at 250ng/pl 
(1750ng)
Serum free media: 2200pl
48 hours after these transfections, extraction of media for the analysis of reporter 
activity was performed with either the Great EscAPe SEAP Chemiluminescence 
Detection Kit or the MightyLight™ Rluc Assay kit (section 2.2.34).
Immediately following the removal of the media, the transfected cells were 
trypsinised (section 2.2.32) before the nuclear and cytoplasmic fractions were
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extracted as described in the Nucbuster protocol. These fractions were each then 
subdivided into 10 separate aliquots before storage at -70°C.
Protein Quantification
Protein quantification was carried out with a BioRad Dc Protein Assay kit as 
described in the manufacturers instructions, with the following reagent quantities: 
Sample or standard: 25pi 
Reagent A’: 125pl 
Reagent B: lOOOpl
BSA was used for the protein standard at 20 pg/pl, 10 pg/pl, 2 pg/pl, 1 pg/pl,
0.5 pg/pl, 0.25pg/pl and 0.125 pg/pl.
EMSA Reaction and Analysis
The DNA binding reaction described in the Nucbuster protocol was performed with 
the following reagent quantities:
4 X Binding buffer: 5pi
Cotl DNA or Salmon sperm DNA: lpl at 50ng/pl 
Poly (dl-dC): 0.01 - 0.03u (l-3pl at O.Olu/pl)
Nuclear extract: 15, 30 or 40pg 
ddH20 to 17pl
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These reagents were mixed by pipette before adding lpl of the Dig labelled probe at 
50fmol, mixing, and incubating on ice for 30 minutes. The binding mixture was then 
either loaded onto a protein gel immediately or 1 jlxI FOXF2 antibody (either FOXF2 
antibody 1 (Abeam) or FOXF2 antibody 2 (Abnova)) was added and the mixture 
was incubated on ice for a further 2 0  minutes before loading onto the gel for a 
supershift assay. Proteinase inhibitor was added to antibody 2 for some of the 
supershift runs. Unlabelled probe was also added as a specific inhibitor at 1X-100X 
the concentration of the labelled probe. Following this reaction, the binding mixture 
was loaded onto a native polyacrylamide gel.
Two gel systems were used in order to optimise visualisation conditions.
1. Bio-Rad Mini-Gel System. Recipes of 5% and 6%  were used:
5% Polyacrylamide Gel
40 % polyacrylamide (29:1): 1250pl
10XTBE: 500pl
ddH20: 8135pl
Temed: 15pl
APS: lOOpl
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6% Polyacrylamide Gel
40 % polyacrylamide (29:1): 1500pl
10XTBE: 500pl
ddH20: 7885pl
Temed: 15pl
APS: lOOpil
2. CriterionTM 5%TBE pre-cast gels (Bio-Rad)
Gels were pre-run at 4°C for 30 minutes at lOOv in 0.5 X TBE. Samples were then 
loaded and the gel was run for an additional 1 hour. Gels were blotted onto Hybond 
N+ membrane overnight at 4°C in 0.5 X TBE at 30v. Membranes were then cross- 
linked with a UV Stratalinker (Stratagene).
A DIG Wash and Block Buffer Set (Roche Diagnostics GmbH) was used to develop 
EMSA membranes as described in the manufacturer’s instructions. CSPD was added 
to the membrane which was then wrapped in Saran wrap (Dow) before incubating at 
37°C for 10 minutes. The wrapped membrane was then exposed to 
chemiluminescence film in cassettes with intensifying screens at 25°C, from 20 
minutes to 1 hour. The film was fixed and developed using an X-ograph Compact 
X4. Band strengths were quantified using a TD2 Transmission Densitometer.
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2.2.36 Antibody Detection for FOXF2 transfection confirmation
Protein from each FOXF2 transfection and a HepG2 control were added to 2.5pi 
NuPage LDS sample buffer, lpl Nupage reducing agent and H2O to make the 
sample up to 6 .5pi before heating to 70°C for 10 minutes. These samples were then 
loaded onto a Nupage® Novex Bis-Tris gel and run with XCell Surelock™ Mini- 
Cell apparatus at 200v in 1XSDS Running buffer with 0.25% NuPage® antioxidant. 
Blotting was carried out at 30v for 1 hour onto 0.45 pm nitrocellulose membrane 
(Invitrogen) as described in the gel manufacturers instructions.
After blocking the non-specific binding sites with either 5% powdered milk or 5% 
BSA for 1 hour on an orbital shaker, the membranes were washed for 5 minutes in 
PBS-T or TBS-T containing 
0%-l .5% blocking reagent (wash solution).
FOXF2 antibody 1 (Abeam) was added to PBS-T or TBS-T with 1.2%-1.5% 
blocking reagent, to a concentration of 0.5-5pg/ml. This antibody solution was 
added to the membrane and incubated at room temperature on an orbital shaker for 1 
hour. Following a 15 minute wash and two 5 minute washes in wash solution, the 
membrane was incubated in a 1:75,000 dilution of the secondary antibody, Anti- 
Rabbit IgG peroxidise, in PBS-T or TBS-T with 1.2%-1.5% blocking reagent.
The membrane was washed on an orbital shaker once for 15 minutes and four times 
for 5 minutes in wash solution before developing the membrane. 500pl of ECL
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solution 1 and 500jal ECL solution 2 which were supplied with the ECL™ Western 
Blotting Analysis System were mixed after allowing both reagents to equilibrate to 
room temperature. This mixture was added to the surface of the membrane and 
incubated at room temperature for 1 minute before draining the excess fluid and 
wrapping the membrane in Saran wrap. The wrapped membrane was then exposed 
to chemiluminescence film in cassettes with intensifying screens at 25°C, from 2-10 
minutes. The film was fixed and developed using an X-ograph Compact X4.
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Chapter 3: Mapping the Region of Mouse Chromosome 13 Deleted 
in the Del(13)Svea36H Mutation
3.1 Introduction
The Del(13)Svea36H deleted region (henceforth known as the Del36H region) was 
detected at Harwell during an X-ray mutagenesis screen[82]. The deletion causes 
early embryonic lethality in homozygote carriers, indicating the presence of 
developmentally significant genes within the region. A recessive coat-colour allele 
(the Satin allele of Foxql) located within the deleted interval has allowed the use of 
this deletion as a tool for the detection of lethal recessive mutations. The 
mutagenised genes that cause the lethal phenotype can then be identified and their 
function investigated [26].
This region of the mouse genome shows conserved synteny with human 
chromosome 6p22.1- 6p22.3 and 6p25. Large sections of these two genomic regions 
have been deleted in 6p deletion syndromes, which consist of distinct but 
overlapping deletions. Symptoms of these syndromes include ocular dysgenesis, 
orofacial clefting, deafness, and brain, heart and kidney defects; although the range 
of symptoms varies widely depending on the extent of the respective deletion. There 
are also several specific diseases which map to the region such as Fanconi’s anaemia 
[214], haemochromatosis [215], schizophrenia [216], Behcet’s disease [217] and 
cervical carcinoma [218,219]. A characterisation of mutations within the mouse 
Del36H deletion may help to shed light on the genes involved in both the 6 p deletion 
syndromes and other diseases caused by mutations within the chromosome 6 p 
region.
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The construction of a sequence ready, annotated map was initiated in order to 
facilitate the mapping of mutations arising from the lethal recessive phenotype 
screen. The Del36H region spans 12.7Mb of proximal mouse chromosome 13 and is 
relatively gene-rich (201 genes) in comparison with the genome average [84]
Original estimates put the size of the region at approximately -25 Mb based on 
cytogenetic data and genetic maps derived from the EUCIB resource. This is 
significantly larger than the 12.7Mb observed in the physical map, but because the 
physical map is now fully contiguous, this 12.7Mb calculation is the more reliable 
figure. Potential reasons for the apparent discrepancy between the size predicted by 
the sequence and genetic maps may involve recombination hotspots within the 
interval.
Markers within the region had been placed on radiation hybrid maps [21,36], 
allowing their incorporation into genetic and YAC maps [37, 220] as shown in 
figure 3.1. The STS data accrued during the construction of these maps provided a 
framework for subsequent bacterial clone-based physical maps. This region was 
selected by the MRC UK mouse sequencing consortium as one of the sites to be 
targeted for a hierarchical, clone based sequencing approach, in addition to the 
whole genome sequencing approach that was used for sequencing the majority of the 
mouse genome. PACs from the RPCI-21 library were used in preliminary stages of 
the physical map construction, but the larger size of BAC inserts (in addition to their 
increased stability compared with YAC clone inserts) meant that BACs were
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selected as the best clone system available at the time in terms of efficiency and data 
reliability.
The clone based approach has the advantage over the whole genome shotgun 
approach in that it is less likely to result in the loss of sequence data due to the 
compression of regions with a high level of sequence identity [43] [221].
A panel of informative markers has been identified for mapping of mutant lines 
arising from the lethal recessive screen. This has been used to reduce the critical 
regions of 11 mutants
3.2 Physical Mapping of DeI36H
An array of markers were selected from the estimated Del36H region [184, 220,
222] including 24 MIT/Whitehead markers [35], 10 genic probes, 50 ESTs 
(Expressed Sequence Tags) and 8 human homologous STS (Sequence Tagged 
Sites). These markers were used to probe RPCI-23 Mouse genomic BAC libraries 
(provided by MRC HGMP-RC for members of the Mouse sequencing consortium). 
The majority (155) of these 176 probes were pooled in batches of 5-10 when 
performing the hybridisations although 57 hybridisations were performed with 
single probes (32 probes were hybridised both singly and in pools). Pool sets are 
listed in table 3.1.
The MIT markers were not used to probe the BAC libraries directly because the 
microsatellite regions within these sequences would have resulted in hybridisations
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to multiple genomic loci. Instead, the known flanking sequence was used by M. 
Cadman to design overlapping oligonucleotides (overgos). These overgos were 
incubated with a Klenow polymerase and dNTPs including 32P labelled cytosine. 
This formed a double stranded probe which was labelled on one strand with 32P 
which was then denatured before exposure to the BAC library for hybridisation.
3.3 Source of Probes used for Hybridisation of the RPCI-23 BAC Library
The probes which were used to screen the RPCI-23 BAC library were from a wide 
range of sources, a majority of them had previously been used for radiation hybrid 
and genetic mapping of the deleted interval [21]. Many of the probe sequences 
originated from the MIT/Whitehead institute, including the D13Mit markers, 
random STS markers and the M-prefixed ESTs. Many of these had been localised to 
proximal chromosome 13 by radiation hybrid mapping at the MIT/Whitehead 
institute, whilst others were previously mapped by YAC contigs anchored to 
chromosome 13.
The Cwr markers are STSs which were identified by Hong and Chakravarti et al 
[184] during positional cloning of the ch (congenital hydrocephalus) phenotype, 
which they localised to Foxcl (then known as mfl).
ESTs which had previously been mapped to the region by the MRC UK Mouse 
Genome Centre and the EEC Mouse Transcript Mapping Consortium were also 
used.
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Pools of Probes Used to Screen the RPCI-23 BAC Library
FS1 FS2 FS3 FS4 FS5 |FS6 FS7
D13Mit294 M-08497 Hfe3 M-01319 Btn M151-C02 M176-C02
D13Mit265 M-09785 M141-B07 M-07528 M161-G05 AA407021
D13Mit307 M-131-E02 M-11510 M135-A07 M199-H07 Ail 15341
cvvrl 1 M-11527 AI225904 M122-d09 584bl6t7 M203-D06 Sox4_l
cwr6 M-142-1101 M153-A03 M-09543 Cwrl M211-E01 Sox4_4
cwr 10 KOI661 Cwr3 M212-E04 O lfrll
Mfl Cwr31 M220-E01 D 13 M it 79
M-156-dll Cwr32 AA516957 K00020
M-09825 AA571384 K00153
M-04234 R 74621 K03922
M-08353
M-01316
FS8 |FS9 FS10 FS11 FS12 FS13 FS14
K00879 K00181 M257-E09 M-00890 HB001 39M12sp6 72cl3t7
K01931 K00829 M275-F01 M-08279 HB002 290i8t7 51a l 1sp6
K02035 KOI 193 M280-d05 M-10786 HB003 468M24sp6 94bl0t7
16F12t7 80cl8sp6 M301-H08 M-08298 HB004 Y12294 335h9t7
16F12sp6 87cl0sp6 M239-C02 M-08493 HB005 241e24sp6
18F15 t7 92gl3t7 M265-G02 HB007 K03211
18F15sp6 92gl3sp6 M253-H12 27E3sp6 K03265
34M15sp6 278el6t7 M237-F06 11F17sp6 M-08270
34M15t7 278el6sp6 M284-F11 414kl3sp6
80cl8t7 298jl2sp6 M285-C08 404N10t7
467F12t7
71F 18t7
439F14sp6
FS15 FS16 FS17a FS17b |FS18 FS19 FS20
M203-B05 Cwr26 12F15t7 271B10sp6 D13Mitl 97 D13Mit306 K01931
M289-B08 Cwr27 312d21sp6 266F10t7 D13Mit273 D13Mitl5 K02035
K03576 HI .: | 310c7t7 326c24sp6 D13Mitl33
310c7sp6 408j22t7 D13Mit220
11 112ol6t7 254H12sp6 D13Mitl5
509H17t7 254H12sp6 HB008 D13Mit84
Cwr 12 349k3sp6
Cwr 13 148F2 lt7
392L15sp6 122c3sp6
Cwr30
Key for Probes used  to screen  
RPCI-23 BAC Libraries
=Human BAC
| =PAC end sequence
=BAC end sequence
=Genic probe
=STS
=ESTs
Table 3.1: Pooled hybridisation probes
The pooled probes which were hybridised to the RPCI-23 BAC library.
I l l
Richard McKeone PhD Thesis
Sin g le  P robes U sed to  Screen the RPCI-23 BAC Library
D13Mit58 D13Mitl33 D13Mitl36 D13Mit241 D13Mit265 D13Mit294 D13Mit307 D13Mit206
D 13Mit81 D13Mitl54 D13Mit82 D13Mit86 D13Mit83 D13Mit273 D13Mit84 D13Mitl 16
D13Mitl75 D13Mit220 D 13Mit 135 D13Mit85 D13Mit 16 D13Mitl4 D 13Mit 15 D13Mit 17
D13Mitl97 D13Mitl63 D13Mitl76 M-09785 M-11691 M-09543 M-11510 M-07528
M-05084 M-01319 M-11527 M-08497 M-00442 M-09825 M-05614 M-01316
M-08353 M-04245 M-04234 Cwr6 Cwr 10 Cwr 11
M-122-D09 M-135-A07 M-153-A03 M-142-H01 M-131-E02 M-156-Dll Al 225904 K01661
Hfe3 Gpx5 Inti Spi3
Table 3.2: Single hybridisation probes
List o f the single probe hybridisations performed against the RPCI-23 BAC Library. The colour code 
is as shown in table 3.1 (multiple probe hybridisations).
3.4 Construction of the Physical Map
The single probes outlined in table 3.2 were hybridised to the RPCI-23 library 
membranes as outlined in section 2.2.9. Clones to which these probes hybridised 
were sequenced at their T7 and Sp6 sites by C. Sellick, in order to obtain end 
sequence data which could be used for a chromosome walking approach in contig 
construction. Probes designed from this sequence were pooled into batches of 3-13 
probes for an increased throughput rate (table 3.1). Probes which had been mapped 
to similar regions were pooled together where possible, but probes were usually not 
fine-mapped so were pooled at random.
Singleton data from this screening is shown in appendix 3.4. These were clones that 
hybridised to only a single probe or probe pool. They couldn’t be used in the 
construction of the physical map as an approximation o f the orientation, position and 
size of a clone within a contig is impossible without multiple hits. A second hit on a 
clone is also further evidence that the clone is not a false positive.
112
Richard McKeone PhD Thesis
The hybridisation data were combined with fingerprint data from the RPCI-23 and 
RPCI-24 BAC libraries[223] by Matthew Cadman, who used the output to construct 
a physical map of the region [26] -  (figure 3.1). A BAC coverage of at least 9-12 
fold was required before selecting clones for sequencing. This was in order to 
minimise the probability of the selection of chimaeras or unstable clones and to 
reduce the potential for sequence redundancy. The physical map of Del36H now 
consists of a fully contiguous minimal tiling path (MTP) that was submitted to the 
Sanger centre for shotgun sequencing [224]. This was to contribute towards the 
eventual construction of the mouse genome sequence.
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3.5 Lethal Recessive Screen
The Early Development group at Harwell utilised the Del36H deletion for a regional 
lethal recessive screen. Satin, a recessive coat colour allele of Foxql was used to 
highlight potential lethal mutations. Homozygous Satin males were mutagenised 
with ENU and their male offspring were mated to del36 deletion carriers. Progeny 
resulting from this cross that exhibited a Satin coat would be hemizygous deletion 
carriers which carried the Satin allele (see figure 3.2). A reduction in the numbers of 
Satin coated individuals resulting from such a cross would suggest linkage between 
Foxql and a hemizygously lethal mutation.
ENU
3H1BALB/c
BALB/c 3H1 sa
Del 3H1
C57BL/6J BALB/c (+)
+ / * (sa )  Del / *  (sa)+ / Del
F i g u r e  3 . 2 :  B r e e d i n g  S c h e m e  f o r  t h e  L e t h a l  R e c e s s i v e  S c r e e n
Following ENU injection, Satin coated C3101F1 (3H1) males were bred with BALB/c females until 
30 male progeny were available for further breeding. Male offspring were then mated with female 
Del36H deletion carriers until at least 25 progeny were obtained from each G1 cross. Those lines 
which produced a significantly lower than expected ratio of Satin coated individuals (Del/^sa)) were 
considered as potential lethal mutations and underwent inheritance testing for evidence of the 
heritability of the mutation.
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3.6 Mouse Strains Used for the Lethal Recessive Screen
Four mouse strains were involved in the lethal recessive screen as shown in figure 
3.2. The FI hybrid progeny of C3H/HeH (henceforth known as C3H) and 101/H 
have been referred to as 3H1 throughout this work.
ENU mutagenesis was performed on males that were homozygous for the Satin 
allele. The satin colony was maintained as a closed colony segregating C3H and 101 
alleles
The two mouse strains BALB/c and C57BL/6J (henceforth known as B6 ) were used 
at various stages of outcrossing during mutation testing and recombinant mapping of 
mutant lines (see sections 3.5 and 3.12 for further details).
3.7 Microsatellite Marker Design and Polymorphism Testing
A dense STS map was built up during and prior to the construction of the minimal 
tiling path contig as described in sections 3.1-3.4. Despite this, however, there was a 
dearth of available polymorphic markers for fine mapping of mutant loci. Markers 
were required within the Del36H region that were polymorphic between the strains 
involved in the lethal recessive screen (figure 3.2). These were intended for 
recombinant mapping for the localisation of mutations arising from the screen. 
Microsatellites have a tendency to undergo ‘slippage’ on replication [225] causing 
variability in the size of their alleles, making them ideal loci to screen for 
polymorphisms between inbred mouse strains.
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Novel microsatellite markers were generated within the Del36H region using draft 
sequencing data from the BACs selected for the sequencing of the Del36H interval 
(section 3.4).
BAC sequence was screened for microsatellite repeats using web-based repeat 
masker software [220]. Primers were designed flanking these repeats, which were 
then used to amplify loci in each of the strains involved in the recessive screen in 
addition to mice with a 3H1 background and homozygous carriers of the satin allele 
(B6 ; BALB/c; C3H; 101/H; 3H1; satin). SSCP and agarose gel analysis was then 
performed on each sample to identify polymorphisms between the strains as 
described in sections 2.2.13 & 2.2.14.
117
Richard McKeone PhD Thesis
tel w* S 3  W» a s
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Figure 3.3: An SSCP gel
This technique involved adding denatured PCR products to the wells o f a 0.5% bis-acrylamide gel 
and subjecting the gel to a low voltage current for 8-16 hours as described in section 2.2.13. This 
technique was pioneered by Orita et al [208] but has been adapted to allow the detection o f single 
nucleotide polymorphisms as well as microsatellites. Single stranded DNA is affected by factors 
other than size during its migration through an electrophoretic gel. Single nucleotide polymorphisms 
(SNPs) within the sequence may also affect the electrostatic nature and therefore potentially the 
migration o f the fragment. Image taken from http://instruct.uwo.ca/biology/366b/SSCPgel.
Markers designed around dinucleotide repeats were prefixed “DNR”, those 
containing trinucleotide repeats were prefixed “TNR”, and those surrounding 
tetranucleotide repeats were prefixed “TetNR”.
The microsatellites tested were a rich source o f informative markers for the strains 
involved in the lethal recessive screen. O f the 117 markers which were successfully 
amplified and tested, 64 showed some level o f polymorphism between the strains. 
There was however, a range o f levels o f polymorphism between the different strains 
as can be seen in table 3.3.
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C3H 
101/H 
B6 
BALB/c 
sa
T a b l e  3 . 3 :  P o l y m o r p h i s m s  i d e n t i f i e d  d u r i n g  t h e  m i c r o s a t e l l i t e  s c r e e n
The number o f polymorphisms found in novel microsatellite markers from the Del36H region within 
those strains that were used for the lethal recessive screen.
There were distinctive regional patterns of polymorphism across the deleted region 
(Table 3.4) -  some BACs contain microsatellites which were primarily non- 
informative between the screen strains (e.g.: 80c 18,461o24,128m23). BACs at the 
distal and proximal ends of the region contain microsatellite markers which 
predominantly were not differentiable between C3H, BALB/c and Satin strains, but 
were informative between any one of these strains and B6  (i.e.: 38e20 at the 
proximal end, and 412p21,408hl7,235j20 and 262j21 at the distal end. The BAC 
41121 which was also located towards the distal portion of the region showed 
uniformity in microsatellite sizes between the strains C3H and BALB/c with a 
different sized product in B6  and 101/H, but the Satin strain was not tested with 
markers derived from the sequence of this BAC).
Strain 101/H exhibited the largest number of microsatellite markers with unique 
product sizes (a total of 41). However, in markers where 101/H could be 
differentiated from some strains but not others, 101/H shared its SSCP profile with 
B6  in 8  of the 10 instances. Seven of these are from the three most distal BACs to be
BALB/c
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characterised in the interval. The exception was marker DNR138 in which 101/H is 
the same size as 3H1 whereas B6  has a unique product size.
SSCP profiles of the mouse species Mus spretus and the sub-species Mus musculus 
castaneus were also compared with those of the lethal screen strains. This was 
because these less related strains were considered for potential future outcrosses.
6 6  markers were tested for polymorphisms between M. m. castaneus and the screen 
strains. Of these, 9 markers failed to amplify in M. m. castaneus and 2 were not 
informative (DNR006 and DNR009). 74 markers were tested for polymorphisms 
between M. spretus and the screen strains (including all but one of those tested on 
M. m. castaneus), of which 4 failed to amplify in M. spretus and 1 was not 
polymorphic with the screen strains (DNR114 which was not tested in M. m. 
castaneus).
Evidence of haplotype blocks can be seen in these data (table 3.4). These are regions 
in which closely linked markers exhibit similar or identical patterns of 
polymorphism between the strains. Tim Wiltshire and colleagues carried out a study 
of the haplotype patterns seen with SNPs in 8 different laboratory mouse strains and 
noted that these blocks often extend for tens of megabases and ended abruptly, 
where they are bordered by recombination hotspots [226]. The polymorphism 
patterns that can be seen in table 3.4 frequently produced identical haplotypes for 3- 
4 markers sourced from the same BAC and occasionally also in the closest BAC
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from which microsatellites were selected for screening. BACs were screened on 
average at intervals of once per 5 BACs across the deleted region which equates to 
intervals of ~6 6 8 kb given that the MTP of the 12.7Mb region consists of 95 BACs. 
Haplotype blocks were however smaller in these data than those described by 
Wiltshire. If as this preliminary analysis suggests, the haplotype blocks within the 
Del36H interval are smaller than the genome average block size (3.57Mb according 
to Wiltshire), then the number of recombination hotspots are likely to be more 
numerous. This could explain the expanded size that was predicted from genetic 
map data.
The deletion is also larger when estimated cytogenetically than with the physical 
map. Chromosomes and chromosomal regions have traditionally been determined by 
measuring their length at metaphase, then estimating the percentage of the whole 
genome from the size of all the chromosomes combined at an assumed figure of 
3000Mb [227]. Some modifications to this approach have since been suggested 
[228] due to the faster speeds at which the giemsa positive bands condense during 
metaphase [229] and also due to a more accurate figure for whole genome size since 
the completion of the mouse genome. Furey and Haussler analysed data from -9500 
previous Fluorescent In-Situ Hybridisation (FISH) BAC mapping experiments and 
compared these data with previous cytogenetic size estimations. They found that the 
giemsa positive bands were larger than previous estimations by between 4% and 
24%, depending on staining intensity [228].
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The deleted cytogenetic bands in the Del36H deletion are from A3.3 to A5 inclusive 
[21]. Estimations of chromosomal length placed this region at 20.1 % of the length 
of chromosome 13 and (using a whole genome size estimation of 3.2Gb) -  a 
physical size of 25.6Mb [21]. These figures equate closely with the deletion size 
predicted by the genetic map but not with the 12.7Mb from the BAC contig 
sequence.
The structural factors that Furey and Haussler highlighted as sources of chromosome 
density variability are likely to have contributed to inconsistencies in the estimation 
of the deletion’s length - GC content, repeat structures, CpG island density, gene 
density and degree of condensation are all likely to effect the apparent size of a 
chromosomal region during cytogenetic analysis. The deleted region is 
comparatively rich in G positive band material -  of the 3 bands that make up the 
deleted region, two are G positive (13A3.3 and 13A5) and these are both visually 
larger than the 13A4 G- negative band
(http://www.ensembl.org/Mus_musculus/index.html). This suggests that if Furey’s 
hypothesis is correct, the deletion should be larger than initially estimated whereas 
BAC sequencing indicated a smaller size.
False Positive Results
Some indication of the level of incorrect scoring from the SSCP and agarose 
polymorphism screen can be ascertained by comparison of this data with the allele 
size data determined for a selection of these markers as described in section 3.12.
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SSCP occasionally resulted in bands that could be seen in some samples but were 
hidden in others due to slight differences in signal strength.
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BAC RPCI- 
23 Clone 
No.
BAC 
Position in 
Contig
Total No. 
Markers 
T ested
No. of 
Polym orphic  
Markers B6 101 3H1 satin C3H BALB/c
38E20 5 3 u u C :L S :L C :S
480B19 21 11
4 u S;C;L ■ A 1;S;L 1;S;C
1 u L u U 1
1 1;C;L B;C;L u B; 1; L B: 1 :C
80c18 26 4 0 N N N N N N
461024 29 4 0 N N N N N N
211M15 32 8 1 U U
2 S:C:L U B:C:L B;S:L B:S:C
19a04 33 3 1 S:C:L U B;C;L B:S:L B:S:C
169M24 41 2 1 S:C:L u B;C;L B:S;L B:S:C
189A16 46 3 1 U u L U S
128M23 54 10 1 U 3:S:C:L 1:S:C:L 1:3:C;L 1:3:S:L 1:3:S:C
262C06 60 12
1 u 3;S;C;L 1;S;C;L 1;3;C;L 1;3;S;L 1;3;S;C
1 1 B U C;L S;L S;C
3 S;C;L U U B;C;L B;S;L B;S;C
1 1;3;S;C B;3;S;C B;1;S;C B;1;3;C B;1;3;S u
202F03 63 5 4 S;C;L U B;C:L B:S:L B;S;C
47A02 65 8
4 S;C;L U U B;C;L B;S;L B;S;C
1 3;S;C u B;S;C B;3;C B;3;S U
1 1:S:L B;S;L U B: 1 :L U B: 1 :S
23501 66 8 3 S;C;L U U B;C;L B;S;L B;S;C
1 1:S:L B:S;L u B:1:L U B:1:S
232M10 67 9
1 L u u U U B
1 S U B L C
3 3;S;C;L u B;S;C;L B;3;C;L B;3;S;L B;3;S;C
2 S:C:L u U B:C:L B:S:L B:S:C
412P21 73 3 1 U u u C ;L S ;L C ;S
1 u 3 1 C :L S :L C ;S
408H17 75 3 3 . u u u C :L S ;L C :S
235J20 76 1 1 u u u C :L S ;L C :S
322J11 78 8
1 u u U U U
1 u u u C ;L S :L c  ;S
2 S;C;L u u B;C;L B;S;L B;S;C
1 S:C:L u B;C:L B;S:L B;S:C
43L14 86 3 1 U u S;C;L 3;C;L 3;S;L 3;S;C
1 1 B C :L S :L C :S
41L21 93 6 3 1 B L C
262J21 95 3 3 1 B C :L S :L C :S
Key to Polym orphism  R esults
B Product size = C57BL/6J = 1 other product size
1 Product size = 101/H u Unique Product size
3 Product size = 3H1 N Not informative
S Product size = Satin strain Not tested or failed to amplify
C Product size = C3H/HeH
L Product size = BALB/c
Table 3.4: Polymorphism data for informative BACs
The number o f  markers tested are shown by clone, alongside the number o f polymorphic markers 
with each pattern o f polymorphism shown. BAC clones are in their respective order within the 
deletion interval. For complete dataset, see appendix 3.3.
3.8 Satin and 3H1 Unexpected SSCP Profiles
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3H1 mice are the offspring of matings between C3H and 101/H mice. The SSCP 
profiles were scored on the basis of whether a difference was seen between profiles, 
so an individual which was heterozygous for a particular polymorphic allele would 
be classed as different from either of the two mono-allelic forms. The SSCP profiles 
for 3H1 were therefore often classified as “unique” when the C3H profile differed 
from that of 101/H and when the 3H1 strain carried both alleles.
Of the 64 markers tested with 3H1 DNA, 24 (37.5%) showed what was classified as 
a “unique” product profile. All of these markers were polymorphic between the C3H 
and 101/H alleles. There were 5 markers which were not classified as “unique” in 
3H1 despite a difference between the products of C3H and 101/H. All of these 
markers shared a profile with C3H rather than 101/H when tested with C3H mice. It 
is possible that preferential amplification of the C3H allele may have occurred, 
although it would be surprising if all 5 of the markers preferentially amplified the 
C3H allele rather than the 101/H allele. Another possibility is that the unique profile 
of 101/H did not represent a real difference, but again -  it is unlikely that the C3H 
allele would dominate in all 5 of the alleles by such a chance event. These spurious 
results are unlikely to represent a double recombination because for each example of 
markers which showed a difference in profile between C3H and 101/H but not C3H 
and 3H1, there were other markers from the same BAC sequence which did show a 
difference between C3H and 3H1.
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There was a higher than expected variability between 3H1 and Satin mice. Of the 37 
polymorphic markers which were tested for 3H1 alleles, only 8 produced the same 
SSCP profile as the Satin mice (the same markers for which 3H1 shared a profile 
pattern with C3H). Fifty of the 58 polymorphic markers that were tested in both 
Satin and C3H produced the same profile, so it appears that the background of the 
Satin strain has more in common with C3H than with 3H1.
The satin mutation has a complex history following its discovery by LB Russell in 
1955 ([230] referred to in [220]) - prior to the lethal recessive screen it was on a 
lineage which also contained pearl, muted and vestigial tail. Before and after its re­
derivation, satin was maintained as a closed colony of salsa mice segregating C3H 
and 101/H alleles. However during the screen, the satin strain was bred onto a C3H 
lineage until it was congenic for C3H. This background may go some way to explain 
why some regions of the Satin genome do not have a 1:1 ratio of C3H and 101/H 
backgrounds.
3.9 Marker Redundancy
Two markers showed redundancy with other markers in the del36 region: DNR 50 
and DNR51 (See appendix 3.2). These microsatellites have almost identical primer 
sequences, only one base differs between them (the 5th base in the reverse primer is 
an A in DNR050 and a T in DNR051). It was later discovered that these 
microsatellites were contained within two related genes which formed a prolactin 
cluster -  DNR50 in prolactin3d3 (Prl3d3) and DNR51 in prolactin 3dl (Prl3dl).
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e-PCR
On screening of the microsatellite sequences with e-PCR
(http://www.ncbi.nlm.nih.gov/sutils/e-pcr/), seven of the microsatellites were found 
to be markers with previous designations.
Redundant Designated
Marker Marker
DNR008 d13mit154
DNR012 d13 Mit 79
DNR023 d13cwr7
DNR050 Al325057
DNR051 Al325057
DNR114 D13Mit81
DNR131 PMC315447P1
T a b l e  3 . 5 :  R e d u n d a n t  M a r k e r s
Markers identified during microsatellite screening which were already designated markers. DNR050 
and DNR051 were highlighted as redundant to the same existing marker -  Al 325057. This is also 
reflected in the UNISTS description o f AI325057 which warns o f matches to multiple loci 
(http://www.ncbi.nlm.nih.gov/genome/sts/sts.cgi?uid=l 85969).
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3.10 SNP Discovery
SNPs have the advantage over microsatellites that they can be run on systems such 
as the pyrosequencing unit described in section 2.2.26. It was therefore decided that 
a pilot study could be carried out to investigate the potential for SNP discovery 
within the Del36H interval.
Regions of repeat masked BAC sequence were screened with Pipmaker (section 
2.2.14) prior to testing, so that only regions of low homology between mouse and 
human were tested. It was considered important to avoid regions of high homology 
because this can imply functional significance of a region and therefore reduce the 
probability of polymorphisms between the strains.
Single base changes can be visualised by SSCP when the denatured (upper) bands 
are clearly visible. Detection of these bands is more sensitive to differences in salt, 
temperature, solvents, and ionic strength of the buffer than the lower, dsDNA bands. 
Because of this, it was decided to run the PCR products in four different conditions. 
Temperature and buffer type were both varied. Straight TBE was used as well as 
TBE containing HEPES. An air cooled SSCP tank allowed 20°C runs in addition to 
the usual runs at 4°C
SSCP gels were run under the various ionic and thermal conditions described in 
section 2.2.14. This method was used in order to maximise the probability of SNP 
detection with an SSCP approach.
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Primer set c l3SNP lc (cl3SNPl R & cl3SNPlc L) produced SSCP bands which 
suggested a conformational change between B6 and Bc/C3H. This was detected with 
HEPES/TBE at 4oC and 20oC, and with TBE at 20oC although no difference was 
observed in TBE at 4oC following standard SSCP running conditions. No 
polymorphisms were detected in this PCR product.
SSCP of primer set cl 3 SNP 9b (cl3SNP9 L & cl3SNP9b R) suggested a 
conformational change between 101/H and all other strains. This was detected at 
4oC in both TBE with HEPES and TBE alone. A series of 10 polymorphisms were 
discovered within this sequence as listed in table 3.6.
Polymorphism
Number
Base Change 
(B6/Bc/C3H to 
101/H)
Ensembl
v46
Position
1 C-G 29321009
2 C-A 29321083
3 C-T 29321133
4 G-A 29321150
5 G-A 29321155
6 T-C 29321191
7 G-T 29321193
8 T-G 29321199
9 G-T 29321200
10 T-G 29321204
Table 3.6: Single Nucleotide Polymorphisms (SNPs)
These SNPs were discovered in the PCR product cl3SNP9b. Ensembl positions are within 
chromosome 13 and are according to Ensembl version 46.
No SNPs were detected with SSCP in any of the other PCR products. Although 
several polymorphisms were discovered with this approach, all of them were 
between 101/H and the other strains of the screen. There were already a large 
number of microsatellites in the interval with this haplotype so these SNPs did not
129
Richard McKeone PhD Thesis
provide an additional level of informativeness. The microsatellite polymorphism 
discovery process was more efficient at the provision of informative markers than 
was the SNP discovery process -  there was no way of telling which regions were 
likely to contain variability without screening large quantities of PCR products. 
Conversely, microsatellites are inherently unstable and therefore prone to variation. 
The relatively small scale of the polymorphism detection aspect of the project meant 
that SNP discovery was discontinued to allow for a focus on the more efficient 
microsatellite polymorphism discovery approach. An alternative technology that 
wasn’t available for SNP discovery at the time is dHPLC (described in chapter 4). 
This would have provided a high throughput and reliable tool for the detection of 
SNPs.
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3.11 Construction of the Genotyping Panels
Marker Panel 1
A total of 17 polymorphic markers were selected from across the region to identify 
recombination breakpoints (figure 3.4). Seven of the markers were from the 
Whitehead/MIT marker resource and had previously been tested for polymorphisms 
by M. Cadman and T. Marsland (unpublished data), 11 were uncovered during the 
microsatellite polymorphism screen (sections 2.2.14 and 3.7). Allelic sizes of an 
initial genotyping panel of 10 markers were determined by J. Ragoussis at the 
Wellcome Trust Centre for Human Genetics (WTCHG), then reanalysed at Harwell. 
There were some differences between the datasets as can be seen on table 3.7. Some 
of the size calculation variations could be explained by the use of different capillary 
electrophoresis systems (the Ragoussis group used the MegaBACE system 
(Amersham Biosciences), Harwell genotyping was performed with an AB3100 
Prism system) and different size standards (the Ragoussis group utilised the ET 
ROX 400 size standard system (Amersham Biosciences) whereas at Harwell, a NED 
labelled size standard was used as described in section 2.2.15), but there were some 
discrepancies which cannot be explained simply on this basis alone.
The same pattern of polymorphism and order of allele sizes was observed in each 
dataset for the majority of markers. This suggests that most of the variation could 
result from a difference in the method of size determination by the two systems 
rather than the amplification of different regions.
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DNR003, DNR059 and DNR 024 consist of alternative reverse primers in Harwell 
set 1 (see table 3.8) whereas the original reverse sequence was used at the WTCHG. 
This explains the large differences between the product sizes seen in DNR003 and 
DNR059 at the two centres. The marker TetNRlO showed a size difference of 9bp 
between the Harwell and WTCHG sets. This difference was exactly the same in each 
strain -  and the Ensembl size prediction for the B6 allele (212bp) was closer to the 
Harwell prediction of 21 lbp than the WTCHG prediction of 220, suggesting that 
different primers may have been used at the WTCHG to amplify the same 
microsatellite. It is also possible however, that this difference is due to the 
differences in systems and size standards.
D13Mitl7 has a difference of 8.2 bp for the B6 allele, but less than 4 for the others. 
The Harwell B6 prediction of 169bp appears closer to the Ensembl prediction of 
168bp than does the WTCHG prediction of 177.2. The differences seen in these size 
calculations are small enough that they could be due to size standard or system 
differences.
The initial Harwell panel was replaced by a second panel of markers after the third 
plate of 96 samples were genotyped. The primary reason for this was because there 
was a large gap (8.25Mb) between the markers DNR 59 and TetNR5. In order to 
achieve an improved breakpoint resolution in the event of recombination and to 
reduce the risk of double recombinants going undetected, a number of additional 
markers were inserted into this gap.
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Figure 3.4: Position of Genotyping Markers
The position o f each marker used for genotyping o f individuals from lines generated by the lethal 
recessive screen for mutations within the Del36H region. These positions were calculated by Ensembl 
version 41 as shown in appendix 3.2. Red markers are those markers which were in the first panel but 
removed from the second panel. Pink markers were in both the first and second panels. Blue markers 
were only present in the second panel. The Black divisions represent intervals o f 5Mb across the 
region.
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Table 3.7: Marker Panels Used in the different genotyping schemes
Markers used to genotype individuals arising from the lethal screen. Underlined markers are those 
which were modified to produce different product sizes for the Harwell panels as described in table 
3.8. Each forward primer was labelled with a fluorescent dye as indicated by the highlighted colour 
and by the dye listed below each marker heading. The figures from Harwell are medians o f the size 
ranges seen for each marker (all markers had a range o f less than +/- 1.)
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Marker Panel 2
The markers DNR 059, DNR003 and DNR 016 were removed from the second 
panel because adjacent markers were available which had the same level of 
informativeness.
DNR 59, although informative between B6, 101/H and BALB/c/C3H/&tfw, is only 
0.5 Mb from D13Mitl7 (figure 3.4) and has the same level of informativeness as this 
marker (see table 3.7). DNR003 and DNR016 are both very close to marker 
D13Mitl36 (0.41Mb and 0.002Mb respectively) and all three had the same level of 
informativeness (101/H # B6 ^ C3H = Be = Satin). In order to allow an easy 
transition to genotyping with the increased number of markers, DNR059, DNR003 
and DNR016 were removed from panel 2.
It was intended that D13Mitl 17 should be added to the second panel of markers.
This marker ( at 34980274bp Ensembl v.41) lies outside the deletion at the distal end 
(the deletion breakpoints were determined by the Ragoussis group to 20870225- 
34915188 in Ensembl v41 (20954629 -  34999592 in Ensembl v50) but is more 
informative than D13Mitl98 because it is polymorphic between B6 and 101/H, in 
addition to differentiating between those strains and the other screen strains. 
Unfortunately optimisation with the multiplex PCR conditions used for this aspect of 
the project was unsuccessful and D13Mitl 17 was not amplified in the presence of 
the other HEX labelled primers.
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DNR11 l(Ri) was a variation of marker DNR111 with an alternative reverse primer 
that produced an appropriately sized product for incorporation into the Harwell 
marker set (see table 3.8). This was a ROX labelled marker that was intended for 
multiplex PCR with DNR 37 and D13Mitl5 (F+Ri), but it failed to amplify in their 
presence. Although DNR111 lies close to DNR 101 (0.3Mb separates the markers), 
its presence in the panel could have increased informativeness because it 
distinguishes between 101/H and B6. Unfortunately, despite apparently successful 
optimisation in a preliminary study, the product was not robust in response to small 
variations in DNA quality so very few individuals were successfully genotyped for 
this marker.
As can be seen from tables 3.4 and 3.7, there is a varying degree of informativeness 
across the deleted region. The absence of a panel of fully informative markers limits 
genotyping confidence when screening individuals from a screen as complex, and 
with as many strains involved, as this type of screen. It was therefore not possible to 
specify the genetic origin of each locus.
The mutagenised or potentially mutagenised parental chromosome in each of the 
mutant lines should be derived from Satin - 3H1. The reason that both C3H and 
101/H were tested for polymorphism is because 3H1 consists of both C3H and 
101/H alleles. Any recombinations between chromosomes derived from these strains 
is not significant for the purposes of this study because either may have been 
mutated whereas B6 and BALB/c should be wildtype.
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Alleles derived from BALB/c, C3H and Satin show similar profiles at several 
markers. This has meant that where a recombination has occurred between BALB/c 
and C3H, there cannot be as high a degree of confidence in determining the 
breakpoint position as there would be in a recombination between B6 and C3H. B6 
parental origin could be uniquely determined at 10 of the 14 loci selected for the 
second panel of polymorphic markers allowing higher degree of accuracy in 
determining the breakpoints between B6 and mutagenised chromosomes.
Optimising product size of genotyping markers
Four of the panel 1 markers required further optimisation for a robust PCR and clear 
distance between marker band sizes (on agarose optimisation tests) in multiplex 
conditions: DNR016, DNR059, DNR003 and DNR024. Alternative reverse primers 
for these markers are shown in table 3.8.
Due to the increased number of markers in the second panel, there were a number of 
markers which shared product sizes. B6 product sizes could be predicted from the 
available sequence data, but the exact sizes of products for each of the other strains 
were not known.
Reverse primers were therefore designed for a range of markers that overlapped or 
were of a similar size when amplified. This approach maximised the combination of
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different sized products and was intended to allow the construction of a marker 
panel with clear differences between each product within the dye sets.
PCR optimisation was carried out with the original dye labelled forward primers and 
each of the reverse primers individually - in order to achieve clear, strong signals for 
each product. The estimated sizes were used to construct batches of markers for 
genotyping with discemable distances between each product when run on an agarose 
gel.
Four markers were altered for genotyping panel 2 (see table 3.8) and one, DNR059 
was altered for genotyping panel 1, due to a more robust PCR and a greater 
difference between marker product sizes with this sequence.
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Primer Alternative Reverse Sequence 1 (Ri)
Alternative Reverse 
Sequence 2 (Rii)
Alternative Reverse 
Sequence 3 (Riii)
DNR076 ACAAAGAAGTGCTCCCAACC CCCAGCTTAGCAAACCAATAC ACAGGTGTGCATCAACAGAAC
DNR123 CGGCAGGATGCCTATTATATTG TGATAAGTAGTTCCAGGCCTTAGC CCACAGATCATCTAGCTTGTGC
DNR101 TTTCTTCCGCTTCCATTAGG CTTCCAACTGGGCCAAAAC TCCATTAGGCAGATCAAATGTC
DNR048 GCAGATTCAGGTGTCTGAGG GGGTTACTTGTATCACCCTACCC GAGGGTTATTGAGATCTTGATGG
DNR111 AACAGAGACCCTTTGTGAGAGC GACTCCTGAGTGGTTGTGAGC AAGCACAGCAGGAAAACTAACAG
DNR016 TCCTAAGCCACACCCAAGAG ATCCCTGGAACCTCAAATCC
DNR059 TTTTGCCCTATCCAGACCAG CGGAAAAGGAAAAGAATAAAAGG
DNR003 ATAAGGCATTGGCGAGAATC TAAAGGGCATTTCCTTGGTC
DNR024 TCACTCAACACTTACATCATAGGC GGGGTACCTCAATCACTCAAC
D13Mit15 CCGTTTAGGI I I I IAAG I IAGAGG
T a b l e  3 . 8 :  A l t e r n a t i v e  r e v e r s e  p r i m e r s  f o r  g e n o t y p i n g  p r i m e r s
The primer sequences in red were those which replaced the original reverse primers for the 
genotyping screen i.e.: DNR123 Rii, DNR101 Rii, DNR048 Ri, DNR024 Rii, D13Mitl5 Ri. DNR111 
was not included in the genotyping panels due to the lack of a robust product for PCR with any of the 
reverse primers.
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3.12 Analysis of Genotyping Data
The nature of this genotyping project and the number of strains involved increased 
the possibilities for ambiguities within the data. There were effectively four strains 
which required differentiation during the genotyping of individuals from the lethal 
recessive screen. For simplicity, satin alleles were characterised as “C3H”. Most of 
the markers would not differentiate between these two origins and for the purposes 
of the project the difference was irrelevant because the allele sizes of C3H and sa 
both indicate origin from the mutagenised lineage. The two strains were therefore 
grouped together for convenience of data organisation.
Ideally, each marker used for characterising the genetic origin of the Del36H region 
would be polymorphic between each of the in-bred mouse strains involved in the 
screen. This is unrealistic however given the close degree of relatedness of some of 
these lineages. It was therefore necessary to select a panel of markers which 
provided the maximum level of polymorphism between the strains selected from the 
available set, at approximately regular intervals across the interval.
In order to simplify genotyping output, the combined informativeness of markers 
was employed in order to regionally determine the specific strain origin across the 
deletion. In recombinant individuals, strain origin was frequently ambiguous but 
strain information could be inferred by utilising the differing polymorphisms of the 
surrounding markers, thus limiting the region of ambiguity.
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For example, the haplotype pattern shown in the genotyping data of figure3.5A 
shows a (C3H x B6)F1 individual. Five of the 10 markers in panel 1 (and 10 of 14 
markers in panel 2) can differentiate B6 from the other strains and it is clear that B6 
is present across the region on one of the two chromosomes. Many of the markers 
though, cannot differentiate between C3H and BALB/c, but those that do 
differentiate suggest the presence of C3H and not BALB/c therefore this individual 
was scored as a non recombinant individual.
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Potential Strains 1 B B B B/L B/1 B B B/1 B/1 B/1
Assumed Strain 1 B B B B B B B B B B
Allele Size 1 148 177 210 312 220 224 194 214 170 93
Allele Size 2 138 155 205 255 216 234 188 219 188 95
Assumed Strain 2 C C C C C C C C C C
Potential Strains 2 C L/C L/C C C/L C C/L C/L C/L C/L
B
Potential Strains 1 B B B B/L B/1 B B B/1 B/1 b r
Assumed Strain 1 B B B B B B B B B B
Allele Size 1 148 177 210 312 220 224 194 214 170 93
Allele Size 2 134 155 205 255 216 234 188 219 188 95
Assumed Strain 2 L L/C L/C C C C C C C C
Potential Strains 2 L L/C L/C C L/C C L/C L/C L/C L/C
F i g u r e  3 . 5 :  E x a m p l e  o f  D e l 3 6 H  G e n o t y p e  D e t e r m i n a t i o n
Marker combinations were used to infer strain origin within regions of the interval. A is a non­
recombinant B6/C3H individual (D36/1409.01 in appendix 3.1). B is a recombinant individual with 
B6 and a recombination between BALB/c and C3H. (Mud/1616.05 in appendix 3.1). Note that double 
recombinants between these strains could be missed due to a lack of markers that can be used to 
distinguish between BALB/c and C3H.
Although a large number of markers were screened, there remains a dearth of 
markers which are informative between BALB/c and C3H. DNR037 and TetNr05 
were uncovered during the screen, and there are several markers that can
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differentiate BALB/c from either satin alleles or C3H alleles but not both. However, 
this was not of interest within the context of this project because genotyping was 
performed in order to identify the alleles on chromosomal segments which could 
potentially carry the mutation (C3H, Satin, 101/H) from those which wouldn’t (B6 
and BALB/c) in order to define the critical regions in which mutations were most 
likely to be found.
Ambiguous 296bp FAM Product
An oversight in the design of marker panel 2 resulted in a FAM product at 296bp 
which could be either a DNR123 product of 101/H origin or a TetNR05 product of 
BALB/c or 101/H origin. This was a potential problem for unambiguous genotyping. 
In hindsight, one of the primers for these markers should have been reordered with a 
different dye (either ROX or FAM) label in order to benefit from the maximum 
informativeness of the panel.
Fortunately, the markers on either side of DNR123 (D13Mitl5 and D13Mitl7) were 
informative for BALB/c and 101/H when combined. The combination of markers 
adjacent to TetNR05 (TetNRlO and DNR101) was also informative for 101/H. In 
addition to this, many of the other markers within the panel are also informative for 
101/H.
Of the 741 suspected recombinants from genotyping at all stages, only 25 
individuals carried a BALB/c or 101/H allele at DNR123 or carried a 101/H allele at
141
Richard McKeone PhD Thesis
TetNR05. Most of the BALB/c and/or 101/H alleles at these loci fitted the general 
pattern of the region and could be confirmed as either both loci of 101/H origin, both 
of BALB/c origin, or one loci of BALB/c and one of 101/H origin -  by analysis of 
the adjacent markers.
There were three individuals, however, for which the information from the 
surrounding markers did not resolve the ambiguity at these loci.
The two individuals with the genotype seen in Ml 239.29 (the 29th listed haplotype 
for animals of line 1239 after its confirmation as a heritable mutation) of appendix
3.1 were scored as 101/H at DNR123 and C3H at TetNR05. However, the size 
overlap of the FAM product at 296bp would suggest that a 101/H allele could also 
be present at the TetNR05 locus. This ambiguity would not affect the significance of 
the result as either 101/H or C3H could represent the mutagenised background of 
3H1.
The one individual with the haplotype indicated by M412.22 in appendix 3.1 was 
scored as B6 at DNR123, which is the most distal marker of a region of B6 (adjacent 
to a region of B6/101/H), and B6/101/H at TetNR05. The presence of the 101/H 
allele at TetNR05 suggests that a 101/H allele could also be present at DNR123. 
However the marker proximal of DNR123 is D13Mitl7 -  this was conclusively B6 
without the presence of a 101/H allele so a region of only B6 origin is definitely 
present in this individual but the extent of this region is uncertain. In this case the
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size ambiguity limited the resolution of the breakpoint position following a 
recombination between B6 and 101/H.
One event which could have been missed as a result of the overlapping product sizes 
is a double recombination leading to 101/H or BALB/c at DNR 123, or 101/H at 
TetNR05, between the surrounding markers. However, given the relatively low 
numbers of individual genotyped with Harwell marker panel 2 that carried either 
BALB/c or 101/H alleles within the interval, this seems an unlikely occurrence.
Genotyping
Genotyping of each of the mutant lines was performed in collaboration with J. 
Ragoussis and analysis of the combined results was performed by D. Bogani and C. 
Willoughby. All animal work in this section was performed by the Early 
Development group and animal staff from building 383 (MRC Harwell). Data from 
1325 animals genotyped at MRC Harwell was added to data from 6446 animals 
genotyped by the J. Ragoussis laboratory for a total of 7771 animals. The screening 
of mutant lines was carried out in three different stages: Lethality testing, inheritance 
testing, and mapping.
Lethality testing
Animals were bred for lethality testing as described in figure 3.2. Genotyping was 
carried out to ensure that the mutagenised chromosome wasn’t disrupted by 
recombination within the Del36H interval in animals to be used for the
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determination of embryonic lethality. The exact one-tailed binomial test was used to 
compare the birth-rate of satin coated animals with the expected birth-rate. This 
allowed the determination of whether a lethal recessive mutation was present in the 
lineage or not (D. Bogani, personal communication). Individuals with the prefix 
“Mud” in appendix 3.1 were those animals resulting from the lethality testing stage 
of screening.
Inheritance testing
The inheritance testing stage also required genotyping to ensure that the mutation 
wasn’t lost due to recombination. Satin coat locus data from all of the individuals of 
each cross was subjected to the one tail binomial test at 95% and 99% significance 
levels. It was at this stage that the severity and dominance relationship of the 
mutation could be determined. Individuals with the prefix “Mudy” in appendix 3.1 
were those animals resulting from the inheritance testing stage of screening.
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Q 3H1 X
Del
C57BL/6J (+) C57BL/6J (+)
+ / + + / Del + / *  (sa) Del / *  (sa)
3H1 *  sa *  sa
X
C57BL/6J (+) C57BL/6J (+)
+ /  + + / *  (sa) + / *  (sa) *  (sa) / *  (sa)
F i g u r e  3 . 6 :  B r e e d i n g  S c h e m e s  f o r  I n h e r i t a n c e  T e s t i n g
Two breeding schemes were used for the inheritance testing stage of the lethal recessive screen. +/sa 
heterozygotes were either intercrossed or crossed to Del36H deletion carriers until at least 60 progeny 
were bom and tested for the Satin coat locus from each line.
Mapping and Mutant Line Maintenance
Mutants were crossed with Del36H deletion carriers and offspring were genotyped 
to identify recombinants. Recombinant individuals were mated as illustrated in 
figure 3.6 and the numbers of Satin progeny from recombinant lines underwent the 
exact one-tailed binomial test to determine if the mutation effect persisted. This 
approach enabled mutations with varying levels of penetrance to be mapped.
These offspring, in addition to animals which were bred for the maintenance of 
proven mutant lines were designated with the prefix “m”. Genotyping was required 
to ensure that haplotypes were maintained between generations during recombinant
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mapping and colony maintenance. The majority of animals with this designation 
listed in appendix 3.1 were genotyped for colony maintenance.
The mutations in the mutant lines were localised to the following regions (as shown 
in figure 3.7):
54: Between TetNRlO and D13Mit 136.
91: Sox4.
241: Between D13Mit 17 and 15.
369: Between TetNRlO and D13Mitl36.
412: Between TetNR5 andD13Mitl36.
624: Between TetNR5 and DNR24.
876: Between DNR24 and D13Mitl36.
1073: BetweenD13Mitl33 andD13Mitl36.
1185: Between TetNRlO and D13Mit 136.
1616: Between D13Mit84 andD13Mitl36.
1239: Between D13Mitl 7 and 15.
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Figure 3.7: Critical Regions of the Del 36H Mutants
Critical regions of the 11 mutant lines identified during the lethal recessive screen, including the line 
91 mutation which was mapped to Sox4. Mapping analysis o f each of the mutant lines except line 
91 was performed by C. Willoughby and D. Bogani using the genotyping data shown in appendix 3.1 
combined with genotyping data from J. Ragoussis. Image taken from Bogani et al [26].
3.13 Line 91 Recombinant Genotyping
Line 91 homozygous mutant embryos died at 14.5 dpc due to circulation defects 
caused by malformation of the atria and ventricular septa, a dysplastic mitral valve, 
and a reduced aortic arch [26]. The mutation was mapped to Sox4 (Ser70Pro) by M. 
Cadman [26].
Three surviving mud91 recombinant B6 / 3H1 deletion carriers were identified by J. 
Davies with the genotyping markers D13Mitl 15, D13Mitl33 and D13Mit 17. 
Further analysis of these individuals with the novel S SLP markers identified in 
section 3.7 indicated that the mud91 mutation lay between TetNR5 and DNR 201 
(see table 3.9). This is a physical distance of approximately 4.97Mb according to the 
Ensembl marker positions as listed in appendix 3.2. Frequency of recombination 
placed the mutation within 0.8cM of Foxql, further defining the critical region [26].
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Each of the recombinants that were mapped survived, so the region containing the 
mutation which would have occurred on a Satin chromosome has been replaced with 
B6 derived alleles in these individuals.
Marker BAC R1 R2 R3
BAC
Order
DNR59,63 38E20 B6 5
DNR60 38E20 B6 sa sa 5
DNR123 480B19 B6 sa sa 21
DNR201 211M15 B6 B6 sa 32
D13Mit133 201H16 B6 B6 B6 39
DNR48 189A16 B6 B6 46
DNR76 128M23 B6 54
DNR101 262C06 B6 60
DNR111 262C06 B6 60
TetNR5 232M10 sa B6 B6 67
DNR138 412P21 sa 73
TetNRlO 412P21 sa 73
DNR152,157,158 408H17 sa 75
DNR173 235J20 sa 76
DNR37 322J11 sa B6 B6 78
DNR 21,24 43L14 sa 86
DNR 2,3,4 41L21 sa 93
DNR 16,17 262J21 sa 95
Table 3.9: Genotyping of Mud91 for Confirmation of Sox4 Localisation
Mud91 is a mutant line derived from the lethal Recessive screen. R I, R2 and R3 are recombinant 
individuals which were initially identified by genotyping with the markers D 13M itl7  and D 13M itl36 
which occur near opposite ends o f the deleted interval. These data reduced the critical region to 
between the markers DNR201 and TetNR5 which is an interval o f 4.97Mb. This region included the 
transcription factor Sox4 (on BAC 262C06) in which a mutation had previously been identified in 
line 91 -  the recombinant mapping therefore supported the hypothesis that this mutation was 
responsible for the line 91 phenotype.
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3.14 FoxC Mutation Detection
Foxf2 lies within the Dell3(Svea)36H deleted region and was considered a strong 
candidate for several of the recessive lethal mutant lines. Midline development 
defects have been observed in the form of cleft palate in Foxf2 knockouts [153]. 
Although this was not as severe as the phenotypes seen in any of the lines from the 
lethal screen, holoprosencephaly is caused by the incomplete cleavage of the 
embryonic forebrain - which is also the result of a midline defect. It was therefore 
considered that a common mechanism may underlie these mutant forms. The 
occurrence of holoprosencephaly at varying degrees of severity in lines 54, 241, 369, 
624, 1073 and 1239 was considered as evidence for the potential involvement of 
Foxf2 in mutations from these lines.
DNA from one confirmed mutation carrier of each of the lethal lines except line 91 
was sequenced for mutations in the coding sequence of Foxf2. Although genotyping 
data would suggest the exclusion of Foxfi as a potential candidate from several of 
these lines, the low penetrance of some phenotypes did not allow such exclusions 
with a high degree of confidence. Mistakes in map location could have occurred 
with these low numbers, so all of the mutants that weren’t already cloned were 
sequenced. Some of these lines did not show a holoprosencephaly phenotype, but the 
transcriptional activity of this gene combined with its wide expression throughout 
the developing embryo suggested that it potentially has important and diverse roles 
in the regulation of development that have not yet been identified. Foxf2 maintains a 
persistent presence within a highly conserved cluster of forkhead box genes 
throughout the bilaterian group [126], and the benefit of potentially expanding the
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allelic series that are described in sections 4.5-4.6 meant that it was worth 
investigating each of the lines for mutations in this gene. Comparative sequence 
analysis of each of the different lines was performed on Contig Express before 
alignment with the consensus mouse genome sequence.
Despite the strong candidacy of the gene, no mutations were identified in the open 
reading frame of Foxj2 in any of the lethal lines. The absence of a Foxf2 coding 
sequence allele however, does not mean that Foxf2 is not critical for the survival of 
early embryos. It has been predicted that with the analysis of 1730 ENU 
mutagenised pedigrees, the probability of a functional allele being present within 
any one of the deletion interval genes is 80% [26, 201].
This calculation though, is based on the assumption that a functional allele would be 
detected. The selective parameters of a phenotype approach such as a lethal 
recessive screen are much narrower than the genotype-based approach that was used 
in the calculation of these probabilities -  A gene which has the potential for causing 
a prenatal lethal phenotype if mutated could instead become mutated at a locus 
which results in a less severe phenotype. So there is less than an 80% chance of a 
lethal phenotype being discovered in any potentially lethal gene in the region unless 
all potential coding mutations in each of these genes would result in lethality.
Foxf2 has not yet been thoroughly characterised, and its expression in embryonic 
tissues such as the CNS, ear, eye and limb buds where its close paralogue Foxfl is
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not expressed, suggest important roles for the gene in the developing embryo. Even 
within the mutants for which the open reading frame of Foxf2 has been sequenced, it 
may also be worth sequencing the UTRs and it is certainly worth investigating Foxf2 
promoter regions.
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Chapter 4: Foxf2 Mutation Detection
4.1 Introduction
Foxf2 was screened with Two ENU mouse mutagenesis archives to increase the 
probability of obtaining an informative allelic series for the gene. It was considered a 
strong candidate for the mutations that were envisaged could be uncovered using the 
deletion-based lethal recessive screening approach. Candidate selection before 
mutation discovery was possible because the nature of the screen meant that any 
mutations would be pre-mapped to within the 12.7Mb deleted region, and would 
result in embryonic lethality. Therefore genes in the deletion interval that were 
implicated in early development were key potential targets to screen the ENU 
archives.
Forkhead box (Fox) transcription factors are frequently involved in cell fate 
determination and pattern formation during organogenesis. Foxf2 is one member of 
a tightly linked and highly conserved cluster of three Fox genes in the Del36H 
region on proximal mouse chromosome 13 (consisting of Foxcl, Foxf2 and Foxql). 
It shares close sequence homology with Foxfl which is located in a semi paralogous 
cluster on mouse chromosome 8 (Foxll, Foxc2 and Foxfl).
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Foxfl and Foxf2 Expression and Sequence Homology
The DNA binding domain of Foxfl has 100% sequence identity with the DNA 
binding domain of Foxf2. Aitola and co-workers carried out a systematic 
comparison of the expression patterns of the two genes [188]. They found a 
significant overlap between the expression of the genes during embryonic 
development in the alimentary, respiratory and urinary tracts. However in contrast to 
Foxfl, Foxf2 is expressed in the central nervous system (CNS), sensory organs and 
limb buds; and is absent from the liver capsule. It has also recently been shown to 
have a role in the regulation of potassium channel formation in heart muscle [231].
Ormestad has shown that Foxfl is present at high levels throughout the gut whereas 
Foxf2 is more localised to the oral cavity and posterior gut [232]. He also detected 
much higher levels of Foxfl expression in the extraembryonic and lateral plate 
mesoderm, and suggested that this was a possible explanation for the greater severity 
of the Foxfl mutant phenotype compared with the Foxf2 knockout which was 
described by Wang et al [153].
Foxf2 in the eye
Foxf2 expression was observed in eye tissue in both the developing embryo and 
adults [188] and was considered a candidate for the gummy eyes and irregular pupil 
phenotype that was observed in the Del36H hemizygotes [21, 82]. Foxcl was 
already known as an important gene in eye development due to the discovery of 
Foxcl mutations associated with Axenfeld-Rieger anomaly [130,131], including
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incorrectly aligned corneal cells and hypoplastic stromal mesenchyme and iris 
pigmented epithelium [81]. However, the eye phenotype observed in the Del36H 
animal did not match that of known Foxcl mutants and work carried out by 
Nishimura and colleagues suggested linkage of a heritable glaucoma (and therefore 
eye development locus) to an additional gene within human 6p25 [131].
Mutations in a number of different forkhead genes such as human FOXE3, FOXL2 
and FOXC2.cause a wide spectrum of different eye disorders in humans[126]. The 
expression of Foxf2 in the eye [188] and the further localisation to the mesenchyme 
adjacent to the optic stalks [232] highlighted this gene as an immediate candidate for 
the further analysis of the eye defect.
The selection of Foxf2 for the gene-driven screen approach was vindicated to some 
degree by the subsequent discovery of holoprosencephaly in lines 54,241,412, 624, 
1073 and 1239 from the deletion screen. Holoprosencephaly is caused by mid-line 
defects and is characterised by the incomplete cleavage of the embryonic forebrain. 
Palate malformations are also caused by midline defects and these have since been 
discovered in Foxf2 knockouts [153]. This highlighted Foxf2 as a key candidate for 
the above mutant lines, although no open reading frame mutations were present in 
Foxf2 for any of these lineages (as discussed in section 3.14).
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4.2 Why Search for an Allelic Series?
The gene driven screen approach was envisaged as having the potential to 
complement the deletion screen. It would maximise the probability for obtaining an 
allelic series of Foxf2 -  one of the least well understood candidates in the region.
An allelic series of point mutations within a gene can provide a richer source of 
information about the functional activity of a gene than only a single point mutation 
or gene knockout. A range of effects on protein function caused by different point 
mutations within a gene could include amorphic mutations (loss of function), 
hypomorphic (partial loss of function), antimorphic (opposing/dominant negative 
function), hypermorphic (exaggerated function), and neomorphic mutations (novel 
gain of function)[233].
The value of an allelic series in the analysis of the functional activity of a gene was 
highlighted by Roger Cox and co-workers [234], who localised five mutant alleles to 
the quaking gene. These alleles caused a range of phenotypes from early embryonic 
lethality to uncontrolled tremors that were the result of dysmyelination of the CNS. 
Each of the alleles differed in some way from the others -  there was a spectrum of 
tremor severity between the mutations; the deaths of embryos occurred at differing 
stages of development; and male infertility resulted from one of the mutations.
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The Gene Driven Screen & The ENU Archives
The knockout mouse project [235,236] aims to induce targeted knockout mutations 
at every single gene in the mouse genome and to analyse the result that this has on 
the phenotype.
The Gene driven screen approach requires archives of mutagenised animal lines and 
a parallel archive of their DNA. The animal lines can take the form of either: sperm 
[201] [202], embryonic stem cells [237] or live animals [238]. The DNA is screened 
for mutations, and if any are discovered, animal carriers are available for mutation 
characterisation. This approach has the advantage over the phenotype driven 
approach that specific genes of interest can be targeted, and it is possible to proceed 
directly from sequence information to the isolation of mutations.
A mutagenesis programme was undertaken at MRC Harwell which utilized the 
mutagen ENU in a phenotypic screen of 26,000 FI progeny from crosses between 
C3H females and mutagenised BALB/c males [55].
DNA was extracted from tail biopsies of 2230 of these FI individuals and archived 
in conjunction with sperm samples taken from the same individuals. A pilot study 
demonstrated the feasibility of the high throughput screening of this DNA, followed 
by the recovery of any identified mutants from the sperm bank [201]. This initial 
resource has since been expanded by the ongoing construction of an additional MRC
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Harwell archive of over 4000 further individuals, greatly increasing the probability 
of detecting one or more functional allele(s) [202].
4.3 Identification of Mutations with Denaturing HPLC
Two DNA archives have been produced at MRC Harwell. The first was made in 
collaboration with Glaxo-Smithkline [201] but the second larger archive was 
produced by the MRC alone [202]. Both of these archives were screened for 
mutations within the gene Foxf2 using Denaturing High Powered Liquid 
Chromatography (dHPLC).
Pooled PCR product from the region of interest is denatured then hybridised when 
using this approach. Opposing strands from each individual will anneal. If however, 
there is a sequence variant or SNP in one individual, some of the opposing strands in 
the pooled sample would contain non-complementary base-pairs (heteroduplexes) 
which would repulse each other and weaken the bond between the two strands as 
shown in figure 4.1.
157
Richard McKeone PhD Thesis
wild-type mutant heteroduplexes homodupiexes
3 1 ? at *
| ? heat 1 1
i 1 i 1
j j COOl 1 1
1 1 ^ i
T  i i  /S a • f \  / k
A TII G C1 3
A C
V (
A T GC
. i 5
1 i
Figure 4.1: Heteroduplexes in dHPLC Mutation Detection
Heteroduplexes cause the separation of DNA strands at the site of a mutation and therefore the two 
strands have a reduced affinity for each other.
After hybridisation, the pooled PCR product is injected into the dHPLC where it 
forms a complex with the TEA+ ions of TEAA (triethylammonium acetate) that 
binds to the dHPLC column.
As the run progresses, the buffers which are pumped through the column, contain a 
gradually increasing percentage of acetonitrile. This eventually disrupts the chemical 
interaction between the TEAA-DNA complex and the column. Heteroduplexes elute 
from the column first when the column temperature is high enough to partially 
denature the region of the fragment that contains the sequence variation.
One potential problem which can occur during the screening of FI archives such as 
those produced by MRC Harwell and Glaxo-SmithKline, is that sequence 
polymorphisms between the strains may interfere with the screening process. 
Heteroduplexes would form on fragments which contain these polymorphisms, 
resulting in additional peaks on a dHPLC profile. However, once a polymorphism is
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identified as such, the peak profile can still be compared with the profiles of later 
samples. Despite the reduced detection efficiency, fragments which contain such 
polymorphisms can still reveal the presence of point mutations (M. Quwailid, 
personal communication). .
4.4 Optimum Temperature Conditions for Mutation Detection
The optimum temperature conditions for mutation detection recommended by 
Transgenomic require that the helical fractions are between 70%-85% [239]. As can 
be seen in figure 4.2, these specifications mean that a very small percentage of the 
fragment is at the optimum melting temperature for mutation detection at any one 
temperature.
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F i g u r e  4 . 2 :  O p t i m a l  D e t e c t i o n  L i m i t s  o f  t h e  F o x f 2 _ l _ l  F r a g m e n t
Regions within the Fox£2_l_l fragment which would have the recommended optimum helical 
fractions o f between 70-85% at 66°C, 68°C and 71°C. Highlighted regions represent regions which 
have a helical fraction of between 70-85% - Pink regions: at 71°C, blue regions: at 68°C, red regions: 
at 66°C
However, Transgenomic suggested that in practice, less stringent criteria for 
temperature selection of a helical fraction of between 60% to just under 100% would 
be acceptable. These less stringent conditions mean that a significantly larger
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fraction of each fragment could be considered to have a good chance of having any 
mutations within them detected.
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F i g u r e  4 . 3 :  R e l a x a t i o n  o f  d H P L C  H e l i c a l  F r a c t i o n  L i m i t s
Regions within the Foxf2_l_l fragment which would have helical fractions of between 60-99% at 
66°C, 68°C and 71°C, as suggested by Transgenomic for a high probability o f mutation detection.
These specifications would still require a large number of temperature settings in 
order to gain full coverage of each fragment, this would prove costly and time 
consuming. Even under these more lenient conditions, many fragments would 
contain regions where it was impossible to achieve such helical fractions using the 
WAVE machines in which temperatures can only be altered in increments of 1°C. 
However, data from Transgenomic suggests that mutations can be detected at a wide 
range of temperatures outside optimum denaturing temperature (1°C higher and 5°C 
lower than the optimum temperature) (see figure 4.4). This implies that a 1°C leeway 
could be allowed without reducing mutation detection probability by any significant 
degree.
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Figure 4.4 Temperature affects mutation detection
Figure 4.4 [240]: Sample temperature is an important factor in optimising the conditions for detection 
of a mutation when using dHPLC. If the temperature is too high, each heteroduplex and homoduplex 
will be fully denatured and will all elute as single stranded DNA. If the temperatures are too low, 
each of the heteroduplexes and homoduplexes will be fully annealed and will all elute as double 
stranded DNA from the column. It is only when the temperature is at a point which will partially 
denature the region containing the mutation, that heteroduplexes will be detected due to differing 
ratios of single stranded to double stranded DNA. The wide range of temperatures at which the above 
mutation in DYS271 was detected (a range of 4°C), meant that a 1°C leeway was allowed for the 
optimum detection conditions suggested by the melting profiles o f each Foxf2 amplicon.
Regions of fragment were therefore considered to carry an acceptable probability of 
mutation detection when any temperature +/-1°C of the run temperature was 
predicted to have a helical fraction of 60-99% i.e. all regions which were predicted 
to be 60-99% helical at either 65, 66 or 67°C would be considered to carry an 
acceptable probability of mutation detection at 66°C (figure 4.5).
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Figure 4.5: Relaxation of dHPLC Temperature Limits
Figure 4.5: Regions o f the Foxf2_l_ l amplicon which would be considered to have an acceptable 
probability o f mutation detection at 66°C. Predicted helical fractions o f  60-99% for the fragment at 
66°C, in addition to fraction percentages o f  60-99% at 1°C above and below this temperature, were 
considered when determining optimum temperatures for screening each fragment.
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For each Foxf2 amplicon, these rules were applied in the design o f the temperature 
methods, so that all but the extreme ends o f each amplicon had a reasonable chance 
o f mutations being detected along the entire length of each fragment. This is 
demonstrated in the selected temperatures for Foxf2_l_l as shown in figure 4.6.
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Figure 4.6: Optimal Detection Zones of Foxf2_l_l at Three dHPLC Temperatures
The regions o f Foxf2_l _ l that had an acceptable probability o f mutation detection at 66°C, 68°C and 
71°C.
4.5 Amplicon Descriptions and dHPLC Runs
The Foxf2 gene sequence was taken from the finished sequence o f BAC 467m8 
from the RPCI-23 library and submitted to primer3 (http://frodo.w i.m it.edu/) in order 
to design primers across the gene. Transgenomic recommended that PCR amplicons 
should be below 450bp for optimum probability o f mutation detection, but that
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mutations have been detected with fragments as large as 1.5kb [240]. Some of the 
amplicons designed were over the recommended optimum size (figure 4.7). 
Following optimisation of PCR products, and selection of those which gave the 
clearest bands, 5 amplicons were selected with which to screen the GSK archive:
Primer Set Forward Reverse Product Size
Foxf2 1 1 CTCGCCCGATTTGTGGAC AGCGCGATGTACGAGTAAGG 414
Foxf2 1 1c AGT G GAG G C ACC AAG AAG G G G AACG AACCCT CCT CAAAC 316
Foxf2 1 2a TT CCCCTTTTT CCGT G GCG C TGGCCATATAGGTGGAGCCC 460
Foxf2 1 3a* TCAAGGCGGTTATGGTGGCC AGAGGCTCTCAGAGGCTCCG 513
Foxf2 1 4&3a* ACACCACCTCCACCACCAC AG AG G CTCT CAG AG G CTCC G 433
Foxf2 2 01 AG CT G CCTTTAC ACCCT CAG ACAGT GT GAGTCCGTTGCAG 384
T a b l e  4 . 1 :  P r i m e r s  u s e d  t o  s c r e e n  t h e  a r c h i v e .
Primers used for Genotypic Screening of the mutagenised DNA archives.
* Primer set Foxf2_l_4&3a replaced Foxf2_l_3a for the screen o f the MRC archive.
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. .  cgcAGCTGTCCAGCTCTGGGCAGCGTCGCCTCAGTGGCTTAGGAGACGGTTGCGCAAGGAGCCGGCCGGAGGCTCGGAAGAGGGATGCGCGG 
GTTGCCTCCGACCCGCCGCCGCCGCCGCCGCCCGAAGCCCCAGAGGAGCTGAGGGAGGCGACGCCGAAGCGCTGGCCCGCAGTGGCCCGGGCTGC 
GCGGCCGGCGCAGTAGGGCACTCGCCCGATTTGTGGACCGACCCGGCTCCGGCGCCGCCGATCCCGGTCCGGGGTCCGCCCCCCAGGCCCGGCCT 
TCCCGATTCCCAGATGAGCACCGAGGGCGGGCCTCCGCCACCCCCGCCGCGCCCGCCGCCTGCCCCACTCCGCCGCGCGTGCAGCCCGGCGCCCG 
CGCTCCAGGCCGCCTTGATGAGCCCGCCACCCGCCGCCACCCTGGAGTCCACTTCGTCGTCGTCATCATCATCCTCTGCCTCCTGTGCCTCGTCC 
TCTAACTCCGTCAGCGCCTCGGCCGGTGCTTGCAAGAGTGCGGCTAGCAGCGGCGGCGCGGGCGCCGGGAGTGGAGGCACCAAGAAGGCAACCTC 
GCTGCGGCGGCCGGAGAAGCCTCCTTACTCGTACATCGCGCTCATCGTCATGGCCATCCAGAGCTCGCCCAGCAAGCGCCTGACGCTCAGTGAGA 
ACCAGTTCCTACAGGCGCGCTTCCCCTTTTTCCGTGGCGCCTACCAGGGCTGGAAGAACTCCGTGCGCCACAACCTCTCGCTCAACGAGTGCTTC 
AAGCTjGCCCAAGGGCCTCGGGAGACCTGGTAAGGGCCACTACHGGACCATCGACCCGGCCAGCGAATTCATGTTTGAGGAGGGTTCGTTCCGCCG 
GCCGCGCGGCTTCAGGCGGAAGTGCCAGGCTCTCAAACCCATGTACCATCGCGTGGTGAGCGGCTTGGGCTTCGGGGCCTCGCTGCTGCCCCAGG 
TCGACTTCCAAGCGCCCCCGTCGGCGCCTCTGGGTTGCCACGGTCAAGGCGGTTATGGTGGCCTCGACATGATGCCCGCGGGCTATGATACAGGG 
GGTGCTCCGGGCCACGCGCATCCACACCACCTCCACCACCACCACGTCCCCCACATGTCGCCCAACCCGGGCTCCACCTATATGGCCAGCTGCCC
GCCCGCAGGTCCTGCGGGCGTCGGTGCGGCAGCGGGTGGCGGCGGTGGCGGCGGGGACTATGGGCCGGACAGCAGCAGCAGCCCTGTGCCCTCAT
CGGCTATGGCAAGCGCCATTGAGTGTCACTCGCCCTACACTAGCCCTGCGGCACATTGGAGCTCGCCTGGCGCTTCACCTTACCTCAAGCAGCCG
GCCCTGACGCCAAGCAGTAATCCCGCGGCCTCTGCTGGTCTGCACCCCAGCATGTCTTCCTACTCGTTGGAGCAGAGCTACTTGCACCAGAACGC
C G A G G A T C T C T C A G g tH a ta a a g a g c g c c a a g g c tg g c tg c a a g c g g a g c c tc tg a g a g c c tc tg a g g g  c c a c c a g c t g c c t t t a c a c c c  
g t c a a a a a t a a c a c a a a t t a a t g g g a a a t t t c g a a c t a a t a c a c c c c a c c a t c a g c t g g g t g a c t t t c a c t g a a a a g a t t t t t t t t c t t t c t t c t  
agTCGGACTGCCCCGTTACCAGCACCACTCCACTCCAGTGTGCGACAGGAAAGATTTCj§TCCTCAATTTCAATGGCATTTCTTCTTTCCACCCTT
c t a g t g g c t c t t a t t a t c a c c a t c a t c a c c a g a g c g t | t g c c a a g a t a t t a a g c c c t g t g t t a t g t g a a t g g a c a g a g g c c t t g a a g g c c a c t c t
CTCCCTCTTCTGCCTTCTTCTCCTCTCCCCTCCGAGAGGGGCAGCCAGGAACTGCAACGGACTCACACTGTGCACGCTGGATAGCGAATAGCAGT 
TAGCACACCCATCACTTAGACAAATACCCAAGGGAGTTCTGCTCACCGATATTTGCCCGGCCCCTGGAAGAGGAAACCTTTCGAAAGCTAATATC 
GAAGAGCGACAGACAGAGGAGGTGACTACATGTAAGACATATGTTACTGTGTGGAGGACATAAAACTTTTCAGTTCTGGGGTGGCCATTGCATTC 
AATCAGGGTCTGAAAAGGGAGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCTTTTCAAAATTGCAGTGCTAAAAGCACACAATTTC2 
AAGCCTTCTCTAGTTCCCTGGCTCAGTAGGACATTTCTTCCACCCACTCCCAGTCCCCCAACACTCCCTTCTTCGGATACAGGTGCCAAAGAAC2 
TGAAGAAATGAAGAACCGATAGTCTAGTTTAAGAAAGTGGCTCTCAGTATTGTGACAGTACATTTTTACAAGGTTGTTTTTCTACCACCGTATTT 
AAGTATTTTTATGATCTTCGTATACTCACACTTCGCTTGTATTGTAAAAGGAGGGTATATTTGCACTTATGTATACTTTGACAGTTTGCCAAGA1 
TTG ATG TAAG G TTTTTTTTTTTTC AATAAAATG TG TATAAC aag. . .
K e y :
Text with yellow highlight: PCR amplicon.
Text with light blue highlight: Region of amplicon overlap.
Text with red highlight: Bases in which mutations have been discovered 
Annotation Between lines of Sequence: Amplicon name.
CAPITAL LETTERS: Coding sequence
Underlined letters: Alternative to Foxf2_l_4&3a (=Foxf2_l_3a)
P IN K  C A P IT A L S : UTR region
B lu e  lo w e r  c a s e  l e t t e r s :  Intronic region
... : Not all sequence shown
Green lower case letters: Non-genic DNA
Figure 4.7: Foxf2 transcript
Foxf2 transcript and exon information showing highlighted WAVE and sequencing amplicons.
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The first four amplicons: Foxf2_l_l -  Foxf2_l_3a were designed using coding
thsequence of the first exon of the gene. The 5 amplicon included the entire coding 
region of the second exon. All primers can be seen in table 4.1
The PCRs were optimised as described in section 2.2.5 and screening of the GSK 
archive was carried out as described in section 2.2.25. The high GC content of 
fragment Foxf2_l_l meant that betaine was required for amplification of this 
fragment. Although the use of betaine can cause problems with the dHPLC columns, 
Transgenomic Ltd investigated its use and found that concentrations of under 2M 
were compatible with the columns. The concentration of betaine used in these PCRs 
(1.35M) was therefore below the maximum levels recommended by Transgenomic.
After the completion of the GSK archive screen, further optimisation was carried out 
to increase the strength of signal within each sample. This was necessary due to the 
high ratio of samples which failed to amplify. Following this additional 
optimisation, the forward primer which was used for the amplicon Foxf2_l_3a was 
replaced with an alternative primer to produce a different fragment to cover this 
region: Foxf2_l_4&3a. This amplicon produced a stronger, cleaner signal than the 
Foxf2_l_3a product.
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Figure 4.8: Helical fractions for each amplicon
Helical Fractions o f the amplicons which were used to screen Foxf2, including the mutations which 
were discovered and their positions within the fragments.
A. Foxf2_l_l at 66°C, 68°C and 71°C. B. Foxf2_l_lc at 64°C and 65°C including mutations SI = 
Silent 1. R = W174R. C. Foxf2_l_2a at 63°C, 64°C and 65°C also including mutations SI and R. D. 
Foxf2_l_3 at 62°C, 64.5°C and 68°C. E. Foxf2_l_4&3a at 62.7°C, 64.5°C and 68°C including the 
mutation Sp = Splice site mutation. F. Foxf2_2_l at 60°C including the mutations S2 = Silent 2 and F 
= V412F.
166
Richard McKeone PhD Thesis
Foxf2 1 1
Foxf2 1 1c
D
« . . .
JFoxf2 1 2a
Foxf2 1 3a
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Foxf2 1 4&3a
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Foxf2 2 1
Figure 4.9: dHPLC Electropherograms
The amplicons which were used in the screening o f both archives are shown. These are archive 
samples which did not contain any detectable mutations. Each amplicon is shown at each o f the run 
temperatures used, with the lowest temperatures on the left. A-C: Foxf2_l_l at 66°C, 68°C and 71°C. 
D-E: Foxf2_l_lc at 63.9°C and 64.9°C. F-G: Foxf2_l_2a at 63°C and 65°C. H-J: Foxf2_l_3a at 
62°C, 64.5°C and 68°C. K-M: Foxf2_l_4&3a at 62.7°C, 64.5°C and 68°C. N: Foxf2_2_l at 60°C
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Mutations
64.5°C
F i g u r e  4 . 1 0 :  E l e c t r o p h e r o g r a m s  f o r  S p l i c e  M u t a n t
Electropherograms from the splice site mutation which was identified in MRC archive sample pool 
31H8 with primer set Foxf2_l_4&3a at 62.7oC and 64.5oC. Results from each pool containing a 
mutant individual is shown superimposed upon 4 other adjacent pooled samples, which act as 
controls. The mutant pool is shown in orange at each temperature. No difference was detected 
between the mutant sample and controls at 680C.
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F i g u r e  4 . 1 1 :  E l e c t r o p h e r o g r a m s  f o r  m i s s e n s e  m u t a t i o n s
Electropherograms from dHPLC output for the two missense mutations that were identified. Each 
pool of four samples containing a mutant individual is shown superimposed on 4 other adjacent 
pooled samples which act as controls. The mutant pool is shown in orange at each temperature. The 
Missense mutation in mutant A is from the GSK archive in individual 14H3 and was amplified by 
primer set Foxf2_l_lc at 64°C and 65°C, and primer set Foxf2_l_2a at 63°C and 65°C. The mutation 
was detected in the Foxf2_l_lc product at 64oC and in the Foxf2_l_2a product at 65oC. Mutation B 
is from the MRC archive in individual 18cl and was identified from product amplified by primer set 
Foxf2 2 1 at 60°C.
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F i g u r e  4 . 1 2 :  E l e c t r o p h e r o g r a m s  f o r  s i l e n t  m u t a t i o n s
Electropherograms from dHPLC output for the two silent mutations that were identified. Each pool 
containing a mutant individual is shown superimposed upon 4 other pooled samples which act as 
controls. A: Silent mutation SI is from the GSK archive in individual 1B11. This was amplified by 
primer set Foxf2_l_lc at 64°C and 65°C, and primer set Foxf2_l_2a at 63°C and 65°C. The mutation 
was detected in the Foxf2_l_lc product at both temperatures and in the Foxf2_l_2a product at 65oC. 
B: Silent mutation S2 is from the MRC archive at 25H1 and was identified from product amplified 
with primer set Foxf2_2_l at 60°C.
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4.6 Mutant Peak Analysis
Each of the mutations detected by dHPLC are described by referring to the sample in 
which they were detected. The complete plate coordinates of each sample have been 
indicated by the archive source (i.e.: GSK or MRC archives), followed by the plate 
number then the well reference according to a standard 96 well grid (A-H;l-12). For 
example, “GSK 1B11” refers to GSK archive plate 1, well co-ordinate B11.
Mutation 1 - GSK 1B11
This mutation was detectable at both 64°C and 65°C with amplicon Foxf2_l_lc 
(fig4.12 A). The mutation was less clear with the Foxf2_l_2a product than with 
Foxf2_l_lc at both of the run temperatures for this fragment. A very subtle 
additional shoulder is present on the peak at 63°C. There is a marked increase in the 
size of an additional early peak at 65°C.
Each of the DNAs within the pool GSK plate 1-4 B 11 were sequenced with primers 
for Foxf2_l_lc. This showed that individual GSK 1B11 carried a G-T mutation in 
base 784 of the Foxf2 transcript (fig 4.15 A). This base change is a silent mutation, 
so the leucine for which it codes at amino acid position 161 remains unchanged.
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Splice Site Mutation - MRC 31H8
The mutant peak stands out clearly from the other samples at 62.7 °C and 64.5 °C but 
cannot be differentiated from the other samples at 68°C (fig 4.10).
Each of the DNAs within the pool MRC plate 29-32 H8 were sequenced with 
primers for Foxf2_l_4&3a. The sequence showed that individual MRC 31H8 
carried an A-G mutation in base 3 of the only intron within Foxf2 (fig 4.15C).
V-F mutation - MRC 18C1
Two additional peaks prior to the main peak were present in individual MRC 
18C1 which could not be seen on adjacent samples, suggesting the presence of a 
mutation (fig 4.11 B). Each of the DNAs within the pool MRC plate 17-20 Cl were 
sequenced with Foxf2_2_l. The sequence showed that individual MRC 18C1 
carried a G-T mutation in base 1535 of the Foxf2 transcript(fig 4.15D) which would 
result in an amino acid change from a valine to a phenylalanine at position 412 of 
the protein.
W174R mutant peak - GSK: 14H3
A sharp, distinctive additional peak prior to the main elution peak could be seen at 
64°C but not at 65°C with amplicon Foxf2_l_lc (fig 4.11 A). This sample and those 
around it have produced low product yields, and the peaks seem particularly small at 
65°C. There is a high background signal in the region prior to the main peak at 65°C.
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Despite low absorbance levels of under 2mV in the W174R sample and adjacent 
samples with Fox£2_l_2a at 65°C, the mutation is clearly visible. There is no 
difference between the mutant and surrounding peaks when Foxf2_l_2a was used to 
screen the W174R mutant at 63°C (fig 4.11 A).
Each of the DNAs within the pool GSK plate 13-16 H3 were sequenced with both 
Foxf2_l_lc and Foxf2_l_2a primer sets. The cleanest sequence was from 
Foxf2_l_2a -  this showed that individual GSK 14H3 carried a T-A mutation in base 
821 of the Foxf2 transcript (fig 4.15E) which would result in an amino acid change 
from a tryptophan to an arginine at amino acid position 174 of the protein.
Additional proof of the mutation was gained from Sfcl digestion of the PCR product 
(figure 4.13). No Sfcl sites exist within the wildtype amplicon, but this mutation 
would create one (figure 4.14).
Figure 4.13: Sfcl mutation confirmation of W174R mutation
The double band on the right is Sfc I digested Foxf2_l_2a PCR fragment from a heterozygous 
W174R mutant individual. The Two single bands are C3H & BALB/c respectively -  these remained 
undigested in the presence o f Sfc I.
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Sfcl
W174R
Mutant Sequence
Wildtype sequence
CAT R Y A  G
G A Y R T AC
C C A C T A C A G
G G T G A T G T C
C A  
G T
G A  C C A  T 
C T G G T A
Digestion
A  C T G G A  
T G A  C |C T
C C A  T 
G G T A
A C T G G N A
T G A O > O N
BsrI
Key
Y Pyrimidine (T/C)
R Purine (A/G)
N Any base
l^-i Restriction enzyme
1 1^ recognition sequence
F i g u r e  4 . 1 4 :  R e s t r i c t i o n  s i t e s  i n  F o x f 2  W 1 7 4 R  m u t a n t
The A to T point mutation in the W174R mutant results in the removal o f a BsrI recognition sequence 
and its replacement with an Sfcl site. The mutant base pair is shown in red.
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Mutation Silent 2 - MRC: 25H1 (MRC plate 25, co-ordinate HI)
This mutation was the second to be detected within amplicon Foxf2_2_l, and as
such, was only run at one temperature: 60°C (fig 4.12, image B). A significant 
additional peak can be seen prior to and within the shoulder region of the main 
elution peak.
Each of the DNAs within the pool MRC plate 25-28 HI were sequenced with 
Foxf2_2_l .This showed that individual GSK 25H1 carried a G-C mutation in base 
1575 of the Foxf2 transcript (fig 4.15B). This base change is a silent mutation, so the 
valine for which it codes at amino acid position 437 remains unchanged.
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Figure 4.15: Mutation sequencing
Sequence chromatograms o f  each o f the 5 mutations discovered in Foxf2. In each example, wildtype 
control sequence (C3H or BALBc -  both o f which carry the same sequence throughout Foxf2) is 
shown at the top and the mutant sequence at the bottom. Red arrows indicate the precise position o f 
each mutation. A. Silent Mutation 1 within the amplicon F ox f2_ l_ lc  in mouse (GSK ID) 1B11. B. 
Silent Mutation 2 within the amplicon Foxf2_2_l in mouse MRC 25H1. C. Splice Site Mutation 
within amplicon Foxf2_l_4& 3a in mouse (MRC archive ID) 31H8. D. V412F Mutation within the 
amplicon Foxf2_2_l in mouse (MRC archive ID) 18C1. E. W 174R Mutation within the amplicon 
Foxf2_l_2a in mouse (GSK ID) 14H3.
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ATG AGC ACC GAG GGC GGG CCT CCG CCA CCC CCG CCG CGC CCG CCG CCT GCC CCA CTC CGC CGC GCG TGC AGC
Met Ser Thr Glu Gly Gly Pro Pro Pro Pro Pro Pro Arg Pro Pro Pro Ala Pro Leu Arg Arg Ala Cys Ser
CCG GCG CCC GGC GCG CTC CAG GCC GCC TTG ATG AGC CCG CCA CCC GCC GCC ACC CTG GAG TCC ACT TCG TCG
Pro Ala Pro Gly Ala Leu Gin Ala Ala Leu Met Ser Pro Pro Pro Ala Ala Thr Leu Glu Ser Thr Ser Ser
TCG TCA TCA TCA TCC TCT GCC TCC TGT GCC TCG TCC TCT TCT AAC TCC GTC AGC GCC TCG GCC GGT GCT TGC
Ser Ser Ser Ser Ser Ser Ala Ser Cys Ala Ser Ser Ser Ser Asn Ser Val Ser Ala Ser Ala Gly Ala Cys
AAG AGT GCG GCT AGC AGC GGC GGC GCG GGC GCC GGG AGT GGA GGC ACC AAG AAG GCA ACC TCG GGG CTG CGG
Lys Ser Ala Ala Ser Ser Gly Gly Ala Gly Ala Gly Ser Gly Gly Thr Lys Lys Ala Thr Ser Gly Leu Arg
CGG CCG GAG AAG CCT CCT TAC TCG TAC ATC GCG CTC ATC GTC ATG GCC ATC CAG AGC TCG CCC AGC AAG CGC
Arg Pro Glu Lys Pro Pro Tyr Ser Tyr lie Ala Leu lie Val Met Ala lie Gin Ser Ser Pro Ser Lys Arg
CTG ACG CTC AGT GAG ATC TAC CAG TTC CTA CAG GCG CGC TTC CCC TTT TTC CGT GGC GCC TAC CAG GGC TGG
Leu Thr Leu Ser Glu lie Tyr Gin Phe Leu Gin Ala Arg Phe Pro Phe Phe Arg Gly Ala Tyr Gin Gly Trp
(T)
AAG AAC TCC GTG CGC CAC AAC CTC TCG CTC AAC GAG TGC TTC ATC AAG CTG CCC AAG GGC CTC GGG AGA CCT
Lys Asn Ser Val Arg His Asn Leu Ser Leu Asn Glu Cys Phe lie Lys Leu Pro Lys Gly Leu Gly Arg Pro
(Leu)
(A)
GGT AAG GGC CAC TAC TGG ACC ATC GAC CCG GCC AGC GAA TTC ATG TTT GAG GAG GGT TCG TTC CGC CGC CGG
Gly Lys Gly His Tyr Trp Thr lie Asp Pro Ala Ser Glu Phe Met Phe Glu Glu Gly Ser Phe Arg Arg Arg
(Arg)
CCG CGC GGC TTC AGG CGG AAG TGC CAG GCT CTC AAA CCC ATG TAC CAT CGC GTG GTG AGC GGC TTG GGC TTC
Pro Arg Gly Phe Arg Arg Lys Cys Gin Ala Leu Lys Pro Met Tyr His Arg Val Val Ser Gly Leu Gly Phe
GGG GCC TCG CTG CTG CCC CAG GGC TTC GAC TTC CAA GCG CCC CCG TCG GCG CCT CTG GGT TGC CAC GGT CAA
Gly Ala Ser Leu Leu Pro Gin Gly Phe Asp Phe Gin Ala Pro Pro Ser Ala Pro Leu Gly Cys His Gly Gin
GGC GGT TAT GGT GGC CTC GAC ATG ATG CCC GCG GGC TAT GAT ACA GGG GCG GGT GCT CCG GGC CAC GCG CAT
Gly Gly Tyr Gly Gly Leu Asp Met Met Pro Ala Gly Tyr Asp Thr Gly Ala Gly Ala Pro Gly His Ala His
CCA CAC CAC CTC CAC CAC CAC CAC GTC CCC CAC ATG TCG CCC AAC CCG GGC TCC ACC TAT ATG GCC AGC TGC
Pro His His Leu His His His His Val Pro His Met Ser Pro Asn Pro Gly Ser Thr Tyr Met Ala Ser Cys
CCG GTG CCC GCA GGT CCT GCG GGC GTC GGT GCG GCA GCG GGT GGC GGC GGT GGC ATG GCA AGC GCC GGC GGG
Pro Val Pro Ala Gly Pro Ala Gly Val Gly Ala Ala Ala Gly Gly Gly Gly Gly Gly Gly Asp Tyr Gly Pro
GAC TAT GGG CCG GAC AGC AGC AGC AGC CCT GTG CCC TCA TCC CCG GCT ATT GAG TGT CAC TCG CCC TAC ACT
Asp Ser Ser Ser Ser Pro Val Pro Ser Ser Pro Ala Met Ala Ser Ala lie Glu Cys His Ser Pro Tyr Thr
AGC CCT GCG GCA CAT TGG AGC TCG CCT GGC GCT TCA CCT TAC CTC AAG CAG CCG CCT GCC CTG ACG CCA AGC
Ser Pro Ala Ala His Trp Ser Ser Pro Gly Ala Ser Pro Tyr Leu Lys Gin Pro Pro Ala Leu Thr Pro Ser
AGT AAT CCC GCG GCC TCT GCT GGT CTG CAC CCC AGC ATG TCT TCC TAC TCG TTG GAG CAG AGC TAC TTG CAC
Ser Asn Pro Ala Ala Ser Ala Gly Leu His Pro Ser Met Ser Ser Tyr Ser Leu Glu Gin Ser Tyr Leu His
(g)
CAG AAC GCC CGC GAG GAT CTC TCA Ggtaa...cagTC GGA CTG CCC CGT TAC CAG CAC CAC TCC ACT CCA GTG TGC 
Gin Asn Ala Arg Glu Asp Leu Ser Val(Intron) Gly Leu Pro Arg Tyr Gin His His Ser Thr Pro Val Cys
(T)
GAC AGG AAA GAT TTC GTC CTC AAT TTC AAT GGC ATT TCT TCT TTC CAC CCT TCC GCT AGT GGC TCT TAT TAT
Asp Arg Lys Asp Phe Val Leu Asn Phe Asn Gly lie Ser Ser Phe His Pro Ser Ala Ser Gly Ser Tyr Tyr
(Phe)
(C)
CAC CAT CAT CAC CAG AGC GTG TGC CAA GAT ATT AAG CCC TGT GTT ATG TGA
His His His His Gin Ser Val Cys Gin Asp lie Lys Pro Cys Val Met STOP
(Val)
Figure 4.16: Foxf2 Mutations in relation to the transcript
Each mutation within the transcript and abbreviated intron (red text). The mutation 
positions have been highlighted within the wildtype transcript sequence and mutant 
bases and amino acids are annotated in brackets.
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4.7 Mutation Discovery Discussion
= Silent Mutation
= Coding Mutation 
= Splice Site Mutation
Forkhead 
DNA binding
Inhibitory
Domain Activation domains 2 and 1
domain "v
 J  = AD 2
@ = A D 1
F i g u r e  4 . 1 7 :  F o x f 2  m u t a t i o n s  i n  r e l a t i o n  t o  t h e  f u n c t i o n a l  d o m a i n s
Illustration o f the four known functional domains of Foxf2 including the approximate locations of 
mutations which were discovered with the gene driven screen. The domain structure is shown as 
described in the mouse study by Miura [241]. These activation domains are shown overlayed by the 
synergistic sub-domains that were described for the human gene [242]. Sequence identity between the 
human and mouse transcript is -89% and this suggests a high degree of functional conservation, 
which is why it was considered reasonable to combine mouse and human domain studies. The non- 
synonymous mutations have been represented as stars in both the DNA and protein images, the splice 
site mutation has been indicated with a dotted line above the region o f protein derived from exon 2, 
representing an unknown splicing efficiency.
G-T mutation (Silent 1) at position 231 GSK archive 1B11 
This mutation was obvious in Foxf2_l_lc at both 64°C and 65°C (fig 4.12A), 
supporting the practice of allowing 1°C leeway in the design of temperature methods 
for each fragment. The mutation was less obvious in the Foxf2_l_2a product in 
which the mutation was also located (in the overlapping region of the two products). 
The very subtle additional shoulder which could be seen at 63°C was unlikely to 
have been recognised without prior knowledge of the increased probability of a
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mutation in this sample. The increased resolution of the mutant peak at 65°C is a 
surprise given the low level of the peak at this temperature, especially when the 
helical fraction prediction indicates that mutation detection is more likely at 63°C 
(fig 4.8C). (See also section Foxf2_l_2a with W174R and Silent 1)
Splice Site Mutation. MRC archive 31H8
That this mutation is detectable at 62.7°C is not surprising given that the helical 
fraction prediction for this position at 62.7°C lies at around 50% (fig 4.8E). It is of 
interest, however, that the mutation was even more clearly differentiated at 64.5°C 
when the predicted helical fraction for the position at this temperature was 0%. This 
gives further credence to the practice of allowing a 1°C leeway when designing 
temperature methods to achieve helical fractions of between 60 and 99%.
This mutation occurs at the 3rd base after the end of the 1st exon (fig 4.18). It could 
be regarded as a conservative change as approximately 35% of splice sites contain a 
G at this position [243]. Each of the other bases within the splice region are much 
more highly conserved within splice sites than this one, indicating that this mutation 
at this locus is less likely to have a severe affect on splicing efficiency than would 
other mutant forms within this seven base region.
There has been one recorded case in which an identical base change in splice site 
donor sequence (A-G at intron position +3) has affected splicing however. This 
occurred at the 5’ end of intron 7 of ornithine transcarbamylase (OTC) and caused
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the excision of the preceding exon (exon 7), resulting in OTC deficiency and 
subsequent ammonia intoxication [244]. Carstens proposed two potentially 
compounding reasons for the failure of correct splicing. The proposal hinges on a 
model that was previously suggested by Robberson for the recognition of exons by 
the spliceosome: the spliceosome pre-defines the exon before the commencement of 
splicing by first recognising the acceptor site at the 3’ end of one intron, and then the 
downstream donor site at the 5’ end of the next intron [245]. Carstens hypothesised 
that the efficiency of this exon recognition may be reduced by the base change. He 
also suggested that the short length of the Intron (80 nucleotides) may have further 
reduced splicing efficiency resulting in the removal of exon 7.
The environment of the OTC splice site that was of interest to Carstens is very 
different from that seen in the mouse Foxf2 mutation. In Foxf2 for example, the 
recognition of the first donor sequence in a gene is likely to be mediated by different 
factors than those bordering internal exons because there is no upstream 3’ acceptor. 
Another difference is that the Foxf2 intron length (3.2kb in mouse and 3.5kb in 
human) easily exceeds the minimum length for correct splicing activity. It is 
therefore difficult to predict the potential consequences of this splice site mutation in 
Foxf2. The longer intron suggests that the recognition sequence may not be as 
critical because intron length is not limiting splicing efficiency. However the OTC 
mutation provides evidence that such a mutation could affect splicing efficiency, 
making this mutation worth further investigation, not least because it may provide an
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insight into the hypotheses which were used to explain the OTC mutant splice 
pattern.
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Consensus splice site: AGGTqAGT
Wildtype Foxf2: AGGTAAGT
Mutant Foxf2: AGGTGAGT
Exon 1 Intron
F i g u r e  4 . 1 8 :  S p l i c e  s i t e  m u t a t i o n  i n  r e l a t i o n  t o  t h e  e x o n / i n t r o n  b o u n d a r y
The intron/exon boundary is indicated by a vertical orange line within the sequence. The mutation 
occurs on the third base into the intron and is a G-A mutation. Approximately 60% of splice sites 
have a G at this position and 35% have an A, whereas none o f the other positions contain a secondary 
base at such a high frequency ([243]). This suggests that the mutation may not have a significant 
effect on splicing efficiency.
V-F mutation. MRC18cl
The position of the valine to phenylalanine mutation is predicted to fall within the 
optimum helical fraction parameters for mutation detection at the run temperature of 
60°C. The peaks were clear and the mutation was easily detected as would be 
expected from the helical fraction prediction data.
The mutated residue is located within the most C terminal sub-domain of AD2 (fig 
4.17 and 4.19). This is the same domain, although different sub-domain, in which a 
glycine insertion within a poly-glycine site in a human family of glaucoma sufferers 
was identified (C. Gregory Evans, unpublished data). It has been suggested that the
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subdomains act synergistically with each other to allow full transcriptional activity 
[242]. Both valine and phenylalanine are hydrophobic although phenylalanine is 
hydrophobic to a much greater degree. Valine has an aliphatic side chain whereas 
phenylalanine is aromatic, so the sizes of the two amino acids are different and this 
could affect the structure of the protein.
Human FOXF1 
Mouse Foxfl 
Mouse Foxf2 
Human FOXF2 
Fugu homolog
(SINFRUG00000128884)
CDRK
CDRK
CDRK
CDRK
CDRK
SMHSAGG
SMHTTGG
FHPSAS
FHPSAS
Poly-glycine 
site
= AD 2 
. , = AD 1
F i g u r e 4 . 1 9 :  V 4 1 2 F  M u t a t i o n  i n  r e l a t i o n  t o  t h e  d o m a i n  a r c h i t e c t u r e
The valine at residue 412 of Mouse Foxf2 is conserved throughout the Foxf clade in vertebrates. It is 
located within a subdomain of activation domain 2. This is the same domain, although different 
subdomain, from the location in which a glycine insertion into a polyglycine repeat was identified in 
a family of glaucoma sufferers.
Silent 2 Mutation (MRC 25H1)
This peak was clearly different from other samples as would be expected from a 
mutation at this point within the fragment, according to the helical fraction 
prediction of between 60-99% at the 60°C run temperature.
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W174R Mutation (GSK 14H3)
The poor quality and low yield (less than 2mV) of this product seen with amplicon 
Foxf2_l_lc at 65°C is likely to be obscuring evidence of potential heteroduplexes.
It is surprising that the mutation was not detectable in the Foxf2_l_2a product at 
63°C when it was distinguishable at 65°C. The helical fraction at the region in which 
the mutation occurs is predicted to be just under 100% at 63°C (fig 4.8c). 63°C looks 
to be the most suitable temperature possible for mutation detection in this region of 
the fragment. In contrast to this, at 65°C the predicted helical fraction is 0%, which 
would suggest that all of the DNA in the sample at this region would be single 
stranded DNA and therefore not likely to produce heteroduplexes.
Figure 4.20: W174R mutation in relation to the forkhead domain
The W174R mutation occurs within the DNA binding (forkhead) domain of Foxf2. W174 is a very 
highly conserved residue which can be seen in every known member of the forkhead family. 
Tryptophan (W) has different physical properties from arginine (R).
100% Consensus 1 . p .................... [ § s  I  h ®  . J.p . . . . /T T 'T t- t
90% Consensus l s + t  . t p d ^ G s a h i b  i c S  11  . . h h  . 1 _
80% Consensus i f e p  . t  p P G ^ G s a p  tjLcr t  S  t  p h fp  . cJG
70% Consensus l |r t f jp  . s c j P G i G s H s E l P s  AltsfClPi— b
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Foxf2_l_2a with W174R and Silent 1
An unexpected result in both the W174R mutation and the Silent 1 mutation, was 
that the differentiation of mutant samples was clearer at 65°C than at 63°C. An 
important premise of the technique is that mutations reduce the ratio of double 
stranded DNA when temperatures are at partial denaturing levels. With predicted 
helical fractions at 0% for both mutation sites at 65°C, I would have expected that if 
one of the temperatures was to produce results with improved mutation resolution, it 
was likely to be at 63°C. This tryptophan to arginine mutation was the first Foxf2 
mutation found within the GSK archive. It occurs within the DNA binding 
(forkhead) domain in a residue which is conserved in all family members (fig4.20).
These two amino acids have very different physical properties from each other. 
Tryptophan has a neutral pH, is hydrophobic and has a neutral charge whereas 
arginine is basic and hydrophilic with a positive charge. Because the mutation 
occurred within the DNA binding domain at an extremely highly conserved position, 
we believed that this significant amino acid change could cause disruption to the 
activity of the Foxf2 protein.
The mutated tryptophan locus is within a p-sheet of the protein (fig4.21). This is 
predicted to be completely disrupted by the mutation according to results from the 
secondary structure prediction programme DSC, and shortened with additional 
downstream effects by another programme (Simpa96) as shown in figure 4.22.
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NORSp (Non regular secondary structure prediction) written by Jinfeng Liu & 
Burkhard Rost [246] predicted no affect on the p-sheet containing the mutant 
residue, but did predict the alteration of the exposure/burial status to a wide range of 
residues across the protein, and the complete disruption of two strand structures at 
the carboxyl end of the protein (figure 4.21 C).
Consolidation of these secondary structure predictions is difficult due to the apparent 
inconsistency between the output of each software -  there is not conclusive evidence 
that the b-sheet containing the mutant residue is altered or disrupted. However, each 
of the programmes predict the presence of the P-sheet structure surrounding the 
tryptophan residue in the wildtype and all of them suggest an alteration to the basic 
protein structure in the mutant, albeit to varying degrees of severity.
PIX was a programme hosted by the Human Genome Mapping Project Resource 
Centre (HGMP-RC) at www.hgmn.mrc.ac.uk/. which is no longer operational. DSC 
itself was also hosted by the HGMP and is also therefore individually unavailable, 
however, Simpa96 (http://npsa-pbil.ibcp.fr/cgi- 
bin/npsa_automat.pl?page ~/NPSA/npsa_simpa96. html) and Predator 
(http://www.embl-heidelberg.de/cgi/predator_serv.pl) are both independently 
available.
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Figure 4.21: W174R mutation & 3D structure of a related forkhead domain
The DNA binding domain of Rat Foxd3 as it binds to DNA[247]: There is a 62.9% sequence identity 
between the binding domains o f Foxf2 and Foxd3 (http://expasy.org/tools/sim-prot.html). The 
physical structure of the domain is thought to be well conserved throughout the gene family. The 
Tryptophan residue which is mutated in the W174R mutation in conserved in Foxd3 and is 
highlighted in yellow within one o f the beta sheets (shown here in pink). The golden coil structures 
are alpha helices. This diagram was produced by Protein Explorer using accession number 2HDC ( 
http://molvis.sdsc.edu/protexpl/fmtdoor.htm).
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Figure 4.22: Effect of W174R on secondary structure predictions
Secondary structure was predicted by a range o f different software. (A) Data from three separate 
programmes incorporated into the PIX analysis suite; each o f the three programmes is represented as 
a separate horizontal strip for a region o f the protein surrounding both the wildtype and mutant 
alleles. (3-sheets are shown as yellow bands and alpha helices as pink bands. Disruption o f a beta 
sheet structure at the mutant locus (arrow 1), is predicted in the first programme (i: DSC). In a second 
programme (ii: Simpa96), the beta sheet containing the mutation is shortened and, downstream, a 
different beta sheet region is predicted to be disrupted by the formation o f a novel alpha helix in the 
mutant form o f the protein (arrow 2). The third programme (iii: PREDATOR) did not show any affect 
at the mutant residue although a downstream a-helix was extended. However, a more recent version 
o f  this programme when run independently (B) showed that the b-sheet structure containing the 
mutant residue shifted one position towards the carboxyl terminus o f  the protein in the mutant. The 
programme nnpredict (C) predicted a small strand structure at the tryptophan residue at position 174 
and the adjacent threonine at 175, that is reduced to only the threonine residue in the mutant, whereas 
the rest o f  the protein remains unaffected. Analysis o f the whole protein by NORSp (D) was 
converted into the same graphical format as the PIX programmes, the secondary structure (pink and 
yellow bands = helices and strand structures respectively) and exposure/burial status o f each residue 
is shown (red = buried, black = exposed). The site o f the W 174R mutation is indicated by arrow 3 -  
no alteration o f the secondary structure at the mutant loci or the region immediately surrounding it is
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predicted. However, the exposure status o f other residues from across the protein have been altered, 
with the most significant effect occurring near to the carboxyl terminus, where two strand structures 
have been disrupted in the mutant (arrows 4 &5). Both nnpredict and NORSp were accessed via the 
PredictProtein-Meta portal (http://www.predictprotein.org/meta.php).
Mutation Detection Probabilities
During this screen, 5 mutations were discovered from a screen of 10.98Mb of total 
DNA screened, this equates to 1 mutation per 2.2Mb. Three of these mutations were 
potentially functional which corresponds to 1 potentially functional mutation per 
3.66Mb. Two were coding mutations, giving a rate of 1 coding mutation per 
5.49Mb.
Mutation rates from the combined data of 15 gene driven screens, including the GSK 
data for Foxf2, found a mutation rate of 1 in 1.01Mb, of which 1 in 1.82Mb was 
coding [202]. The rates of detection of Foxf2 was therefore lower than those of other 
screens of the same archive. However, some natural variation is likely in any 
stochastic process and this variation could be explained by chance.
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Peak Quality within the Foxf2 Gene 
Driven Screen
□  GSK Archive 
■  MRC Archive
PCR Amplicon
F i g u r e  4 . 2 3 :  R e l a t i v e  P C R  P e a k  q u a l i t y  d u r i n g  a r c h i v e  s c r e e n i n g
Relative Peak Quality for each amplicon within both archives used for screening Foxf2. A Significant 
increase in Peak quality can be seen, following further optimisation after screening the GSK archive.
There are a range of factors which may have led to this outcome. The sub-optimal 
PCR conditions which were being used for the GSK archive (see figure 4.23) may 
have caused mutations to remain undetected. The low percentage of good quality 
peaks for amplicon Foxf2_l_l during the screening of the GSK archive in 
particular, may have reduced the possibility of mutation detection in this region -  
and no mutations were detected within this fragment. However, when the statistics 
for each archive were analysed individually, the mutation detection rate for the MRC 
archive (1 mutation per 2.4Mb) was lower than for the GSK archive (1 per 1.9Mb).
It is interesting to compare these figures with those of the larger study. However 
such a comparison cannot be used to reliably assess the presence of local mutability
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variations or sub-optimal PCR conditions, because the number of individuals in each 
archive is too small for a statistically robust comparison.
The Mutations
Three potentially functional mutations were discovered with the gene driven screen. 
Judging by the level of conservation between species and the differing physical 
properties of mutant and wildtype amino acids, the Foxf2W174R mutation looked 
the most likely to disrupt the function of the gene product. This line was therefore 
rederived for further analysis.
The V410F mutation and splice site mutation are also of great potential interest due 
partly because they may provide phenotypes of reduced severity to other Foxf2 
mutations, although there is also the distinct possibility that neither would impinge 
on gene function enough to produce a testable mouse phenotype. Valine and 
phenylalanine are both hydrophobic and neutral, but with differing levels of 
hydrophobicity and different side chains. Another factor that suggests the severity of 
this mutation might not be as great as the W174R mutation is its position within the 
domain architecture. Despite the relative similarity of the physical properties of 
valine and phenylalanine, a comparison of various amino acid substitution matrices 
[248] appeared to show that a replacement of phenylalanine for valine or vice-versa 
is not a common event -  suggesting that this is a non-conservative mutation and its 
effect may be significant.
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W174R is located on a predicted P-sheet of the forkhead domain, and therefore an 
alteration at this locus may disrupt a critical element to the structure of the region 
that is responsible for DNA binding. V412F is not positioned within any predicted 
regular structures but does fall within an activation domain that has been shown to 
act synergistically with two other domains [242]. The nature of the relationship 
between these domains has not been investigated further since Hellqvist carried out 
this preliminary investigation of truncated FOXF2 peptides. The V412F mutation 
provides a potential opportunity to do this, and it would be particularly interesting to 
view its activity in comparison with the polyglycine mutation that was identified in 
glaucoma patients -in  one of the other synergistic activation domains [155].
One powerful experiment for the investigation of mutations in the activation 
domains of transcription factors is the transactivation assay. This involves inserting a 
transcription factor’s known binding site into a reporter vector, co-transfecting the 
reporter and an expression plasmid & gene of interest, then recording if the 
transcription factor activates or represses the reporter.
One possible method that could be used to analyse the function or otherwise of the 
potential splice site mutation would be to perform real-time PCR on tissues of 
interest. However, the low level of conservation of this base between splice sites, 
despite its proximity to the intron/exon boundary -  would suggest that this mutation 
was less likely than the two coding mutations to cause a visible phenotype.
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Chapter 5: Phenotyping of Mouse Mutant Foxf2wl74R
5.1 Introduction
In order to maximise the information from mutations that are identified with the 
gene-driven screen approach, mutant mice can undergo a systematic phenotyping 
procedure to detect subtle behavioural, morphological and metabolic deviations from 
the wildtype norm. The broad-based phenotyping platform SHIRPA [57] has 
previously been utilised in the preliminary characterisation of large numbers of ENU 
mutagenised mice, including the FI male offspring of mutagenised animals that 
constitute the Harwell ENU archives [55].
The Foxf2wl74R founder male would have already been screened for abnormal 
phenotypes during this dominant mutation screen because all the individuals which 
contributed DNA to the archive were screened. Further screening of heterozygotes is 
therefore likely to produce results within the normal range. However, subtle 
phenotypic differences are more likely to be detected when comparing cohorts of 
mice that carry a known mutation with their wildtype littermates than when ENU 
mutagenised FI mice are compared which each other. Therefore the SHIRPA screen 
remained a valuable tool despite the fact that the FI founder male had already been 
subjected to many of these tests.
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One other limitation of the original SHIRPA screen is that it was only likely to have 
detected dominant mutations because it is unlikely that one locus would be 
mutagenised by ENU twice in the same individual. The analysis of recessive 
phenotypes is critical for the effective characterisation of genes. Organs and tissues 
which express the gene of interest need to be the focus of phenotypic analysis 
because these are the most likely regions to express such a phenotype. Foxf2 is 
expressed in the respiratory, urinary and digestive tracts in common with its closest 
paralogue Foxfl, and is also expressed in tissues that don’t express Foxfl such as 
the sensory organs, limb buds, and CNS [188] including the brain. Those tissues 
where Foxf2 but not Foxfl is expressed are of particular interest because the 
probability of redundancy is reduced.
Eve analysis: Foxf2 is expressed in the developing eye and the eye is one of only 
two tissues showing significant levels of Foxf2 in the adult [188]. The eye defects 
that were observed in Del36 mice [21, 82], highlighted the potential value of 
investigating genes from the deleted region that are expressed in the eye.
Mutations in Foxcl, the closest physical neighbour of Foxf2 and a closely related 
paralogue, are responsible for many cases of anterior segment dysgenesis in mice 
[81] and mutations in other Fox genes including FOXE3, FOXL2 and FOXC2 cause 
a wide variety of eye defects. The eye is recognised as sensitive to the dosage 
alterations of many genes because of the delicately balanced interacting pathways 
involved in eye formation [193]. The discovery of a Foxf2 mutation in glaucoma
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patients by Vieira and Gregory-Evans [155] provided particular impetus for the 
detailed analysis of the eye in Foxf2wl74R mutants.
CNS: The central nervous system is another site in which Foxf2, but not Foxfl, is 
expressed during development [188]. A large proportion of the tests that constitute 
the SHIRPA platform are for behavioural phenotyping, and behavioural anomalies 
are an important indicator of CNS defects. SHIRA can therefore be considered as a 
primary screen for CNS phenotypes
Heterozygous carriers of each mutation that was identified in the lethal recessive 
screen discussed in chapter 3, underwent SHIRPA testing. Five of ten tested lineages 
exhibited distinct neurobehavioural phenotypes, three of which were associated with 
overt neurodevelopmental defects [26].
Limbs: There are high levels of Foxf2 but undetectable levels of Foxfl in the 
developing limbs of mice [188]. SHIRPA includes a general appearance screen with 
a digit count and a grip strength test. These are both important primary screening 
methods for the detection of limb deformities.
Digestive tract: Following the publication of the Foxf2 knockout which described 
the presence of a cleft palate [153] in that mutant, it was considered important to 
determine whether the palate is affected in the Foxf2wl74R mutant.
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Although not analysed during this work, the gut and tongue are also of interest. 
Malformation of the tongue was described by Wang in the original knockout 
publication [153]. Aitola noted differences in expression between Foxfl and Foxf2 
in the developing gut [188] and subsequently, Ormestad revealed a loss of structural 
integrity of the intestines and a wide spectrum of other gut phenotypes in Foxf2 
homozygous knockouts and to a lesser extent in Foxfl/Foxf2 compound 
heterozygotes [154].
Lung analysis: As in the eye, expression of Foxf2 occurs in the adult as well as the 
developing lung. Foxfl shows similar expression in the lung [188], suggesting 
possible redundancy. However, the continuing expression of the gene in the adult 
tissue warrants further investigation.
There is a very high probability that multiple mutations will be present in the 
genome of any individual that is subjected to ENU mutagenesis. These additional 
mutations could confound the characterisation of phenodeviants because abnormal 
phenotypes may result from combinatorial effects of multiple mutations. In order to 
reduce the probability of the presence of additional mutations, Foxf2wl74R carriers 
were outcrossed for successive generations to non mutagenised mice. Mutant 
Phenotyping was delayed until the colony reached generation G4.
196
Richard McKeone PhD Thesis
5.2 Heterozygote Screening
The first Foxf2wl74R heterozygous mutants were superficially normal at birth and 
SHIRPA was therefore considered an ideal preliminary screening platform from 
which subtle phenotypes could be uncovered.
A G4 cohort of 16 Foxf2wl74R heterozygotes and 16 wildtype littermate controls 
were selected to undergo testing in order to determine whether there was any 
difference in appearance, behaviour or metabolism. Due to the potential for gender- 
specific effects in some of the tests, males and females were equally represented 
within each genotype group (8 individuals of each sex, within each genotype group 
of 16). All of the mice were between 5-8 weeks old during the test period in order to 
minimise age related effects. Urinalysis and Intra-peritoneal glucose tolerance tests 
(IPGTT) were performed by the phenotyping core at MRC Harwell; SHIRPA 
behavioural tests were performed by the phenotyping core and the author. Startle 
and PPI of the initial cohort of 16 test-mice were also performed by the phenotyping 
core but subsequent Startle and PPI tests were performed by the author. Metabolic 
bleeds were performed by the phenotyping core and metabolic analysis of these 
samples was carried out by Dr T. Hough.
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C3H/HeH $ BALB/c
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IVF
C3H/HeH
G2
C3H/HeH
G3...
F i g u r e  5 . 1 :  G e n e  d r i v e n  s c r e e n  b r e e d i n g  s c h e m e
Mating scheme for mutant mice derived from the Gene driven screen. BALB/c males are 
mutagenised with ENU and mated with C3H/HeH females. Archived sperm from the FI progeny of  
this mating is used for in vitro fertilisation with a C3H/HeH female to revive required mutant lines at 
the G2 generation. Several subsequent matings to C3H/HeH mice are recommended before analysing 
a mutant line, in order to reduce the probability o f the presence o f other confounding mutations.
5.3 Appearance
Systematic recording of the presence or absence of abnormalities in specific physical 
features was used to produce a detailed analysis of the appearance of the test mice. 
Traits which were examined were: Coat, Skin, Ears, Eyes, Teeth, Vibrissae, Limbs, 
Paws, Nails, Tail, Head shape and digits. Of these only the “Head shape” category 
resulted in any abnormal scoring. The heads of these animals were subtly shorter 
than their littermates; they were described as having a “short snout”. It is likely that 
this was the result of a background strain effect however, as two of the abnormal 
heads belonged to wildtype individuals. Four heads were categorised as abnormal
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amongst the mutants -  all six abnormal heads from the cohort of 32 individuals, 
belonged to males.
The Harwell strain of C3H mice (C3H/HeH) have been known to produce offspring 
with subtly shortened heads (S. Polley, Somerset, R. Hardisty and H. Tateossian - 
personal communication) without any other noticeable abnormalities. There was no 
correlation between the mutation and the abnormal head shape -  so this was not 
investigated further.
5.4 Behaviour
5.4.1 Behavioural Observations and Response to Simple Stimuli
Following the appearance observations, all mice undergoing SHIRPA are subjected 
to a range of behavioural tests. Initial testing is based on an assessment of 
undisturbed mice within a viewing jar. Gait, tail elevation, transfer arousal and body 
position are all monitored for abnormalities -  none were seen in any of the tested 
animals. Unusual behaviour which can be characteristic of neurological or 
physiological defects is also looked for at this stage. Such activities could include 
head shaking or bobbing, circling, retropulsion (walking backwards), excessive 
grooming or spatial disorientation. None of these behaviours or any activity which 
appeared outside the normal behavioural range were observed in any individuals 
within the Foxf2wl74R cohort.
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Activity levels and levels of defecation were quantified by the number of grid 
squares entered within the arena and the number of faecal pellets produced. A 
student T-test was performed on each of these quantifiable behaviours. No 
significant difference between mutants and wildtypes was detected (See table 5.3).
One trait at this stage of screening which showed some variability between 
individuals was the transfer arousal observation. This is a test of how long the mice 
take to begin exploring upon entering the test arena. One wildtype male and one 
heterozygous female froze for longer than 5 seconds before moving. A larger 
number of the animals froze only briefly before moving; these included 6 male 
heterozygotes, 5 male wildtypes, 4 female heterozygotes and 5 female wildtypes.
The remaining animals all moved immediately once they were within the arena. 
There did not appear to be any correlation between the mutation and any of these 
different behaviours.
The mice are exposed to an auditory stimulus -  a click-box, and a touch stimulus -  a 
metal rod lightly touching their nose; in order to observe their response. All animals 
responded to touch by the expected escape reflex. On hearing the click box, three of 
the eight heterozygote males tested did not exhibit the preyer reflex which is a 
characteristic sharp movement of the ear pinna in response to sound. None of the 
wildtype males lacked this response, although two wildtype and two heterozygous 
females also failed to exhibit the preyer reflex. The lack of this response could 
indicate hearing problems in these individuals. This trait was analysed in more detail
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during the acoustic startle stages of the modified SHIRPA screen (section 5.5). All 
of the test mice had startle responses within the normal range, suggesting that the 
lack of preyer response did not indicate impaired hearing in these individuals.
Further spontaneous behavioural responses to different situations and stimuli were 
observed outside the arena. These tests were designed to test the motor reflexes, 
balance, coordination, and aggression of the animals. Observations included whether 
the mice struggled when either held by the tail or when scruffed; if the mice 
responded with a trunk curl when suspended by the tail; their ability to hang on to a 
wire suspended 20cm above their cage; pinnal reflex; corneal reflex; contact righting 
reflex; and whether there was any aggression or vocalisation from the mouse during 
the screening process.
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Animal Group S ize o f Foxf2 W 174R Mice Exhibiting Named B ehaviours
T est B ehaviour Exhibited
Male Fem ale
m/+ +/+ m/+ +/+
Body position
inactive 0 0 0 0
Acitve 8 8 8 8
Excessively active 0 0 0 0
T remor Present 0 0 0 0
T ransfer arousal
Freeze for > 5 seconds 0 1 1 0
Freeze briefly 6 5 4 5
move immediately 2 2 4 3
Gait Normal 8 8 8 8
Abnormal 0 0 0 0
Tail elevation
Draqqinq 0 0 0 0
Horizontal extension 8 8 8 8
Elevated/straub tail 0 0 0 0
Startle response
None 0 0 0 0
Prever relex 5 8 6 6
body move & preyer reflex 3 0 2 2
Touch escape
No reponse 0 0 0 0
R esponse to touch 8 8 8 8
Flees prior to touch 0 0 0 0
Additional Information
Head flickinq/shakinq 0 0 0 0
Head bobbinq 0 0 0 0
Circlinq (intermittent) 0 0 0 0
Circlinq (continuous) 0 0 0 0
Retropulsion 0 0 0 0
Spatial disorientation 0 0 0 0
Positional passivity struqqles when held by tail 3 1 3 1
struqqles when scruffed 8 6 7 6
Trunk curl Present 0 0 0 0
Wire manoeuvre Hanqs on 8 8 8 8
Falls off immediately 0 1 0 0
Limb Grasoina Present 0 1 0 0
Pinna reflex present 8 8 8 8
Corneal reflex Present 8 8 8 8
Contact riahtina reflex Present 7 5 6 7
Bitina or aaaression Evident durinq screen? 0 0 0 0
Vocalisation Evident durinq screen? 0 0 0 0
Totals tested 8 8 8 8
T a b l e  5 . 1 :  B e h a v i o u r a l  t e s t i n g
Animal group size of Foxf2wl74R heterozygotes (m/+) and their wildtype littermates (+/+) for the non­
numeric behavioural tests within and above the arena and in the viewing jar.
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Animal Group Size of Normal Physical Traits In Foxf2 W174R
mice
Physical Trait Male Male Female Femalem/+ +/+ m/+ +/+
Coat 8 8 8 8
Skin 8 8 8 8
Head shape 4 6 8 8
Ears 8 8 8 8
Eves 8 8 8 8
Teeth 8 8 8 8
Vibrissae 8 8 8 8
Limbs 8 8 8 8
Paws 8 8 8 8
Diaits 6 8 8 8
Nails 8 8 8 8
Tail 8 8 8 8
Totals Tested 8 8 8 8
T a b l e  5 . 2 :  P h y s i c a l  T r a i t s
Animal group sizes of Foxf2wl74R heterozygotes (m/+) and their wildtype littermates (+/+) for all 
physical traits analysed prior to SHIRPA testing.
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Foxf2 W174R Phenoty ping Screen : Statistics
Screen Test Genotype Sex Mean SD P=
Weight (g) m/+ M 25.74 2.17 0.65
+/+ M 26.22 2.00Weight (g) m/+ F 21.04 1.57 0.57
+/+ F 21.43 1.07
Faecal pellets m/+ 3.25 1.75 0.33
(number) +/+ 4 1.2
m/+ F 4.5 2.67 0.08
SHIRPA +/+ F 2.38 1.77
Locomotor activity m/+ 2.875 2.48 0.7
(number of squares) +/+ 3.38 2.72
m/+ F 4.5 2.39 0.34
+/+ F 3 2.71
Forelimbs m/+ 109.4 14.8 0.95
(arbitrary units of measuring
equipment) +/+ 108.7 22.2
m/+ F 96.7 17.5 0.78
Grip Strength +/+ 98.9 11.8
Fore and Hind limbs m/+ 207.9 13 0.15
+ /+ 193.5 23.5
m/+ F 150.5 11.3 0.07
+/+ F 161.7 11.4
Latency m/+ 42.63 50.6 0.39
(seconds) +/+ 78 99.8
m/+ F 65 96 0.44
Spontaneous +/+ F 37.18 41.3
alternation % alternation m/+ 47 32 0.5
(%) +/+ 61 50
m/+ F 46 23 0.98
+ /+ F 46 28
% inhibition 12Hz m/+ 67.5 10.2 0.009
+/+ 53.11 7.4
m/+ F 59.6 13.2 0.29
PPI + /+ F 50 16.4% inhibition 20Hz m/+ 65.1 14.4 0.07
+ /+ 53.2 17.1
m/+ F 51.1 17.6 0.91
+/+ F 51 16.8
white noise m/+ 1048.7 343 0.85
+ /+ 1084.2 367.3
m/+ F 666.3 130.9 0.71
+ /+ F 632.7 217.9
response to 12Hz m/+ 1003.6 327.9 0.61
+/+ 1087 284.3
o la R I6 m/+ F 617 251 0.5
+/+ F 697.8 217.7
response to 20Hz m/+ 1102.1 184.9 0.46
+/+ 1227.3 421.7
m/+ F 872.2 259 0.1
+/+ F 676.9 188.5
T a b l e  4 . 3 :  P r i m a r y  s c r e e n  S t a t i s t i c s
A statistical summary of the behavioural phenotyping of Foxf2wl74R hetero2ygotes (m/+) and their 
wildtype littermates (+/+). Of those tests which could be compared statistically by the student T-test, 
the only test which indicated a significant difference between wildtypes and Foxf2wl74R heterozygotes 
was the PPI o f males at 12 kHz. The single significant result, where p<0.05 is highlighted in yellow.
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In both gender groups, three mutants from a total of eight struggled when held by the 
tail, whereas only one wildtype in eight struggled. During the scruff test, only two 
wildtype males, one heterozygous female and two wildtype females did not struggle 
when scruffed.
Only one animal, a wildtype male, fell from the wire immediately on being placed 
there. This same animal was also the only individual which demonstrated the limb 
grasping reflex.
During the contact righting reflex test, the animal is placed in a Perspex tube and 
inverted. Several animals were slow to regain an upright position. These included 
one mutant and three wildtype males, and two mutant and one wildtype female. The 
remaining animals showed a normal righting reflex.
None of these tests showed a strong enough correlation between mutation and 
behaviour to be of interest. All other tests showed no variability between mutants 
and wildtypes in their normal response.
5.4.2 Light Dark Box Test
The Light-dark box automatically monitors the movement of test mice within an 
area containing both dark and light regions. They are a useful tool in the detection of 
a range of different mouse models for anxiety [249], which tend to spend a reduced 
time in the light areas. The parameters measured for this screen were: Latency, 
number of moves, time spent moving, velocity, distance covered, time spent in the
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light area, time spent in the dark area, number of times the light area was entered, 
vertical plane entries (rearing), central area entries in the light region, central area 
entries in the dark region.
None of these parameters showed a significant difference between the wildtype and 
mutant heterozygotes when the light-dark box output was analysed with a student-t 
test (see figure 5.1 and appendix 5.8).
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Foxf2 W174R Phenotyping Screen: 
Statistics - (Light-Dark Box)
Test Genotype Sex Mean SD P=
Latency m/+ M 20.7 14.9 0.87
(seconds) < +/+ M 19.4 13.6
m/+ F 25.8 12.6 0.74
+/+ F 29.5 20.8
Moves m/+ 35.3 9.4 0.19
(number) +/+ 30.6 2.2
m/+ F 35.2 4.2 0.42
+/+ F 38 6.3
Move time m/+ 250.5 10.9 0.14
(seconds) +/+ 257.5 5.5
m/+ F 254.6 9.8 0.49
+/+ F 250.2 10.5
Velocity m/+ 799.9 161.5 0.29
+/+ 869.4 69.1
m/+ F 905.4 107.6 0.36
+/+ F 819.7 145
Distance m/+ 159.9 32.3 0.46
(cm) +/+ 173.9 14
m/+ F 181 21.5 0.3
+/+ F 163.9 29
Time in the dark m /+ 132.2 22 0.47
(seconds) +/+ 141.3 22.7
m/+ F 139.8 28.9 0.8
+/+ F 145.2 37.8
Time in the light m/+ 167.8 22 0.47
(seconds) +/+ 158.8 22.7
m/+ F 160.2 28.9 0.8
+/+ F 154.9 37.8
Entry into the light m/+ 10 3.5 0.72
+/+ 10 2
m/+ F 11 2.3 0.29
+/+ F 12.5 2.1
Rearing m/+ M 49.2 10.4 0.6
+/+ M 46.3 9.6
m/+ F 43.4 5.2 0.94
+/+ F 43.8 11.6
Table 5.4: Light-Dark box testing
This test is based on the premise that there is a direct correlation between increased exploratory 
behaviour and reduced anxiety [250]. There were no significant differences between Foxf2wl74R 
heterozygotes (m/+) and their wildtype littermates (+/+) in any o f the tested parameters.
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5.4.3 Spontaneous Alternation
The spontaneous alternation test involves placing a mouse at one end of a Y-shaped 
arrangement of Perspex tubes, in which the mouse is free to explore. This is a test 
designed to detect defects in spatial learning. The latency period before the mouse 
leaves the starting arm and the number of alternations between arms are recorded.
There was no significant difference between wildtypes and mutant heterozygotes in 
either latency or alternation percentage on analysis with a 2-tailed student T test.
5.4.4 Swim Test
Mice are lowered into water at 37°C, and allowed to free swim for 1 minute. Any 
unusual swimming patterns are recorded. The swim test is one method of detecting 
vestibular dysfunction in mice.
No unusual swimming patterns or immobility was detected in any of the test mice.
5.4.5 Neuromuscular test (Grip Strength test)
Forelimb and hindlimb strength is measured during this test. There were no 
statistically significant differences between the mutants and wildtypes on analysis of 
the results with a 2-tailed student T test.
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5.5 Startle Tests
A brief, strong acoustic stimulus can induce a “startle” reflex in vertebrates -  a 
protective behavioural reaction consisting of an involuntary motor response. Tests 
for acoustic startle can provide evidence of deafness, or potentially for evidence of 
defects in the fear-potentiated startle reflex. This is a spontaneous reaction 
associated with the basolateral amygdala region of the brain, via the thalamus and 
perirhinal or insular cortex[251]. Abnormalities in this neural pathway are thought to 
be responsible for several anxiety disorders [252], and have also been identified in 
patients suffering from the early stages of Parkinson’s disease[253].
No differences between the wildtypes and mutant heterozygotes were seen on 
analysis of the startle output from the original cohort with a 2-tailed student T test 
(see table 5.3)
T-test comparisons were also made between those individuals that did not exhibit a 
preyer reflex on exposure to click box stimulation with wildtypes exhibiting a preyer 
reflex. Startle data from the male preyer deficient individuals were compared with 
each of the wildtype males (p=0.79(white noise); p=0.97 (12 kHz); p=0.94 (20 
kHz)). Because the female preyer deficient individuals were heterozygotes and 
wildtypes, two different comparisons were made: All preyer deficient females were 
compared with the preyer exhibiting wildtypes in the first analysis (p=0.86 for white 
noise; p=0.54 for 12 kHz, p=0.25 for 20kHz.). This was followed by a comparison
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of only the heterozygous preyer deficient females with the preyer exhibiting 
wildtypes (p=0.37 for white noise; p=0.28 for 12 kHz, p=0.28 for 20kHz.).
Despite the absence of a preyer reflex in some individuals, they seemed to respond 
to acoustic startle within the normal range demonstrated by the preyer exhibiting 
wildtypes. Absence of the preyer reflex is thought to be an indication of severe 
hearing deficiencies -  it is not thought to be a useful test for mild deafness. It can 
therefore be concluded that the absence of a preyer reflex in these individuals was 
not an indication of deafness.
Further Startle experiments were carried out to complement the additional PPI tests 
which were required to investigate the difference in PPI between mutant and 
wildtype males using a 12 kHz prepulse (See section 5.6).
The acoustic startle programme Startle-1 was used to test a further 7 males (m/+ (n) 
=3; +/+ (n) =4) which were used to supplement the original dataset. No significant 
difference between mutants and wildtypes was seen with this dataset either by itself 
(p=0.70 (white noise), p=0.96 (12 kHz), p=0.91(20 kHz)), or in combination with 
data from the original cohort.
5.5.1 Problems with Programmes Startle-1 and PPI-1
The sound waves produced at either 12 kHz or 20 kHz in either PPI or acoustic 
startle testing, should increase gradually to a plateau then gradually reduce towards
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the end of each pulse. However, when measurements were made of the 12khz and 
20khz sound bursts, the waveforms were spiking at two different time points within 
each test pulse (A. Parker, E. Coghill and F. Mackenzie: personal communication).
PPI and startle programmes which were used in the initial screening, PPI-1 and 
Startle-1, both contained 10ms pulses at 12 kHz and 20 kHz. The information from 
the waveform measurements therefore suggested that data from the original tests at 
these frequencies may not be reliable. Further PPI and acoustic startle tests were 
therefore required with programmes PPI-2 and Startle-2
5.5.2 Startle-2
A further two cohorts were screened, but with an alternative set of parameters -  
using the programme Startle-2. The first batch to be screened with Startle-2 (cohort 
2) contained both males (m/+ (n= 4); +/+ (n=9)) and females (m/+ (n=12); +/+ 
(n=12)). The low number of heterozygous males in this batch meant that further 
screening was required. However, this cohort was still analysed individually by two- 
tailed T-Test. Neither the females (p=0.46) nor the males (p=0.79), showed a 
significant difference between mutants and wildtypes in their response to the white 
noise frequency, which is the only frequency used in Startle-2, as described in 
section 2.2.28
In the second of these cohorts (cohort 3), which consisted of males only (m/+ (n=8); 
+/+ (n=10)), a significant difference was observed between the mutants and
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wildtypes (p=0.012) (See figure 5.2). These data were combined with the other 
Startle-2 dataset and analysed with a 2-tailed T-test. A significant difference 
between heterozygote and wildtype males was not seen in the combined Startle-2 
data (p=0.175). The two datasets combined therefore do not show a significant 
difference between mutants and wildtypes. However, various factors such as the 
increased environmental control, larger cohort size and reduction in background 
heterogeneity meant that the second tests were more reliable. Therefore there is a
good chance that there is a genuine startle response in these mice.
Startle Response of Mouse cohort 2 to  Acoustic 
Startle P rogram m e: Startle-2.
Startle Response of Mouse cohort 3 to  Acoustic 
Startle P rogram m e: Startle-2.
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Figure 5.2: Startle Response to Startle-2
Response o f 2 cohorts of Foxf2wl74R heterozygotes (m/+) and wildtype littermates (+/+), which were 
tested with Startle-2. The mutants demonstrated a significant startle increase in one cohort but the 
other showed an insignificant decrease. The combined data did not show a significant difference 
between mutant and wildtype.
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5.5.3 Analysis of the Startle Data
Although there was no significant difference in the acoustic startle data from initial 
tests using the Startle-2 programme, the significant difference seen in the larger of 
the two cohorts (cohort 3) warranted further analysis.
These two cohorts were from different generations and had been raised in different 
environments. Cohort 2 which were from generation G5, were raised and tested in a 
standard mouse facility (building 371 of MRC Harwell). Cohort 3 were G8 and were 
raised in a facility with individually ventilated cages (the Mary Lyon Centre), then 
transferred to building 383 before testing. It is possible that either these differing 
environments or the distance in generations from the founder male could have 
affected the animals’ response to the startle test. Previous experiments have 
demonstrated that subtle alterations in environmental enrichment conditions can 
affect the response of mice to various forms of behavioural phenotyping assessment 
[67]. A generational effect could have been caused by a loss of additional ENU 
induced mutations, or by a reduction in the BALB/c to C3H/HeH background ratio.
213
Richard McKeone PhD Thesis
Comparison of Startle Tests
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A comparison o f Startle data from all individuals tested with Startle-2. Test numbers 1-5 were tests 
performed on cohort 2 in building 371, test numbers 6-8 were performed on cohort 3, which were 
mice that were bom and raised in the Mary Lyon Centre and tested in building 383. Wildtype (+/+) 
startle responses are represented by a triangle and Foxf2W174R heterozygote responses are 
represented by a cross.
The order of testing was compared with the startle data to compare data ranges 
between cohorts 2 and 3. The data obtained from cohort 2 (tests 1-5 of figure 5.3) did 
seem to be more widely dispersed than in cohort 3 (tests 6-8). This could be viewed 
as evidence that there is an effect on the data caused by the different test conditions 
between the two sample groups. A more diverse range of startle responses could also 
be an indication of the less genetically homogenous population in cohort 2 which 
were G5 rather than G8 mice.
There are known to be differences between in-bred mouse strains in their response to 
acoustic startle [254]. B ALB/cJ and C3H/HeJ were amongst the 40 strains compared
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for acoustic startle response in a study by James Willott and Kenneth Johnson 
included in the Mouse Phenome Database [255]. They identified a large and 
significant increase in the startle response of BALB/cJ individuals by comparison 
with C3H/HeJ mice (a mean difference in males from -120SU at 70dB to -600SU at 
lOOdB). This may explain the wider range of data points in earlier generations that 
may have masked the difference in the earlier data (figure 5.3). Cohort 2 was from 
generation G5 so these mice would carry a higher percentage of B ALB/c derived 
genome than cohort 3, which were G8 mice.
Equally though, the elevated startle in BALB/c mice allows the possibility that 
heterozygous mice may exhibit higher startle responses due to a BALB/c allele with 
close linkage to Foxf2.
When histograms were constructed to view the data distribution for the wildtypes 
and heterozygotes within the combined dataset, there looked to be two clearly 
different response ranges for the two genotypes, despite possible differences caused 
by the sample conditions (see figure5.4). Heterozygotes were more numerous at the 
1625-1750 SU range and wildtype mice were more frequent at the 1000-1125 SU 
range. There were definite slopes leading to these values with adjacent ranges also 
showing high frequencies, adding weight to the hypothesis that the heterozygotes 
and wildtypes have different startle responses.
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The numbers o f mice at a range o f startle response (SU). The heterozygous mice (m/+) have a greater 
frequency at the 1625-1750 SU range, whereas the greatest frequency for the wildtype mice (+/+) is 
at the 1000-1125 SU range.
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One of the results from the wildtype data looked to be an outlier when viewed on 
both the histogram and test comparison plot. A box and whisker plot was therefore 
constructed to determine whether this was the case (figure 5.5). There is a general 
rule in statistics which states that if a data point is below 1.5 X the interquartile 
range below the first quartile, or 1.5 X the interquartile range above the third 
quartile, it can be viewed as being too far from the central values to be reasonably 
included.
Box Plot of Male Startle Data from Startle-2
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Figure 5.5: Box-plot of startle-2 data
Startle-2 data from wildtype (+/+) and Foxf2wl74R heterozygote (m/+) littermates. One value (2413 
SU for individual 24. le) from the wildtype mice could be considered an outlier because it is above Q3 
+ 1.5xIQR (Interquartile Range) within the wildtype group. The boxes represent the interquartile 
range for each dataset and the whiskers represent below Qi -  1.5xIQR and above Q3 + 1.5xIQR; 
beyond which, data could be considered outliers.
Individual 24.le showed a startle response of 2413 SU. This was a very high startle 
response compared with all the other animals tested, and particularly when 
compared with other wildtypes. It was classified as an outlier within the wildtype
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group (Q3 + 1 .5 xIQR = 2204) or the heterozygote group (Q3 + 1.5><IQR = 2218). 
However, when both groups were combined (Q3 + 1.5xIQR = 2572), it was not 
considered an outlier.
If individual 24. le is classified as an outlier; the T-test that compares heterozygotes 
and wildtypes gives a p value of 0.04 when applied to the whole Startle-2 dataset, a 
significant, albeit a mildly significant result. There is no doubt that these are an 
inconclusive set of results. It cannot be concluded from this data that Foxf2wl74R 
heterozygotes have an increased startle response in comparison with wildtypes, but 
nor can this hypothesis be discounted.
When viewed as individual cohorts however, the weight of evidence -  with a highly 
significant p value of 0 .0 1 2  in the larger, later cohort suggests that there is a 
difference induced by the mutation that had been previously been masked by other 
factors. None of the individuals scored below 500SU during testing, so deafness is 
unlikely to be a factor contributing to the difference.
The secondary startle tests were only performed because of the significant difference 
in PPI response between mouse cohorts at 12kHz. Acoustic startle testing is 
inherently linked to PPI tests and the two tests are often performed together in order 
to better define any phenotype that is highlighted. Although the significance of the 
PPI result is less convincing following subsequent PPI tests and the correction for 
multiple testing, it is possible that the significant results of the two tests are
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phenotypically linked. Two significant results from such closely related tests could 
be construed as acquiring a degree of cumulative credibility. However, although 
both tests measure a startle response in the experimental subject, startle has been 
shown to be linked to the spinocerebellar region of the brain whereas PPI is linked to 
the midbrain and cortex regions.
Each of the regions of the CNS that were analysed by Aitola [188] expressed Foxf2 
during embryonic development, but there was temporal variation as well as varying 
strengths of expression between the regions. The strongest signal appeared in the 
Entorhinal cortex at 36 hours after birth. Strong signals relative to other CNS regions 
were also seen in the Pia mater at between E l7 and 36 hours after birth, the 
subicular area at E l7 and at 3 days after birth and in the tectum between at E l 1 (the 
earliest stage measured) to E l3.
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5.6 Pre-pulse Inhibition (PPI)
Pre-pulse inhibition is the reduction of the startle response by exposure to a milder, 
non startle inducing stimulus immediately before the acoustic startle (10-500 
milliseconds before the startle in mammals). It has proved to be a valuable tool for 
assessing deficits of sensorimotor gating and information processing in a broad 
range of psychiatric disorders such as schizophrenia, obsessive compulsive disorder 
and Tourette’s syndrome (reviewed by Braff et al [256]).
Mice are placed onto a transducer platform within an acoustic chamber. The whole- 
body response of the mouse is measured in reaction to the stimulus in an acoustic 
startle test, in which only the startle inducing stimulus is produced. Once the 
baseline data for the responsiveness of the mouse is established, further acoustic 
tests which include both the startle pulse and pre-pulse can be performed and the 
inhibition percentage can be calculated at a range of frequencies
The initial screen involved a PPI programme (PPI-1) which subjected the mice to a 
white-noise startle, preceded by a pulse of either 12kHz or 20kHz. as described in 
section 2.2.28.
220
Richard McKeone PhD Thesis
M Male m/+
□  Male +/+
g  Female m/+
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Figure 5.5: PPI-1 Response
Pre-pulse inhibition with programme PPI-1 o f the initial cohort (A), and this data from males only 
with the addition o f data from 7 further individual males (3 heterozygotes, 4 wildtypes) to the dataset 
(B). 2-tailed student T-tests suggested that there was a significant difference (p<0.01) between 
heterozygote (m/+) and wildtype (+/+) males when exposed to a pre-pulse o f 12kHz in the original 
cohort (A). However, the small subset o f males which were added had a marked effect on the p value 
which was increased to 0.02 following their inclusion in the analysis.
On analysis of the PPI startle data, 2-tailed T-tests gave a P value of 0.009 in 
comparisons between male heterozygotes and wildtypes when exposed to a prepulse 
of 12kHz (see figure 5.2a). There was no significant difference between male 
heterozygotes and wildtypes at 20kHz although again - there was an increase in the 
mutants, and at p=0.07, the result was close to the standard significance threshold of 
0.05. No significant difference was seen between female heterozygotes and 
wildtypes at either 12kHz or 20kHz.
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The males from original cohort of mice were retested with PPI programme PPI-2. 
This programme runs test pulses to determine the baseline response of the mice at 
70dB, 80dB, 85dB and 90dB. Tests are then carried out in which a 1 lOdB pulse is 
preceded by pre-pulses of 70, 80, 85 or 90dB which occur 50msec before the 1 lOdB 
pulse. All tones were at the white noise frequency. Full details of the PPI parameters 
are described in section 2.2.28. There was no significant difference between 
heterozygote and wildtype males in these retests (p > 0.05 at 70dB, 80dB, 85dB and 
90dB).
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Figure 5.6: PPI-2 Response
The response of Foxf2 heterozygote (+/m) and wildtype (+/+) mice to the programme PPI-2. 
Following tests with PPI-1, males from the original cohort were retested with PPI-2 (A). A second 
cohort o f males (m/+(n)=4; +/+(n)=9) and females (m/+(n)=12; +/+(n)=12) at G5 was tested with the 
PPI-2 experiment (B). Startle data from prepulse and pulse baseline tests was used to exclude data 
from animals which demonstrated either a significant startle response (>350 SU) to pre-pulse 
volumes alone (70, 80, 85 or 90dB), or a very low startle response (<350SU) to pulse volumes of  
1 lOdB. This resulted in the exclusion o f all PPI data where an 85dB or 90dB pre-pulse was used, all 
70dB data remained unchanged, 80dB data had the following alterations to test size: +/-males(n)=3; 
+/+ males(n)=4; +/- females(n)=4; +/- females(n)=7 (C). A third cohort o f mice at G8 which included 
only males (m/+(n)=8; +/+(n)=l 1), was tested for PPI in order to increase the amount o f data for 
heterozygous mutant males (D). This data was modified by the exclusion o f data which showed low 
startle response to a test pulse or a high startle response to a pre-pulse test as previously described. 
Again, no alterations were needed for the 70dB dataset and the 85dB and 90dB datasets were 
excluded. Data for the 85dB dataset contained the following alterations to test mice numbers: +/- 
males(n)=5; +/+ males(n)=6 (E). Both sets o f modified data were combined (F). None of the data 
showed a significant difference between wildtypes and Foxf2wl74R heterozygotes.
Seven additional individual males were tested with the original PPI programme 
(PPI-1). 2-tailed student T tests for this small subset of animals resulted in a P value 
of 0.99. When combined with the original data set, the increase in PPI observed in
223
92
Richard McKeone PhD Thesis
the heterozygotes remained significant, but the P value was increased to 0.0205, so 
the difference in this larger population was less significant than in the original 
cohort.
The reduction in pre-pulse inhibition is a trait that can be symptomatic of 
schizophrenia or bipolar disorder in humans. PPI was significantly higher in 
Foxf2wl74R heterozygotes than in their wildtype littermates in preliminary tests with 
programme PPI-1. Screens for models of psychiatric disorders would tend to favour 
those animals with a lower than average PPI in order to mirror those conditions.
Despite this, it was considered worth investigating the effect further. An allele that 
results in a high PPI could provide an interesting insight into the activity of the gene 
and its potential role in the neural pathway involved in pre-pulse inhibition. A 
mutation at an alternative allele within such a gene could have a different effect on 
gene activity and may result in a reduction or an increase in PPI. A genuine increase 
in PPI could therefore highlight Foxf2 as a potential candidate for schizophrenia and 
related disorders. Therefore further investigation of the PPI of these mutants was 
considered important to assess the robustness of the preliminary results.
5.6.1 PPI-2: Retesting of the Initial Male Cohort
On retesting the first cohort with programme PPI-2, the difference between mutants 
and wildtypes was not significant. Previous studies have indicated that there may be 
a test-retest effect with PPI [257,258] and preconditioning may have affected the 
response of the test mice and obscured the difference between the mutant and
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wildtype individuals. This second dataset did, however, suggest that the difference 
seen in the initial dataset may not be as robust as initially thought.
5.6.2 Is there a difference in the PPI Response of Foxf2wl74R Mutants?
The significant difference between male heterozygotes and wildtypes at 12kHz, 
which was seen in the output from PPI programme PPI-1, looked less convincing 
following the addition of data from more individuals tested with the same method. 
However, most of the additional testing carried out used the PPI-2 programme, 
which did not incorporate a pulse at 12kHz. Further testing is required to completely 
rule out a PPI difference between mutants and wildtypes, but the combination of 
data from the additional small PPI-1 dataset, PPI-2 data and results from the PPI-1 
retest build a strong case for the absence of a genuine difference.
5.7 Metabolism Tests
5.7.1 Blood Tests Using the Olympus AU400 Clinical Chemistry Analyser
The mice were tested for levels of a range of different blood biochemical markers as 
described in section 2.2.29. Testing occurred initially at 5 months on 05/08/04.
Mice were then aged for an additional 3 months before retesting at 19/11/04 to 
detect later onset phenotypes.
The following parameters were measured: Sodium, potassium, chloride, urea, 
creatinine, total calcium, phosphate, ALP, ALT, AST, total protein, albumin, total
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cholesterol, triglycerides and glucose. Unfortunately, not enough blood was 
collected for testing of the complete cohort so there was not a full dataset.
Triglycerides were not measured in a sufficient number of individuals for 
comparisons between wildtypes and heterozygotes of either sex. Total cholesterol 
was not measured in enough females for comparisons of heterozygous and wildtype 
females. Each of the tests were performed on varying numbers of samples from 
within each mouse sex/genotype group as described in table 5.1.
Those tests which were performed on at least 3 individuals from each of these 
groups were compared by T-test. Data from test 1 and test 2 were analysed 
individually where possible, and a comparison between heterozygotes and wildtypes 
of both sexes within the combined dataset was also made.
Results from the first test showed potassium, chloride and calcium to be 
significantly higher in male heterozygotes than male wildtypes, and urea was 
significantly higher in heterozygote females than wildtype females (figure5.8). The 
level of confidence in the significant difference between heterozygotes and 
wildtypes with the calcium (males) and urea (females) was at p < 0.05, whereas a 
greater level of confidence is seen in the potassium and chloride levels of males 
where p < 0.01. However, if the Bonferroni correction for multiple testing is applied 
as described in appendix 5.11, then the significance threshold for each of these 
parameters would fall well below 0.05 to 0.001 for females or 0.0008 for males -
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thus rendering the results insignificant. It is surprising however, that so many of the 
significant results that arose from the phenotyping screen, occurred during metabolic 
testing. With the high numbers of tests performed, type II errors are to be expected, 
but four significant results from the metabolic screen is unusually high with respect 
to the relatively small number of tests in the metabolic screen.
The results from the second set of tests, on the mice after they had aged for 3 
months, showed no significant difference between heterozygotes and wildtypes in 
any of these tests.
Despite this though, the potassium result remains of particular interest in light of 
recent work by Philip-Couderc et al, who identified human FOXF2 as a regulator of 
ATP-dependent potassium channel (KATP) sub-units [231]. When HL-1 mouse 
atrial cells were transfected with a human FOXF2 plasmid, the KATP proteins 
KIR6.1, KIR6.2 and SUR2A were upregulated -  and there was a tenfold increase in 
F0X01/F0X03 expression, which in turn were also shown to be potent activators 
of KATP sub-unit expression. A highly significant positive association with KIR6.1, 
SUR1 A, SUR2A and SUR2B was seen in ventricular tissue following the induction 
of myocardial infarction.
Interestingly and in apparent contrast with these findings; FOXF2 showed a negative 
association with KIR6.1 and SUR1A in rat neonate cardiomyocytes. Despite the 
upregulation of FOXO genes by FOXF2, FOXO over-expression has an inhibitory
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effect on the expression of FOXF2, indicating the genes involvement in a negative 
feedback system.
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□ Number of Animals used in Comparable Metabolism Tests with 2 repetitions for 
Male & Female Cohorts.
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Sodium 8 5 7 4 8 4 6 4
Potassium 8 5 7 4 8 4 6 4
Chloride 8 5 7 4 8 4 6 4
Urea 8 3 7 4 8 4 6 4
Creatinine 8 3 4 4 6 4 6 4
Glucose 8 3 6 4 7 4 6 4
Number of Males Used in 
Comparable Metabolism 
Tests with 2 Repetitions
T est
T est 1 Test 2
+/
+
m
/+
+/
+
m
/+
ALT 5 3 3 4
Tot. Calcium 8 3 5 4
ALP 5 3 4 4
Number of Males Used in 
Comparable Metabolism 
Tests with 1 Repetition
Test +/+ m/+
AST 3 4
Tot Protein 3 4
Albumin 3 4
Tot. Cholesterol 3 4
Phos 5 3
Number of Fem ales Used
in Comparable
Metabolism Tests with 1
Repetition
T est +/+ m/+
ALT 5 4
Tot. Calcium 5 4
Table 5.5: Metabolic screen
Number of individuals used for each of the Metabolic measurements that were comparable by T-Test 
between Foxf2W174R heterozygote (m/+) and wildtype (+/+) cohorts. Some of the bleeds did not provide 
enough blood for measurements of all potential parameters. In cases where fewer than 3 individuals were 
successfully tested, a t-test has not been presented here, but the data is available in appendices 5.3-5.4. 
Image A shows those tests for which enough measurements for comparisons were obtained on two dates 
for both the male and female cohorts. B lists the tests where enough measurements were obtained on two 
dates for males only. C lists the tests where measurements from one date were comparable in males. D lists 
those tests for which measurements of females were obtained from one date only.
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□ +/+ 
m m/+
Figure 5.8: Significant results from metabolic screen
The blood biochemical markers which showed a significant difference between wildtypes (+/+) and 
heterozygotes (m/+). Data from each metabolite was compared using a 2-tailed student-T test. None 
o f the parameters which showed a significant difference in test 1, showed a significant difference in 
test 2. Significant P values are shown in red.
5.7.2 Urine Dipstick Tests
Urine dipsticks were used for approximate measurements of the following 
metabolites/constituents in the urine of the mouse cohort: Bilirubin, urobilinogen, 
ketones, ascorbic acid, glucose, protein, blood, and nitrites, alongside pH. The 
numbers of individuals varied within each mouse group, there were 6  heterozygous 
males, 8 wildtype males, 5 heterozygous females and 6  wildtype females.
The negligible levels detected of Bilirubin, glucose, and blood showed no variation 
between any of the individuals. The urobilinogen test also showed no variation 
between individuals in their “normal” reading. On measuring ketones, one wildtype 
male individual was recorded as “negligible” whereas the other individuals were 
recorded as “+/neg”. The dipstick documentation lists the lowest detectable levels of
Blood po tassium  levels in w ildtype and 
Foxf2(W174R) heterozygo te mice.
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Testl Test 2 Ma esTest 1 Males Test 2 
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acetoacetic acid as lOmg/dl and the “+” reading as approximately 25mg/dl, so a 
+/neg can be interpreted as between 10 and 25 mg/dl acetoacetic acid [259]. This is 
above the expected level of <5mg/dl acetoacetic acid levels that are expected in 
healthy mice [260]. The nitrite test indicated that one heterozygote and one wildtype 
female had “negligible” nitrite levels whereas all the other mice had “none”.
It was immediately apparent that these tests showed very little variability. The 
slightly elevated ketone levels in all but one individual could be an indication of 
diabetes mellitus or a number of other metabolic disorders [261] and suggests that 
additional mutations may be present in the Foxf2wl74R line which have the potential 
to confound the phenotypic testing of metabolism.
It is possible however, that the dipsticks were incorrectly read for this test. 
Interpreting the colour information on urine dipsticks and inferring intermediate 
datapoints between the basic “Negligible”, “+”, ”++” and ”+++” categories is only 
an approximation and a technician who is inexperienced with the analysis of this 
type of data could have inadvertently elevated the results. If the ketone elevation was 
real and caused by another mutation, the expected numbers of Foxf2 wildtype 
individuals expressing the phenotype would be low, whether or not there was 
linkage to Foxf2 -  because wildtype littermates were also screened. These ketone 
results are therefore likely to be false positives.
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Protein levels and ascorbic acid levels both exhibited a higher level of variability, 
and further analyses of these datasets were required. The readings for levels of each 
of these constituents were indicated on the urine stick as either “neg”,
“+++” or intermediate values where the reading looked to fall between 2  of these 
defined parameters. The approximate amounts of each constituent represented by the 
symbols that were used are shown in table 5.6.
Sym bol Protein (mg/dl) ascorb ic  acid (mg/dl)
neg 0 0
neg/+ 15 10
+ 30 20
+/++ 65 30
++ 100 40
T a b l e  5 . 6  P r o t e i n  a n d  A s c o r b i c  a c i d  d i p s t i c k  u n i t  c o n v e r s i o n
Key to urine dipstick measurements of the approximate amounts o f protein and ascorbic acid.
Ascorbic Acid Concentrations in wildtype and W174R heterozygote mice
Ascorbic Acid 
(Dipstick Reading)
+/m +/+
Numoer ot 
males
iNumoer ot 
females
in urn per ot 
males
Numoer ot 
females
neg
neg/+
+
+/++ 4 4 2
++ 6 1 4 4
Protein Concentrations in wildtype and W174R heterozygote mice
Protein (Dipstick 
Reading)
+/m +/+
iNumoer ot 
males
iNumoer ot 
females
INumoer ot 
males
iNumoer ot 
females
neg 1
neg/+ 5
+ 4 3 2 6
+/++ 2 1 1
++
T a b l e  5 . 7 :  A s c o r b i c  A c i d  a n d  P r o t e i n  F r e q u e n c i e s
Frequencies of mice with the approximate concentrations of ascorbic acid and protein in their urine, 
as determined by the urine dipstick method.
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Comparisons between different groups of frequency data are often made using chi- 
squared tests. However, this test is only approximate and is thought to be unreliable 
for small datasets, particularly when comparing ordinal data (data which is 
categorised and there is a logical order between the categories). A test that is more 
appropriate for the ascorbic acid and protein datasets (both of which are small and 
ordinal) is the Fisher exact test. This was therefore used to compare the wildtypes 
and heterozygotes for ascorbic acid and protein in males, females and in both sexes 
combined.
Although the Fisher’s Exact test is considered by some to be overly conservative, 
there is general consensus in the research community that this test is preferred to the 
Chi-square test for small data sets, (http://www.childrens-mercy.org/stats/ ). The 
numbers of individuals tested were low for the comparison of frequency data 
however, even with the Fisher’s exact test -  so these data should be treated with 
caution. The p values for these tests were therefore calculated with the Fisher Exact 
test, using R version 2.7.0 (The R Foundation for Statistical Computing). R Code is 
shown in appendix 5.2.
Ascorbic Acid
Difference between heterozygote Foxf2W174R mutants and wildtypes for ascorbic 
acid concentrations in urine:
Males only = No significant difference (p-value = 0.0606)
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Females only = No significant difference (p-value = 0.2424)
Males & Females = No significant difference (p-value =1)
Protein
Difference between heterozygote Foxf2W174R mutants and wildtypes for protein 
concentrations in urine:
Males only = Significant difference (p-value = 0.04928)
Females only = No significant difference (p-value = 0.1818)
Males & Females = No significant difference (p-value = 0.06437)
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5.8 Intra-Peritoneal Glucose Tolerance Tests
The glucose tolerance test is a means of determining the efficiency of glucose 
clearing from the blood. The animals were fasted for 16 hours before the 
administration of an intra-pedtoneal glucose injection. Blood glucose was measured 
immediately, then at 60 minutes and 1 2 0  minutes after the injection.
No significant difference between wildtypes and heterozygotes was seen in glucose 
clearance at any of the time points from the initial tests. P values from T-test 
comparisons of wildtypes and heterozygotes ranged from 0.4 to 1. A Two way 
ANOVA with repeated measures was also performed -  although there was a data- 
point missing for the male cohort and it is not generally recommended to perform 
this type of analysis without a balanced dataset. This gave a p value of 0.97 for 
males and 0.3 for females, so the lack of correlation between mutant and wildtype 
IPGTT results was clear for both tests.
The values for each individual that underwent this test were unusually low compared 
to the expected range at each stage of the experiment. This suggests there is a 
possibility that insufficient amounts of blood were extracted which would have 
compromised the data (M.Goldsworthy, personal communication). The IPGT tests 
have since been repeated by M.Goldsworthy & L. Moir of the MRC Harwell 
diabetes group with a larger cohort of mice. These additional experiments exhibited 
a trend towards protection from insulin resistance when fed a high fat diet, when
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measurements were taken at 12  weeks, although these results were not significant 
(as shown in figure 5.10). However tests at 16 weeks on the same mice showed no 
discemable difference.
One possible explanation for the apparent failure of the original tests to detect a 
difference between the cohorts is the low number of test animals used for this 
experiment.
10.0010.00 - |
1.001 .0 0  -
6.00 f 1.00—o— m/+ 
—. — +/+
—o— m/+ 
_._+ /+4.004.00 -
2.00  - 2.00
0.00 0.00
0 50 100
Time (min) after glucose exposure
150 1500 50 100
Time (min) after glucose exposure
Figure 5.9: IPGTT Preliminary testing
Response to Intra Peritoneal Glucose Tolerance Test by male (A) and Female (B) Foxf2 
Foxf2W174R heterozygotes (m/+) and their wildtype littermates (+/+).
236
Richard McKeone PhD Thesis
20  - m/+
15 -
15050 100
Time (min) after glucose exposure Time (min) after glucose exposure
Figure 5.10: IPGTT secondary testing
Reduced Glucose tolerance in Foxf2W174R mice fed on a high fat diet. Intra-peritoneal glucose 
tolerance tests following a high fat diet in 12 week old (A), and 16 week old (B) wildtype(n=5) and 
Foxf2wl74R(n=7) mice . Foxf2wl74R mice demonstrated a trend towards protection from insulin 
resistance when fed a high fat diet was observed at 12 weeks. Analysis with single factor ANOVA 
showed p values o f 0.065, 0.106 & 0.083 at successive time points in the 12 week old pups. This 
work was carried out by Michelle Goldsworthy and Lee Moir o f the Diabetes group at MRC Harwell.
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5.9 Weight Screen
The failure of the Foxf2wl74R homozygotes to thrive or to gain weight meant that 
analysis of the weight gain of heterozygotes during their early post-natal 
development was of interest.
11 female heterozygotes, 16 female wildtypes, 16 male heterozygotes and 1 2  male 
wildtypes were weighed every 3 days from birth until they reached 21 days. 
Following this, they were weighed every 7 days until they reached 49 days of age 
(see figure 5.11). Weight measurements until day 21 were obtained by the animal 
technicians of building 371. ANOVA with repeated measures was performed on the 
data. This demonstrated that there was no significant difference between the 
heterozygotes and wildtypes in either the male or female groups.
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W eight of female mice during post-natal developm ent
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W eight of male mice during post-natal developm ent
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F i g u r e  5 . 1 1 :  H e t e r o z y g o t e  w e i g h t s
Respective weights o f heterozygote and wildtype pups between birth and P49. ANOVA with repeated 
measures was performed on this data: No significant difference between heterozygotes and wildtypes 
was observed in either female (top graph) or male (bottom graph) weights up to 49 days from birth.
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5.10 Eye Analysis
Development of the Ocular Anterior Segment
The anterior segment of the eye is critical for correct ocular function not only 
because it is the region through which light must pass before contacting the lens, but 
also because many of its structures are essential for the correct regulation of 
hydrostatic pressure within the eye. Spaces between the cells of the sponge-like 
trabecular meshwork, allow the movement of fluid into the canal of Schlemm, from 
which drainage of aqueous humour into the surrounding venous system can occur 
[193].
The canal of Schlemm is located at the iridocorneal angle -  the site at which the iris, 
cornea and ciliary body meet. Therefore the correct morphology of this region is 
critical for regulated drainage -  and this is why aberrant development of the 
iridocorneal angle can cause an increase in intra-ocular pressure.
The ciliary body contains muscles which control the aperture of the iris and 
therefore the amount of light allowed to pass, via the lens - to the retina. The 
contraction and expansion of the ciliary muscles can also affect the drainage rate 
from the adjacent canal of Schlemm. Ciliary processes, the inward folding layers of 
the ciliary body -  also secrete aqueous humour into the anterior chamber, so this 
feature is key to the regulation of intraocular pressure.
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As can be seen in figure 5.12, many of the tissues that are responsible for the control 
of intra-ocular pressure including the ciliary body, trabecular meshwork and canal of 
Schlemm are all formed from the periocular mesenchyme. Inappropriate positioning 
of either the iris stroma or corneal endothelium, which are also of periocular 
mesenchymal origin, can also impede drainage. It is these tissues which are affected 
in iridogoniodysgenesis and the anterior segment anomalies.
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Figure 5.12: Eye development
Surface ectoderm (SE) at the lens placode (LP) invaginates into the surrounding mesenchyme (M) to 
form a vesicle that separates from the eye-field ectoderm which is destined for the comeal epithelium 
(CE), to become the lens (L). This vesicle is formed following contact with the optic cup (OC) which 
is o f neuroectodermal origin (NE). The optic cup folds around the lens to form the neural retina (NR) 
and retinal pigmented epithelium (RPE). These tissues are precursors for the epithelia of the iris (IE) 
and ciliary body (CBE) in the anterior segment o f the adult eye, in addition to forming the retina 
which is posterior to the lens. The periocular mesenchyme meanwhile, forms the iris stroma (IS), 
corneal stroma (CS), ciliary body (CB), trabecular meshwork (TM), and the canal o f Schlemm (SC). 
Diagram adapted from Gould et al [193]
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F i g u r e  5 . 1 3 :  A n t e r i o r  s e g m e n t  d y s g e n e s i s  c a n  c a u s e  a n  i n c r e a s e  i n  i n t r a o c u l a r  p r e s s u r e
Cartoon indicating how a closure of the angle between the iris and the cornea could potentially 
disrupt the flow of aqueous humour into the trabecular meshwork and ocular drainage system. This 
would increase intraocular pressure (IOP) and could lead to damage to the optic nerve and retinal 
nerve fibres. Diagram adapted from medocs.ucdavis.edu/ cha/402/pix/others/eye.gif.
Preliminary analysis of eye histology from Foxf2wl74R heterozygotes began with the 
enucleation and fixation of eyes from 10 heterozygotes (6  females and 4 males) and 
4 wildtypes (2 females and 2 males) as described in section 2.2.27. Each of these 
samples underwent histological analysis by C. Gregory Evans. This analysis was 
performed with prior knowledge of which tissue came from mutation carriers.
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The mice used for this analysis were progeny from a G4 Foxf2wl74R heterozygote 
female and a C57BL/6 male. This cross was required because the inbred mouse 
strain C3H, which was the predominant background of Foxf2wl74R heterozygotes at 
G4, carries the recessive retinal degeneration allele, Pde6 brdl [262,263]. 
Homozygotes for rdl exhibit a gradual deterioration of vision which could confound 
any phenotyping of the eyes or visual acuity of the Foxf2wl74R mutant. Retinal 
degeneration would affect analysis of a potential glaucoma locus as retinal damage 
is one of the symptoms caused by an elevation of intraocular pressure in 
glaucomatous eyes. Foxf2wl74R mutants on a background containing C57BL/6 mice 
have henceforth been referred to both by the number of generations since the 
founder male (Gl-8 ), and the number of outcrosses since the C3H line (Nl-4).
Following genotyping for Foxf2wl74R, each individual was therefore genotyped for 
rdl as described in section 2.2.5 and as expected, each was heterozygous for that 
allele. The recessive nature of rdl meant that the presence of this allele in a 
heterozygous state would not confuse phenotypic results.
General morphological features of the regions of interest were collectively analysed 
in their genotype subgroups (i.e.: regions where a phenotype was observed in the 
Foxf2 knockout and Foxcl mutants).
The iris stroma of several mice showed an irregular thinning of the tissue (see figure 
5.14), which is characteristic of a transillumination defect in humans, a common trait
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of irido-goniodysgenesis. This condition is detected when a narrow beam of light is 
focused though the pupil at an acute angle, thereby illuminating the retina. Regions 
of iris thinning will become illuminated by the reflected light when present.
F i g u r e  5 . 1 4 :  I r i s  s t r o m a  m a l f o r m a t i o n
A comparison o f wildtype (+/+) and heterozygous (m/+) Foxf2wl74R mutant iris stroma. Each of the 
heterozygote stromas (the three lower images) possess a flattening of the tissue and an apparent 
reduction of structural integrity. The lowest image shows marked variation in tissue thickness and a 
loss o f structural organisation (in common with the transillumination defect that is seen in human 
anterior segment anomalies)..
A number of unusual features were observed in the irido-comeal angle of several 
individuals. The canal of Schlemm was smaller in some of the individuals and was 
not seen at all in others; the trabecular meshwork showed signs of hypoplasticity; 
One individual had a hypoplastic ciliary muscle (see figure 5.15).
In several individuals the angle between the cornea and iris was significantly 
reduced and in one individual the two tissues appear to have fused together. This 
trait, particularly when associated with the defects in other tissues involved in the
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ocular drainage process, could inhibit the outflow of aqueous humour and result in 
an increase in intraocular pressure. The trabecular meshwork is the point at which 
the aqueous humour first enters the drainage system and this is located at the irido­
corneal angle, which is at the base of both the iris and cornea. A closure of this angle 
could result in reduction of fluid flow as illustrated in figure 5.13.
Malformation of either the trabecular meshwork or the canal of Schlemm, could also 
disrupt the drainage of aqueous humour and increase intra-ocular pressure.
A variable phenotype was observed between mice - not all of the eyes had a thinned 
iris and not all eyes had Schlemm canal or trabecular meshwork defects. Some of the 
mutants that were tested exhibited both defects, but some only exhibited one.
245
Richard McKeone PhD Thesis
Key i = wildtype
White arrows = ends o f 
Schlemm’s canal
White * = Trabecular 
Meshwork
CB = Ciliary body processes
A = Normal irido-comeal angle
Green arrowhead = Ciliary 
muscle
ii - v = Foxf2(174R) heterozygotes
Figure 5.15: Iridocorneal Angle Malformation
(i) is a section from the iridocorneal angle from a wildtype mouse, ii-v are from Foxf2wl74R 
heterozygotes. The Schlemm’s canal (arrows) are short or absent in all images. The trabecular 
meshwork is absent or hypoplastic in all images. The iridocorneal angle is not properly formed, and 
the iris is attached to the cornea in some cases (v). The ciliary muscle is hypoplastic, in image iii. 
There is no trabecular meshwork (TM), but there are cells with large nuclei resembling mesenchyme 
from which the TM is derived - no Schlemm’s canal (SC) in this image. (Images supplied by C. 
Gregory Evans)
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The structural changes which were seen in the mutant suggested that a rise in 
intraocular pressure could occur in these individuals, with the potential to cause 
damage of the cornea, optic nerve and retinal nerve fibres. Histological analysis 
showed no sign of any such symptoms in the initial cohort of animals. The 
phenotype which was seen had the potential to cause a cumulative effect however, 
so further analysis of older individuals was required to test this hypothesis.
IVFs from Foxf2wl74R heterozygote males (N1 C57BL/6) and C57BL/6 females 
were performed to transfer the colony from a standard mouse facility (Building 371), 
into a mouse facility with individually ventilated cages (Building MLC). Four 
heterozygote males, one heterozygote female and one wildtype littermate of each sex 
were examined with an ophthalmoscope at ~ 6  months after birth, before humane 
culling and histological analysis. The histology involved examining sections for 
retinal and optic nerve defects in addition to looking for the phenotypes seen in the 
previous cohort. As in the previous cohorts, the wildtypes were phenotypically 
normal and the heterozygotes showed a range of iridogoniodysgenesis effects.
Two male and nine female B6  N ls from the MLC were also examined by 
ophthalmoscope and histologically examined at 310-350 days after birth; and 
another cohort of 4 male and 3 female B6  N2s at 400 days old. Of these two aged 
cohorts, three of 18 mutants demonstrated a thinning iris stroma. Two of the female 
N ls showed possible eye bulging, which is a symptom of raised intraocular pressure. 
One of these eyes revealed an unidentified amorphous material between the retina 
and the lens (figure 5.17).
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mmm
Figure 5.16: Retinal and Corneal Sections from Foxf2W174R Heterozygotes.
As in the younger individuals, no gross abnormalities were seen in either the cornea (top) or retina 
(bottom) o f aged Foxf2wl74R heterozygote mice
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Lens
Retina
Figure 5.17: Bulging Eyes
Two 318 day old females appeared to have bulging eyes on analysis with an ophthalmoscope, a 
characteristic trait o f raised intraocular pressure. One o f the individuals had eyes that contained an 
unidentified amorphous material between the lens and the retina (arrow) in the posterior chamber, 
which is occupied by clear aqueous humour in phenotypically normal individuals. This phenomenon 
was not seen in any other individuals.
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Figure 5.18: Ciliary Body
Some Foxf2wl74R aged individuals (B&C) exhibited underdeveloped ciliary bodies, lacking 
projections towards the retina (arrows) that are present in wildtype eyes (A). A thinned, flattened iris 
stroma (E&F) as seen in the younger individuals and lacking the structural complexity o f the wildtype 
(D). Three o f the 18 heterozygote mice that were analysed at this stage demonstrated thinning o f the 
iris stroma. There were no additional cumulative effects in the older individuals, suggesting that if  the 
pressure within the eye is elevated, the increase is not sufficiently high to cause glaucoma symptoms.
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Figure 5.19: Foxf2'vl74R heterozygote Optic Nerves
Optic nerve sections from Foxf2wl74R heterozygote (m/+), wildtype (+/+) and glaucomatous 
individuals at -180-540 days. Heterozygotes (A, B & C ) at 6 months, glaucomatous eyes (E &F), 
and a previously published wildtype eye (D). Image A Shows a Foxf2vvl74R eye which contains neural 
tissue entering the optic nerve region as occurs in phenotypically normal individuals (D). Images B 
and C show two sections through the optic nerve o f a different Foxf2wl74R individual that exhibits a 
bulge in the nerve fibre layer, (arrow heads). The retina can be seen to continue at the surface o f  this 
bulging tissue, whereas normal retinal tissue terminates at the junction with the optic nerve (A and 
D). V=Vein. C=Choroid. P=Pias. Image E is from an 18 month old mouse with advanced glaucoma, 
demonstrating excavation o f the optic nerve head, a phenomenon which was not present in any o f  the 
Foxf2wl74R individuals. Image F highlights “cupping” at the optic nerve head in a 12 month old 
individual. Again, this was not seen in any o f  the Foxf2W 174R individuals. The optic cups o f  a 
wildtype 399 day old B6 N2 female (G) and 344 day old B6 N1 male (J) is shown in comparison with 
a 399 day old B6 N2 heterozygote individual (H) and 310-320 day old B6 N1 female heterozygotes 
(K, I & L). None o f the Foxf2W 174R heterozygotes from either o f the older N1 or N2 cohorts 
demonstrated any signs o f damage to the optic nerve head.
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Eye Screen of heterozygotes aged 330-340(days)
Histological examination was performed on heterozygotes at 330-340 days by 
Michael Cheeseman during a general screen of their pathological condition. There 
was no evidence of glaucoma induced injury to the eye. The sections were not 
perfectly transverse through the optic nerve, but there was definitely no gross 
enlargement, exopthalmos, injury to the cornea, or disruption of the retinal layers 
suggestive of prolonged intraocular pressure.
5.10.2 Eye Histology of Homozygote Embryos
El 8.5 embryos showed a clear abnormality in the forming ciliary body (See figure 
5.20) that was identified during analysis by C. Gregory Evans. There is a complete 
absence of evagination of tissue in the homozygotes -  which can be clearly seen in 
their wildtype littermates. This evidence supports the hypothesis that the Foxf2wl74R 
mutation influences ciliary development. The parents of these matings were 
screened to ensure that no rdl alleles were present, in order to avoid rdl 
homozygosity in the Foxf2wl74R mutant offspring.
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Foxf2 +/+ Foxf2m/m
Figure 5.20: Formative ciliary body
The ciliary body is forming in the E l 8.5 wildtype (+/+) pigment epithelium which has two fingers o f  
evaginating tissue. This was not observed in Foxf2wl74R homozygote (m/+) embryos at the same 
developmental stage. These images suggest that the initiation o f ciliary body development is delayed 
in Foxf2WI74R eyes.
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5.11 Foxf2wl74R Homozygote Analysis
In a preliminary study to examine the effect of the homozygous mutation, a number 
of G4 intercross matings were set up. Of the initial 3 homozygous individuals which 
were bom, one survived until 13 days and one died at 3 days old. The remaining 
homozygote was culled at 3 days for pathological analysis. Homozygotes appeared 
normal at birth, but their condition deteriorated over several days -  they did not 
appear to gain weight at the same rate as their wildtype and heterozygote littermates, 
and developed dry scaly skin. Hair failed to appear in the individual which died at 13 
days although it was present in littermates by 4 days. Milk was seen in very small 
quantities in the stomachs of some individuals, but was not observed in others. It has 
been suggested that the homozygote individual shown in figure 5.21C may have 
developed Chylous Ascites (S. Ball, personal communication), which is the leakage 
of lymph fluid into the peritoneal cavity.
5.11.1 Genotype Ratios
The wildtype(+/+):heterozygote (m/+):homozygote mutant (m/m) ratio was 16:28:8 
in the first Foxf2wl74R intercrosses. When this ratio was tested with a chi-squared 
test; X = 2.77 and p=0.25 at 2 d.f. (degrees of freedom). This suggests that there is a 
-25% probability that chance could cause the observed genotype ratio. Therefore 
lethality of mutant embryos is unlikely to have contributed to the lower numbers of 
observed homozygotes.
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The number of still-births observed from intercrosses was 1:2:1 which, although too 
low for any meaningful statistical analysis, is the exact ratio expected if the 
genotypes varied according to chance alone.
Genotype data from openings carried out at different stages was used to further 
investigate the possibility of lethality during development in the Foxf2wl74R line 
(table 5.8). The number of live pups at 18.5 days, the stage at which the majority of 
openings were carried out, was 44 wildtypes: 58 heterozygotes: 34 homozygotes. 
Again, the chi-square test did not suggest a deviation from the expected ratio of 
34:68:34 with a X2 of 4.41 at 2d.f. which produces a p-value of 0.11.
X2 and the associated p values were calculated with Microsoft excel.
The Exact binomial test was used to determine whether the heterozygote : wildtype 
ratios were as expected following Foxf2wl74R outcrosses in the Mary Lyon Centre 
(table 5.10). The calculation was performed using the online binomial test calculator 
at http://faculty.vassar.edu/lowiy/binomialX.html. None of these ratio’s were 
significantly different from the expected ratio of 1 :1 , suggesting that the 
Foxf2W174R mutation does not result in an embryonically lethal phenotype -  even 
at low penetrance.
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Mouse Cohort
Parental Background
All B6 C3H
Frequency P= Frequency P= Frequency P=
Total 136
0.11
102
0.23
34
0.20Foxf2 +/+ 44 32 10Foxf2 m/+ 58 46 12
Foxf2 m/m 34 21 12
At 18.5 days: 91
0.07
79
0.07
12
0.78Foxf2 +/+ 32 28 3Foxf2 m/+ 39 34 5
Foxf2 m/m 19 15 4
At16.5 days: 23
0.76
23
0.76 NAFoxf2 +/+ 4 4 NAFoxf2 m/+ 12 12 NA
Foxf2 m/m 6 6 NA
14.5,15.5,17.5 
days 22
0.22 NA
22
0.22Foxf2 +/+ 7 NA 7
Foxf2 m/+ 7 NA 7
Foxf2 m/m 8 NA 8
T a b l e  5 . 8 :  L i v e  e m b r y o  f r e q u e n c i e s
Genotype Frequencies o f each live embryo, primarily from openings at E16.5 and E18.5. 
Foxf2W174R heterozygotes are represented by “m/+”; wildtypes are represented by “+/+”. Data from 
C3H mice at E14.5, E15.5 and E17.5 has also been added, although they are not shown individually 
due to the low number o f openings carried out at these stages -  and can only therefore be used to 
estimate mutant mortality prior to E 14.5. No significant difference between observed numbers and 
the expected ratio bom to each genotype on comparison by chi-squared test.
Sex Genotype BackgroundB6N1 B6N2 B6N3 B6N4 C3H G7 C3H G8
Female
+/+ 14 12 12 10 13 11
m /+ 8 7 12 9 13 8
P = 0.29 0.36 1.00 1.00 1.00 0.65
Male +/+ 15 17 15 11 14 13m/+ 10 14 12 9 15 15
P = 0.4 0.7 0.7 0.8 1.0 0.9
T a b l e  5 . 9 :  F r e q u e n c i e s  o f  a l l  l i v e  b i r t h s  i n  t h e  M a r y  L y o n  C e n t r e .
Foxf2W174R heterozygotes are represented by “m/+”; wildtypes are represented by “+/+”. C3H mice 
are at generations G7 and G8 with respect to the founder male. B6 N2, N3 and N4 mice were derived 
from a preliminary outcross of C3H mice at G4 (and are therefore G6, G7 and G8 generations of 
outcrosses from the founder male). The B6N1 mice were the offspring o f C3H carriers at G6, so were 
at G7 with respect to the founder male.
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Foxf2 +/+
Foxf2 m/m
Foxf2 m/mFoxf2 +/+
Figure 5.21: Homozygous pup
A three day old wildtype (+/+: upper pup on A and pup B) and Foxf2 homozygote (m/m: lower pup 
on A and pup C). There is no evidence of milk in the stomach o f the homozygote pictured, although 
small amounts were observed in some homozygote individuals.
A further set o f 5 intercross matings were set up, followed by the live births o f 5 
confirmed homozygotes from a total combined litter size o f 27 live births. One 
homozygote was bom dead. There were also four additional still births which 
weren’t homozygotes. There was therefore a total o f 6 homozygotes from 34 births 
and a ratio o f 11:13:5 ((+/+):(+/m):(m/m))in this second batch.
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The surviving five homozygotes all showed the same signs of deterioration as seen 
in the first three homozygote individuals to be bom, i.e.: failure to thrive or gain 
weight, absence or only small quantities of milk in the stomach, lack of hair and at 3 
days, dry flaky skin. These were culled before their natural deaths due to project 
licence restrictions.
The high incidence of still-births bom from intercrosses cannot be explained by the 
Foxf2 mutation alone, because there was only one homozygote amongst the 5 still­
births which occurred. It seems likely that the higher incidence of stillbirths in 
intercross matings was the result of additional ENU induced mutations. If this is the 
case, intercrosses from later generations would be expected to result in lower 
numbers of still births because a smaller percentage of the parents’ genome would 
originate from the mutagenised founder male. One alternative hypothesis is that 
Foxf2W174R heterozygous mothers are not delivering sufficient nutrition to the 
unborn pups.
Matings to produce Foxf2wl74R homozygote births were stopped before the cause of 
death could be established, due to severity limits imposed by the project licence. The 
intercrosses were however used to produce homozygous foetuses for analysis of the 
eyes, lungs and palates.
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5.12 Pathology/Necropsy Reports
5.12.1 Heterozygote Pathology Screen
Four Foxf2wl74R G7 heterozygote mice (three B6  N1 males and one B6  N3 female) 
of between 330 and 400 days of age underwent a general pathology screen (carried 
out by M. Cheeseman) in order to identify potential age-onset conditions associated 
with the Foxf2wl74R mutation. Particular attention was paid to the gut in this screen, 
following a report that mentioned the thinning of the gut walls in Foxf2 homozygous 
knockouts [154].
Nothing unusual was found in the guts of these individuals. One individual male had 
an epithelial cyst of the tongue. The only female to be examined had white specks on 
her trachea, and on observation under a microscope, this region showed tracheal 
gland dilation. Another male had mineralisation of the blood vessels of the thalamus. 
None of these observations were regarded as anything other than age related 
incidental findings.
5.12.2 Screen of Homozygotes at day 3
The homozygote pup which was culled at 3 days for pathological analysis had 
developed sinusitis associated with inhaled bedding. It had also developed 
bronchiolitis with a solitary microabscess of the lung, accompanied by inhalation of 
milk. The middle ear had mild otitis media.
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Each of these inflammatory changes were classified as mild to minimal, acute onset 
and associated with a neutrophil leukocyte reaction. The low severity level of each 
of these conditions meant that they may not be clinically significant and were 
probably secondary to the primary lesion.
It was suggested in the report that the bronchiolitis and mild otitis media were 
possibly caused by the accidental inhalation of bedding and milk rather than due to 
the mutation.
Milk inhalation can be an indicator of a cleft palate, however the low-level milk 
inhalation in this animal could have been within the normal spectrum expected in 
animals at three days of age.
There was no dilation of the oesophagus. This was highlighted as evidence against 
the presence of a cleft palate as those animals with a cleft can have distended 
stomachs caused by unsuccessful attempts at feeding. A cleft was not identified in 
this individual. It was suggested by Michael Cheeseman that the inhalation of milk 
may have been due to a physiological discoordination in the swallowing reflex.
5.13 Cleft Palate Tests
The Foxf2 -/- knockout described by Wang [153], had a severe cleft palate which 
resulted in a gas distended gut, and died within 18 hours. The cause of death was 
probably starvation due to an inability to suckle. The comparatively extended lives
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of the Foxf2wl74R homozygotes, and absence of a distended, air-filled stomach 
indicated that a severe cleft palate was unlikely in these individuals. However, the 
reduction in milk uptake and inability to thrive followed by an early death, suggested 
that the Foxf2wl74R individuals could have had a less severe cleft.
Sixteen homozygote individuals were examined for clefts of the primary and 
secondary palate microscopically with assistance from H. Tatteossian. Confirmation 
of a cleft palate was not seen in any of these individuals.
Of the homozygote individuals examined, three were from openings at E14.5, one 
was at stage El 5.5 and a further four were at E16.5. These stages cover the period 
during which the maxillae of the secondary palate are in the process of fusing. Any 
developmental problems with the fusion process are more likely to be made clear at 
this stage. No abnormalities in the early stages of fusion were detected, however.
Palates were also examined at the later stages of El 7.5 (n=4) and El 8.5 (n=4), when 
the palate should be fully formed. There was no evidence of abnormalities in 
thoracic contents. None of these homozygotes had a cleft palate in the serial sections 
investigated, although one individual had tissue damage of the palate that appears to 
have occurred during sample preparation (figure 5.22). This may indicate a 
deficiency in the structural integrity of the palate. Anatomically normal incisive 
foramina, which are a pair of openings into the palate positioned behind the incisor teeth, 
were present in rostral sections of all individuals.
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Figure 5.22: Secondary palate of Foxf2wl74R Homozygotes
Secondary palates o f three E l 8.5 individuals: Two Foxf2wl74R homozygotes (m/m) and one wildtype 
(+/+)• One homozygote individual was identified with a suspected cleft o f the secondary palate (B -  
the cleft is highlighted by the black arrow). However, analysis o f 15 additional homozygote 
individuals (e.g.: C), failed to identify further individuals with cleft palates. On closer examination, it 
appears that the cleft seen in image B, may be the result o f tearing during histological preparation 
rather than a developmental malformation, although it is possible that there is a reduction in the 
structural integrity in this tissue which facilitated this tearing.
5.14 Lung Histology
Whole lungs from 12 embryos and the accessory lobes from 9 embryos were 
extracted as described in section 2.2.27 with assistance and training from Dr. 
Charlotte Dean of MRC Harwell. Following the extraction o f lung tissue, tail tissue 
was extracted and digested as described in method 2 o f section 2.2.2 for subsequent 
genotyping and identification o f Foxf2wl74R homozygotes. The whole lung o f one 
homozygote El 8.5 individual and the accessory lobe o f the lung from another E l 8.5 
homozygote individual were examined for deformities and compared with wildtype 
littermates with the assistance o f Dr C. Dean. There was nothing unusual in the 
structure or organisation o f the pneumocytes or parenchyma in the heterozygote 
lungs.
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5.15 Prognosis
There remain many questions about the effect of the Foxf2wl74R mutation. There 
seems to be a good chance that the homozygous mutation is responsible for the 
deaths of the pups in the homozygote study but the cause of death remains unclear. 
Initial suspicions that a subtle cleft palate may be responsible for the deaths have 
been disproved and there is no obvious defect in the lungs. The focus in any further 
work to identify the cause of deaths should include a study of the gut, following 
work carried out by Ormestad which identified severe structural problems and 
aganglia of the guts of Foxf2 knockout mice[154].
One other possible route would be a detailed analysis of the tongue. In his pathology 
investigation, Michael Cheeseman suggested that the inhalation of milk (which 
could have been the cause of both the bronchiolitis and the otitis media) may have 
been due to a “physiological discoordination in the swallowing reflex”. Normal 
function of the tongue is necessary for controlled swallowing, and the malformed 
tongue identified by Wang in the Foxf2 knockout [153] would suggest this as a 
further route of investigation. However no obvious tongue defects were detected 
during the screening of transverse head sections for the analysis of palate 
development.
The irido-goniodysgenesis phenotype in the Foxf2wl74R heterozygotes has provided 
further evidence for the involvement of the gene in glaucoma. No glaucoma was 
identified in these mice, but because the mutation seems to disrupt the normal
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formation of every ocular drainage tissue, it is possible that intraocular pressure is 
affected. Although not utilised in this study, the measurement of intraocular pressure 
in mice could be achieved by cannulation of the eyes of an anesthetised individual 
with a microneedle linked to a pressure transducer as previously described [264].
The initial significant PPI result was not repeatable with either the same group of 
animals or another smaller cohort. Further tests under alternative volume and 
frequency conditions with further, larger cohorts did not yield significant results. As 
such, it does not appear that the preliminary data shows a genuine difference.
The startle effect however, produced highly significant results when the testing was 
under tightly regulated conditions and when the mice used were less likely to be 
affected by background heterogeneity. Although not entirely conclusive due to the 
earlier absence of a significant affect, these results suggest that Foxf2W174R mice 
appear to demonstrate a genuine elevated startle response.
Differences between heterozygote mutants and wildtypes were detected in calcium 
(p<0.05), potassium (p<0.01), and chloride (p<0.01) in bleeds taken from 5 month 
old males and urea (p<0.05) in females. However further analysis at 8 months 
showed no significant difference between the mutants and wildtypes in any of these 
metabolites. Urea, potassium and chloride can all act as indicators of renal problems. 
The significant urine dipstick results could also be a sign of kidney malfunction:
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ascorbic acid is reabsorbed in the kidney [265] as is serum protein [266] - 
proteinurea is often associated with renal disorders.
Foxf2 expression was not detected in the mouse kidney by Aitola [188] either during 
development or in adults, and this absence was specifically mentioned by the author. 
The antibody company Abeam, recommend the use of kidney tissue as a positive 
control for their anti-human FOXF2 polyclonal antibody (at 
http://www.abcam.com/index.html?datasheet=23306). The reliability or perhaps the 
identity of this antibody was initially called into question, by its failure to detect 
FOXF2 in Cos-7 cells that were transfected with a FOXF2 construct when other 
evidence suggested the presence of the protein (see section 6.2.6)). However, this 
antibody was used successfully by Philip-Couderc to identify the presence of the 
FOXF2 protein [231]- which was derived from the same plasmid [203] as the one 
used in the experiments described in chapter 6 .
A kidney phenotype is possible even if the gene is not expressed in the kidney. For 
example, diabetes mellitus is a common cause of kidney disorders due to the 
damaging effect of high blood-sugar levels on renal blood vessels and may be the 
result of abnormal expression of genes in other tissues. No difference was seen in 
the blood glucose levels of mutants but unpublished data from glucose tolerance 
experiments that were performed by Dr M. Goldsworthy of the diabetes group at 
MRC Harwell suggest that Foxf2wl74R mice have innate protection against insulin 
resistance when fed a high fat diet.
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Chapter 6: Molecular Phenotyping of Two FOXF2 mutations
6.1 Introduction
The Foxf2 protein is a transcription factor and as such, it binds to promoter elements 
and increases or reduces the expression rates of target genes. Previous reports 
suggest that it is a transcriptional activator [203,242]. The mRNA transcript is 
present in cells of the mesenchyme adjacent to the endoderm-derived epithelium in 
the gut, genitals and lungs [154] and adjacent to the ectoderm derived epithelium in 
the tongue [153,154].
Following the publication of the Foxf2 knockout by Wang et al [153], the 
characterisation of the physical phenotype was expanded and the molecular effects 
further characterised by Ormestad and colleagues with the analysis of the knockout 
and Foxf2/Foxfl compound heterozygotes. They discovered that Foxf2 played an 
active role regulating the Bmp, hedgehog and Wnt pathways [153, 154].
Immunohistochemistry showed a drastic decrease in types I and IV collagen and a 
lesser but still significant reduction in Laminin [154] (see figure 6.1). These proteins 
are major constituents of the extracellular matrix (ECM) and accordingly there was a 
severe reduction in the ECM of mutant intestines.
A deficiency of ECM was observed in the intestines of FOXF2 -/- knockouts, and a 
reduction in collagen formation led to the suggestion that ECM abnormalities may 
contribute to anterior eye defects in Foxcl and Foxc2 mutants [81,138] as well as
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mice with mutations in Bmp4 [267] and Tgfb2 [268]. In addition, Foxcl 
homozygous knockout mice have ECM abnormalities in other tissues such as the 
arachnoid layer of the meninges in the central nervous system and the 
prechondrogenic mesenchyme of cartilage [81], [110]. The analysis of Foxf2 
interactions in the gut has highlighted the gene’s involvement in extracellular matrix 
production.
The eye phenotype of the Foxf2wl74R mutant has remarkable similarities to the 
published Foxcl knockout [81] and it is possible that a deficiency in ECM is the 
common cause. One or more types of collagen are candidate downstream targets of 
these genes, and aberrant collagen expression could forseeably cause a deterioration 
in ECM quality that would result in anterior eye defects like those seen in 
Fox£2w174R mice.
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Figure 6.1: Foxf2 Molecular interactions
A general scheme of the known molecular interactions of FOXF2 at the time of writing. Direct and 
indirect regulatory effects are not differentiated in this figure -  many of the developmental 
interactions were deduced by Ormestad et al [154] from immunohistochemical experiments on Foxf2 
knockout mice and Foxfl/Foxf2 knockout compound heterozygotes. It is not yet lmown whether 
Wnt5 interacts directly with Foxf2, but the levels o f this molecule increase in FOXF2 homozygous 
knockout mice, suggesting that the forkhead molecule has an inhibitory effect on the Wnt pathway in 
Foxf2 wildtypes. All the metabolic interactions, including those with the KATP subunits were 
substantiated by Philip-Couderc et al [231] by immunofluorescence, western blots and quantitative 
RT-PCR
Gould and co-workers presented a model of ocular anterior segment development, 
which was inspired by the similar phenotypes of Tgf]32, Bmp4, Foxcl and Foxc2 
mouse mutants, amongst others. All of these mice contain deficiencies of the ECM 
in the iridocorneal structures. The authors suggest that cell surface recognition of 
BMP4 and TGFp2 triggers a SMAD pathway which is regulated by several 
suggested molecules including Foxcl and Foxc2. These transcription factors may 
control the quantity and structural integrity of extracellular matrix [193]. The same
268
Richard McKeone PhD Thesis
logic could also be extended to include Foxf2, due to the phenotype in the anterior 
segment that was observed in the F0XF2W174R mutant (section 5.10).
During intestinal development, Bmp4 has been identified as a downstream target of 
Fox/2 [154]. This contrasts with the suggested Fox/Bmp interaction in the eye 
model, in which Foxcl and Foxc2 were hypothesised to be upstream regulators of 
Bmp4 [193]. It is possible that the Foxf genes occupy a different level of the 
hierarchy within some of the same pathways as the Foxc genes, but it also remains 
possible that they perform similar functions in some tissues and are partially 
redundant.
Following work which demonstrated reduced levels of Bmp4 and increased levels of 
Wnt5a in the Foxf2 mutant, a possible role can be seen for Bmp4 as an intermediary 
between Foxf2 and the canonical Wnt pathway [154]. Wnt5a levels were increased 
in Foxf2 knockout explant cultures but were not increased in these tissues when 
exposed to Bmp4. An increase of Wnt5a was also seen in wildtype explant cultures 
that had been exposed to the Bmp4 antagonist noggin* suggesting that Bmp4 inhibits 
Wnt activity.
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6.1.1 FOXF2 Nuclear Localisation & Mode of Action
Like other forkhead-box proteins, FOXF2 is localized primarily to the nucleus of the 
cell. Hellqvist et al discovered that FOXF2 nuclear localisation depended on 
sequences from both ends of the forkhead domain [242]. As with other features of 
the forkhead domain, the highly conserved amino acid sequence means that this may 
be a widespread trait throughout the gene family and indeed, Foxcl also contains 
nuclear localisation signals at the N- and C- termini of the forkhead box [269]. One 
member of the forkhead family, FOXP2 -appears to be localized to the nucleus but 
excluded from the nucleoli [270] and again, this may also be true of other forkhead 
genes but is yet to be investigated in the wider gene family.
In addition to binding DNA and nuclear localization, the forkhead domain also 
facilitates interaction with the basal transcription machinery by binding to the 
TATA-binding protein (TBP) and TFIIB [242]. The amino acid sequence at the C- 
terminal portion of the domain that binds to TBP is highly conserved [205]. This 
suggests that TBP binding may be another feature that is common to all members of 
the forkhead box family.
The forkhead domain is responsible for the recognition of target sequences. There is 
a wide variety of recognition sequences however, and it has been suggested that the 
amino acids that flank the forkhead domain as well as differences within this domain 
may be responsible for the different specificities of the forkhead protein family 
[205]. Fox genes with indistinguishable DNA binding specificities can have distinct 
biological functions. For example although both FOXF2 and FOXF1 proteins bind
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to and activate the surfactant protein B promoter, the gene for another lung-specific 
protein, CC10, is only activated by FOXF1 due to the presence of a cell type-specific 
activation domain in this molecule [203].
Two mis-sense mutations in the forkhead domain of Foxcl described by Saleem et 
al [271], allowed DNA binding to occur as normal, but disrupted transactivation.
There is strong evidence for an anterior eye defect in the W174R mutant and several 
additional potential phenotypes that require further investigation. It therefore seemed 
pertinent to examine the molecular interactions that are responsible for these mutant 
characteristics.
In addition, although the V412F mutant line has not yet been re-derived at the time 
of writing, it also seemed worthwhile to replicate the W174R experiments with this 
mutation as a preliminary investigation into the effect that the mutation has on DNA 
binding and activational activity. Although not in the binding domain and therefore 
less likely to effect DNA binding, its position within one of the activation domains 
could provide useful information about the functional structure of these regions.
The third mutation discovered in chapter 4 occurs within the splice site of FOXF2 
immediately adjacent to the 5’ end of exon 1. As such, experiments that are designed 
to analyse binding and activation are not appropriate for this mutation because a 
more important issue in this case is the splicing efficiency of Foxf2 and total levels
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of the intact protein in these animals. An intronic splice site mutation is unlikely to 
impact on DNA binding
6.1.2 The Foxf2 Binding Sequence
A consensus core binding sequence for four forkhead (previously known as 
“FREAC” for Forkhead Related Activators) proteins was described by Pierrou et al 
[205] who performed gelshift assays with random sequence oligonucleotides, and 
confirmed the consensus sequence by DNA footprinting. This core of RTAAAYA 
was common to each of these forkhead proteins and there was a complete absence of 
any bases other than the consensus core in any of the random oligonucleotides 
tested. However the flanking sequence favoured by each of the proteins varied -  as 
did the purines in the core at position R and pyrimidines at position Y.
The Purine at position R in the core sequence was a guanine in 74% and an adenine 
in 26% of the oligonucleotides that bound to FOXF2, the position Y pyrimidine was 
a Cytosine in 93% and a Thymine in 7% of oligonucleotides (see figure 6.25C). The 
flanking sequence demonstrated a definite preference for particular nucleotides - 
each of the other bases were observed at these flanking positions but at significantly 
lower percentages, and Pierrou was therefore able to highlight a binding sequence 
specific to FOXF2: aacGTAAACAa.
Miura used the FOXF2 protein-DNA binding data obtained by Pierrou et al [205] to 
design oligonucleotides for a transactivation assay, in which he compared the
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activity of different truncated regions of the mouse Foxf2 protein [241] (previously 
known as “LUN”). He incorporated each of the 16 nucleotides that were examined 
by Pierrou et al at and near the core sequence, including those bases which Pierrou 
and colleagues did not consider frequent enough to highlight as significant. This 
expanded the binding sequence contained within these oligonucleotides to: 
caaacGTAAACAatcc.
These oligonucleotides have been adapted for a comparison of the activational 
properties of wildtype and mutant FOXF2 proteins using pTAL-SEAP as a reporter 
vector (see figure 6 .2 1 ).
6.2 EMSA
The EMSA (Electrophoretic Mobility Shift Assay) or Band Shift Assay is a method 
for studying protein-DNA interactions in-vitro [272]. Oligonucleotide probes which 
contain target sequence or candidate target sequence for the protein of interest are 
labelled with a visualisation molecule before mixing this probe with the protein and 
running through an electrophoretic gel.
These gels are run under native (non-denaturing) conditions and therefore the 
charge, morphology and molecular weight of the protein influence its migration. 
Native gels are necessary because DNA binding is highly sensitive to alterations in 
molecular morphology and an appropriate interaction depends on the correct 
alignment of these molecules.
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Protein-probe complexes will migrate slower through agarose or acrylamide gels 
than free probe. Unbound probe is added to some lanes in order to compare its rate 
of migration with potential probe-protein complexes. Binding of the probe to the 
protein would result in a reduction in the migration rate through the gel - due to the 
larger size of the complex than either of the molecules alone.
Antibody specific to a protein of interest is often added to EMSA binding mixtures. 
If this antibody binds to the protein-DNA complex, then an additional band should 
be seen with a slower migration rate than either the unbound DNA probe or the 
DNA-protein complex. This test is known as a “supershift” assay and a positive 
result acts as unambiguous proof of a proteins identity.
An increasing gradient of unlabelled probe can be added to the binding mixture in 
several wells as a further control. If the interaction between the probe and the protein 
is specific, then there should be a sharp reduction in the strength of signal as the 
concentration of inhibitor increases. Non-specific competitor should require a much 
higher concentration in order to eliminate the labelled probe-protein complex than 
the specific competitor.
The oligonucleotides that were initially designed for the pTAL-SEAP/FOXF2 
transactivation assay (section 6.3) form a double stranded FOXF2 binding sequence 
and therefore also suffice as an EMSA probe.
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EMSA (Band Shift Assay)
pEVRFO
(Each 
Expression 
vector)
Transfection
pTAL-SEAP
4“ " " a # *  (Empty)
^ «  U A y i  C 9 9 I U I I
I Transfection \  vector)j t r j  Cos-7 Cells | %
Media Extracted
48 hours Post transfection
/ IDIG Labelled d s  
Binding site ollgo’s  Preteln Extraction/
s'
SEAP levels 
determined: 
Transfection control
\
DIG Detection Native Gel Electrophoresis 
& Blotting
Transactivation Assay
OR
rir  pTAL-SEAP
t  (Empty OR' > “ with
binding sites)
\
Transfection Ratio:
EGFP Transfected: Non-transfected
Transfection
\  l  ✓
Cos-7 Cells
OR
pEVRFO
(ONE of each 
expression 
vector)
Luminometer
Media Extracted
24,48,72 hours 
Post transfection
Normalised SEAP Levels
Figure 6.2 EMSA & Transactivation Assay schemes
Schemes planned for the study o f the effects o f the W174R and V410F mutations on the DNA 
binding affinity and transcriptional activity o f FOXF2. A: For the EMSA, each o f the pEVRFO 
expression plasmids (F0XF2W174R, FOXF2V410F, FOXF2pg and the empty pEVRFO vector) were 
transfected into separate Cos7 cultures alongside the empty pTAL-SEAP vector which acted as a 
transfection control. Media was extracted to measure alkaline phosphatase levels, which it was 
thought would be secreted at levels that varied only according to the transfection efficiency o f the 
control vector in each sample. Nuclear protein was extracted from the cells and added to a DIG
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labelled probe which contained the FOXF2 binding sequence. This mixture was then run on an 
electrophoretic gel in order to visualise the binding efficiency o f each FOXF2 isotype. B: The 
transactivation assay involved the transfection in triplicate o f each FOXF2 expression plasmid and a 
reporter. The reporter was pTAL-SEAP with multiple copies of the FOXF2 binding site adjacent to 
the pTAL promoter. pTAL-SEAP without the binding sequence was also added to some of the 
transfections as a control against which the regulation of SEAP could be measured. GFP was also 
added as a transfection control.
6.2.1 Mouse cDNA Expression Vector Construction
Foxf2 cDNA primers were designed to the 5’ and 3’ UTRs of the gene with the 
restriction sequences Sail and BamHI on separate primers and a random sequence 
tail at the 5’ end of each primer. Sail and BamHI were selected as restriction sites 
because they weren’t present in FOXF2, so digestion would not occur in the plasmid 
at extraneous positions. Both enzymes also function at 100% efficiency in a single 
buffer:-NEB3.
Construction of the plasmid was planned as follows:
1. RNA extraction from mouse tissue known to express Foxf2
2. Reverse transcription of RNA to produce cDNA
3. Amplification of cDNA with the primers designed to Foxf2 UTRs as shown 
in figure 6.3
4. SA1I and BamHI restriction enzyme digestion of the expression plasmid.
5. Treat the linearised plasmid with phosphatase in order to remove phosphate 
groups to inhibit self ligation of the plasmid and to enable ligation of the 
amplified cDNA product.
6 . Ligation of the cDNA product and plasmid.
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7. Transformation of competent bacterial cells with the ligation product.
8 . PCR of transformed colonies with primers designed to surround the multiple 
cloning site of pIRES-EGFP plasmid.
9. Size determination of PCR products.
10. Purification of plasmid from transformed bacterial cultures.
11. Sequence confirmation of insert presence and integrity.
Random 
Sequence tail
Sail
site
Foxf2 sequence
J L
c a t a q a lGTC GACAAG C C C C AG AG GAG C T GAG
C fa tc c q gGATCCFGCTACTTACTGCTATTCGCTATCC
BamHI
s'te cDNA template
  J
->...................................
Sail site Sail J . BamHI
BamHI
site
Sail o
BamHI
Vector+
Foxf2
Expression
Vector
Linearised
Vector
Mouse FOXF2 
Construct
F i g u r e  6 . 3 :  I n t e n d e d  F o x f 2  E x p r e s s i o n  p l a s m i d  d e s i g n
Approach for the Intended Construction o f a Mouse Foxf2 expression construct. Primers were 
designed within the 5’ and 3’ UTR o f mouse Foxf2. Sail and BamHI restriction site sequence were 
incorporated at the 5’ end o f the gene sequence o f these primers for the later insertion into a pIRES- 
EGFP expression vector. A randomised 6bp tail was added to the restriction sequence to minimise the 
opportunity for inappropriate annealing and interference with Foxf2 amplification.
RNA was extracted from the lungs and eyes of ~ 8  week old mice as described in 
section 2.2.20. These tissues were selected because according to expression studies
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that were carried out by Aitola and co-workers [188], the gene maintains expression 
into adulthood in these mouse organs.
□
— i-------- 1— H —
Time (seconds)
[U DT3
Time (seconds)
Time (seconds)
-U
t* ^ ■*
Time (seconds)
F i g u r e  6 . 4 :  R N A  p u r i t i e s
RNA Agilent Analysis for Eye and lung tissue from 1 male and 1 female heterozygote individual. 
Good quality, undegraded RNA produces two distinct peaks resulting from 18S and 28S rRNA in a 
28S:18S ratio of ~2; a ratio which decreases as degradation proceeds in RNA samples. These two 
cytoplasmic ribosomal components together with the 5S ribosomal subunit constitute -95% of total 
RNA and are therefore an easily detectable indicator of the general quality of total RNA. RNA from 
eye tissue o f the female produced a broad, indistinct peak, suggesting that either degradation or 
contamination had occurred in this sample. B: RNA from eye tissue of the male produced sharp but 
low peaks -  indicating a low yield (34.07ng/ul) o f clean and good quality RNA. Total RNA from 
lung tissue from the female (C) from the male (D) were both of high quality, at concentrations of 
23.13ng/ul and 53.99ng/ul respectively.
Initial attempts to obtain a cDNA product with the tailed primer set described in 
figure 6.3 were unsuccessful. However, following optimisation and changes to the 
Reverse transcription (RT) kit used, cDNA which produced a strong sharp PCR 
product from the primers Foxf2cDNAnested4 were obtained with the conditions
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described in section 2.2.22. These products however were significantly shorter than 
the predicted size o f2340, so a range of different primer sets were applied to these 
RT products in order to obtain Foxf2 cDNA. None of the product sizes were of the 
correct size as shown in table 6.1. However, when 2 of the shorter products were 
sequenced, they showed exact sequence identity with the expected product for the 3’ 
half of the molecule. The 5’ half appeared truncated to different extents within each 
product, but in each case, sequence was missing from the product near the 5’ primer.
Trehalose was added to some of the reverse transcription reactions because its 
presence allows enzymatic reactions to proceed at higher temperatures than is 
otherwise possible [273, 274]. This is useful when performing reverse transcription 
because higher temperatures can remove problematic secondary structure within
RNA thus facilitating the synthesis of full length cDNA. I was only possible to 
amplify Foxf2 cDNA in the presence of trehalose.
Forward R everse
Expected
S ize
O bserved s iz e  
(Approx)
Foxf2cDNA4_nested Foxf2cDNA4_nested 2340 1300
Foxf2cDNA3 Foxf2cDNA3 1728 700
CDNA5 F Foxf2cDNA3 1475 700
Table 6.1: Expected and Observed Product sizes from Foxf2 cDNA PCRs.
These were the preliminary attempts to produce full length cDNA from Foxf2wl74R tissue. The 
product sizes were smaller than expected and did not therefore contain full length FOXF2 cDNA.
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Following the initial failure to produce full length cDNA directly, another approach 
was taken. Primers were designed for the production of shorter overlapping 
fragments of the cDNA which it was envisaged would be easier to synthesise and 
could be joined together with restriction enzymes following amplification and 
purification of the products.
These primers however also failed to produce product of the expected size -each 
pair produced two smaller products as can be seen on table 6.2. Amplification of the 
shorter fragments of cDNA was intended to ease the production of full length 
cDNA. A series of restriction digests would have been required with this method. 
Both bands from each product were therefore sequenced. It was speculated that the 
bands could together contain the required sequence and although an unlikely option 
due to the technical challenges involved, one potential strategy was the utilisation of 
additional restriction digests to fuse all the required cDNA sequence.
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BLAST Alignm ent of cDNA Fragm ent seq u en ce  with Ensem bl v45
Foxf2 T ranscrip t
Large PCR 
Product 1
Small PCR 
Product 1
Large PCR 
Product 2
Small PCR 
Product 2
Ensembl Sequence Range F (A) 630-824 - 1342-1713 -
Ensembl Sequence Range F (B) 311-352 - 826-863 -
Ensembl Sequence Range R 626-897 620-902 1550-1665 1560-1658
Region between F alignments in 
Fragment Sequence 94 Not Applicable 27 Not Applicable
Region between F alignments in 
Ensembl Transcript 275 Not Applicable 480 Not Applicable
Total readable aligned seq 314 283 410 99
Total fragment sequence 408 283 437 99
estimated size on gel 480 410 530 320
Expected Size 644 966
Table 6.2: Incomplete Foxf2 cDNA fragments
Alignments of the sequence from cDNA PCR products produced from cDNA PCRs with the primers 
Foxf2cDNAsmlRi and Foxf2cDNA5F (Small and Large PCR productl); and with the primers 
Foxf2cDNA3_R and Foxf2cDNAsml_F (Small and Large PCR product 2). Two products resulted 
from each PCR. The Forward reads that produced viable sequence had 2 separate regions of 
alignment, these have been nominated as A and B. Forward sequencing o f both small fragments 
failed to produce viable data, indicating that these fragments were missing the 5’ end o f the required 
sequence.
Despite these unexpected product sizes, sequence data suggests that they are of 
Foxf2 origin. All of the amplified Foxf2 primer sets produced a strong product and 
sequence from these fragments aligned well with the sequence of Foxf2 in Ensembl, 
but each with a section of the 5’ end missing. In each case a section of sequence data 
was missing from close to the 5’ primer on sequencing the products.
The amount of total aligned sequence does not account for the entire PCR product in 
any of these samples. However, information about the nature of the PCR products 
can be obtained from the available sequence data.
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A BLAST search of the PCR product sequence produces significant alignment 
uniquely with Foxf2, suggesting that these are PCR products of Foxf2 cDNA. In 
both large PCR products, the initial 40-50bp that immediately follows each 5’ 
primer, aligns with the Ensembl transcript. A larger region of alignment at the 
predicted 3’ end of the expected sequence is also seen in both PCR products. 
However, between these regions in both PCR products, lies sequence with no 
alignment matches to either Foxf2 or any other genomic sequence. The region 
between alignments is significantly larger in the Ensembl sequence than in either 
PCR product sequence (94bp and 27bp for the cDNA sequence of PCR products 1 
and 2 respectively compared to 275bp and 480bp for the Ensembl equivalent regions 
of PCR products 1 and 2 respectively)
This phenomenon can only be seen in the forward sequencing of each PCR product, 
the reverse primer does not produce the sequence seen with the forward primers in 
the 5’ aligned region, probably due the distance from the 5’ region to the reverse 
primer sequence.
Each PCR also produced a second, smaller band which was also sequenced. Again, 
when analysed with BLAST, these PCR product sequences only produced 
significant alignment with FoxfZ and no other genomic sequence. The forward 
sequencing primer failed to produce any sequence for either PCR product, despite 
attaining sequence of high quality for the reverse primers. This suggests that the 5’ 
end of the expected PCR product is missing from these smaller amplicons.
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The discovery of these unusual larger PCR products was a by-product of an attempt 
to produce a full length mouse cDNA for the manufacture of an expression plasmid. 
Because the cDNA was proving difficult to obtain, it was decided that an available 
human FOXF2 expression construct would be used instead. Further characterisation 
of the cDNA was therefore not considered a priority but an investigation into 
whether these are genuine transcriptional isoforms and if so, the identification of the 
precise breakpoints could be interesting, particularly as there is only one intron in 
the gene.
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Forward Primer Reverse Primer
Product Size Calculated 
from Sequence
Product Size 
Estimation from 
Agarose Gel
Foxf2cDNA4nested Foxf2cDNA4nested 2340 1300
Foxf2cDNA3 Foxf2cDNA3 1728 700
Foxf2cDNA3 1475 700
Foxf2cDNAsmlRi 644 500
1 Foxf2cDNA3 966 520 & 300
|Region of Primer Overlap - -
AGCTGTCCAGCTCTGGGCAGCGTCGCCTCAGTGGCTTAGGAGACGGTTGCGCAAGGAGCCGGCCGGAGGCTCGGA 
AGAGGGATGCGCGGGGCGTTGCCTCCGACCCGCCGCCGCCGCCGCCGCCCGAAGCCCCAGAGGAGCTGAGGGAGG 
CGACGCCGAAGCGCTGGCCCGCAGTGGCCCGGGCTGCAGCGCGGCCGGCGCAGTAGGGCACTCGCCCGATTTGTG 
GACCGArrr.GGCTCCGGCGCCGCCGATCCCGGTCCGGGGTCCGCCCCGCAGGCCCGGcMnfcfcWu^fchfcdi&lrtMg! 
^■WeyfeV^CGAGGGCGGGCCTCCGCCACCCCCGCCGCGCCCGCCGCCTGCCCCACTCCGCCGCGCGTGCAGCCC 
GGCGCCCGGCGCGCTCCAGGCCGCCTTGATGAGCCCGCCACCCGCCGCCACCCTGGAGTCCACTTCGTCGTCGTC 
ATCATCATCCTCTGCCTCCTGTGCCTCGTCCTCTTCTAACTCCGTCAGCGCCTCGGCCGGTGCTTGCAAGAGTGC 
GGCTAGCAGCGGCGGCGCGGGCGCCGGGAGTGGAGGCACCAAGAAGGCAACCTCGGGGCTGCGGCGGCCGGAGAA 
GCCTCCTTACTCGTACATCGCGCTCATCGTCATGGCCATCCAGAGCTCGCCCAGCAAGCGCCTGACGCTCAGTGA 
GATCTACCAGTTCCTACAGGCGCGCTTCCCCTTTTTCCGTGGCGCCTACCAGGGCTGGAAGAACTCCGTGCGCCA 
CAACCTCTCGCTCAACGAGTGCTTCATCAAGCTGCCCAAGGG GGCCACTACTGGAC
CATCGACCCGGCCAGCGAATTCATGTTTGAGGAGGGTTCGTTCCGCCGCCGGCCGCGCGGCTTCAGGCGGAAGTG 
CCAGGCTCTCAAACCCATGTACCATCGCGTGGTGAGCGGCTTGGGCTTCGGGGCCTCGCTGCTGCCCCAGGGCTT 
CGACTTCCAAGCGCCCCCGTCGGCGCCTCTGGGTTGCCACGGTCAAGGCGGTTATGGTGGCCTCGACATGATGCC 
CGCGGGCTATGATACAGGGGCGGGTGCTCCGGGCCACGCGCATCCACACCACCTCCACCACCACCACGTCCCCCA 
CATGTCGCCCAACCCGGGCTCCACCTATATGGCCAGCTGCCCGGTGCCCGCAGGTCCTGCGGGCGTCGGTGCGGC 
AGCGGGTGGCGGCGGTGGCGGCGGGGACTATGGGCCGGACAGCAGCAGCAGCCCTGTGCCCTCATCCCCGGCTAT 
GGCAAGCGCCATTGAGTGTCACTCGCCCTACACTAGCCCTGCGGCACATTGGAGCTCGCCTGGCGCTTCACCTTA 
CCTCAAGCAGCCGCCTGCCCTGACGCCAAGCAGTAATCCCGCGGCCTCTGCTGGTCTGCACCCCAGCATGTCTTC 
CTACTCGTTGGAGCAGAGCTACTTGCACCAGAACGCCCGCGAGGATCTCTCAGTCGGACTGCCCCGTTACCAGCA 
CCACTCCACTCCAGTGTGCGACAGGAAAGATTTCGTCCTCAATTTCAATGGCATTTCTTCTTTCCACCCTTCCGC 
TAGTGGCTCTTATTATCACCATCATCACCAGAGCGTGTGCCAAGATATTAAGCCCTGTGTTATGTGAATGGACAG 
AGGCCTTGAAGGCCACTCTGCTCTCCCTCTTCTGCCTTCTTCTCCTCTCCCCTCCGAGAGGGGCAGCCAGGAACT 
GCAAChGACTCACACTGTGCACGCTGGATAGCGAATAGCAGTAAGTAGCACACCCATCACTTAGACAAATACCCA 
AGGGAGTTCTGCTCACCGATATTTGCCCGGCCCCTGGAAGAGGAAACCTTTCGAAAGCTAATATCCCAGAAGAGC 
GACAGACAGAGGAGGTGACTACATGTAAGACATATGTTACTGTGTGGAGGACATAAAACTTTTCAGTTCTGGGGT 
GGCCATTGCATTCACTAATCAGGGTCTGAAAAGGGAGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGC 
TTTTCAAAATTGCAGTGCTAAAAGCACACAATTTCAAGAAAGCCTTCTCTAGTTCCCTGGCTCAGTAGGACATTT 
CTTCCACCCACTCCCAGTCCCCCAACACTCCCTTCTTCGGATACAGGTGCCAAAGAACATTGTGZVAGAAATGAAG 
AACCGATAGTCTAGTTTAAGAAAGTGGCTCTCAGTATTGTGACAGTACATTTTTACAAGGTTGTTTTTCTACCAC 
CGTATTTTTAAAGTATTTTTATGATCTTCGTATACTCACACTTCGCTTGTATTGTAAAAGGAGGGTATATTTGCA 
CTTATGTATACTTTGACAGTTTGCCAAGATATTTTGATGTAAGGTTTTTTTTTTTTCAATAAAATGTGTATAAC
Figure 6.5: cDNA fragments in relation to the transcript
The Foxf2 transcript as predicted by Ensembl v45 and positions within the sequence o f  the primers 
used to amplify cDNA. Underlined, bold sequence is translated into protein.
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6.2.2 A Human FOXF2 Expression Construct
A FOXF2 expression construct was kindly supplied by Dr Cheryl Gregory Evans. 
This was originally constructed by Marika Hellqvist and co-workers [203] who 
inserted a FOXF2 cDNA sequence into a pEVRFO plasmid [204]. The inserted 
cDNA is not the full length and the resulting protein is therefore missing 39 amino 
acids from the amino terminus.
The pEV vector set of which pEVRFO is one member, allows the expression of 
incomplete coding sequence in any reading frame by selection of a specific vector 
according to the position of the first coding base available. Three of the four vectors 
within the set are designed for inserts missing their 5’ end, each of these translates 
sequence within a different reading frame. The translation initiation region of HSV 
TK (Herpes Simplex Virus - Thymidine Kinase) is located upstream of a multiple 
cloning site at different positions in each vector to allow for different reading frame 
insertions [204]. The translated products are therefore fusion proteins that contain 9 
N-terminal amino acids of vector origin. The promoter region is derived from the 
human CMV (Cytomegalovirus) promoter and the origin of replication is from the 
SV40 (Simian Virus 40) ori locus.
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pEVRFO iGAlTCdGGTlACddGGGGAGCTCT
pEVRF2 IGAlTCdGGdTAdcdGGGGAGCTCT 
pEVRFI iGAlTCdGGdGTAlCCdGGGGAGCTCT
ICTEieamiiiracHeSg
BafriHI
CTAGA
Xbal
AAAJ CMVTK
IhWcfcfyiggggnggg
Smal Kpnl/
SacI -— *— < Asp718 NheI CTAGA
pEV3S GATCCGAGCTCCCCGGGTACCTAGCTAGCTAGT
Figure6.6: pEVRFO Expression plasmid
The pEV plasmid set, copied from Matthias et al [204]. pEVRFO, 1 and 2 allow the expression of 
products which are missing their 5’ initiation region by the presence of a Thymidine kinase initiation 
sequence adjacent to the cloning site. The multiple cloning site allows for insertions within each 
possible reading frame
In addition to the protein truncation and presence of amino acids encoded by the 
vector, three amino acids which Hellqvist identified as the 3 terminal FOXF2 
residues of the insert differ from the Ensembl FOXF2 sequence; these are Q F R in 
the construct whereas the sequence in Ensembl identifies the amino acids at this 
position as: A A A within a (9X) poly-alanine repeat. The predicted product from 
this construct is therefore either a fusion of 1 2  foreign amino acids onto a truncated 
FOXF2 that is missing 39 amino acids if the Ensembl cDNA sequence is correct, or 
a 9 residue product fused to a FOXF2 protein that is missing 36 amino acids -  if the 
cDNA and associated peptide sequence described in Hellqvisf s paper [203] is 
accurate.
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Cheryl Gregory-Evans and Helena Vieira had subsequently mutagenised this 
construct to include an additional glycine within a poly glycine tract (Gly302- 
306ins3bp), replicating an insertion mutation which they had identified in a family 
of glaucoma patients [155].
The two mutations that were identified in the ENU archive which required further 
analysis were W174R and V412F in mouse Foxf2. In the human gene, the 
designation of the tryptophan to arginine mutation remains unchanged at amino acid 
position 174, but the valine position is at amino acid position 410, not 412 as is the 
case in mouse. The valine to phenylalanine mutation will therefore be referred to as 
V410F for all subsequent work involving the human FOXF2 plasmid.
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6.2.3 Vector Mutagenesis
The difficulties experienced with the Foxf2 cDNA production meant that another 
approach was required for the production of an expression plasmid. A human 
FOXF2 plasmid was available which could be mutagenised by site-directed 
mutagenesis to induce the equivalent mutations that were obtained from the ENU 
mouse archive. Although the 5’ end of this vector was missing, the entire forkhead 
domain and all the protein sequence 3’ of the forkhead domain was present.
6.2. 4 Mutant Plasmid Production
Site directed mutagenesis was used to introduce the mutations of interest into the 
human FOXF2 expression plasmid. This procedure required the design of 
overlapping primers that contained the target sequence with the desired mutation as 
described in section 2.2.30 (see also figure 6.7). These primers were used to amplify 
the entire plasmid using a template plasmid that had been harvested from Dam+ host 
bacteria. Dpnl is added to the resulting product which degrades only Dam+ DNA so 
should remove the non mutagenised parental plasmid and leave the mutagenised 
PCR product. This can then be transformed into a host bacteria to repair the nicks for 
the finished mutagenised plasmid.
The polyglycine mutant was amplified using the conditions described in section 
2.2.5, programme 4. This was followed by Dpnl digestion with 10 units of Dpnl in 
50ul PCR product mixture. Transformation of XL 1-Blue cells was performed as 
described in section 2.2.18 with lul, 2ul and 5ul volumes the Dpnl reaction mixture.
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14 colonies were grown overnight in LB with ampicillin. 750ul of these cultures 
were stored as glycerol stock and the remaining culture purified using a Wizard prep 
kit as described in section 2 .2 .1  before direct sequencing with primers designed to 
the region that contained the site of the desired mutation (see table 6.4 for all primers 
that were used to sequence potential mutants). Of these purified vectors, 7 were 
missing sections of the expected sequence. One of the seven remaining vectors was 
successfully mutagenised to remove the additional GGC triplet in order to produce 
the wildtype version of the FOXF2 plasmid.
This procedure was then repeated to induce the W174R mutation and the V410F 
mutation with the primer sets and amplification programmes as described in table
6.3.
Primers For Site Directed Mutagenesis
Mutation Primer se t Forward Reverse PCR Programme
Wildtype from
Gly302-
306ins3bp
HFOXF2_7G-6G
GGGGGCGGCGGCGGCGGCG
ACTACGGGCCGGACAGC
GCTGTCCGGCCCGTAGTCGC
CGCCGCCGCCGCCCCC
55C annealing. 68C  
extension. 16 cycles
W174R HFOXF2_W-Ri
CGGCAAGGGCCACTACAGGA
CCATCGACCCG
CGGGTCGATGGTCCTGTAGT
GGCCCTTGCCG
58.8C annealing. 
72Cextension. Betaine. 12 
cycles
V410F FOXF2_V-F
GTGTGT GACAGAAAAGATTT C 
TTCCTCAACTTCAATGGG
CCCATT G AAGTT G AGG AAG AA 
AT CTTTT CTGT CACACAC
66.8C annealing. 72C 
extension. Betaine. 12 cycles
T a b l e  6 . 3 :  S i t e  d i r e c t e d  m u t a g e n e s i s  t h e r m a l  c y c l i n g  c o n d i t i o n s
Primers and PCR conditions which produced the required mutations within the FOXF2 pEVRFO 
plasmid.
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Following sequencing identification of the mutant plasmids, further sequencing with 
the primer sets listed below was performed to ensure that polymerase induced errors 
had not occurred during amplification, and that the FOXF2 open reading frames 
were maintained.
Primer Sets Used for Plasmid Integrity Testing
Primer ID Forward Primer R everse Primer
pEVRFO: N GGGGGATCTTGGTGGCGTG Not Applicable
MFUXF2_1A Not Applicable GGATGGCCAT GACGAT GAGC
HhUXh2_1b AGCCGCCCTACTCGTACATC ATGTCGAGGCCGCCGTAG
HhUAh2_1(J CAGGGCTT CGACTT CCAG T GCAAGTAGCT CT GCT CCAG
HFUXF2_2A AATGCCACTCGCCCTACAC Not Applicable
pEVRFO: C Not Applicable CCCT G AAAACTTT GCCCCCT CC
T a b l e  6 . 4 :  P r i m e r s  f o r  T e s t i n g  t h e  I n t e g r i t y  o f  p E V R F O  C o n s t r u c t s
Primer sets used for expression plasmid integrity testing. The pEVRFO: N & C primers are designed 
to the vector sequence surrounding the insert and the HFOXF2 primers are designed to human 
FOXF2 sequence. The primers at the terminal ends of the expressed sequence were not included for 
this screen because the sequence homologous to HFOXF21A (forward) is missing from the 
truncated sequence o f the plasmid and the sequencing data from HFOXF2_2A (reverse) would be 
redundant due to the pEVRF0_C sequencing data. The Vector sequence primers were used to check 
for construct integrity in addition to the FOXF2 primers because they provide sequence data for the 
region which spans the insert boundaries.
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FOXF2(7G)
i' \ S.D.
\ Mutagenesis 
pEVRFO I
FOXF2VVT
pEVRFO
FOXF2v"mF
I
S.D.
Mutagenesis
pEVRFO
pEVRFO & r~. pEVRFO &
FOXF2’AT FOXF2V410F
pEVRFO & 
FOXF2PG Xba I 
BamH I pEVRFO
V J
pEVRFO
(Empty)
Mutagenesis EQXF2W 74R
pEVRFO
\
pEVRFO & 
FOXF2’A'174R
Figure 6.7: FOXF2 Expression Construct Mutagenesis
Mutagenesis strategy for the FOXF2 expression constructs. The construct supplied contained the 
polyglycine expansion that was seen in human glaucoma carriers. This mutation was removed by 
mutagenising the polyglycine region with wildtype primers before further site directed mutagenesis 
was performed to induce the V410F mutation and W174R mutation. The empty vector was produced 
with a double digest o f the original construct using Xbal and BamHI.
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A: Human FOXF2 Protein Sequence
M T T E G G P P P A P L R R A C S P V P G A L Q A A L M S P P P A A A A A A A A A P E T T S S S S S S S S A S C A S S  
S S S S N S A S A P S A A C K S A G G G G A G A G S G G A K K A S S G L R R P E K P P Y S Y I A L I V M A I Q S S P S  
K R L T L S E I Y Q F L Q A R F P F F R G A Y Q G W K N S V R H N L S L N E C F I K L P K G L G R P G K G H Y W T I D  
P A S E F M F E E G S F R R R P R G F R R K C Q A L K P M Y H R V V S G L G F G A S L L P Q G F D F Q A P P S A P L G  
CHS QG G Y G GL D M M P A GY D A GA G A PS H AH P HH H H HH H V PH M S PN P GS T Y M A SC P V PA G PG  
G V G A A G G G G G G D Y G P D S S S S P V P S S P A M A S A I E C H S P Y T S P A A H W S S P G A S P Y L K Q P P A  
L T P S S N P A A S A G L H S S M S S Y S L E Q S Y L H Q N A R E D L S V G L P R Y Q H H S T P V C D R K D F V L N F  
N G I S S F H P S A S G S Y Y H H H H Q S V C Q D I K P C V M
B: FOXF2 & pEVRFO construct:
---------------------------------------------------------------------m a s w g s g t q f r a a p e t t s s s s s s s s a s c a
S S S S S S N S A S A P S A A C K S A G G G G A G A G S G G A K K A S S G L R R P E K P P Y S Y I A L I V M A I Q S S  
P S K R L T L S E I Y Q F L Q A R F P F F R G A Y Q G W K N S V R H N L S L N E C F I K L P K G L G R P G K G H Y W T  
I D P A S E F M F E E G S F R R R P R G F R R K C Q A L K P M Y H R V V S G L G F G A S L L P Q G F D F Q A P P S A P  
LG CH SQ G G YG G L D MM PA G Y DA G A G AP SH A H PH H H HH H H VP H MS PN PG ST Y MA SC PV PA G  
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Figure 6.8 Amino acid sequence of FOXF2 and the truncated FOXF2 of the peptide
Amino acid sequence o f FOXF2 and the truncated FOXF2 o f the peptide 
Amino Acid sequence o f A: Human FOXF2 and B: The truncated FOXF2 fusion product produced 
by the pEVRFO construct. Red letters indicate the position o f  the forkhead domain within each 
molecule. The vector encoded sequence is underlined on the fusion p ro d u ct. The polyglycine 
expansion region is highlighted in yellow and shows the human wildtype copy number (6 residues) in 
A, and the expanded copy number (7 residues) in B. The first 3 amino acids o f FOXF2 origin in 
sequence B (QFR) are not present in sequence A which was sourced from Ensembl but were 
identified as part o f a cDNA derived peptide in H ellqvisf s paper [203]. Blue underlined text is amino 
acid sequence originating from the plasmid.
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6.2.5 Production of the Empty pEVRFO Expression Plasmid
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Figure 6.9 Evidence of Empty pEVRFO plasmid
A range of Xbal and BamHI concentrations were added to 2ul (approx 400ng DNA) of plasmid 
(following purification with a wizard kit) to ensure its complete digestion. Lane 1 = Original digest; 
Lane 2 = Original digest then a further 10 units o f BamHI; Lane 3 = Original digest + lOu Xbal; 
Lane 4 = Original digest + lOu BamHI + lOu Xbal; Lane 5 = Original digest + 20u BamHI + 20u 
Xbal. Complete digestion o f the linearised plasmid has occurred in lanes 4 and 5 where only the cut 
plasmid (middle band) and free insert (lower band) is present, and not the upper band (undigested 
plasmid + insert). Double digests were possible because both enzymes are 100% efficient in buffer 2 
in the presence of BSA
Following digestion with Xbal and BamHI and subsequent DNA purification with a 
Qiaquick PCR purification kit (Qiagen), the sticky ends of the linearised pEVRFO 
vector were filled using DNA polymerase I (klenow), before recircularising with 
blunt ended ligation as described in sections 2.2.17 and 2.2.30.
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6.2.6 EMSA Results
Two potential oligonucleotide probes were labelled with Digoxigenin-11-ddUTP 
(DIG) -  these probes are oligonucleotides (described in section 2.2.31) that contain 
the FOXF2 binding site and would therefore be expected to allow binding of the 
FOXF2 protein. Serial dilutions of these DIG labelled oligonucleotides and a control 
oligonucleotide that was labelled under standard conditions by the manufacturer of 
the labelling kit (sequence from the lac Z region of pUC and M l3 plasmids: pTTG 
GGT AAC GCC AGG GTT TTC CCA GTC ACG). In order to visualise the 
efficiency of labelling, the membranes were treated with an alkaline phosphatase 
(AP) conjugated anti-DIG antibody, before the application of the chemiluminescent 
AP substrate CSPD and subsequent exposure to X-ray film. Oligonucleotide 
concentrations for optimal signal strength and resolution were determined from the 
image produced (figure 6.10). Subsequent binding assays utilised the Bglll 
oligonucleotide annealed to an unlabelled version of the Mlul oligonucleotide at 
50fmol/pl.
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Dig Labelled 
Oligonucleotide Oligonucleotide Concentration (fmol/uD
1 0 0
BglD/
FOXF2 Binding Site
Mlul/
FOXF2 Binding Site
Control
Figure 6.10: DIG oligonucleotide labelling efficiency tests
Following the DIG labelling procedure, the labelled oligonucleotides were serially diluted and blotted 
onto Hybond N+ membrane before cross-linking before detection o f DIG levels with an alkaline 
phosphatase conjugated anti-DIG antibody.
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Proteins that bind to DNA irrespective of the nucleotide sequence will be present 
within the experimental nuclear extract. This is likely to have a confounding effect 
on the interpretation of any analysis of specific binding of extracted proteins to the 
DIG labelled probe. The most common way to reduce this phenomenon is the 
addition of non-specific competitors. Different combinations of Salmon sperm 
DNA, Cotl DNA and poly dl-dC were therefore tested to discover which competitor 
provided the greatest improvement to band quality. The non specific competitors 
that allowed the greatest clarity and resolution of visible bands was a combination of 
Cotl and poly dl-dC as can be seen in figure 6.11.
F i g u r e  6 . 1 1 :  N o n  S p e c i f i c  C o m p e t i t o r  S e l e c t i o n
This test was carried out with a range of different non specific inhibitors with 15ug nuclear protein 
extracted from cells that were transfected with the wildtype FOXF2 construct. The non-specific 
competitor which produced the strongest bands that still maintained a clear resolution was a 
combination o f Cotl and poly dl-dC. SS=salmon sperm DNA at 50ng/ul. dI-dC= poly dl-dC at 
O.OlU/ul. Cotl = Mouse Cotl DNA at 50ng/ul. A total o f 2ul non-specific inhibitor was added to each 
sample.
Protein from cells transfected Protein from non-
with wildtype FOXF2-pEVRFO transfected cells
Protein/probe 
complex 1
Protein/probe 
complex 2
Unbound *
probe
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Levels of nuclear extract within the binding mixture also required optimisation, so 
following an evaluation of protein concentration within the extracts, a range of 
different dilutions of the extract were added to the binding mixture. In an attempt to 
gain further insight into which if any of the visible bands were FOXF2/probe 
complexes, an anti-FOXF2 antibody was added to replicate samples. The presence 
of a supershift would have provided confirmation of the presence of FOXF2 in the 
nuclear extracts of transfected cells, but no supershift was visible (figure 6 .1 2 ).
Protein Gradient and Antibody Test. 14/06/07
Protein Concentration 
(ug):
FOXF2 Antibody: - +
30 20
Protein/probe 
complex 1
Protein/probe 
complex 2 \
15
+ +
10 5
+ - +
Unbound. 
probe
F i g u r e  6 . 1 2 :  P r o t e i n  c o n c e n t r a t i o n  o p t i m i s a t i o n
Six different protein concentrations were tested with and without FOXF2 antibody 1 (Abnova). A  
supershift was not immediately apparent. Two potential protein/complex bands were seen when 
nuclear protein from the wildtype FOXF2 transfected cells were run with the probe in an EMSA in 
either the presence or absence o f antibody. However, the samples containing antibody have greater 
signal strengths on the lower of the two prominent bands than do the samples without antibody. The 
apparent detection limit o f the two probe-protein complex bands is between lOug and 15ug protein.
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Specific Inhibitor - rz ?
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Protein/probe
complex 1
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Figure 6.13 Specific competitor assay
Specific competitor assay. A reduction in the signal strength can be observed from both the upper and 
lower protein/probe complex bands corresponding with an increasing concentration o f the specific 
inhibitor. This suggests that the specific inhibitor interferes with the binding o f both bands and could 
lead to the conclusion that both bands may be the products o f different forkhead genes. An increase in 
the signal strength from the unbound free oligonucleotide can also be seen to correlate with 
increasing specific inhibitor strength, reflecting the increasing amount o f DIG labelled 
oligonucleotide that was unable to bind to a recognition site.
An additional approach taken to improve the clarity of the visible bands and to 
determine whether or not the binding interaction was specific - was the addition of a 
specifc competitor. A specific competitor in a band shift assay is unlabelled DNA 
that is identical in its sequence to the labelled probe. Any molecule that binds 
specifically to the probe is likely to have an equal affinity to the specific competitor 
and therefore an increase in the concentration o f the competitor should result in an 
equivalent reduction in the amount of bound probe and therefore also in the strength 
o f signal produced by the specific interaction. There is an inverse relationship 
between the strength of signal and the concentration o f specific competitor in the
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two prominent bands that can be seen in samples containing nuclear extract of 
FOXF2 transfected Cos-7 cells (figure 6.13 and 6.14). This result suggests that 
binding to both bands is specific. A supershift assay that was performed alongside 
another specific competitor test produced additional bands that emigrated slower 
than the suspected FOXF2 band (protein/probe 2 on figure 6.16). This would be 
expected if the probe was bound to FOXF2 given that a FOXF2 antibody should 
bind to FOXF2 thus increasing the size and slowing the progress of a DNA/FOXF2 
complex. However, another band of greater intensity that emigrated faster than the 
potential FOXF2/probe band was evidence that the antibody may also be binding to 
something other than FOXF2. Further evidence against specific binding of the 
antibody was seen when the DIG probe was added to wells without any nuclear 
extract and a similar although weaker run profile was observed (figure 6.16 *) 
although this may have been cased by contamination from adjacent wells.
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Figure 6.14: Specific competitor assay
A = 1 ul Cot I, lu l dl-dC, 15ug WT protein. B = 1 ul Cot I, 3ul dl-dC, 30ug WT protein. Controls 
added: “A b l” = Foxf2 Antibody 1 (Abnova) added. “X25”, “X100” = Unlabelled probe (specific 
inhibitor) added at a concentration o f X25 OR X I 00 the concentration o f labelled probe. = no 
specific inhibitor added. A supershift assay was performed alongside a specific competitor test in the 
hope that it may provide additional evidence as to the identity o f a FOXF2 band. The addition o f  the 
antibody 1 (A bl) appears to have enhanced the strength o f the signal generated. * = potential 
supershift bands which are not present in any o f the other samples that are higher than the suspected 
FOXF2 band (Protein/probe 2). ** = a more intense band below the suspected FOXF2 position. If 
non-specific binding to the antibody has occurred, it is possible that the lower band is the antibody 
bound to the probe. Another possibility is that the FOXF2 band was previously mis-identified and the 
lower band in lane 2 is FOXF2 bound to the probe and the higher band (*) remains the supershift.
The reduction o f signal strength caused by the presence o f the specific inhibitor however, goes some 
way to discount this theory. There is also a noticeable weakening o f  the signal from the upper 
protein/probe 1 band. This band is not visible at all in the antibody lane in image 6.14B.
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F i g u r e  6 . 0 - 3  E M S A
F i g u r e  6 . 1 5 :  E M S A  o f  C o s - 7  C e l l  l y s a t e  F o l l o w i n g  T r a n s f e c t i o n  w i t h  F O X F 2  C o n s t r u c t s
EMSA of FOXF2 with DIG labelled dsDNA containing the FOXF2 recognition sequence 
CAAACGTAAACAATCC. Nuclear protein was extracted from Cos-7 cells following transfection 
with a range of FOXF2 expression constructs. Controls are to the right of each gel image and include: 
0 = nuclear protein extract from empty pEVRFO vector; NT = nuclear protein extract from non­
transfected cells. Antibody was added to extract from cells transfected with the wildtype FOXF2 
expression plasmid (WT). Other samples tested were the FOXF2V410f construct (VF), the polyglycine 
mutant FOXF2 construct (PG) and the F0XF2W174R construct (WR). It was also added to the DIG 
probe alone (*) in order to determine whether a banding pattern occurred without the presence of 
protein. A Proteinase inhibitor cocktail (PI) was added to a mixture of nuclear extract from cells 
transfected with the wildtype expression plasmid and FOXF2 antibody 1 (Abnova). It was hoped that 
the presence of PI would reduce the potential for degradation of FOXF2 to impact on the quality of 
data -  There is a more defined separation o f the bands in the PI sample but the signal is weaker. Gel 
A was run with 15ug protein, 50ng Cotl and 0.01 units poly(dl-dC). Gel B samples contained 30ug 
protein, 50ng Cotl and 0.03 units poly(dl-dC).
Following optimisation of sample conditions, the EMSA was performed as shown in 
figures 6.15 and 6.16. There is a clear absence of protein/probe complex 2 from both 
the non transfected cell nuclear extract (NT) and from the empty expression vector 
extract (0). This indicates that protein/probe complex 2 is indeed the FOXF2 
peptide. Further evidence for the identity of this band can be seen in figure 6.16 in 
which the band produced by nuclear extract taken from cells transfected with the
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poly glycine expansion mutant FOXF2 (PG) is clearly emigrating slower than either 
the wildtype (WT) or V410F mutant (VF) forms of the peptide.
The key finding from this analysis however, was the absence of a clear band in the 
sample that contained nuclear extract of cells transfected with the F0XF2W174R 
mutant peptide. This suggested that DNA binding by the protein with this mutation 
is either very weak or absent and could explain the primary cause of the deficiency 
in gene function that leads to the phenotype of mutant individuals observed in 
chapter 5.
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Expression Plasm id
2
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Protein/probe 2
Figure 6.16: Enlarged view of EMSA
Variable band intensities from nuclear protein extracts taken from cells transfected with different 
isoforms o f  a FOXF2 expression plasmid. The red lines are positioned to emphasise a subtle elevation 
o f the protein/probe 2 band in the polyglycine mutant sample (FOXF2PG). There is no clear band in 
the nuclear extract taken from cells transfected with the FOXF2W 174R plasmid, indicating a reduced 
affinity for the probe sequence.
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EMSA Optical Density Ratios
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Figure 6.17 Optical Densities of EMSA bands
The optical densities of the bands hypothesised to result from FOXF2-probe complexes in figure 6.13 
A. The background intensity o f the membrane was 0.44. A lower signal strength in the W174R 
sample compared with the other FOXF2 construct transfections can be seen although there is a high 
background signal in each lane that hinders this analysis. The W174R sample showed an optical 
density of 0.6-0.7 OD which is the same range as the empty expression vector (0) and the non­
transfected control (NT). This is likely to be caused by non-specific binding o f the DIG labelled 
probe to other constituents o f the samples.
In figures 6.15 & 6.16, an upper potential protein/probe band is seen in each of the 
samples including the non transfected and empty vector transfected extracts 
indicating the possible presence of an endogenous forkhead protein in the Cos7 
nuclear extracts. The lower band (protein/probe 2) is present in the wildtype, V410F 
mutant and polyglycine mutant extracts but was not detected in the empty vector or 
non-transfected extracts. The W174R mutant sample does not show a clear second 
band as seen in the other FOXF2 transfected samples although a faint smear can be 
seen which stops at the same level as the second band in the other samples.
The absence of the second band in the empty expression vector and non-transfected 
control nuclear lysates; and the bands strong presence in all FOXF2 transfected
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cultures except for the F0XF2W174R isoform, provide credible evidence that this 
band was FOXF2.
Antibody assays though, did not provide such consistent evidence. Additional bands 
were seen in the antibody containing samples in figures 6.14-6.15, but no bands 
could be seen during an earlier attempt to optimise the signal strength generated by 
adjusting the total protein concentration within the antibody/nuclear extract mixture 
(figure 6.12).
One difference between these mixtures was the absence of DNA loading dye in the 
supershift optimisation gel (figure 6.12). It is therefore possible that the DNA was 
less likely to sink to the bottom of the wells when loading the samples without 
loading buffer. However the reason that loading dye was initially excluded from the 
binding mixture was because the glycerol in the binding buffer was considered 
sufficient to bring the sample to the bottom of the well during loading and it was 
considered preferable to remove as many potentially interfering factors from the 
binding mixture as possible before experimental runs. Despite the lack of colour in 
either the sample or the probe, the differing viscosities of the binding buffer and the 
surrounding running buffer allowed visualisation of sample loading albeit with less 
clarity; all samples appeared to be correctly loaded into the wells.
The banding pattern in the preliminary supershift optimisation (figure 6.12) matched 
samples without antibody. Subsequent samples which contained loading dye, did
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exhibit additional bands on addition of the antibody (figure 6.14). It is difficult to 
speculate why the addition of loading dye may have affected the run profile. It 
seems unlikely that the recommended EMSA loading dye would be inconsistent 
with antibody binding and even if this were the case it would be a remarkable 
coincidence if the loading dye corrected the alteration that had previously caused the 
loss of additional bands.
It is possible that the additional bands seen with the supershifts weren’t complexes 
of antibody and FOXF2. There was a weak banding pattern which reflected the band 
sizes seen in the apparent positive samples when antibody was added to the DIG 
probe alone. This indicated that non-specific binding of the antibody may have 
occurred. Although the signal is weaker in this control lane than in the other 
antibody containing lanes, this feature is not necessarily reassurance that the binding 
is not non-specific. Nuclear extracts would contain higher concentrations of material 
which could act as a substrate for non-specific binding.
In gel 6.15B of the EMSA, the upper band is present in all samples but is strongest 
in the empty vector and non-transfected samples, where there are no second bands.
In the wildtype, V410F mutant and poly glycine mutant samples, the second bands 
are stronger than the top bands. There does not appear to be a second band present in 
the W174R mutant sample. The second band was very slightly larger in the 
poly glycine mutant sample (figure 6.16), providing further evidence of its identity as 
the product of the transfected vector.
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The relatively weaker top bands in those samples in gel B that also contain a lower 
band suggest that there may be an inverse relationship between the strength of the 
top band with the strength of the lower band. One possible explanation for this is 
that when FOXF2 is absent or is present in a form with reduced sequence affinity, 
the probe may be bound more efficiently by this other protein. If this is the case, 
when FOXF2 is present, it could provide direct competition for the available 
labelled sequence and thus reduce the signal from the other protein. However the 
probe is present in excess in the binding mixture judging by the strength of signal 
from free probe in all samples. This would suggest that the effects of differential 
affinity should be minimised.
The lack of a visible, distinct lower band in the W174R sample in either set of 
binding conditions suggests that binding efficiency is dramatically reduced, and 
possibly completely disrupted in this mutant form of the protein. Although the ratios 
for the W174R mutant and the empty expression vector show significantly higher 
band intensities than the image background, analysis of the image shows a smear 
between the top band and the position at which the lower potential FOXF2 band is 
found in those samples which have a distinct band at this position. This smear is 
present in all samples whether a distinct lower band is visible or not.
The smear could result from degradation of the protein represented in these images 
by the top band, or it may result from other proteins which demonstrate some level
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of specificity to the binding sequence, or proteins with a non specific affinity to this 
sequence. Whatever the cause of this smear, its presence in the band shift suggests 
that it is not indicative of FOXF2 binding. For the purposes of this investigation, this 
signal can therefore be regarded as background noise.
Previous structural predictions of forkhead proteins suggest that one of the a-helices 
which are common to all of these proteins, fits into the DNA major groove and one 
of the two wings has contact with the minor groove at the 5’ end of the core 
sequence [95]. This suggests a requirement for precision in the DNA interaction of 
forkhead transcription factors and it is possible that an alteration to the structural 
integrity of the molecule could disrupt the arrangement necessary for DNA binding.
The FOXF2wl74R mutation has occurred at the centre of one of the structurally 
significant p-sheets (See figure 4.17). The wildtype tryptophan residue is not 
predicted to have direct contact with DNA during the interaction of FOXF2 with its 
target sequence but because the morphology of the protein could be drastically 
altered by this mutation -  the F0XF2W174R isoform may not function normally.
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6.3 Transactivation Assay
Transactivation Assays are useful tools for examining the interaction of transcription 
factors with specific DNA sequences and the transcriptional machinery. The cDNA 
of a transcription factor of interest is incorporated into an expression vector and the 
target sequence is attached to a gene directing the synthesis of a reporter molecule. 
Reporters are required to be easily detectable and quantifiable molecules such as 
luciferase or alkaline phosphatase [275]. Levels of this molecule can therefore be 
used to ascertain the activational behaviour of the gene product of interest on DNA 
target sequence.
This test was considered appropriate for preliminary analysis of the molecular 
effects of the V412F mutation and to contribute towards the understanding of how 
and why the W174R mutation has an effect on the phenotype of the animal. It was 
hoped that it may clarify what change occurs in the activity of the W174R FOXF2 
protein and could also determine whether an alteration in the transcriptional activity 
of the protein occurs in mutants
6.3.1 Construction of the Reporter Plasmid
The pTAL-SEAP reporter vector contains a modified alkaline phosphatase gene, 
which encodes a secreted form of alkaline phosphatase (SEAP). The promoter 
(pTAL) is a region from the Herpes simplex virus thymidine kinase (HSV-TK) 
promoter. The secreted alkaline phosphatase can be taken directly from the cell 
media for quantitative chemiluminescent assays of gene activation. This system
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therefore has the advantage that cell lysates are not required and several time points 
can be taken for a single batch of transfected cells.
T E  »  T r a n s c r ip th n  U n i t r
tf/jid III 
MCS A <155 
jwi;v j
X
GGTACOS& GCTCT'RCGOGT'jt'RGCCOijGCCTCGAGATCT
.V.'j I A V ul
^G C n aA A T C G C G A iT T C G C C C A C C A T G  CTG 
KM  III
F i g u r e  6 . 1 8 :  p T A L - S E A P  R e p o r t e r
The pTAL-SEAP vector and restriction sites available for the insertion of binding regions.
The restriction sites Mlul and Bglll were selected from the multiple cloning site 
(MCS) as appropriate insertion loci, due to their identical optimal activation 
conditions (see section 2.2.12) and also because they are not immediately adjacent to 
each other within the MCS. Both of these factors facilitated their use in a double 
digest.
Two Primers were adapted from those used by Miura et al [241], incorporating the 
FOXF2 recognition sequence which had previously been determined by Pierrou et al 
[205], but replacing the Hindlll and Sail restriction sites with Mlul and Bglll sites 
(see appendix 6.1.5 and figure 6.21).
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These primers that contained the FOXF2 recognition sequence were intended for 
multimerisation to produce a reporter insert containing a multiple copy binding site 
as illustrated in figure 6.20.
However, although multimerisation of the oligonucleotide was induced as can be 
seen in figure 6.19, the multimerised product was not successfully incorporated into 
pTAL-SEAP. Colony PCR with the pTAL-SEAP primers (appendix 6.1.1) of 130 
clones that resulted from transformation of XL 1-Blue cells with the ligation product 
of the multimer and linearised plasmid was carried out following Qiaquick gel 
purification of the plasmid DNA. Ligations had used the X5, X7 and X9 product 
sizes, and T4 ligase concentrations of 1.6u/ul and 4u/ul. All of the PCRs resulted in a 
340bp product which indicated that incorporation of the multimer into the pTAL- 
SEAP plasmid had not occurred in any of these clones.
One likely explanation for the failure to identify a recombinant pTAL-SEAP 
plasmid containing the multimer is that the purification method may not have been 
100% efficient in the removal of restriction enzymes. This would have resulted in 
the digestion of the multimer during the ligation step.
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Figure 6.19: Multimerisation of the single binding site oligonucleotides
Band sizes suggesting they contained multimers with odd numbers o f binding sites (124bp= X 5 
copies; 172bp= X 7 copies;220bp= X 9 copies) were selected because Bglll and Mlul terminal 
restriction sites were required at either end o f the multimer for incorporation into the plasmid. These 
bands were cut and gel purified as described in section 2.2.8. This product was then added to 
linearised pTAL-SEAP in a ligation mix as described in section 2.2.17. None o f the plasmids that 
were analysed for size differences on agarose gels indicated the insertion o f any o f these products.
Following the difficulty in inserting the binding site multimerisation product, 
another pair o f complementary oligonucleotides was designed which included five 
FOXF2 binding sites. A Mlu I site at the 5’ end o f the forward sequence, and a Bgl 
II site at the 5’ end o f the reverse sequence were incorporated into the design of 
these oligonucleotides.
A “spacer” sequence o f TTC (GAA on the reverse strand) was also added between 
each binding sequence on the forward sequence to add space between binding sites 
and reduce the possibility o f an inhibitory effect by binding at one site to binding at 
adjacent sites (These oligonucleotides are identified as FOXF2_BS in appendix 6.1.5 
and are illustrated in figure 6.21). However, it should be noted that the space
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between binding sites on these oligonucleotides (3 bases in length) is less than the 
space that occurs between binding sites on the multimer (figure 6.21).
Of the 68 colonies that were produced from the transfections which were performed 
in the construction of the pTAL-SEAP reporter vector with FOXF2 binding sites, 4 
colonies gave products in the range of the 441 bp that would be expected if the 
binding site oligonucleotide was inserted into a pTAL-SEAP cloning site. Three of 
these were from the 300:1 oligonucleotide to plasmid ratio and 1 of them was from 
the 30:1 oligonucleotide to plasmid ratio. On sequencing this product, all of these 
clones contained the binding site insert and one of them was selected for transfection 
of Cos7 cells (as described in sections 2.2.33-2.2.35).
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CGCGTCCAAACGTAAACAATCCGA
AGGTTTGCATTTGTTAGGCTCTAG
Mlul
FOXF2 Binding Site
Bgl I
GATCTCGGATTGTTTACGTTTGGA
CGCGTCCAAACGTAAACAATCCGA " # •  
Y 0 9 ,1 I,L 9 O Y ,L J . I ,9 I I ,V 9 9 D I0 I1V 9I T4 Ligase Multimerisation
Mlul Bgl II Mlul Bgl II
CGCGTCCAAACGTAAACAATCCGAGATCTCGGATTGTTTACGTTTGGACGCGTCCAAACGTAAACAATCCGA
Y 09 ,L I,L 9 O Y ,L I,L 9 ,L lLY 990 ,I,0 ,IY 9Y 900,LY Y 0Y Y Y ,L9D Y Y Y 0O ,I,909O Y 99 ,I„I„L9O Y 1L,L ,L9 ,L ,LY 990 I0 I,Y 9
F i g u r e  6 . 2 0 :  F O X F 2  r e p o r t e r  p l a s m i d  c o n s t r u c t i o n  s c h e m e
Scheme illustrating the first method for the construction o f a FOXF2 reporter plasmid. Phosphate 
labelled oligonucleotides which contain the FOXF2 binding site and either a Bgl II or Mlu I 
restriction site are multimerised with T4 ligase to form double stranded DNA containing multiple 
FOXF2 binding sites. The pTAL-SEAP plasmid is linearised with Bgl II and Mlu I before 
purification with a Qiaquick DNA purification kit. The multimer is then ligated to the linearised 
plasmid with T4 ligase.
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^  Oligos Used by Miura for the TKLuc transactivation assay
Hindm FO XF2 Binding Site HindHI &  Sail
AGCTTCCAAACGTAAACAATCCGG SalI “ p to l
AGGTTTGCATTTGTTAGGCCAGCT
Multimerisation
Hindlll Sail HindHI ▼ Sail HindHI I Sail
Lsl Oligos Initially Intended for the pTAL-SEAP transactivation assay 
m m  FO XF2 Binding Site______
CGCGTCCAAACGTAAACAATCCGA BglII 
AGGTTTGCATTTGTTAGGCTCTAG
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A comparison o f the oligonucleotides and their products for 3 FOXF2 transactivation assay schemes. 
Blue text is FOXF2 binding sequence. Red text is restriction sequence. A: The previously reported 
oligonucleotides and 5X multimerisation product incorporated by Miura into the TKLuc reporter 
vector [241]. B: The oligonucleotides were adapted to allow insertion into pTAL-SEAP by replacing 
the HindHI and Sail sequence at the 5’ ends, with Mlul and Bglll respectively. A guanine at the 3’ 
end o f the Mlul oligonucleotide was also changed to an adenine to allow annealing to a thymine in 
the Bglll restriction sequence. Nucleotides that vary between these sequences and those designed by 
Miura are highlighted in yellow. C: Extended oligonucleotides containing 5X FOXF2 binding sites 
that eliminated the requirement for multimerisation and therefore also eradicated the problems 
associated with the insertion o f a multimerised product. The space between binding sites in this 
double stranded product is only 3 nucleotides in length in contrast to the 8 nucleotides between 
binding sites in the two multimerisation products.
The transactivation assay was intended to highlight whether there was a difference 
between the activational activity of the different FOXF2 isoforms. In this study, 
SEAP production is the quantifiable molecule that provides a relative measure of the 
activation profiles of the different FOXF2 isoforms. SEAP levels were significantly 
higher when the reporter plasmid was co-transfected with the wildtype FOXF2 
expression plasmid than with the W174R mutant form (figure 6.23 & appendix table
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6.10). However this was the case with both the empty pTAL-SEAP vector and with 
the reporter containing the binding site. Levels of SEAP were lower in transfections 
with the FOXf2 binding site reporter than in transfections of the empty vector 
(figure 6.23). It therefore appears that the pTAL-SEAP vector may be activated by 
FOXF2 in the_absence of the binding site.
Large differences between SEAP samples were seen in the EMSA control data, 
causing early EMS A results to be discounted - the lack of signal in the W174R 
signal correlated with low SEAP levels. Differences in SEAP activity were several 
orders of magnitude greater in the EMSA flasks than in the smaller wells used for 
transactivation assays with the same vectors. The unexpectedly high levels of these 
empty SEAP vector results could be considered as further evidence that the empty 
reporter vector may be activated by FOXF2 (see figure 6.22 and table 6.7).
SEAP levels in the media of FOXF2V410F transfected cells were higher than in the 
media of FOXF2WT transfected cells when co-cultured with PTAL-SEAP. This was 
in contrast to the transactivation assay which indicated a slight reduction in levels of 
FOXF2v410f SEAP activation when compared with wildtype levels.
Amounts of the transfection reagents were considerably larger for the EMSA flasks 
than for the wells of the transactivation assay due to the larger vessel sizes. However 
none of the conditions or reagents were exactly proportional (appendix table 6.11) 
and this will have affected the activity of the FOXF2 protein.
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Expression vector volumes in the EMSA transfections were added at equivalent 
levels. pTAL-SEAP volumes added to the transfection reaction were ~4X greater in 
the EMSA, but ~5X greater in the transactivation assay when calculations were 
corrected for surface area.
These volumes were different because of the transfection conditions for the different 
vessel types that were recommended by Merck Biosciences, but were also due to 
different requirements of the control vectors in the two experiments. For example, in 
the EMSA, pTAL-SEAP acted as the transfection control whereas for the 
transactivation assay -  GFP filled this role because pTAL-SEAP had a more central 
role in the experimental setup.
One important point to consider is that the experimental design for the EMSA 
transfections did not incorporate pTAL-SEAP to obtain stand-alone experimental 
data but as a transfection control. The inconsistent SEAP production and possible 
activation of pTAL-SEAP by the FOXF2 peptide complicates the trans-activation 
picture, but has allowed an additional dimension to the data analysis.
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6.3.2 Control Levels in EMSA Transfections
Transfection A SEAP Concentrations
a 8000.0
b. 6000.0
2  §  ”5) 4000.0 
w  2000.0
® 0.0 JSL
WR VF WT PG NT 
Construct Type
Transfection B SEAP Concentrations
2000.0
a. S
Ui u
s i  500.0
■a 1000.0
~  500.0 
0.0
WR VF WT PG NT 
Construct type
Luciferase Concentrations from the 
final EMSA Transfection
O £  
tg _
S i t
B l l 5 - -
WT W-R V-F PG 
C onstruct Type
NT
F i g u r e  6 . 2 2  T r a n s f e c t i o n  e f f i c i e n c y  c o n t r o l  d a t a
Figure 6.22: Transfection efficiency control data. SEAP data from two different EMSA transfections 
in which pTAL-SEAP was used as a transfection control and one in which pMLuc-3 CMV was the 
control. The large variability between the samples in A led to a different approach used for the 
transfection o f the samples in B: In A, the genejuice/vector complex was added to the cells directly, 
by tilting the T175 flask and pipetting the complex onto the cells. However, complete coverage of the 
cells with the complex was not achieved in any of the cultures before recovering the cells with media 
and mixing, and there were therefore concerns that this uneven distribution o f the genejuice/vector 
complex may have affected the transfection efficiency within each sample. The transfection reagents 
in B were prepared in the same way, but they were added to the media at the bottom of vertical flasks 
before bringing them to a horizontal position then mixing by tilting from side to side. This approach 
was also applied to the transfection shown in C, in which pMLuc3-CMV was used as the transfection 
control. The variability between sample controls was greatly reduced in this transfection -  meaning 
that the EMSA gels could be analysed without concerns about data variability and reliability. The 
EMSA gels shown in figures 6.15 & 6.16 utilised the pMLuc3-CMV transfection control.
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6.3.3 SEAP Data
SEAP levels increased in the presence of FOXF2WT and FOXF2V410F expression 
plasmids above the levels associated with the empty expression vector, but the only 
significant increase when co-transfected with the binding site containing reporter, 
according to the Tukey test was the wildtype FOXF2 transfection at 24 days.
There were other more significant increases when the binding sites were absent from 
the reporter, when empty pTAL-SEAP.
Transcriptional activity was increased compared to the empty reporter vector in 
every sample in which the FOXF2 binding site was present in pTAL-SEAP. WT 
shows the strongest increase, followed by V410F. The W174R mutant doesn’t 
demonstrate an increase in transcription levels in the reporter containing the binding 
site, but there is an increase much higher than those seen with the empty expression 
vector.
A two-factor ANOVA with replication was performed on normalised SEAP data for 
each of the three time points. These data were analysed separately in order to 
maximise the probability of detecting a SEAP production differentiation between 
samples.
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There were highly significant differences within both the reporter (6.28 XI O'6 to
3.02 XIO'5) and expression plasmid groups (1.02 XIO’8 to 4.37 XIO'6). In both cases 
the most significant differences occurred at 24hrs.
This test does not however show where the differences occurred, and it was 
therefore necessary to perform subsequent post-hoc tests. A Tukey test was used to 
compare each transfection with the other transfections (appendix table 6.10).
Previous studies have shown that pTAL-SEAP without modification has a very high 
basal promoter activity at -6650 RLU/105 cells [276]. It could be feasible that the 
levels of SEAP with the empty pTAL-SEAP vector were at background levels. 
However, this hypothesis would ignore the significant difference of SEAP 
production between the different expression plasmids.
The Tukey test demonstrated that there was a highly significant difference (p<0.01) 
between the empty pTAL-SEAP and the binding site reporter when co-transfected 
with the wildtype FOXF2 expression plasmid. The difference between the reporters 
was less marked in the presence of the V410F isoform, with significance levels 
around the p=0.05 level (q~4.9) at each time point and were marginally significant 
(p<0.05) at 24 and 48 hours and marginally insignificant (p>0.05) at 72 hours.
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The empty and binding site reporter vectors however do not show a significant 
difference in SEAP production when co-transfected with either the empty expression 
vector or the FOXF2wl74R isoform.
a: aoooo30000
30000 -,
2000020000E  25000 -o
UJ 20000-
g  10000 10000
£  15000- 
2 10000 - 
<  5000 -
8. 60000
40000 40000U. 50000 -
40000
20000 20000
E 30000 
D)
Q. 20000
EP VF \AR WTEP VF V\R WT10000
S. 300000
300000 -|
U- 250000-
200000  -
E 150000 - 
2  1 0 0 0 0 0 -
EP VF V\fi WT EP VF V\R WT50000 -
■ pTAL-SEAP with FOXF2 ------ Highly significant difference (p<0.01)
binding site (BS) between samples
□ pTAL-SEAP with FOXF2 ------ Significant difference (p<0.05)
binding site (BS) between samples
Small charts only
n Highly significant difference (p<0.01) 
between (0) and (BS)
j Significant difference (p<0.05) 
between (0) and (BS)
F i g u r e  6 . 2 3  T r a n s a c t i v a t i o n  a s s a y  d a t a
Normalised SEAP Levels for each expression vector in the presence o f either empty pTAL-SEAP or 
pTAL-SEAP with the FOXF2 binding site insert. (A) normalised SEAP levels at 24 hours, (B) at 48 
hours and (C) at 72 hours after transfection. The larger charts represent each o f the significant 
differences between samples from either reporter plasmid whereas the small charts represent 
significant differences between expression plasmids transfected with the same reporter. Error bars 
represent Standard deviation from three cultures per sample. The horizontal lines indicate significant 
differences between the samples at either end as determined by Tukey test. !=significant difference 
between reporters for the same expression vector (p<0.05), !!=highly significant difference between 
reporters for the same expression vector (p<0.05).
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Figure 6.24: EGFP was used a a transfection control in the transactivation assay 
Views with a blue filter (A + C) which highlight DAPI stained cell nuclei alongside identical view 
fields with a green filter (B + D) which allows the visualisation o f cells transfected with EGFP. 
Transfection ratios were determined by comparing the numbers o f GFP transfected nuclei with the 
blue DAPI stained nuclei. This ratio was then be used to assess the transfection efficiency for each 
culture thereby allowing the normalisation o f reporter yields. Images A+B were taken from an 
Olympus BX40 Microscope. Green and blue wavelengths were filtered electronically with 
Smartcapture (Digitalscientific UK Ltd) following image capture. The EGFP view could then be 
superimposed onto the DAPI view as in B. Photographs C + D were obtained with a Zeiss Axioplan 2 
Microscope using green and blue physical filters. These images were processed with the software 
Axiovision v4.5.
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6.4 Potential pTAL-SEAP Endogenous FOXF2 Binding Sites
One possible explanation for the upregulation of alkaline phosphatase in those 
transfections which contained empty pTAL-SEAP is that this plasmid already 
contains a number of potential binding sites for wildtype FOXF2.
The core consensus Forkhead Binding Sequence that was determined by Pieirou et al 
[205] is: RTAAAYA 
R = Purine = Adenine & Guanine (A + G)
Y = Pyrimidine = Thymine & Cytosine (T + C)
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Consensus Core 
sequence:
Forward
RTAAAYA
Reverse
TRAAATY
ATAAATA 
GTAAATA 
ATAAACA < 
GTAAACA
TATTTAT 
TATTTAC 
TGTTTAT < 
TGTTTAC
S
1 .  gcaATAAACAa (pT A L -SE A P 1 at position  1886-1896 within the vector
sequence).
2 . aaaATAAACAa (pTAL-SEAP 2 at position 4018-4028 within the vector
sequence).
3 . aacGTAAACAa (The optimum binding sequence determined by
Pierrou)
a t
Nucl
Olic
eotide Position Frequencies (%) of Random 
onucleotides that bound to FOXF2 Protein
-3 -2 -1 1 2 3 4 5 6 7 +1
G 7 18 30 74 7
A 63 48 11 26 100 100 100 100 59
T 15 15 18 100 7 18
C 15 18 41 93 15
Figure 6.25: Potential Foxf2 binding sites on endogenous pTAL-SEAP
Figure 6.25: Core consensus binding sequence recognised by Fox genes, determined by Pierrou et al 
[205] - and their similarity to two potential FOXF2 binding sites within the pTAL-SEAP cloning 
vector. The Binding site in each figure is highlighted in yellow. A= The Forward and complementary 
sequence o f  the consensus forkhead binding sequence. Taking into account the different possible 
nucleotides at the purine and pyrimidine positions, the consensus binding sequence could take the 
form of any o f  the sequence combinations listed below the core sequence. The arrow points towards 
the sequence that was identified in pTAL-SEAP. B= The binding sequence determined by Pierrou for 
Foxf2 at B3 is compared with the two potential forkhead binding sites from the pTAL-SEAP 
sequence at B1 and B2. pTAL-SEAP potential binding sequence 1 is at nucleotide position 1886- 
1896 within the listed vector sequence (http://www.clontech.com/images/pt/PT3271-SEQ.pdf for 
sequence and http://www.clontech.com/images/pt/PT3271-5.pdf for feature map). This region 
contains the SV40 late mRNA polyadenylation signal at position 1888-1893. pTAL-SEAP potential 
FOXF2 binding sequence 2 is at position 4018-4028 o f the vector. This is 3 ’ o f an ampicillin 
resistance promoter which lies at 4012-4007. C=Data extracted from Pierrou et al [205] showing the 
frequency o f  nucleotides present at positions in relation to the core sequence (yellow highlight) 
within 27 random oligonucleotides that bound to FOXF2 protein.
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One of the four potential sequence combinations can be found within the pTAL- 
SEAP Vector Sequence at two separate locations as shown in figure 6.25B.
In the FOXF2 binding site study discussed in section 6.1.2, none of the nucleotides 
identified by Pierrou were exclusively present at any position in the flanking 
sequence. This is in contrast to the nucleotides within the core sequence where only 
oligonucleotides containing the listed sequence bound successfully to the protein 
(see figure 6.25C). This indicates that the flanking sequence tolerates a greater 
degree of variation than the core sequence.
Both of the pTAL-SEAP potential binding sequences contain a sub-optimal 
nucleotide at position 1 of the core sequence. As can be seen in figure 6.25C, this 
Purine specific position was occupied by a guanine in 74% of Pierrou’s binding 
oligonucleotides whereas both potential sites on pTAL-SEAP contain an adenine at 
this position as was present in 26% of the oligonucleotides.
The two pTAL-SEAP sequences contain an identical FOXF2 binding sequence at 
their assumed core although their flanking sequence differs. As can be seen in figure 
6.25B, pTAL-SEAP potential binding site 1 contains the sequence GCA at position - 
3 to -1; binding site 2 contains three adenosines at these positions relative to its core 
sequence. The optimal flanking sequence at this position according to Pierrou was
j
AAC, which only differs from the 2 pTAL-SEAP sequence by one base -  in which 
the nucleotide immediately 5’ of the core sequence is an Adenosine
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In the oligonucleotide binding experiments -  An A was present at this position in 
11% of the oligos that bound to FOXF2; lower than the percentage of any other 
base. C was seen in 41% of the oligos at this position, G was in 30% and T was in 
18%.
6.5 Conclusions
The high levels of SEAP that were associated with the empty pTAL-SEAP vector 
may be due to the presence of potential endogenous FOXF2 binding sites. Two such 
sites were identified on analysis of the pTAL-SEAP sequence. This explanation is 
given further credibility by the enhanced SEAP activation when empty pTAL-SEAP 
was co-transfected with a wildtype FOXF2 expression vector. The conditions in this 
experiment resulted in a considerably larger difference between wildtype FOXF2 
and control vector when co-transfected with empty pTAL-SEAP, providing more 
evidence that FOXF2 is activating the empty reporter.
Promoter sequence of Prostate specific antigen (PSA) has been shown to increase in 
activity when duplicated on a luciferase reporter but this activity was reduced with 
the addition of a third copy [277]. If the problem with the FOXF2 binding site 
reporter is not specific to the background vector but rather to the insert sequence, it 
is possible that binding site copy number or perhaps the proximity between binding 
sites may inhibit the activity of the transcription factor to below the background 
activity that may be encouraged by endogenous FOXF2 binding sites.
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The W174R mutation appears to severely reduce the affinity of FOXF2 to its 
recognition sequence. Although antibody binding to FOXF2 was not achieved with 
the Western blot experiments, only one of the two available antibodies were tested 
with this approach and this antibody also failed to produce an alteration to the 
suspected FOXF2 band in the EMSA when added to test for a supershift. The other 
antibody that showed some potential in the supershift experiment (FOXF2 antibody 
1) was not applied to a western blot of the nuclear lysate.
6.5.1 Potential Sources of Error that could Explain the Data
Concentration calculation errors are unlikely as the three repetitions were performed 
simultaneously, so variability of sample and reagent concentrations is likely to be 
minimal. One possible explanation for the erroneous data that is more likely given 
the simultaneous sample preparation, is that the two reporters were mixed up before 
their addition. However, high levels of activation were seen in two preliminary 
EMSAs that used SEAP data as transfection controls. This evidence in support of the 
endogenous pTAL-SEAP binding sites also goes some way to preclude the 
possibility that reporters were incorrectly added.
SEAP levels detected in the EMSA transfection controls were ~2X 108 higher than 
those of the transactivation assay. The total amount of pTAL-SEAP added to each 
EMSA transfection was increased by ~4 fold when compared to the amounts added 
to the transactivation assays, but reduced by a factor of 5 when the volumes were
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corrected for surface area of the respective culture vessels. The higher SEAP levels 
in the EMSA suggest that the transfection reagents were added at sub-optimal levels 
in the transactivation assay.
Preliminary optimisation of the transactivation assay was performed prior to the 
investigation proper -  but this involved measurements of GFP vector transfection 
ratios with different concentrations of genejuice rather than specific optimisation of 
pTAL-SEAP. It appears likely that optimal conditions for the transfection of pTAL- 
SEAP are different from those of GFP.
It is interesting to speculate that greater significance levels may have been obtained 
if transfection efficiencies were higher, particularly for the V410F plasmid for which 
in the EMSA there was such a large difference compared to SEAP production from 
the empty expression plasmid.
The fact remains though that even in the EMSA, where pTAL-SEAP transfection 
conditions appear to have been closer to optimal, SEAP production by the empty 
pTAL-SEAP vector is higher in the presence of wildtype FOXF2 than is pTAL- 
SEAP with multiple copies of the FOXF2 binding site. If this is genuine activation 
of the empty reporter, pTAL-SEAP should be excluded from further investigations 
into FOXF2 activity unless the interaction itself was of interest.
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6.5.2 Future Work
The lack of variation in the luciferase production of cells transfected with pMLuc-3 
CMV (figure 6.22 C) suggests that this reporter may not contain endogenous FOXF2 
binding sites . One experiment that could be used to further investigate the elevated 
SEAP levels in the empty pTAL-SEAP transfected cultures would be the 
introduction of the putative pTAL-SEAP binding sites into pMLuc-3 CMV. This 
could be compared with transactivation data from a pMLuc-3 CMV vector 
containing the original binding site insert to see if the improvement in transfection 
efficiency with the pTAL-SEAP endogenous sites is genuine.
The difference between SEAP data for the V410F transfections in the EMSA and in 
the trans-activation assay suggests that the higher initial concentrations of pTAL- 
SEAP in the transactivation assay were sub-optimal. Given the large SEAP increase 
in the EMSA samples, it could be useful to repeat the transactivation assay at the 
same relative concentrations as the EMSA to see if those results are repeated.
In the conditions used for obtaining protein for the EMSA, this mutation appears to 
increase the transcriptional activity by ~2-5 fold when in the presence of the empty 
reporter. Although the SEAP data from these two experiments cannot be directly 
compared with the transactivation data due to the difference of scale, the relative 
difference in activity compared to other expression vectors is of potential interest 
and further analysis in different cell concentrations could help to further characterise 
this mutation.
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These potential future experiments are only worthwhile if the FOXF2 activation of 
unaltered pTAL-SEAP was genuine. The construction of a pMLuc-3 CMV reporter 
containing binding sites is necessary for the investigation of the pTAL-SEAP 
endogenous binding, but a more direct approach to fulfil the initial aims would be to 
repeat the assay with this vector. An investigation of the pTAL-SEAP binding 
sequences may be worthwhile if as would appear from the preliminary SEAP data 
that was obtained, they are more efficient activators of the protein than those 
sequences that were determined by Pierrou et al.
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Chapter 7: Discussion
An accurate physical map of the Del 36 H region has facilitated the mapping of 
mutations arising from the regional screen with a greater resolution than would have 
otherwise been possible. It has also allowed the precise identification of the deletion 
breakpoints, thereby clarifying which of the peripheral genes are deleted.
The minimal tiling path that was selected from the physical B AC map made a direct 
contribution towards the mouse genome sequencing effort and therefore the Ensembl 
sequence (http://www.ensembl.org/Mus_musculus/). Del36H was one of the first 
regions that was sequenced using the hierarchical rather than the whole-genome 
approach and the sequence quality will have therefore benefited from the improved 
confidence in the sequence integrity of the large repetitive regions within the interval 
[43].
A search for polymorphic markers had the fortunate by-product of large amounts of 
haplotype map data for the Del36H region. At smaller than 6 6 8 kb, the average 
haplotype block size for this region was appreciably smaller than the genome 
overage of ~3.57Mb that Wiltshire [226] has previously described. Wiltshire also 
noted that the borders of haplotype blocks are associated with recombination 
hotspots. The smaller blocks within Del36H would therefore suggest that 
recombination is likely to occur at high frequencies within the region and this may 
explain the larger size that the genetic map predicted for the region.
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One key benefit of the intensive characterization of this region was the potential for 
an improved understanding of the syntenic region on human chromosome 6 p that is 
deleted in 6 p deletion syndromes. Patients with these chromosomal anomalies 
exhibit a wide range of physiological and neurological phenotypes; the variation of 
which is caused primarily by the variability in size and positioning of the deletions.
There has been an effort to correlate the varying extents of these deletions with the 
associated phenotypes [2, 75, 80]. This will have implications beyond these rare 
deletion syndromes -  there are also many non-syndromic disease loci within the 
region and an analysis of different monogenic mutations in mouse models should aid 
in the identification of the associated causative genes.
The absence of coding mutations in Foxf2 for any of the lineages derived from the 
lethal recessive screen implies that there are no mutant FOXF2 proteins causing a 
phenotype, but it does not rule out mutations that effect expression of the gene.
There are regions of both the 3’ and the 5’ untranslated regions and promoters that 
were not sequenced, although they may be important for the gene’s correct 
regulation of expression.
In-situ hybridisations of Foxf2 did not highlight any changes in the expression of 
Foxf2 in any of the mutants [26]. However this does not rule out the possibility that 
there may be subtle expression alterations.
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7.1 Physiological Phenotyping
One of the most significant findings of this project was that a mutation in Foxf2 can 
cause lethality without inducing a cleft palate. Previous characterisations of Foxf2 
have involved the analysis of the Foxf2 knockout [153, 154]. Wang observed no 
physiological difference between the mutant and wildtype that could explain the 
deaths of the knockouts other than a deformed tongue and cleft palate which was 
suggested as a possible cause of the associated gas-distended GI tract.
It is possible that these characteristics are the immediate cause of death in the 
knockout animals -  but there was no evidence for any of these features in the 
Foxf2wl74R mice. This opens the door to an expanded investigation into the cause of 
Foxf2wl74R mortality and will allow the characterisation of other phenotypes which 
are impossible to identify in the knockouts due to the overwhelming incidental 
effects of the cleft palate (e.g.: the gas-distended gut). This mutant therefore 
provides an immediate vindication of the use of the ENU archive gene-driven-screen 
approach for the identification of novel functional mutations.
It should be emphasised that the genetic backgrounds of the Foxf2 knockouts and 
Foxfl/Foxf2 compound heterozygote knockouts used by other laboratories were of 
C57BL/6 origin [153, 154]. This is in contrast to the majority of Foxf2wl74R 
phenotyping which was performed on mice that had a majority C3H background but 
with a significant minority (0.4%-6.3%) of BALBc depending on the generational 
gap between founder male and test-subject (lineages were founded by mutagenised
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BALB/c mice that were then outcrossed onto a C3H background for 4-8 generations 
before testing). This difference in background could have affected the phenotype of 
the mice.
Ormestad and colleagues discovered that homozygous Foxf2 knockout mutations 
cause a severe reduction of type I and type IV collagens and laminin in the intestinal 
walls of mice. Therefore the investigation of these molecules, and a physical 
analysis of the guts in the Foxf2wl74R homozygotes would be the next logical step in 
the investigation of Foxf2wl 74R mortality.
Although the tongue morphology of the Foxf2 null mutant was abnormal [153], no 
alterations were observed in the level of MyoD -  a regulator of muscle 
differentiation, or myosin heavy chain. The expression of these molecules are 
therefore unlikely to be altered in the tongues of the Foxf2wl74R mutants, which 
exhibits a generally less severe phenotype than is exhibited by carriers of the null 
allele and did not suffer from an obvious tongue phenotype. One aspect of the 
tongue musculature that may however be worth investigating, is the relative density 
and constituent subunit ratio’s of the potassium channels. The tongue is a highly 
active muscle, and the sporadic nature of its use is likely to incur extremely variable 
energy demands. There are parallels between the activity of the tongue, and the 
activity of the heart -  which was demonstrated to possess potassium channels that 
were regulated by FOXF2 [231]. These similarities are not immediately apparent as 
the heart is required constantly, whereas the tongue is not. However, the energy
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demands on the heart can fluctuate massively depending on an organisms activity 
levels and it during these times of energetic flux that the FOX proteins are thought to 
play a significant role in the activation of targets that are able to alter the heart’s 
energetic state [231]. Analysis of potassium channels of the intestinal musculature 
may also be worthwhile for similar reasons.
7.2 Characterisation of the DeI36H Eye Phenotype
Heterozygous knockouts of Foxcl have a different eye phenotype than that of mice 
with regional monosomy of the Del36H region, so it seems likely that other genes 
were involved in this phenotype. The possibility that Foxf2 is another contributing 
factor is of great interest in respect to the relationship between the overlapping 
function of the genes -  and their chromosomal proximity.
The high level of homology that Foxf2 shares with Foxcl and the similar phenotype 
seen in the anterior section of the eyes of mouse mutants would suggest that there 
may be some redundancy of function between the two genes (although not complete 
redundancy as evidenced by the effect of haploinsufficiency of either gene). It is 
even possible that Foxcl and Foxf2 are responsible for the transactivation of an 
identical array of genes in the eye. It would therefore be interesting to analyse the 
affect on the eye on a combination of Foxf2 and Foxcl mutations in compound 
heterozygotes.
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Gould believes that L-Dopa is likely to be important in the formation of the anterior 
segment of the eye because it is a precursor to catecholamine developmental 
regulators [194]. As such L-Dopa can be linked to known pathways for many of the 
genes involved in angle formation such as PAX6 , LMX1B, PITX2, PITX3 and for 
Bmp4 and Tgfb2 which demonstrate similar phenotypes to Foxcl and Foxc2. PITX2 
binds to and inhibits the activity of the FOXC1 protein [127]. Given the similar 
sequence and structure of these forkhead genes, and the indistinguishable eye 
phenotype in mutants, it is possible that FOXF2 shares a similar expression profile 
to FOXC1 in the eye.
One common theme between the observed phenotype of the gut in Foxf2 mutants 
and the Foxcl mutant phenotype of the ocular anterior segment is that extracellular 
matrix is reduced in both systems [154,278]
Two of the primary structural constituents of ECM are the collagens. Knocking out 
the Coll8 al gene causes the malformation of the ciliary body and iris [191] and 
thinning of the cornea and Descemef s membrane is seen in Col8  mutants [192]. 
These studies indicate that collagen levels are integral to the structure of the anterior 
segment. Collagen therefore appears to be a downstream target of transcription 
factors that are associated with anterior segment malformations.
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7.3 Alternative Candidates for the Lethal Recessive Screen Mutations
Almost all of the terminal 6 p deletions (sub-telomeric deletions) include the 
forkhead cluster. Given the well characterised and intensely researched eye 
phenotype associated with Foxcl it is therefore not surprising that many of the 
accounts of these patients focus on this gene as the primary causative factor within 
the region.
However, one patient who carried a micro-deletion in the telomeric region of 6 p 
expressed many of the symptoms of previous sub-telomeric deletions -  even though 
the deletion was only ~200kb in length [279]. This region consisted of only two 
genes, neither of which were from the forkhead cluster although the deletion 
breakpoints were within 1.2Mb of FOXC1 (and ~900kb of the most distal member 
of the FOX cluster - FOXQ1). These were DUSP22 (dual specificity phosphatase) 
and the most distal 1.4kb of the interferon regulator gene IRF4.
Neither of these genes has previously been associated with the eye and the author 
does not discuss them other than to mention their absence from the affected 
chromosome. Instead, the possibility is raised that a long-range positional affect may 
have disrupted the expression of FOXF2 or FOXC1 [279].
DUSP22 expression in the eye has not been detected, but the eye was not amongst 
the small number of tissues to undergo expression analysis for this gene [280]. It is a 
member of the kinase phosphatase gene family. These genes have reported roles in
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the regulation of cell proliferation, differentiation and apoptosis via the MAP 
kinases. Mutations at putative MapK phosphorylation sites of the drosophila gene 
eyeless (eya) caused the formation of ectopic eyes [281]; eya is now though to be 
directly downstream of the RTK/RAS/MAPK signalling pathway. In mammals, two 
of the four homologues of eya, Eyal and Eya2 are regulated by Pax6  [282].
This information could be used to implicate mouse Dusp22 as another candidate for 
some of the mutants derived from the lethal recessive screen. No coding mutations 
were discovered in any of the three forkhead genes despite screening each of the 
lineages that emerged from the lethal screen for mutations in these genes. There are 
no immediately obvious alternative candidates in the critical regions for the majority 
of mutants that demonstrated an eye phenotype. It will therefore be necessary to 
sequence promoter regions of the forkhead genes, and to also investigate some of the 
genes without known links to eye phenotypes where there are potential pathways to 
such an affect.
Geminin is a gene in the Del36H interval with previous linkage to eye development. 
It is a DNA cell cycle inhibitor that binds and acts antagonistically to the homeobox- 
containing transcription factor Six3 [283]. Loss of geminin induces the over­
proliferation of retinal precursor cells and causes enlarged optic vesicles. However 
this gene lies between dl3Mitl5 and dl3Mit84, a ~1.3Mb region that has not been 
identified as a critical region for any of the mutants derived from the lethal recessive 
screen.
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E2f3 is another potential candidate for some of the Del36H mutants with eye 
phenotypes. It is present in the critical regions of three mutations with structural eye 
anomalies (412, 624 and 1073); and one other mutation (1616) which did not survive 
due to the failure of its allantois to fuse. E2f3 is associated with retinoblastoma and 
its expression can induce lens fibre cells to enter the cell cycle. Cell cycle entry was 
accompanied by apoptotic cell death resulting in microphthalmia (small eyes) [284].
A prolactin or possibly numerous prolactins may contribute to the Del36H eye 
phenotype. In humans, prolactin is involved in the activation of ocular blood vessels 
[189], but a direct comparison of mice and humans is complicated by the large 
expansion in the mouse prolactin family.
Foxql is the third member of the tightly linked chromosome 13 forkhead cluster and 
its open reading frame was analysed for sequence mutations in each of the mutants 
by the Ragoussis group. An eye phenotype induced by a Foxql mutation would be 
of particular interest given that Foxcl and Foxf2 both produce similar ocular 
phenotypes to each other. There is not yet enough data to consider Foxql as a 
candidate for eye phenotypes but it has been suggested that there may be a 
relationship between the chromosomal position and temporal order of expression of 
the genes within the forkhead cluster on mouse chromosome 13 [185]. Microscopic 
analysis of the iridocorneal angle of satin mice may be worthwhile given that the
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phenotype of Foxf2wl74R mouse eyes initially went undetected because of their 
grossly normal appearance.
7.4 Heart Defects
The mutation that was identified in lineage m91 from the lethal recessive screen was 
localized to a serine to proline alteration in the HMG box domain of Sox4. This 
mutation caused atrial and ventricular septal defects, in addition to a dysplastic 
mitral valve [26], which functions to allow blood to pass from the left atrium into the 
left ventricle. Sox4 homozygous null mutants from an earlier study exhibited 
aberrant development of the valves and outflow tracts of the heart [285].
There is a high prevalence of heart disorders within the 6 p deletion patients -  
including those with deletions that include Sox4 at 6p22.3 [286], but also in the 6p25 
terminal deletions [2,287].
These aberrant heart features may also be explained by the presence of Foxcl in 
region 6p25 as Foxcl has a role in heart development which it shares with Foxc2. 
This was highlighted by the analysis of Foxc2 homozygous/Foxcl heterozygous 
compound null mutants. Mutant embryos showed an opening between the dorsal 
aorta and the anterior cardinal vein [1 2 0 ].
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7.5 Metabolic Phenotype
Results from the blood and urine metabolic tests gave results that could link the 
Foxf2 gene to kidney function. Individually these results were tenuous -  blood 
levels of potassium, chloride and calcium in male and urea in female heterozygous 
mutants were significantly different from wildtypes during initial tests, but 
secondary testing showed no difference in these biochemical markers. A significant 
elevation of protein levels was detected in the urine of male heterozygote mutants, 
although the numbers of mice used in that test were not high enough for a truly 
representative comparison of this type of ordinal data.
Despite the ambiguity surrounding this data, results of these tests are suggestive of “ 
renal malfunction in the Foxf2wl74R mutants. It is a tempting hypothesis that Foxf2 
regulates the potassium channels of the kidney by a similar mechanism that which it 
is proposed to regulate the potassium channels in heart muscle [231]. Potassium is 
primarily transported passively in the kidney, but active transport is also required for 
the maintenance of the negative potential of the tubule, the supply of potassium for 
2C1-K and Na-K, and for the secretion of potassium into the cortical collection tube 
[288].
A kidney phenotype in Foxf2 mutants was unexpected given the apparent absence of 
FoxF2 from the embryonic and adult kidneys of human and mouse [188,205] 
However it is possible that the assays used by Aitola were not sensitive enough to 
detect the expression of this gene. Furthermore, unpublished work by the
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commercial antibody company Abeam uses human kidney cells to demonstrate the 
effectiveness of their FOXF2 antibody (http://www.abcam.com/index. 
html?datasheet=23306). The sensitivity of the earlier human expression analysis 
[205] must also be questioned when FOXF2 has been recently shown to exert an 
important regulatory effect in cardiac tissue [231], despite the initial northern blot 
data indicating it was absent from the heart [205].
Alternative hypotheses’ to explain the unexpected metabolic screen results could 
incorporate the potential forkhead binding sites on genes that code for glucose and 
fatty acid transporters, and enzymes involved in the glycolytic and [3-oxidation 
pathways [231]. Another possibility that could at least explain the elevated 
potassium levels in Foxf2wl74R heterozygotes, is that mutations in SUR1 and KIR6.2 
in the pancreas could cause congenital hyperinsulinism [289]. An elevation in 
insulin levels decreases the excretion of potassium from the blood-stream [290].
Although the lack of a significant difference in the second round of tests casts doubt 
on the reliability of the initial results, several factors indicated that the explanation 
may be more involved than a simple type I error. It is unlikely that four of the tested 
blood biochemicals would all demonstrate a significant difference by chance.
Foxf2wl74R mice have shown, in a separate group of experiments, a trend -  albeit an 
insignificant one - towards protection from insulin resistance when fed a high fat 
diet at 12 weeks of age (M.Goldsworthy, personal communication). However there
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was no discemable difference between mutants and wildtypes at 16 weeks. It is 
therefore feasible that the difference in blood biochemistry results seen at the earlier 
age may represent a genuine metabolic abnormality that becomes corrected upon 
homeostatic maturation.
7.6 Startle and FoxO
There was a clear difference between phenotypes in wild-type and mutants in the 
latest and largest startle dataset. The reliability of the earlier tests of both Startle and 
PPI could have been adversely affected by a range of factors that may have 
confounded the data. For example the sound quality in the startle boxes was poor, 
there was a higher degree of background strain variability, and the environment was 
less well regulated before the animals were moved into individually ventilated cages. 
Strain background is particularly important to consider due to the elevated startle 
response of the BALB/c strain [254]which was used for initial mutagenesis of the 
mice that were included in the Harwell ENU archives. Startle results from these data 
therefore indicate that the Foxf2wl74R mutation affects the anxiety pathway
The 6p deletion syndromes are associated with a range of neurological defects -  in 
common with many other large chromosomal deletions, 6 p deletions often cause 
mental retardation [2, 73, 75,287]. There are also a range of loci for specific 
psychological disorders such as schizophrenia [216], attention hyperactivity disorder 
(which co-segregates with dyslexia) [291], anxiety and depression [292] that have 
been localised to 6 p. These types of neurological disorder would be difficult or
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impossible to assess directly in mouse models. However, they are associated with 
intermediate traits that can allow the measurement of a quantifiable phenotype [293].
The acoustic startle response (ASR) is one such intermediate trait. It can provide a 
measure of anxiety -  a neurobehavioural deficit which can show co-morbidity with 
depression [292]. The elevated startle response demonstrated in the Foxf2wl74R 
mutant could therefore suggest that Foxf2 could in future be regarded as a candidate 
for these disorders. However none of the 6 p loci for the human disorders that have 
been identified so far have been localised the 6p25 -  there is a schizophrenia locus at 
6p23 and 6p21, attention hyperactivity disorder at 6 p [291] and a potential 
anxiety/depression locus at 6 p2 1 .2 .
7.7 Molecular Phenotyping
Evidence obtained during the phenotyping aspect of the project would suggest that 
Foxf2wl74R is a hypomorphic mutation and the molecular evidence supports this.
The EMSA profile of the F0XF2W174R mutagenised plasmid is of a greatly reduced 
intensity compared to the other samples, but there is a faint band at the expected 
position which is absent from the negative controls. This suggests that Foxf2wl74R is 
a hypomorphic rather than a null mutation.
Although the reporter that contained FOXF2 binding sites did not appear to be 
activated by the peptide product, there is evidence to suggest that FOXF2 activates 
the empty reporter. As such, despite the lack of a robust experimental model, some
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information can be obtained from these data if the assumption that the endogenous 
activation is a real effect.
There was no significant difference between the cells transfected with the 
FOXF2wl74R plasmid and the empty expression vector. Because of the phenotypic 
and EMSA evidence suggesting that this mutation is a hypomorphic allele however, 
it seems likely that the levels of activation may have been too low to be detected in 
the F0XF2W174R plasmid samples.
The V410F mutant plasmid showed no difference to the wildtype plasmid in the 
EMSA, so DNA binding appears to occur as normal in this mutant. In the activation 
assay, the V410F samples were elevated significantly above the empty expression 
vector samples, and were significantly reduced in comparison with the wildtype 
samples -  a reduction that was significant in two of three timepoints. This implies 
that the V410F mutation causes a slight reduction in the trans-activational properties 
of the FOXF2 peptide -  if the assumption is made that there is genuine activation of 
the endogenous sites on pTAL-SEAP by the FOXF2 fusion peptide.
This data must be viewed with caution due to the apparent failure of the reporter 
containing the inserted binding site. These results are not robust enough to support 
any concrete theories regarding the activities of the different FOXF2 isoforms and 
these experiments will need to be repeated with a redesigned reporter, perhaps with 
the vector pmluc3-cmv, as used in the last EMSA experiment.
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7.8 Future Work
If a repeat of the transactivation assay supported the observation that the 
FOXF2V410F peptide operated at a slightly reduced efficiency, an investigation of 
the Phenotype of the Foxf2V412F mouse could build on the information ascertained 
from this study. The FOXF2V412F mutation is in the same activation domain as the 
polyglycine expansion that is suspected to cause the glaucoma in the human family 
identified by H. Vieira -  so this would be of particular interest to analyse further. 
One potentially exciting prospect with regard to the V412F mutation is that it is 
possible that these mutations will cause a more subtle effect on the function of the 
protein, that may allow the survival of homozygous mutants.
A homozygous mutation with a phenotype that is less severe than Foxf2wl74R could 
be very informative for the analysis of the function of the gene in the tissues of older 
mice. An adult phenotype for a homozygous Foxf2 mutation has not yet been 
possible because the mutations that have been analysed to date all cause neonatal 
lethality, although the severity of the Foxf2wl74R mutation appears to be reduced in 
comparison with the null allele. For this reason, it is definitely worth investigating 
the potential of both the V412F and the splice site mutation.
The key first step in the analysis of the splice site mutant, would be the 
determination of expression of the full mRNA in these mutants. A comparison 
between RNA taken from Foxf2 expressing tissues of splice site mutants and
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wildtype siblings could be achieved by real-time PCR. Primers should span both 
exons.
Previous domain studies have identified the region responsible for TBP binding in 
human FOXF2 [242]. The region as between 146-166 of the FOXF2 construct, 
which is at amino acid positions 182-202 of the full peptide sequence as it is 
currently published. This is only separated from the W174R mutation by 7 amino 
acids. It is therefore possible that the W174R mutation may interfere with the 
interaction between FOXF2 and TBP, in addition to reducing DNA binding affinity.
The weight of phenotypic and molecular evidence would suggest that W174R is a 
hypomorphic mutation. Therefore it may be worth investigating to see if an inhibited 
TBP interaction alleviates or enhances the affect on the peptide function that is 
caused by its reduced DNA affinity.
Another potential effect of the mutation is a reduction in the nuclear localisation 
signal on the Foxf2 protein because this has been localised to the forkhead domain 
[242]. It is possible that the mutant band in the EMSA was weak because the protein 
was not concentrated in the nuclear fraction. An additional experiment to answer this 
question would involve repeating the experiment with the cytoplasmic fraction of 
the transfected cells. If the Foxf2wl74R mutation had affected nuclear localisation but 
not DNA binding, a strong band would be observed in the Foxf2wl74R signal which 
would be absent from the other samples.
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Appendices
Appendices for Chapter 3 
Appendix 3.1
Key to Genotype Definitions
B = C57BL/6J (,) comma = AND
C = C3H (/) backslash = OR*
1 = 101/H
L = BALB/c
c, 1, L, B, 1, B 1/B,
t
C, B
C/B, L, C L/C, L /C , B C/1, B C.B/1 B, L/C/11li
B/1.C/L L. B L/B, L, 1 C, 1 C/1, C, L/1
L, C/1 L/C/1, L/C, 1 L, B/1 L, C/1/B C/1/B, B, L/1
Key to genotyping data in appendix 3.1. *NB: (,) comma equals “AND” and (/) backslash represents 
other potential alleles o f the same size. This would usually equate to “OR”, but when used for an 
individual with only one allele size (no strains after the comma), the backslash equates to 
“AND/OR”.
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Genotyping Data For All Individuals
M
ou
se
 
ID
No
. 
In
di
vi
du
al
d1
3M
it1
15
1co
T3 D
N
R
05
9
D
N
R
12
3
1co
TD d1
3M
it1
33
D
N
R
48
D
N
R
76
D
N
R
10
1
Te
tN
R
5
Te
tN
R
IO
D
N
R
03
7
D
N
R
24
D
N
R
00
3
d1
3M
it1
36
D
N
R
16
d1
3M
it1
98
D36/1409.01 2 Q-P C.B p p G B g,p p p C,p C.B Q,P
D36/1447.01 4 1 B 1 B 1.B 1,B I B 1 iB 1 ,B 1,B 1 B 1 f.
D36/1463.01 1 1 ,B B, B, B. B. B, B. B. B. B. B, B. B, 1.B
D36/1463.02 1 C,B C,B B. C.B C,B 4 C,B C.B C.B C,B C.B C,B G,B C.B C.B
D36/1463.03 3 C.B C,B C,B C,B C,B C.B C.B C,B C.B C,B C,B C.B C.B
D36/1463.04 1
CDO 9,P; 1 B C/1 B C.B c  B C.B C.B CP C.B C,B H C B  . C.B
D36/1525.01 2 1 ,B 1,B 1,B 1 ,B 1 ,B 1,B 1.B 1.B 1 ,B 1.B 1, B 1,B 1.B 1.B
D36/1525.02 2 1, B 1,B 1, B 1 ,B 1,B 1.B 1 ,B 1, B 1.B 1 ,B 1,B 1.B 1.B
D36/1525.03 1 1, B B, B, B. B, B, B. B. B. B. B. B, B. B.
D36/1525.04 1 1 .B B. B, B, B. B. B. R B. B, B, B. 1B
D36/1558.01 6 1 ,B 1, B 1 ,B 1.B 1 ,B 1,B 1.B 1.B 1,B 1.B 1>B 1 ,B 1.B 1.B
D36/1558.02 1 1 ,B B. B, B, B. B. B, B, B, B, B, B, 1.B
D36/1558.03 1 Q,P C.B p p : p p C.B r ; C.B C.B Q.B C,B C.B C.B
D36/1560.01 1 1 ,B B. B, B. B, B. B, B. B, B. B, B, B. B.
D36/1560.02 2 1,B B, B, B. B, B. B. B, B. B, B. B. 1.B
D36/1560.03 1 Q,P C B C P p p p p C.B C.B C.B C.B y .B c ,p C B C.B
D36/1561.01. 1 1,B C,B B, B, B, B. C.B C,B B. B, B. B. B.
D36/1561.01. 1 p p P,P B, C.B C,B C.B 9,P C.B C.B C.B p p CB.... C.B
D36/1562.01 1 Q,B p p Q i B pp Pi 8 p B C,B C.B p p Q,B C.B C.B
M1073.01 1 B, B, B, B, B, B. B. B, B, B, B, B, B.
M1073.02 3 B, B, B. B, B, B, B, B. B, B, B, B. B. B.
M1073.03 4 B, B, B, B, B. B, B, B. B. B,
M1073.04 2 1,B B, B, B. B, B. B. B, B. B. B, B, 1/B, 1/B,
M1073.05 1 1,B B, C,B B, B. B. B, B, B, B, B, B, 1.B
M1073.06 4 1,B B, B, B. B, B. B. B, B. B, B, B. 1.B
M1073.07 1 1,B B, B, B. B, B, B. B. B, B. B, B. B, B.
M1073.08 5 1.B B, B. B, B. B, B, B. B. B,
M1073.09 7 C.B C,B B, B, B, B. B. B, B, B. B, B. B.
M1073.10 2 CtB C,B C,B C.B C,B B, B. B, B, B, B, B, i/B, 1/B,
M 1073.11 1 C,B C.B C.B C,B C.B CtB B, B, B. B,
M1073.12 1 C,1 C, C, C. C, C, C. C. C, C. C, C, C. C.B/1
M1073.13 2 C,1 C, C, C. C, B, B. B. B, B. B, B, 1/B, 1/B,
M1073.14 1 C,1 C, B, B, B. B, B. B. B, B. B, B, 1/B, 1/B,
M1073.15 3 C,1 C, C, C, C. C, C, C, C. C,
M1073.16 6 C,B C,B C.B C.B C.B C,B C,B C,B C.B C,B
M1073.17 1 C.B f t ? Q,B C.B C.B C.B C.B C.B C.B Sf.P C,6 C.B
M1185.01 6 i.B b, , b, B, B, B, 5, hg*-™-* 6, B 1/B, t/b ,
M1185.02 1 1, B B. B, B. B. B, B. B. B, B. B, B, B, 1.B
M1185.03 4 1.B B. B, B, B, B, B. B, B. B, B, B, 1.B
M1185.04 2 1,B b, , B, b, B, B, ) S' B, b, B, b, B, B, B,
M1185.05 20 1,B B, B, B, B. B, B, B, B, B,
M1185.06 1 1.B B, B. C, C. C, C, C, C. C,
M1185.07 1 B, B, B, B, B. B. B, B, B. B, B, B, B.
M1185.08 2 B, B, B, B, B, B. B. B. B, B, B, B, B.
M1185.09 11 i i B. , B, B, B, B, B, B, P, B, B, 6, , P, B, '
M1185.10 5 B, B, B, B, B, B, B. B, B, B. B, B, B.
M1185.11 15 B. B, B. B, B, B, B, B, B, B,
M1185.12 1 B, B, B, B. B, B, B. B, B, C.B ; C,B C,B C.B C.B
M1185.13 1 B, B, B. B, C.B C,B C.B C,B C.B C,
M1185.14 2 B, B, B. B, C.B C,B C.B C,B C.B C,B
M1185.15 1 B, B, b, b, b, b, C,B C,B C,B c,b C,B ClEs C,B C,P
M1185.16 1 B, B, B, B. C,B C,B C.B C.B C,B C.B C,B C,B C.B
M1185.17 1 C,1 C, C,1 B, B. B, B, B. B. B.
M1185.18 1 C,1 C, C, C, C. B. B, B, B. B,
M1185.19 4 C,1 C, C, C. C, C, C. C. C, c. C, C, C. C,B/1
M1185.20 1 C,1 C, C, C, C,1 C, C, C, C, c, C, C, , C, C.B/1
M1185.21 3 C,1 C, C, C, C, C. C. C, c. c, C, C. C,1
M1185.22 1 C,1 C, C, c. C, C, C. C. C, c. c, C, C. C,1
M1185.23 1 C,1 C, C, c. C, C, C. C. C, c. c, C, C.
M1185.24 5 C,1 C, C, C, c. c, C, C, C. C,
M1185.25 3 C,B C,B B, B. B, B. B. B, B, B. B, B, 1/B, 1/B,
M1185.26 1 C.B L/C.B B, B. B. B, B. B, B, B, B, B, B, B,
M1185.27 2 C,B C,B B, B, B, B. B, B, B, B, B. B, B.
M1185.28 1 C,B C,B B, B. B, B, B, B. B. B. B, B, B. B,
M1185.29 2 C,B C,B B, B, B, B, B. B, B. B, B, B. B. I
M1185.30 4 C,B C,B C,B B, B. B, B, B, B. B,
M1185.31 1 C,B C,B B, C.B C.B C.B C.B C.B C,B C.B C,B C,B C.B
M1185.32 8 C,B C,B C,B C.B C.B C.B C.B C,B C.B C,B C,B C.B C.B
M1185.33 14 C,b C,6 c,b C,B C.B C,b C,B TT® C,B C,b c,e C,B , C,B
M1185.34 2 C.B C,B C.B C.B C,B C,B C.B C.B C,B C.B C,B C,B C.B
M1185.35 1 C,B C,B C,B C.B C,B C,B C.B C.B C,B C.B C.B C.B C.B
M1185.36 13 C.B Q,B C.B C.B C.B C,B CiP C.B Q,p
M1239.01 2 1, 1, 1, !r. . 1, 1. 1.B 1. 1, 1. 1,
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M1239.02 2 1 1, * 1, 1, 1, 1. 1,
M1239.03 1 1, 1, 1. ' 1. 1
M1239.04 3 1 ,B 1.B 1, B 1, B 1,6 1.B 1.B 1,6 1.B 1,6 1.B 1. B 1.B
M1239.05 7 1,B 1.B 1 ,B 1,6 1.B 1,6 1.B 1,6 1.B 1,6
M1239.06 1 B, 1 ,B 1 ,B 1,6 1.B 1,6 1.B 1,6 1.B 1,6
M1239.07 1 1 ,B 1,B 1, B 1.B 1,6 1.B 1.B B. 1,6 1.B 1,6 1.B 1.B 1.B
M1239.08 1 1, B 1,B 1 ,B 1.B 1,6 1.B 1.B B. B, 1/B, 1,6 1,6 1/B, 1/B,
M1239.09 1 1,B 1,B 1 ,B 1.B 1,6 1,6 1.B B. B, B. B, B, 1/B, 1/6,
M1239.10 10 1, B B. B, B. B. B, B. B. B, B. B, B, 1/B, 1/6,
M1239.11 1 1, B B, B. B, B, B. B. B, B, B, B, 1/B, 1/6,
M1239.12 2 1, B B, B, B, B. B. B. B, B. B, B, B, B.
M1239.13 9 1 ,B B, B, B, B. B. B. B. B. B. B, B 1.B
M1239.14 1 B. 1.B B. B. B, B, B. B. B, B. B, B, 1/B, 1/B,
M1239.15 8 B. B. B. B. B, B, B. B. B, B. B, B, 1/B, 1/B,
M1239.16 1 B, B, C.B B. B, B, B. B. B, B. B, B. 1/B, 1/B,
M1239.17 1 B, B. B, B, B. C,B C B C.B C.B B. B, B. 1/B, 1/6,
M1239.18 8 B, B. B, B. B, B, B, B. B, B. B. B, B. B.
M1239.19 7 B, B. B. B, B. B. B, B, B. B, B. B. B.
M1239.20 1 B, B, B, B. B. B. B. B, B, B, B. B. B.
M1239.21 2 L,B L.B L,B L.B L, 6 L.B L.B L.B L, B L.B L.B L,6 L.B L.B
M1239.22 1 L,C L,C L.C L.C L,6 L,B L,B L,B L,6 L,B L,6 L,B L,B L.B
M1239.23 5 L.C L.C L.C L.C L,C L,C L.C L.C L.C L.C L.C L.C L.C L.C
M1239.24 1 C,1 C, C, C. C, C, C. C. C, B. B, B, 1/6, 1/6, I
M1239.25 2 C,1 C, C, C. C, C. C. C.B C, B. B, B, 1/B, 1/6,
M1239.26 1 C,1 c, C. C, C, C. C.B C, B. B, B, 1/B, 1/6,
M1239.27 1? 0,1 C, C, C. C, C, C. B. C, 211.35, B, B, 1/B, 1/B,
M1239.28 2 C,1 C. C, C. C, C, C. B. C, 6- B, B, 1/B, 1/B,
M1239.29 2 0,1 C,1 1, C/1 ' : 0,1 C,1 B, C, 1/B, 1,6 1.B 1/6, 1/B,
M1239.30 1 C,1 C, c. C, c, c. C. C. C. C. C, C. s i i l a g
M1239.31 1 C.1 C, C, c. C, c, c. C. C, C. C, C, C. C.1
M1239.32 1 C,1 C, c, C, c, c. C. C, c. C, C, c. C.1
M1239.33 1 C,1 C, C. C, c. C, C, C, c. C,
M1239.34 1 C,1 C, C, C,1 c. C, C, C, c. 0,1
M1239.35 1 C,B C,B C,B C.B C,B C.B B. B. B, B B, B. 1/B, 1/B,
M1239.36 1 C,B C,B C,B C.B C,B C,B C.B B. C,B 1/B, B, B. 1/6, 1/6,
M1239.37 2 C.B C,B C.B C.B C,B C,B C.B B. C,B B, B, B. 1/6, 1/6,
M1239.38 1 C,B C, C,B C.B C.B C,B C.B C.B C,B C.B B, B. 1/6, 1/B,
M1239.39 5 C,B C,B C,B C.B C,B C.B C.B C.B C,B B. B, B, 1/6, 1/B,
M1239.40 1 C,B C,B C,B C.B C,B C,B C.B C.B C,B C.B C,B B, C.B C.B
M1239.41 1 C.B C, C.B C,B C,B C.B C.B C,B C.B C,B C,B C.B C.B
M1239.42 1 C,B C, C,B C,B C.B C.B C,B C,B C.B C.B
M1239.43 11 C,B C,B C,B C.B C,B C,B C.B C.B C,B C.B 0 ,6 C.B C.B C.B
M1239.44 1 C,B C,B C.B C,B C,B C.B C.B C,B C.B C,B C,B C.B C.B
M1239.45 13 9 ,9 C,B 9,6 C.B 9 ,6 9 ,6 9 ,6 C.B 9 ,9
M1616.01 1 B, B, B, B, B, B, B. B, B, B. B, B. B' 6'
M1616.02 1 1,B B. B. B, B, B, B. B. B, B. B, B, 1/6, 1/B,
M1616.03 1 C,1 C, C, C. C, C, C. C. C, C. C, C, C. C.B/1
M1616.04 2 C,B C.B C.B C.B C,B C,B C.B C.B C,B C.B 0 ,6 C,B C.B C.B
M1616.05 1 0,R C B 9,B C.B 9 ,9 C R C.B C.B 9 ,6 C.B 9 ,9 C .B /, :
M1645.01 4 1, B B. B, B. B, B, B. B. B, B. B, B. 1/6, i /b !
M1645.02 1 B. B, B, B, B. B, B. B. B, B. B, B. 1/B, 1/B,
M1645.03 14 B, B. B, B B, B. B. B B, B. B, B. B. B.
M239.01 1 i ,u 1,6 1 ,B 1 ,B C,1 C,1 wm& mm* 1, c ,ts /i ; C,1 0,1 0,1 0,1 j
M239.02 2 1,6 1, B 1,6 1 ,B 1,6 1,6 1,6 1,6 1,B 1,6 1,6 1,6 1/B, 1/B,
M239.03 1 I B B, 6, B, 6, B, B, B, 6, B, B, B, 1/B, 1/B,
M239.04 1 I B B, 6, B, B, B, 6, B, 6, B, 6, B, 1/B,
M239.05 1 1,6 1.B 1,6 C/1 ,B C,B C,1 C/1, wm * c,1 C,1 C,1 C,1 0,1 0,1
M239.06 1 i Eli 1,6 C,6 C,B C.B C,B 0,6 0,6 c,6 C,B 0 ,6 0,6 C,B 0,6
M239.07 5 ■ B, B, B. B, e ■ 6, 6, B,.... B, 6, 6, 6,
M239.08 2 B B, 6, B, C,B 0,6 G,B 0,6 0,6 C,B 0,6 0 ,6 C,B C,B
M239.09 1 C. C, C, C, C, 0, 0 , 0 , 0 , c , C, 0 , 0,6/1
M239.10 2 C.B C B U,B U,b U,b c ,ts C,B 0 ,6 lr,B u.ts U,6 U.ts 0i, 6
M241.01 1 1,B B, B. B, B, B, B. B, B. B, B, 1/6, 1/6,....
M241.02 26 1,B B. B, B, B, B. B, B, B, B, B. B, 1/B, 1/6,
M241.03 7 B, B, B, B, B, B. B, B. B, B, B, B, 1/B, 1/6,
M241.04 1 B, B, B. B, B, B. B, B, B. B, B, 1/B, 1/6,
M241.05 1 1 ,B B. B, B. B, B. B. B, B, B. B, B, 1/6, m m
M241.06 1 1,B B, B, L. B, B, B. B. B, B. B, B, 1/B, 1/B,
M241.07 7 1, B B. B, B, B, B, B. B, B, B. B. B. B. 1/6,
M241.08 1 1 ,B B. B, B. B, B, B, B. B, l/c ,b B, B. B 1/B,
M241.09 1 B, B. B, B, C,B B. B, B. B, B. B, B. 1/B, 1/6,
M241.10 1 B, B C,B B, B, B. B. B, B, B. B, B, 1/6, 1/B,
M241.11 5 1,B B, B, B, B, B, B. B. B, B. B, B, B, B.
M241.12 6 B, B. B, B. B, B, B. B, B, B, B, B. B. 1/B,
M241.13 56 B, B. B, B. B, B, B. B. B, B. B, B. B. ,6,
M241.14 1 1, B B, B, B. B. B. B. B, B, B. B,
M241.15 1 1 ,B B, B, C, C, C. C. C, C. C, c, C. 0.1 \
M241.16 1 1 ,B B, B, B, C, C, C. C. C, C. C,B c, C. C.B/1 |
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M241.17 1 B. B. B, B. B, B, B, B. B. B. B, C.B C.B C.B
M241.18 4 B. B, C,B C.B C,B C,B C.B C.B C,B C.B C,B C.B C.B C.B
M241.19 1 B, B, B, B. B. B, B. C.B C.B C.B C,B C.B C.B C.B
M241.20 5 B, B. B, B. C,B C,B C.B C.B C,B C.B C.B C,B C.B C.B
M241.21 1 L.B B. B, B, B. B, B, B, B, B. B, B. 1/B, 1/B,
M241.22 2 L,B L.B L.B L.B L.B L.B L.B L.B L.B L.B L.B L,B L.B L.B
M241.23 2 L.C L.C L.C L.C L.C L.C L.C L.C L.C L.C L.C L.C L.C L.C
M241.24 1 L.C C.B C.B C.B C,B C,B C.B C.B C,B C.B C,B C,B l/C,B L/C,B
M241.25 2 C, C, C, C. C, C, C. C. C, C. C, C, C. c,
M241.26 3 C,1 C, B, B, B, B, B. B, B, B. B, B, 1/B, 1/B,
M241.27 6 C,1 C, C, C. C, C, C. C. C, C. C, C, C. C.B/1
M241.28 5 C,1 C. C, C. C, C, C. C. C, C. C, c, C, C.1
M241.29 1 C,B L/C,B C,B B. B. B, B. B, B. B, B, B. 1/B, 1/B,
M241.30 1 C,B C,B C,B B. B, B, B. B, B, B. B, B, 1/6, 17B;.....
M241.31 8 C,B C,B B, B, B, B. B. B, B. B. B, B, 77b : .. 1/B,
M241.32 1 C,B C,B B, B, B, B, B. B, B, B. B, B. B. B, i
M241.33 1 C,B C,B C,B C.B C, C, C. C. C, C. C, C, c . c,
M241.34 1 C.B C,B C,B C.B C,B C,B C.B C.B C,B C.B C,B B. 1/B, 1/B,
M241.35 1 C,B C, C,B C.B C,B C,B C.B C.B C,B C.B C,B C,B C.B C.B
M241.36 1 C.B C, C.B C,B C,B C.B C.B C,B C.B C,B C.B C.B
M241.37 2 C,B C,B C,B C.B C,B C.B C.B C.B C.B C.B C.B C,B C.B 1/B,
M241.38 1 C,B C.B C,B L/C. B L/C,b I 7 o B “ L/C/1. E C.B C.B C,B C.B C.B C.B
M241.39 1 C,B C.B B, C.B C,B C,B C.B C.B C,B C.B C.B C.B C.B
M241.40 51 C.B C.B C.B C.B C,B C,B C.B C.B C.B C.B C.B C,B C.B C.B
M241.41 1 C.B C,B C.B C.B C.B C,B C.B C.B C.B C.B C,B C.B C.B
M241.42 _ l  _ f t , B L/C.B f t , ? C.B C.B C,B C BC ' C.B C B C.B C.B ft,B ft,? C.B
M369.01 2 * 6 i,B i.y i,B l .b 1,0 • 7 ? 1 # f,B SB.... 7B “ “ , T, B
M369.02 1 1 ,B 1, B 1, C,1 C,1 C/1 C/1.B C.1 1/B, i , B 1.B 1/B, 1/B,
M369.03 1 1 ,B 1, B 1 S d f e i C.1 C,1 C /1, :: m m C,1 C,1 C.1 c  ■ C.1 C,1
M369.04 1 1, B 1.B 1 W m m C,1 C.1 m m C/1 C,1 c ,1 C,1 C,1 C,1 C,1
M369.05 1 1 ,B B, B, B, B, B, B, “
M369.06 2 1, B B, B, B, B, B, B. B. B, B, B, B, B. B.
M369.07 1 1 ,B B, B, B, B. B.
M369.08 7 B, B, B, B. B, B. B. B, B. B. B, B, B. B.
M369.09 1 B, B, B. B, B, B, B. ~
M369.10 1 B, B, B, B.
M369.11 1 B, B, B, B, B, B. B, ~
M369.12 1 B, B, b, B, B, B, B, B, B, B, B, B, B, , L/C,B
M369.13 1 B, B, B, B, B, B, B. B. B, B, B, L/C,B L/C,B L/C, 6
M369.14 1 B, B, C,B C.B C,B C,B C.B C.B B, C.B C.B C,B C.B C.B
M369.15 1 B, B, C.B C.B C,B C.B C.B C.B C.B C.B C,B C,B C.B C.B
M369.16 1 B, B, B, C,B C.B C,B C,B C.B C.B C~B
M369.17 1 C,1 C, C, C. C, C, C. C.B B. B. B, B, 1/6, 1/B,
M369.18 2 C,1 C, C, C. C, C, C. C. C, C. C, C, c. C.B/1
M369.19 1 C.1 C, C, C, C. C, C, C, c. C ~
M369.20 1 C,1 C,1 C,1 C,1 C,1 C,1 ft,1 C,1 ft,1 C,1 C,1 C,1 , C,1
M369.21 1 C,B C,B C.B C.B C,B C,B C.B C.B C,B C.B C,B B, 1/B, 1/B,
M369.22 10 C.B C.B C,B C.B C,B C,B C.B C.B C,B C.B C.B C.B
CDd C.B
M369.23 2 C,B C,B C,B C.B C.B C,B C.B C~B
M369.24 1 C,B C,B C,B C,B C.B C.B
M369.25 1 C.B .C.B... C,B C.B C B C.B ft B f t .B C.B
_ _
M412.01 1 1,B 1 , B 1 ,B 1.B 1,B 1, B 1.B 1.B 1,B 1.B 1,B 1.B 1.B i .b i
M412.02 1 1 ,B 1,B 1 ,B B, B, B, B. B, B, B, B, B 1/B, 1/B,
M412.03 3 1 ,B B, l/c ,b B, B. B. B; L /c ,e 1/6, 1/B,
M412.04 1 1, B B, B, B. B, B, B. B. ■ m . 1/B, B, B, 1/B, 1/B,
M412.05 25 1, B B, B, B. B, B, B, B, B, B, B, B. 1/6, 1/B,
M412.06 3 1 ,B B, B, B, B, B, B. B B, B. B, ?• > B
M412.07 1 1 B C, C, WM W//A mmm
M412.08 2 1,6 6, c, b, C, C, 6, c , C, C, c . ft, ,
M412.09 1 1.B B, C, B. c, C,1 C. c. c, C. C, c, c. C,B/1
M412.10 1 1 ,B B, c, B, c, c, c. c. C, C. C, c, c. C.1
M412.11 2 1 ,B B, c, B, c, c, c. c. c, C. C, c, c. c ;b/i
M412.12 1 1 ,B 1.B c, 1.B 1,B 1 ,B 1.B 1.B 1 ,B C,1 C,1 C,1 ft,1 C,1
M412.13 1 1 ,B 1 ,B 1 ,B 1.B 1 ,B 1,B 1.B 1.B 1 ,B C,1 c,1 C,1 C,1 C,1
M412.14 2 B, B, L/C,B B, B, B. B, L/C,B 1/B, 1/B,
M412.15 1 B, B. L/C.B B, B, B B, B. 1/6, 1/B,
M412.16 1 B, B, B. B, L/C.B B. B, wxm iii& B, B, l/c ,b , 1/B, , 1/6,
M412.17 3 B, B, B, B, B, B, B, B, B, B, B, B, 1/B, 1/B,
M412.18 26 B, B. B, B, B, B, B. B. B, B, B, B, B, B.
M412.19 10 B, B, B. B. B, B, B. B. B, B, B, B. B,
M412.20 1 B, B. B, B. B. B, B. B, B. B. B.
M412.21 1 B, B, B. B, B, B. B. B, B. B, L/C,B l/c ,b
M412.22 1 B, B, B, 1.B 1.B 1, B 1.B 1.B 1. B C,1 C,1 ft,1 c .1 C,1
M412.23 1 B, B, B, B. B. B, B, B,L/C/1 L/B wm& C,B TKT5
M412.24 1 C. 113 1, B 1.B 1.B 1.B 1.B 1.B 1. B 1.B 1.B 1.B 1.B 1/6,
M412.25 1 C, B, B B, 1/B, 1/6,
M412.26 1 C.1 C, C, B, B-, ■ B, B, B. IB. B. B, B. 1/B, ~T~..
M412.27 3 C.1 c, L/C,B B, B. B. I B, L/C.B , 1/B, 1/B,
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M412.28 1 C.1 C, C, vm mm.
M412.29 2 C,1 C, C, L. C, C. C, c, c. .
M412.30 3 C,1 C, c, c . C, C, C. C. C, C. C, c, c . t
M412.31 1 C,1 C, c, B, c, C, C. C. c, c. C, c , c . C.1
M412.32 2 C,1 C, c, B. c, C, C. C. c, c. C, c, c . . mw&
M412.33 3 C,1 C, c, B, c, C, c . C. c , c. C, c , c. C.6/1
M412.34 1 C,1 C, B. c, C, c. C. c, C. C. c. . C.B/1
M412.35 4 C.B C.B B. B. B. B. B. B. B. B, B B, 1/B, , 1/B,
M412.36 4 C.B CB C.B B, B, B, B, B, B. B, B. B, 1/B, , 1/6,
M412.37 1 0 ,6 C.B C.B 6, B, B, B, B, 6, B, b, B, B, I 6,
M412.38 1 C.B C.B L/C.B B, B. B. B, L/C.B 1/B, 1/B,
M412.39 5 C,B C.B L/C. 6 L/C.B B.L/C/1 L/C/1. E C,B L/C,6 mm ,
M412.40 1 C,B C.B C,B B. C,B C.B C.B C. C, C. C, C, C.B/1 ,
M412.41 1 B, B. B. B. C,B C,B C.B C.B C.B C.B C,B C.B C.B ,
M412.42 2 B, B, B. B. C,B C,B C.B C.B C,B C.B C,B C,B C.B . C.B
M412.43 1 B, B, B. B, B, B. B. B, B. C.B C.B C,B C.B C.B
M412.44 14 B. B. C,B B, C.B C.B C.B C.B C.B C.B C.B C,B C.B ,
M412.45 2 C,B C,B B, B, C.B C,B C.B C.B C;B C.B C,B C,B C.B , C.B
M412.46 1 C,B C,B C,B ,B C,B C,B C.B C.B B, C.B C,B C,B C.B . C.B
M412.47 21 C.B C.B C,B ,B C,B C,B C.B C.B C.B C.B C,B C,B C.B , C.B
M412.48 1 C.B C.B B, C,B C,B C.B C.B C,B C.B C,B C.B , C.B
M412.49 2 C,B C.B C,B B. C,B C.B C.B C.B C.B C.B C.B C.B .
M412.50 4 C,B c .e C.B C.B C.B C.B C.B C.B C,B C,B c,b c .b C.B , C.B
M412.51 1 Q.B Q.B Q B C.B C.B Q.B C,B Q.B Q„B, C.B C.B Q.B f i g
M54.01 18 1.B B. B, B. B. B. B. B. B, B, B, B, , 1/B,
M54.02 1 1,6 B, 6, B, B, B, B. 6, B, b, B, 1/B, 1/B,
M54.03 3 1 ,B B, L/C.B B, B. B, B. B. 1/B, . 1/B, i
M54.04 8 1 ,B B, L/C.B B. B. B. B, L/C.B 1/6, 1/B,
M54.05 4 1.B L/C.B 1,6 L/C/1. E L/C/1. E L/C.B 1/B, , 1/B,
M54.06 1 1. B l/C.B 1.B L/C/1. E L/C/1. E 1.B 1/B, 1/6,
M54.07 1 1,B B. B, B, B. B, B. B. B, B. B. C, c C/,1
M54.08 5 B, B, L/C.B B, B, B, B, L/C, 6 1/B, . 1/6,
M54.09 2 B, B. L/C.B B, B, B. B, B, 1/B, , 1/6,
M54.10 1 B, B, B. B. B. B. B, B, 1/B, , 1/B,
M54.11 2 B, B, B, B, B, B, B, B. B. B. B. B, 1/B, . 1/B,
M54.12 7 B. B, 6, B, B, B, B, B, B, B, b, B, B, 6,
M54.13 1 B, B, B, B. B, B. B, B, B, B, B, B. B, , 1/B,
M54.14 3 B, B, B, B, B. B, B. B, C.B C.B C,B C.B C.B , C.B
M54.15 1 B, B, L/C.B B. B. B, C,B L/C, 6 m m i wm
M54.16 1 1,B B, Y jy //i? Y S //ji r a C, m m *
M54.17 3 C,1 C, C, , i a
M54.18 1 C,1 C, ty l'iw /rZ /A C, L/C,B i /b , 1/6,
M54.19 1 C,1 C, L/C.1 K c O T c L/C.B 1/B, , 1/B,
M54.20 1 C,1 C.1 L/C.B L/C .l]P L/C, 1 8/1.C/L t w m r n
M54.21 3 C,1 L/C, B| L/C.1 P L/C.1 w m r n
M54.22 2 ' c. C, B, C. C, C, c C, c. B, 1/6, 1/6,
M54.23 1 C.1 c, c, B. c, C, c . C. c , C. c, C, c. , C.1
M54.24 1 C,1 c. c, B. c. c . c . c , C. c, C, c. . C.B/1
M54.25 1 CB C.B L/C.B l/c .B B, B. . B, L/C, 6 1/B, , 1/B,
M54.26 1 C,1 JrPi L/C.B L/C.B L/C/1. B L/C/1. B C,B L/c,b i a / e l i ■mmm
M54.27 3 C.B C,B L/C.B L/C.B B. L/C/1 L/C/1. B C,B # / C , B 1/6, , 1/6,
M54.28 3 B, C.B L/C, 6 L/C.B B. L/C/1 L/C/1. B . C.B L/C,b mm . m r?.
M54.29 10 C,B C.B l/C,B L/C.B B, L/C/1 L/C/1. B r € 3 L/C,b B a s e l . m m m
M54.30 1 0,1 L/C, 6 1 ,B B. L/C/1 L/C/1. B 1 ,B 1/6, 1/B,
M54.31 1 C.B C.B C,B C.B C,B B. B, B. B. B, B B. B , B.
M54.32 1 0 ,6 C,6 C.B B, C.B C B C,B C.B C.6 C.6 C.b B, 1/B, 1/B,
M54.33 8 C.B C.B C.B B, C.B C.B C.B TTB C.b C.b C.b c ,6 , C.B
M54.34 4 C,B C,B B, B. C,B C,B C.B C.B c ,b C.B C,B C.B C.B , C.B
M54.35 1 C.B C,B C.B C. C,B C,B C.B C.B C,B C.B C,B C,B C.B C.B
M54.36 3 C,B C.B C,B C,B C.B C.B C.B C,B C.B , C.B
M54.37 3 Q,B C.B C,B Q B C.E3 C.B.. C.B C.B C.B C.B C.B C.B . y ,B . <?.B„
M624.01 1 1 ,B 1, B 1 ,B 1.B 1.B 1.B 1.B 1.B 1 ,B 1.B 1 ,B 1.B 1.B , 1.B
M624.02 1 1 ,B 1, B 1,6 1.B 1,6 1.B 1.B 1,6 1.B 1 ,B 1,6 1.B , 1.B
M624.03 1 . B 1 ,B 1,B 1.B 1.B 1,6 1.B 1.B 1 ,B 1.B 1 ,B 1.B bim m , 1,B
M624.04 1 I.B B, B, B. B. B, B. B. B, B. B, B. ,6/1 ,6/1
M624.05 14 1 ,B B, B, B, B. B, B, B. B, B. B, B. 1/6, . 1/B,
M624.06 2 1 ,B B, B, B. B, B. B. B, B, B. B, B, B. , 1.B
M624.07 2 1 ,B B, B, B. B, B, B, B, B, B, B, B , 1.B
M624.08 2 B, B, B, B. B. B. B, B. B. B, B, B, 1/B, 1/B,
M624.09 21 B, B, B, B. B, B, B. B, B, B, B, B, B, }m B.
M624.10 2 B. B. B, B. B, B. B, B, B, B. B, B, B.
M624.11 3 B. B. B, B, B. B, B, B. B. B, B. B. , B.
M624.12 1 I.B B, B, B. B. B. B. C/1,B B, C. C, C, C. . C,1
M624.13 3 B B, B, B, B. B, B, B. C.B C.B C,B C.B C.B __ C.B
M624.14 2 L.B L,B L,B L.B L.B L.B L.B L.B L.B L.B L,B L,B L.B __ L.B
M624.15 4 L.C L.C L.C L.C L,C L.C L.C L.C L,C L,C L.C , L.C
M624.16 1 i r r C.1 C, 1 1,6 1,6 1 ,B 1,6 T jT 1 ,B 1,6 1,6 1/B, __ 1/B,
M624.17 1 0,1 , lT“ C,1 0,1 0,1 C,1 C,1 ~CJ C.B/1 1,6 C.B 1/B, j__ 1/B,
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M624.18 1 3,1
*------ C, Q. C, B. B. B, B, B. B,
M624.19 1 3.1 c. r>u. c. c, C, c. C. C, C. B. B. B,
M624.20 1 3,1 3,1 1, C.1 C.1 C,1 C.1 C.1 3,1 mmm L/C, 1 m m
M624.21 4 3,1 c, c, c. c, c, c. c. C, c. c, C, c. c m
M624.22 1 13,1 3,1 C,1 C.1 3,1 3,1 C.1 C.1 C.1 C.1 3,1 3,1 C.1 C.1
M624.23 1 3,1 3,1 1. 3,1 3,1 C.1 C/1.B 3,1 C.1 3,1 3,1 C.1 C.1
M624.24 1 3,1 C, c, c. C, C, c. C. C, c. 3,B C, c. C.B
M624.25 2 C,B C,B 3,B C.B 3,B 3,B C.B C.B 3,B C.B B. B.
M624.26 1 9 B C.B B, B, B, B. B. B. 3 B. B, B, 1/B, 1/B,
M624.27 1 c,B L.B C,B C,B C,B C,B C.B C,B C.B C,B B, B, 1/B, 1/fe, ,
M624.28 3 C,B 3,B 3,B C.B C,B 3,B C.B C.B C,B C.B B, B, B, B.
M624.29 2 C,B 3,B 3,B 3,B C,B C.B C.B C.B C.B B, B. B, B.
M624.30 1 C,B C, B, C.B 3,B C.B C.B C.B 3,B C.B C,B 3,B C.B C.B
M624.31 11 C,B 3,B 3,B C.B C.B C.B C.B C.B C.B C.B 3,B C,B C.B C.B
M624.32 1 C,B 3,B 3,B C.B 3,B 3,B C.B C.B 3,B C.B 3,B 3,B C.B
M624.33 3 Q,Q9,? Q.B 9,9 9,9 C.B C.B 9,9 C.B 9,9 9,9 9 9 C.B
M667.01 12 B, B, B, B. B, B, B, B. B, B. B. B, B. B.
M667.02 2 L, L. L. L. L, L, L L, __
M667.03 1 B, L, L.
M667.04 1 L, ,C ,C L.C L,3 L,C L.C L.C L,3 L.C L.C L.C L.C L.C
M667.05 1 L.B ,B C/1.B L/C,B L/C.B L/C,B L/C, 6 L.B L.B L.B L.B L.B L.B
M667.06 3 L.B ,B L.B L.B L.B L.B L.B L.B L.B L,B L.B L.B L.B
M667.07 5 L,B ,B ,B L.B L.B L.B L.B L.B L.B L.B L.B L.B L.B L.B
M667.08 1 C,B 3,B B, L/1 C.B 3,B 3,B C.B C.B C.B C.B 3,B 3,B C.B C.B
M667.09 2 C,B C.B 3,B C.B 3,B 3,B C.B C.B C.B C.B B. B, B. B.
M667.10 3 Q„,9 c, Q.B C.B, m 3,B .. C.B C.B
!Xi
d
C.B Q.B C,B 9,9 C.B I
M876.01 6 1, B B, B, B. B. B, B. B. B, B. B, B, 1/B, 1/B,
M876.02 3 B. B, B, B. B. B. B, B. B, B, B. B, 1/B, 1/B,
M876.03 1 B, B, B, B. B, B. B, B, B,
M876.04 16 B. B, B, B, B. B. B, B, B. B. B, B, B, B,
M876.05 2 C,B C,B B, B. B, B. B. B. B, B. B, B, B. B.
M876.06 4 3,1 C, C, C. C, C, C. C. C, C. C, C, C. m m
M876.07 1 C, C, C, C. C, C. C. C. C, C.B 3,B C.B C.B C.B
M876.08 1 C, C, c, C.B C,B 3,B C.B C.B C.B C.B 3,B 3,B C.B C.B
M876.09 1 c, C, c, 3,B C,B C.B C.B C.B C.B C,B 3,B C.B C.B
M876.10 4 C,B C, C,B 3,B C,B C.B C.B C,B C.B C.B 3,B C.B C.B
M876.11 2 C.B C, 3,B C.B C.B 3,B 3,B 3,B C.B 3,B
M876.12 2 C,B 3.B C,B 3,B C.B 3,B C.B C.B C.B 3,B
M876.13 1 C.B C.B C.B 3,B C,B C.B C.B 3,B C.B C.B C.B C.B C.B
M876.14 17 , ■ Q.B Q.Q Q.B C.B C,B Q.B Q.B 9,9 C.B 9,9 9,9 Q.B C.B
Mud/1368C.01 3 L, 1 L, L, L. L, L, L, L, L, T~
Mud/1368C.02 4 L.B L,B L.B L.B L.B L.B L.B L,B L.B L,B
Mud/1368C.03 8 C,B C.B 3,B 3,B C.B C,B 3,B 3,B C.B 3,B
Mud/1368C.04 2 |  1 C. 3, C . c. c. C, 3, lS g
Mud/1528C.01 3 L, 1 L. L, L, L, L. L. L, L. L,
Mud/1528C.02 1 3,1 C, C, C, C. C, C, C, C. C,
Mud/1528C.03 1 L,B L.B L,B L.B L.B L,B L.B L. L.B L.B
Mud/1528C.04 1 3,B L/C,6 L/C.B L.B L.B L,B L,B L.B L.B L.B
Mud/1528C.05 , 1.i 9,9 CB Q.B C.BE L b Q.B 9,9 C.B 9,9 C.B
Mud/1603.01 2 M L, L, L, L. L, L, L, L. L.
M ud/1603.02 1 L.1 L. L. L, L. L, L. L.
Mud/1603.03 1 L,B L. L.B L,B L.B L.B L.B L.B L.B L.B
M ud/1603.04 5 L,B L,B L.B L,B L.B L.B L,B L,B L.B L.B
M ud/1603.05 1 L,B L.B L,B L,B L.B L.B L.B L.B
Mud/1603.06 1 L,B L,B L,B L,B L.B L.B L.B leT
M ud/1603.07 1 L.B L,B L.B L.B L.B L.B L.B L. L.B L.B
M ud/1603.08 3 3,1 C, C, C, C. C, C, C, C. C,
M ud/1603.09 1 C.1 C, c, C, C. 3,B C, C, C. C,
Mud/1603.10 2 C.B c, C,B 3,B C.B C,B 3,B 3,B C.B C,B
Mud/1603.11 C.B c, 3,B C,B C.B 3,B C,B C.B C.B C.B
Mud/1603.12 7 C,B Q.B C.B 9,BE S ~ “ C.B Q.B 9,9 9,9 -,-Q-B
Mud/1605.01 1 L,B L.B L.B L,B L/Q.tJ 3,B 3,B C.B C.B C.B
Mud/1605.02 „ 1 Q.B C,B 9,9 9,9 C.B 9,9 C B Q.B Q.B £ B
Mud/1616.01 4 L, 1 L, L, L. L. L, L, L. L. L.
M ud/1616.02 1 L,B L, L.B L.B L.B L,B L.B L.B L.B L.B
Mud/1616.03 2 L,B L,B L.B L.B L.B L,B L.B L.B L.B L.B
M ud/1616.04 1 • i-‘- i ■: C, C. C, C, C, C. C.
M ud/1616.05 1 L.B L/C t L/C.B 3,B C.B C.B C.B 3,B C.B C.B
Mud/1616.06 1 3,B 3,B 3,B 3,E C.B C,B 3,B C, C.B m
Mud/1616.07 3 C.B 9,9 9,9 9,9 Q.B. . 99 9,9 9,9 C.B IC.B
Mud/1640.01 2 L.1 L, L. L. L, L, L. L. Tl
Mud/1640.02 1 L.B L. L,B ' UB L/C.B C,B C.B jOB! C.B C.B
Mud/1640.03 1 L.B L,B L.B L.B L/C.B 3,B 3,B C.E! C.B C.B
Mud/1640.04 1 L.B L,B L.B ' L.B L.B C,B 3,B E i I C.B jC*B
Mud/1640.05 1 L.B L, L.B L.B L.B L,B L.B L.B L.B Tlb
Mud/1640.06 2 L.B L,B L,B L.B L.B L.B L.B Tlb L.B L.B
Mud/1640.07 1 C 1 C, C, ‘ c. C. 3,B C, c. C. C.E
Mud/1640.08 1 Tc~T C, C,B la C. 3,B C, Tc~ C. la
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Mud/1640.09 4 C.B C B C.B V B C.B Q.B C.B, Q.B C.B
Mud/1645.01 3 L,B L.B L.B L,B L.B L,B L.B L,B L.B L,B
Mud/1645.02 1 C,1 C, C, C, C. C, C, C, C. C,
Mud/1645.03 1 9 .0
L/C.B L/u,b L.B L.B L,B L.B L.B I B L.B
Mud/1648.01 3 L,B L B LB L,B L.B L,B L.B L.B L.B L.B
Mud/1648.02 1 C,1 L, L. L, L. L, L. L,
Mud/1648.03 1 C,1 , C, C. c . Q c . c.. c . Q _
Mud/1651.01 1 L, B L. L.B L,B L.B L,B L.B L, B L.B L.B
Mud/1651.02 1 L,B L. L.B L,B L.B L,B L.B L. L.B L.B
Mud/1651.03 2 L,B L,B L,B L,B L.B L,B L.B L, L.B L,B
Mud/1651.04 1 L.B L ,B L.B L,B L.B L,B L,B L,B L.B L.B
Mud/1651.05 1 C.B C.B C,B C,B C.B C,B C,B C, C.B C,B
Mud/1651.06 2 Q.B C.B C.B Q,B Q.B Q.B C.B Q,B
Mud/1675.01 3 L,B L,B L.B L.B L.B L,B L.B L,B L.B L.B
Mud/1675.02 1 C.B C.B C.B Q iP h i___ Q.B Q.B C,B C,B
Mud/1683.01 1 1, B C, C, C. C, C, c. C. C, c. C, C, C. C.B/1
Mud/1683.02 6 L, 1 L, L, L, L. L. L. L. L. L,
Mud/1683.03 2 L, 1 L, L, L. L, L, L. L. L, L. L, L. L. L.B/1
Mud/1683.04 1 L.B L,B L.B L.B L.B L.B L.B L.B L.B L.B L.B L.B L.B L.B
Mud/1683.05 1 C,1 C, C, C. C, C, C. C. C, C. C, C, C. C.B/1
Mud/1683.06 1 C,1 C, C, C, C. C, C, C, C. C,
Mud/1683.07 2 C,B C,B C,B C.B C,B C,B C.B C.B C,B C.B C,B C,B C.B C.B
Mud/1683.08 1 .q.B q .b Q.B Q,B Q,B Q.B Q f B C.B C.B
Mud/1686.01 1 L,1 L, L. L. L. L, L. L,
Mud/1686.02 1 L,B L.B L.B L,B L.B L.B L.B L.B L.B L.B
Mud/1686.03 1 L.B L.B L.B L.B L.B L.B L.B L.B
Mud/1686.04 2 C.B C.B C B Q„B C B Q,B C.B C;B C .B P J L
Mud/1693.01 1 L,1 C,B C, c, C. c,
Mud/1693.02 5 L.1 L, L. L, L, L, L. L,
Mud/1693.03 1 L,B L.B L,b L,B L,b L.B L,b L,B L,b
Mud/1693.04 1 L.B L,B L.B L,B L/C.B C.B C.B C,B
Mud/1693.05 1 L.B L.B L.B L.B L/C.B C,B C,B C,B C.B C,B
Mud/1693.06 1 L.B L,B L.B L.b L,6 C,B C,B C,B C.B C,B
Mud/1693.07 5 L.B L,B L.B L.B L.B L,B L,B QB L.B L,B
Mud/1693.08 2 C,1 C, C, C, C. C, C, C, C. C,
Mud/1693.09 1 C,B C,B C,B C,B C.B C,B C,B C.B C.B
Mud/1693.10 8 q .b C B Q.B C.B CB Q.B QiP £ £ Q.B e j3
Mudv/106.01 3 B. B, B. B, B, B, B. B, B, B.
Mudv/106.02 1 B, B, B, C,B C.B C,B C,B C,B C.B C,B
Mudv/106.03 1 C,B B. B, C,B C.B C,B C,B C,B C.B C,B
Mudv/106.04 1 1,B B, B, B. B, B, B, B, B. B.
Mudv/106.05 2 C,B C,B C,B C,B C.B C,B C.B C,B C.B C,B
Mudv/106.06 1 C,B C,B C,B B, B, B. B, B, B. B,
Mudv/106.07 2 C,B C,B C,B C.B C.B C,B C,B C.B C.B : C,B
Mudv/106.08 1 C, C, C, C. C, C, C, c. C,
Mudv/106.09 2 C „, c, C. c , , c c . c. c . , c _
Mudv/115.01 1 i.B B. ' B b. b. B. T ~— B t hi. B, 1/b, Q b , :
Mudv/115.02 1 B, 6, B, B. B, B. B, B, B, B, b, L/C.B L/C.B L/C,B
Mudv/115.03 2 B, B. B. B, B, B, B. B. B. B, B. B, B.
Mudv/115.04 1 1 ,B B, B. B. B, B. B. B, B. B. B. B. 1.B
Mudv/115.05 1 C,B C.B C.B C,B C,B C.B C.B C,B C.B C,B B. B. B.
Mudv/115.06 2 C,1 C, C, C, C. C. C. C, C. C, C, C. C.1
Mudv/115.07 1 C,B C.B , C.B C.B C.B C,B C.B C.B 0 ,6 C,B C.B C.B , C rB , C.B
Mudv/115.08 3 C.B C.B C B C.B C B C.B Q.B ,Q,3 QB C B C.B C,B C.B
Mudv/123.01 1 C,B C.B C,B C,B C.B C,B C,B C,B C.B C,B
Mudv/123.02 1 B, B, B. B, B. B, B. B^_ B. B
Mudv/136.01 1 B, B, B, B. B, B. B. B. B, B. B, C,B C B C.B
Mudv/136.02 1 C,B C,B C,B C.B C.B C,B C.B C.B C,B C.B C,B C,B C.B 1/B,
Mudv/136.03 2 ,Q,P QiP Q.9 C.B QB C B  , Q.B GJB Q B C.B C.B Q,B
Mudv/137.01 1 B B, L/C.b B, B. B, B, i/Q .b i/B. f/B,
Mudv/137.02 1 0,1 C, C, wmm
Mudv/137.03 4 C.B QiP
ltctt 9 c .b L/C/1 E L/C/1. E C.B C/c b B/1 C:l; iQ /QQ Q
Mudv/138.01 1 ! B B, U C .B B, B, L/C/1. E B, B, IB TJK
Mudv/138.02 1 I.B B, L/C.B B. B. B. B, L/C.B 1/B, 1/B,
Mudv/138.03 1 C.B C.B L/U,b L/U,b L/C/1. B L/C/1. E C B L/U, b S '1  Q/i
Mudv/139.01 1 C.B C.B L/C.B L/C.B B.L/C/1 L/C/1. E C,B L/C,b wmm m m .
Mudv/139.02 1 JQ _ B
L/C,B B, B. B. B, L/o,b T7B,"“ 17S,
Mudv/141.01 1 LB B, L/C.B B, B. B. B, L/C.B 1/B, 1/b,
Mudv/141.02 2 B B, L/C.B B. B, B, B, L/C.B 1/B, 1/B, i
Mudv/141.03 1 C.B _ _ ____C.B ____ L/U,b L/U,b L/C/CB L/C/1 bI__ _ B, TJU^E 1/B. " __ 1/b,
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Appendix 3.2
Microsatellites for which primers were tested for polymorphism characteristics in the strains used for 
the lethal recessive screen. Seven STS markers from the MIT are included at the end of the list to 
highlight their position relative to the other markers.__________________________________________
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DNR001 TTTGCTTGATCCCACTCCTC GCAAAGGTCCCTCTCAGAAAC 20 188 33455042 (TG)n 41 l:
DNR002 TTCTG C ACC C AT ATTTT C ATTG ATCAACCTGGGCAAAGACTG 54 176 33537850 (TG)n 41 l :
DNR003 AAGT CAAACAT G G CTG CTAGT G GGAG AAAACAG ACTT CATT CAGG 53 214 33497327 (CA)n 41 l:
DNR004 GTGCACAAGGAAACACCAAC G CAGT GAT GACATCGT CCAG 92 260 33549341 (TC)n 41 l:
DNR005 C AAACC ATTTATAT AC AAAC ATAC AC C AAAATTATGGAGCCTCATTTCATC 26 90 33594418 (CA)n 41 l:
DNR006 ATGCAATAATGCCAGCAATG CCTTT G AAAGTAAACCCT G G AC 69 204 33607871 (CA)n 41 l;
DNR007 CAGGGTCTGAAGGAAGATGC TGCTGGGATATATAAGCTGTGG 84 229 33837654 (TC)n 262.
DNR008 TTCAGGAAGCTCCATCCATC AGGAGTCCACCACAGTCTGC 35 192 30038831 (CA)n 232I
DNR009 GGTGGCTACCTAGAACAGAAGG CCCCATTCAACACACGTACC 33 202 30027728 (CA)n 232I
DNR010 TCTTGTTGGCATTTTCTTTGC TGACACCCCCTTCTGATCTC 46 225 30180014 (TG)n 2321
DNR011 CAGGAAACAGCTAAACATCCTC ACAACT CGATGCCCAATCTC 53 232 30182226 (TG)n 232I
DNR014 GGCATGCAAGTTTCTCACTG TCCATGGTAGACCCAGCTATG 59 199 30047515 (GA)n 232I
DNR016 GGAGAATTGTGAGGGAATGC C AG CCAT CACATACCACACC 44 172 33910960 (TG)n 262.
DNR017 AAG CAAAGAAACATGGTGTGAG C ACCT CTT C AAT G G ATTTTT CC 37 219 33817214 (CA)n 262.
DNR021 CTT GT CAGT G CAAAGGT CTCC GCCACATAT ACCCAACACT CC 60 194 32435566 (TG)n 43L'
DNR024 AGCCCACTTCAACTCCTCAG CCCTCAGGGGTACCTCAATC 91 188 32566444 (TG)n 43L
DNR026 TCTGTACT CTT CTCCCTGCTTG CACACCACCCTCAAGTATGTG 59 196 32597280 (TC)n 43L
DNR029 GAGACGGGAGATGACTGGAC TGGCCGTCCTTTATTAATGC 36 191 31580827 (TG)n 322,
DNR030 TCACAAAGGTTGGCAACAAG GAAAGCAGGGCTCTCCAAC 0 221 31592377 (CA)n 322,
DNR031 CCATGGAATGCTTGTCACTG CCC AATT CT G AC AG CAT GTTC 162 248 31432079 (TG)n 322,
DNR032 CACAAAGACCAGGCAGGATG G CCAGG GTTT C AG AGT GTG 26 199 31434703 (CA)n 322,
DNR035 AGCCATCAAATACCCTCCAG TCGAGCAAGGGCAAGATAAG 80 214 31536877 (TG)n 322,
DNR036 GGGCTTTTCATGGTCAGTTC ACAGAAGGCCCATGTCTCTG 47 204 31569848 (TG)n 322,
DNR037 AACTGCTGGGGAAAGGTAGG CACGGGGACCATTACTTCC 92 219 31572310 (TC)n 322,
DNR038 TCAACAACTTCAAACCAAGAGG TCCAGTAGGTGAAAGAGGAGATAG 156 265 31507106 (CA)n 322,
DNR045 CACCAT CAAGAACACTGCAAC GCAGAAGCACCCCATATACC 90 252 26474106 (TC)n 169
DNR046 CCTTTTGAATGGCCAAGAAG AGCTGAGCTACATCCCATCC 49 221 26474579 (TG)n 169
DNR048 CATGCAGTCAAAACATG CTG CCCTACACACAAGGTTCAGG 75 203 27243233 (TC)n 189,
DNR050 CCAGACCAAGCAGGGTAGTC ACCCCAAATTGAGTGCTGAC 97 247 27169530 (TC)n 189,
DNR051 CCAGTCCAAGCAGGGTAGTC ACCCCAAATTGAGTGCTGAC 69 221 27134518 (TC)n 189,
DNR052 CACTTTCCCTGAGCCTGAAG ACACACTTGGGAAGCAAAGG 40 217 25333315 (TG)n 19G
DNR053 TTCCCATGAGATGGACACAG CCTTGAACTTGGTCATGCTG 43 211 25319783 (CA)n 19G
DNR054 CCAGCATTTTCCTTGTACTCC GAT CTT GG CTT GAG C AGTGG 77 196 25256308 (TG)n 19G
DNR055 TCTGGAACTCACCAGCCTTC TGACAAGGAGGTGCCTACAG 42 192 29356695 (TG)n 202
DNR056 T GTT GCTT CAAAT G AGT GTG C AC AAC AAC AG G C AT G AAT G G 30 188 29362754 (CA)n 202
DNR057 TGGCATTCACTGACATCTGC GGTCATTGCAGAATGGGTATG 45 205 29282143 (TC)n 202
DNR058 GGTTT CT GG AG AAC ATTT C AGG GGGGAAGGATTTGTGTTAGTTTAC 72 202 29373595 (TG)n 202
DNR059 GTTCTCACGGCCATTTCAG CCATGATGTGAGCAAGAAACC 68 199 21786093 (TC)n 38E
DNR060 TAGCTGCCTCTGGGAATCTG CT G GCACTTGTGTCAT CACC 55 220 21784737 (TG)n 38E
DNR061 TTGGAGGTGAACCAGAGTCC GGACAGCCTTAGACAGGCTAC 58 234 21878734 (TG)n 38E
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DNR063 TCTTTCTGCACTGGTGCTTG GGCCCAACCATCTATCTGTC 51 153 21750467 (TG)n 38E20
DNR066 AACTTGTAGCAAAAGGCTAATGG AGTGGCCACAGCTCCTAATC 45 210 24421260 (CA)n 80C18
DNR068 CAAGTCCTACACCCCAAACC CTCCCCTCT CTCGAGTTTCC 40 197 24515259 (CA)n 80C18
DNR070 GAATCCGTTCCCACTCAGTC TTGCTGAACCTTCATTGCTG 50 194 24502489 (TG)n 80C18
DNR071 GGCTTCTTTCATGCTCCAAC TTTGTGGGCAGTTTTAGGTG 112 192 24503750 (CA)n 80C18
DNR073 TAAAAGCCCACCACCATCAC CAGAAGAGCCATTTTGTTGG 47 198 28358882 (CA)n 128M23
DNR074 CAGGGCAGAGAAAACACAAAG ACCAGTGGGTCCAGACAGAG 26 242 28408701 (TG)n 128M23
DNR075 TATCCTCTGCATTGGCCTCT ACCT CCCTCT CT CCATCCT C 27 199 28297955 (GA)n 128M23
DNR076 CATTAAGCTCCACCCATTCC ACAGGAGCAGCTTGTCATTG 104 184 28294295 (GA)n 128M23
DNR077 CCCTGAACACAAACACCAAAC TTCCCTTTTGGGCTTGAAC 44 244 28423066 (TG)n 128M23
DNR078 AGCACAACCTGGAGAAGGAG TTATGTTTGGCCAGCTGTTG 43 208 28425336 (TC)n 128M23
DNR079 AACCCAACCCAGCAAAGAG TGTGGATGTCCCTGGTACTG 56 227 28426337 (TC)n 128M23
DNR080 AGGTTTGACCAAGGCAACTG TCCATTAAATGCAAGCACTCC -41 201 28431686 (CA)n 128M23
DNR081 CAGGGAAAAGTGGAAAGTGG TTCATCCCATGACACTCTGC 47 170 28452930 (TG)n 128M23
DNR082 TTGCAAAGGCAATGTAGTGTG CAGTGGATACCCCACCTTTC 48 144 28472232 (CA)n 128M23
DNR083 T C AAAT GTGTGTGTCG CTCTC CCCTGAGAAATTGGGATGAC 55 204 29612037 (GA)n 47A2
DNR085 GCAAGGGCCTTTCAGATTTA AG CACCTT CCATTGCTGT CT 42 198 29629330 (TG)n 47A2
DNR087 GCTAGTCCCCTGCCCCTAT CGGTGCATGGTGTACAAGTC 47 180 29699626 (TG)n 47A2
DNR089 TCTGGAGAGCGACAACAATG CCTCTGAAACCTTTTCCACTG 51 210 29724871 (TG)n 47A2
DNR091 T GAGTTT GGCATTAG CAAGAG GTGTGCATTGGAACCATTTG 56 224 29735887 (CA)n 47A2
DNR092 AGGAGTTTGCAAGGGACTTTC GAGCAATTGATGCTTGAAACC 29 190 29746135 (TG)n 47A2
DNR097 AGGCCAGCCCAGAAAGTC ATCCACCT CACTGGAACAGG 42 263 29781729 (CA)n 47A2
DNR099 GGAGCCTCTGCTCTAACTGC TGGGAAAATGTCAGGGTCAC 176 297 29784971 (TG)n 47A2
DNR101 G CAATTAGC AG G AAGGT GAT G CAAAACACCCGAAGGAACAG 70 199 28939517 (CA)n 262C06
DNR102 ACAGCGGGCTGATGATTTTC GACGAGGTGAGGCTTCTTTC 66 229 29094193 (CA)n 262C06
DNR103 CATGAAAGCATGTGCCAGTG TTCAATTCCGTATCCCAAGG 37 198 28909972 (CA)n 262c06
DNR104 CTGCAGCATGTTCTCTCTGG CTCCCCGTCTAAGCACCTC 51 206 29062484 (CA)n 262c06
DNR105 GTCCAATTTGTCTGGACTGTTAC TTCCATCCTGGTTGTCTTCTG 94 261 29053218 (TG)n 262C06
DNR106 GCAGGAAATTTTCTTACCTTCC GGCTCTAGACCCTGCTTGC 43 203 29048380 (CA)n 262C06
DNR107 TCACAACCTAGAAGAGATGCAG TGACAGAGACACCCAAACCTC 25 229 29029004 (CA)n 262C06
DNR108 TCCCGCAAATCATTAAAAGC TAATTCCCAGGATGGGTCAC 57 213 29022584 (CA)n 262C06
DNR109 CATGGCTCTTACCTCCCTTG AGACACTGGACACCCACCTC 44 237 29019668 (TG)n 262C06
DNR110 T CCAGAGTGAGACCCAAAGTG ACAGCCAGGGAGAGTCACAC 84 266 29015610 (GA)n 262C06
DNR111 ATTGGCACTTGCCTGGTAAC TGACTGTCATGCCTACACCAG 24 208 28968695 (TG)n 262C06
DNR112 CTCCACATCCTTCCTTCAGC TCTTCTGCCTTGCTGACTCC 43 201 28950732 (TG)n 262C06
DNR113 GCAAGTTCCAAATGTGGTTG GGTGGGATTGCAAGTCTGAG 24 199 29871682 (CA)n 23501
DNR114 GGTCTCTCCGGTGGAAATG AAGGCCATGCGTAAGTGAAG 46 201 29896179 (CA)n 23501
DNR115 TCTCACCTGGCTATCAACACTG TGGTGGTGGTTAGAGCCTTC 57 211 29924084 (CA)n 23501
DNR116 TCTTTACCCCACATGGAAGC GCTGTGGGGAAGGTGTCTG 47 214 29935651 (CA)n 23501
DNR117 TAAAGGTGCAGGTGGCAGTC GAGGGTGGCTTGAGATTCAC 46 198 29968875 (TG)n 23501
DNR118 GCTAGGGTGTCTTCCAGCAC AAAACCAAGGCAACTCAACTC 71 191 29974757 (CA)n 23501
DNR119 GGACAATGCTTACAGCCAGTC AGGGAGGATGGTAGGAGGTG 45 211 29988457 (TG)n 23501
DNR120 ACTTCCCAGGCGCTGATAC AGTCAAAGCACCCAAACCTG 61 227 29988698 (CA)n 23501
DNR121 ACAAAGGTGCTTCCCCACTC CAACTGCCAGTGATGGATTG 31 204 23874568 (TG)n 480B19
DNR122 GACTGCAGGGAGCTGTGTTC TGGGAGCTCTCTGTGACACC 26 192 23851574 (TC)n 480B19
DNR123 GAGGAGTGTATGGCCTGATTTC CCCAGGTAGATGGAATGAGC 34 193 23849188 (GA)n 480B19
DNR124 AACGCTTTCCTCCCTGAATAC CCCTAAGGCAGCTTGCTAAC 36 195 23810696 (TC)n 480B19
DNR126 TGGCATGTGTCTCCATTCAG ATTGCCAGTGCACCTATACC 38 201 23807798 (TG)n 480B19
DNR127 CCAGGCCTATGTGTTTGACC AATTCTCAAGCAACCACATCC 45 196 23801311 (CA)n 480B19
DNR128 ATGATGGCAATGATGACAGC CTTTGTGGCTCTGTGTCTCG 99 215 23787001 (CA)n 480B19
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DNR129 CAGAGCTGTCCAATGAGCTG TCTGGCTCCAAACATTTTCAC 51 209 23780781 (CA)n 480E
DNR130 ATCACAAAGGCCCAAGGAC GGTCCTCCAGCGCATAATC 72 180 23741556 (TG)n 480E
DNR131 CATCTTGAAGCCATTTTCAGG GGCACTTGAAGGGAAAGAGG 36 198 23713598 (TG)n 480E
DNR132 TTGGCTTGGAGAATTCTTGG GGAAGTGAGCATGTGCCATC 88 264 23709822 (TG)n 480E
DNR138 AGACTGACCCTGCCTCAATG CTCATACCTGGCGTGCTTG 88 201 30877721 (CA)n 412F
DNR141 ATGCCTAAGCATGCCCTTAC CTGCTCTGGCTTTAATGTTCTG 49 196 30921261 (GA)n 412F
DNR152 GCCCTAAACTGTGTTCTATCTGC CACACAGAGAGGACCTTTGATAAG 82 233 31154531 (GA)n 412F
DNR157 TCTGGGTGGGGTAGACTTTG TCATTTTGGTGGATCCTTGG 76 197 31201624 (GA)n 412F
DNR158 TCCTGAGCAGGGAGAGATTG AGCAGAAGATGTCCCATTGC 129 210 31193950 (TC)n 412F
DNR173 AGCAGGCAAGGTAAGAATGG GCCATTGCAATCAGAAAATACC 120 249 31329775 (CA)n 235j:
DNR178 GT GGACAGT CACAG CTCCTG AAGGGGAGCTGAGAGGAAAG 28 253 24647201 (CA)n 461C
DNR179 TCCCTCTATCCTGGTCAGTTG CCTATCCATTCCCTGACTGC 129 215 24672611 (TG)n 461 (
DNR180 TTGGGCTGAGACACTGAATG TTGTGGAGGGAGAAAAGGAC 46 218 24691764 (CA)n 461C
DNR181 GCAAAAGAACATGGGATTGC CATGCACTTTAAGGATGAGTGG 50 202 24708116 (CA)n 461C
DNR184 GGGGCATTCATGTTGTCTTC GAGGGGAGCTTTGATTAGGG 53 223 25191920 (CA)n 211P
DNR185 CAGT CCTCC AG G CC AAT AAG GAACCTGTGTCAAGGGAGAAAG 62 221 25188742 (TC)n 211P
DNR188 TGGGCAAATTAAACCAAAGC CTTTTCCACCTGACCCTGAG 58 232 25180028 (CA)n 211P
DNR189 AG CTGAAG CACTGGTGTGTG CCTT CT G ACTT GTGG C AT CT C 384 493 25173039 (CA)n 211P
DNR190 AACATAACATGCTGTCTGTCTGG TCCCTTGTAAGCATCCATCC 82 184 25171464 (CA)n 211 r
DNR194 AGGCTCAGCAGGGATTTGAG ATAGCCAGCAAGGATGGATG 87 228 25138493 (CA)n 211f
DNR195 TTTGCTTTGGGTTTTGTATTG CCTCACATTCCCCGAGAAG 81 250 25127437 (TG)n 211P
DNR201 ACACACACGGCAAGTGCTC TTCATGGCTCCACTGTTCTG 224 299 25057837 (CA)n 211P
TNR001 CACCTCAGAGCTGCAAACAC TGCTGGGTTGTAAGAAATCC 242 395 30085191 (CAG)n 232P
TNR002 TCCAAACAACCAAGAAGCTG ACCATGAATGTGGCTCCATC 62 199 29310462 (CAT)n 202F
TNR003 GAATGAAACCCTGGCGAAG TACTCCCTGGTACCCAATCC 105 196 31011250 (TGG)n 412F
TetNR005 TCTCCTGCATGCTCTGTGTC AACAGCCTGGTCTATAATGCAAG 87 306 30031499 (TTTC)n 232T
TetNR007 CAGCT GAGTGGAACT GAGTCAC GGGAGGTTGAAGACATGTAGG 111 250 30190056 (CATA)n 232F
TetNROlO GCTGATGCTAGGGCTTTCTC CCCTAGGGCACATTTCACTG 44 212 30916300 (CGAA)n 412F
d13mit115 TGGTGAAGTGTTTGGAAAAGG TTTAACCCATTGATCTACTTCAAGG 0 144 20503495 (TG)n MIT
d13mit136 TTTTAT CTATT G AGTAG ATT C ATGGT G TATGCCTGGAGGAAAACAGG 0 95 33908480 (TG)n MIT
d13mit17 CACCCCCAAGTTCTCTTGAA CCC ACATAC AC AT GTG C AC A 0 168 21300731 (TG)n MIT
d13mit133 TAG AC ACTTAATT CTGT GAT G AAATGG AGCAAAAGCCCCAGTTAGTG 4 150 26234267 (TG)n MIT
d13mit117 TGGTGACTACCTGATGGACG TTGCCTGCAAAGTACCCTCT 1 118 37570429 (TG)n MIT
d13mit15 AGGAACAGCAAGCTCTAAGGG GGCCTCCCAAGATATCATCA 0 143 24407417 (AGAT)n MIT
d13mit198 TTCATGAGTCCCTAACCAATAGTC TCTTAAATAGTCCATGCATTGGC 0 133 34980274 (TG)n MIT
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BAC Position 
in Contig
RPCI-23 BAC 
ID Marker CA
SP B6 101 3H1 SA C3H BALBc
5
DNR059 u u C:L S;L C;S
DNR060 u u C;L S;L C;Sv O v ta U DNR061 N N N N N
DNR063 u u C:L S:L C:S
21
DNR121 u u N N N N N
DNR122 u N N N N
DNR123 u u u L U U 1
DNR124 u u u N N N N
DNR126 u N N N N
480B19 DNR127 u u N N U N N
DNR128 0 u N N N N N
DNR129 u u N N N N N
DNR130 u u N N N N N
DNR131 u u N N N N N
DNR132 u u u N N N N
26
DNR066 N N N N N
DNR069 N N N N NOUU 1 O DNR070 N N N N N
DNR071 N N N N ( N
29 461024
DNR178 N N N N N
DNR179 N N N N [ N
DNR180 N N L N N N
DNR181 N N N N N
32 211M15
DNR184 N 0 N N N
DNR185 N U N N N
DNR188 N u N N N
DNR189 N N N N N
DNR190 N N N N N
DNR194 N N 0 0 N
DNR195 N N N N N
DNR201 U U
33 19g04
DNR052 N N N N N
DNR053 N U N N N
DNR054 N N N N N
41 169m24 DNR045 N U N N NDNR046 N N N N N
46 189a16
DNR048 U U L U S
DNR050 N N N N N
DNR051 N N N N N
54 128M23
DNR073 u u N N N N N N
DNR074 u u N N N N N N
DNR075 u u N N N N N N
DNR076 u u U N N N N N
DNR077 N N N N N N
DNR078 u u N N N N N N
DNR079 u u N N N N N N
DNR080 u u N N N N N N
DNR081 u u N N N N N N
DNR082 u u N N N N N N
60 262C06
DNR101 u u U N N N N N
DNR102 u u N N N N N N
DNR103 u u N N N N N N
DNR104 u u N N N N N N
DNR105 u u N U U N N N
DNR106 u u N N N N N N
DNR107 u u N N N N N N
DNR108 u u N U U N N N
DNR109 u u N U U N N N
DNR110 u u N N N N N N
DNR111 u u 1 B U C:L 8 >L C ;S
DNR112 u u N N I N N N U
63 202F03
DNR055 N U N N N
DNR056 N U N N N
DNR057 N u N N N
DNR058 N u N N N i
TNR2 u u N N N N N N
65 47A02
DNR083 0 0 N u U N N N
DNR085 u u N u U N N N
DNR087 u u N N u N U N
DNR089 u u N u N N N U
DNR091 u u N N N N N N
DNR093 u 0 N N N N N N
DNR097 0 u N U U N N N
DNR099 u u N u u N N N
377
BAC Position 
in Contig
RPCI-23 BAC 
ID Marker CA SP B6 101 3H1 SA C3H BALBc
DNR113 u N N N N N N
DNR114 N N N U N U N
DNR115 u N U u N N N
66 23*501 DNR116 0 N u u N N NDNR117 u N N N N N N
DNR118 u N N N ! N N N
DNR119 u N U u N N N
DNR120 u N N N N N N
DNR008 u u N U U N N N
DNR009 N u N U N N N N
DNR010 U u N u N N N N
67 232m10
DNR011 0 u N u N N N N
DNR014 u u S u B L C
TetNR5 0 u L u U U U B
TetNR7 0 u N u U N N N
TNR1 u u N N I N N N N i
TNR3 0 u N N N N N N '
73 412P21
DNR138 u u U 3 1 C.L S;L C;S
DNR141 u u N N N N N N
TetNRIO 0 u U U U C:L S;L C:S
75 408H17
DNR152 u u U U u C;L S;l C;S
DNR157 u u u U u C;L S;L C;S
DNR158 u u u U u C:L S;L C;S
7ft 2 3 5 .1 2 (1 DNR173 u 0 u u u C:L S:L C;S
DNR029 u u N u u N N N
DNR030 u u N N N N N N
DNR031 N N N N N N
78 322j11 DNR032 u u U u u C;L S;L C;SDNR035 N u N N N
DNR036 u u N u u N N N
DNR037 U u U U U
DNR038 N N N N N
86 43L14
DNR021 1 B C;L S;L C;S
DNR024 U u N N N N
DNR026 N N N N N N
DNR001 u u N N N N N
DNR002 u u 1 B L C
93 41L21 DNR003 u u 1 B L CDNR004 u u 1 B L c
DNR005 u u N N N N N
DNR006 N u N N N N N
95 262j 21
DNR007 0 u 1 B C : L S ;l C;S
DNR016 1 B C;L S;L c s
DNR017 1 B C:L S:L C:S
Key to data for appendix 3.3
Polym orphism  data for each o f  the tested m icrosatellites identified in the del36 region.
Green = shared product sizes with 2 or fewer other strains (B)= c57BL/6J. (C)= C3H. (1)= 101/H. (L)= BALB/c. 
Red (U) =  Unique product size. W hite (N) = N ot informative -  shared product size with 3 or more other strains. 
W hite (0) = Product failed to amplify. Grey = N ot tested.
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Appendix3.4
Del36H Hybridisations: Singletons. 
NB: Not every probe set produced singletons. Of the single probe hybridisations, only 
Gpx5Intl and Spi3 resulted in singletons.
33 Overgos
100g12 100h3 101 h21
109a3 109d1 109j1
116g3 116o19 117m10
128n21 129k17 12c24
135d9 136j21 138f15
142p6 146e10 147b15
160g20 162f24 163e19
171e12 171i4 171m8
182k23 184b2 186o2
197h6 198c15 199d13
200p6 202e11 202e17
211o18 212n16 216a19
222e18 224e14 226f16
242j12 242I22 242m1
25p12 260112 264n17
279g23 27I7 281e23
303i12 303j12 304h1
321 p1 322f18 326h 6
341p22 345d8 346p6
366f1 371 g9 373g9
385m12 386j6 388a11
402c9 403b15 403d13
425p16 426I8 42b5
438j10 438j22 438k22
447m 15 448e4 448021
456a20 456e19 456n10
466k12 466k6 466113
478n24 479d22 479n1
57n23 59a 19 59b21
71f7 73f14 73n20
7g7 7j19 7j4
86I2 86m15 86o24
92i6 92j22 92k16
97i15 98e3 98g3
102i6 105j10 105k17
109m17 110b20 110j6
119b6 122f20 123g19
12o21 130b18 130g10
139g1 140k14 142g18
147c15 148m15 150a5
163o6 164d11 164e18
172e10 175b1 175b18
187h1 187n9 18b10
199d7 199o23 19d11
202f3 205b16 206e11
216c22 216C23 218g4
22e13 22o13 230d9
244f22 244p8 251 m l 2
266h16 267d22 26a 14
283a12 283b8 285a21
305a6 305m20 30a12
329e9 329g10 330c17
348h2 34110 350h12
376117 378c21 378f18
391j15 391n15 394d8
404h14 405k19 406n18
432e19 432f11 433c15
441n20 442f 16 442m7
449e11 449h14 449n17
457j21 458110 459I8
466m14 467117 469d23
47f14 50n14 51d10
61121 61 p4 62h20
74b12 74c11 74m 13
80e17 80f16 82f19
87b12 87b6 88f8
92m6 92o18 93j19
98k10 9b15 911
105m8 105n12 105p17
111e13 111 i17 114i6
123n2 124k6 125b5
13019 131n5 133e17
142j 11 142123 142m7
150d9 152d4 153m5
166a16 166g18 166i16
17515 176k14 178f21
18h3 194k8 194p5
19d17 1a17 1d14
207j21 208f8 209O5
218o3 21a9 220a19
230j5 234g21 235o21
253b15 254m3 254n9
26f 15 26h3 27367
288b12 293I24 295i19
310d18 311 h i 7 311 i4
333j6 336i12 336k18
350k4 351k21 356o6
37c8 381f15 381 i15
395a9 395p8 398g13
408110 411n9 413j 16
433f8 434m5 434011
443d20 443I6 444119
450i7 451p22 453i11
459m10 459o9 461e24
469I6 469013 471o18
52c11 52m8 53b20
64c7 64f21 68112
75k14 77g6 77j15
82h20 83k21 84m22
8c15 8i10 8m9
94j6 95d3 96e9
106a17 107g2 107g4
114p18 115n14 116a7
126g17 126j 9 128d15
133g2 133k7 135d8
142n3 142n5 142o8
159i15 159j 15 15n1
167C15 16k11 17016
17o12 181 k16 182i1
195h15 19519 196a16
1o16 200a14 200d22
209p4 20d17 210a15
220b21 220k8 220m23
237j24 23b21 23f16
259h20 259i19 25 k6
274b5 276i19 277f11
297b23 29p5 302I3
314k8 317a19 317p13
33f22 340a6 341 a9
360b12 360b7 363i21
381n18 383g23 385i12
398p4 39j20 401C18
421 c9 422b20 425k8
435114 435O20 437i2
446022 447e23 447g4
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Appendix 3.6
Hybridisation Probe Sequences
Mit / Whithead d13 Markers Used for 
the Design of Overgos
Mit Marker Used For 
Overgo Design
UNISTS
Accession
No.
D 1 3 M it l3 6 126959
D 1 3 M itl7 116537
D 1 3 M it l3 3 126957
D 1 3 M it l5 126972
D 1 3 M it l9 7 127016
D 1 3 M it2 2 0 127035
D 1 3 M it2 6 5 127082
D 1 3 M it2 7 3 127091
D l3 M it2 9 4 127114
D l3 M it3 0 6 127123
D 13M it307 127124
D 13M it7  9 116539
D 13M it84 127182
D 13M it58 127156
D 13M it81 127179
D 1 3 M it l7 5 126990
D 13M it82 127180
D 1 3 M it l3 5 126958
D 1 3 M it l7  6 126991
D 1 3 M it2 4 1 127057
D 13M it86 127184
D 13M it85 127183
D 13M it83 127181
D 1 3 M it l6 116405
D 1 3 M it2 0 6 116540
D 1 3 M it l l6 126942
D 1 3 M itl4 126962
D 1 3 M it l5 4 126976
D 1 3 M it l6 3 126982
401
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Appendix 3.7
Genic Probes Used to Screen the RPCI-23 BAC Library
Gene Accession No. Forward Reverse
S ox4 X 70298 CTCGGGGACTCTAGGTTGG AGTGTTCTCCGCGTTGTTG
S p i3 U 25844 ACAAGGCTGGACAAGATGGA AACAAGCCTTGCTTGGAAGA
B tn U 67065 TCTCTGAGTGCTTGTGTGGC CATTGTGGAACAAGGAAGGG
H fe A F 007558 GGGTATGGCTGTTTGTGACC ACACAAAGTCAGGGACAGGG
F o x c l NA TATCTAGGCCTGCGAGAGACC CCCAACTCCGAAATGATGG
O l f r l l U 28779 CTCTCCATTACTCAGTC GTGGAAGAACACACTCA
Gpx5 I n t i
F o x f2 Y 12294 TCCTGATGGTGGGTCTTCTC TTGGCTTTCCATATCTTGCC
402
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Appendix 3.8
STS Markers Used to Probe the RPCI-23 BAC Libraries
Marker Forward Reverse
M -00442 GCTGGTAAGGTCCTCTCTCCT ATGACACCAGTACCCAGGGA
M -00890 TTGTCCCCATCACTTCATCA CCAATTCAGTTGAGATCTTTTCC
M -01316 AATTGGTTGCCTCTTGGTTG CTCCATTTTGGCATCAGCTT
M -01319 CCTGTGCTTTCAAATTGTGC TGCCTAAAGCATCCTCCACT
M -04234 g tt c t t a t g t t t t c c t c c a a g g c TTTCCAACACCACACCACAT
M -04245 CCATGCCATATACCCTCTGC GAATTTCAGGGCTTGTGAGC
M -05084 TTCCCCAAGATTTGCTCAAG TACGCTAGAAAGGAGGGCTG
M -05614 C C CAGCACAAGC T GAGAAG TTCCTCTTTGTCCTTGTGTCC
M -07528 GCACCAAGGATCTTGTCCTG TCTGGGAAATAGCAATACTTTTCAT
M -08270 AAGATGCCCTTGAACTTCCC TGCCTGCCTGTCTACTCTGA
M -08279 TCAAAGTAGCTCTCCCTTTCTCA TTGAGGGGCAGTAATGTCATC
M -08298 TATCATGGCAAGGAAGGCAT GGACCCAGCAGCTACAGTTT
M -08353 CACAGCACCAGGTACCACAC CAAGGAAGAAAACAAACATGTGA
M -084 93 TCTTCCTGGCTCTGGGACTA TACTTGTTTGGGAAGTCGGC
M -08497 TAAAGTTGGGGGTGGTAGGG CATACATTTTCATCTCTTTCAGACA
M -09543 TGCCACTATGCCTCAAGTTCT CTGCCCTGCCTCTTGTTAAG
M -097 85 CCTCGAGATGAGGCACCA CATTTGTGGAAGATGCAGAAGA
M -09825 CCAATTTCCCTGAACATAGGTG CAGCACTCCCTAATCTCTGGA
M -10786 CCACCATACTGTTCCTTCCC TGGGTGATACCTATGAGGCAC
M -11510 C GCAAGGACAAGACAG GAAT CCAGGCCACTGATTAGGAAC
M -11527 TTAGAGGCAGGCTCCAGAAA AAGGCCTGAGTGACTGACAGA
M -11691 GCCCCAAGAGTTCAGTCTGT CTGCACCTAGGCACATAGCA
C w rl AGCACTCGAGGTGGCTTTTA CAGTTGGGATACTGCCAGGT
Cwr3 CAGTGGGAAGGCTAAAGCAG GGGAGTATCTTGCCAGGACA
cw r6 GGTCCATCTGTTTAAGGACAGC ATGTCTTGCTGTTATGGACGG
cw rlO AAGTGTCCCATTGATGCCTC T CAT T T G C CAACAGAC CAAA
c w r l l TTCCCACCCTCCTGTAAGC CTTTCTGAGAAGGCCCGAG
C w rl2 GGCTGTGAAATGCCCTAAAA TCACGTATCAGAGATGGAAAGG
C w rl 3 AGCTCAAGCAGCTTTTATTTGG CTTGGGCTAAAAAAAAGGGG
Cwr26 TGGTGTTCAGTTACCTTGATGG GCACCTGGGAGACTTAGAAAA
Cwr27 C C T C CAGAAG C CACAGAAAC GTTTGTTTCTGCACCCATCA
Cwr30 TTTAAGCCCAGGTCCTCATG GAGAATGACGGGACCTCAAA
Cwr31 GAGAGACGCTGGTTGTCACA AGAACCTGGCTAGGACTAGCG
Cwr32 TTTAGCACGAATTGGCTGC ACTGGGGACTTGAACCCAG
403
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Appendix 3.9
Markers from the Human 6p Region Syntenic to Mouse 
Del(svea)36H
Marker Forward Reverse
HB001 TAAAAGCCTGTCTGCGGAGT TGTACCCTTTTGCCATAGCC
HB002 GTTAACAGCCTGGACCAACC ACATCCACTATTCCCAAGCG
HB003 TGTGGAAGTGAATGAGGAAGG AAAATGAACGGAT GGT CCAC
HB004 TGGAAGAGGGGAAGATGATG TGCCCTTCTCCATGTACTCC
HB005 TTTGCACCTCAGCTTCAGAG TCAACAGCATCCTTTGCATC
HB007 TTAATGGGGCTTTGAAGTGC AATAGCCCACATTTGCTTGC
HB008 TAATAAACTGGGCACGCTCC CGTTATGTTCATGCCCACAC
404
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Appendix 3.10
EST Probes Used to Screen the RPCI-23 BAC Library
Assay
Accession
No. Forward Reverse
A A 407021 A A 407021 GTTTATTTTTCTTTTAAAAGATGC T T CAAT CAT C T GAT GAAGAA
A A 516957 A A 516957 GCTAAGTGCCTAAAACTGCTGC AAGAGCGACTCCTCATTTCC
A A 571384 A A 571384 CTCCCCACCTTCCGAC CACACTGGACCATGACATTATC
A I 1 1 5 3 4 1 A l l 1 5 3 4 1 TCCATCATTTTCCAGTCAAACC AGTGTAAGTTGTGCTTCCTTC
A I2 2 5 9 0 4 A I2 2 5 9 0 4 TGAAAACCTGGACTTTGGATG TGTCCAGTGTCAAATTCTACGG
R 74621 R 7 4 6 2 1 AAGAATGCTGAACCAAGAGTTTCG CCCAAACTCCAAACTCAATTCAAA
K 00020 A A 407415 AAGGGTCACTTCTTTTCAAA AATGAGTCAGGGGACAATGG
K 00153 A A 409771 TGTACTTTACACAAGTGCATT GGTAATTTTGAAATCAACGA
K 00181 A A 409971 T TAAACACACAAT GT T TAT T T T T C CCTATTGTTTGCATGTTGAT
K 00829 CAGCCCTTAATAAACATTCT TGATAAATGTAACATGCCTG
K 00879 C 76174 AATAC T GACAAGAACAAC C T T T C GTTTCTGTCCAATGTCATACATA
K 01193 C 77649 T GATACAAAC TAAG T T T CATAAAAT GA ATGGAAAGTGCTTTCTATGTAATTA
K 01661 C 78201 C TAGT T T TAC T C CAAAAGAG TAGAAT C GAATAT TACAT T G TAAAAATAAC T G CA
K 01931 C7 92 0 9 GTATTCTACGTGCACTGTAACC GTATCAAACCAAAATAAAGATGAGTAC
K 02035 C 79329 CATAGTTTTGAGAATAAGGTATTTGAT ATTTTACATAGCTATTTTCAGACACTC
K03211 ACAGCAT TAATAT G T GT TATAAAAGAG CTACGTTTTATGACTTGTATGGTT
K03265 CATAAT T T CAAGTAAAATGAGTATGTG GAACCAGAGTCCAGTAAC
K03576 GATAATCCACAGGAATGAACT T G TAATAGAGAATAAGAGT C T G TAGCA
K03922 CAG T T TAT TAAT TCTTCTGTATTAGAC CTTATTCCTCAAAGTTTAGACCTT
M 122-D 09 A I1 3 2 2 5 9 CAGGACTGGGGAAGGAGATT TAACCAACATGGGGACCAGT
M 131-E 02 A A 68204 6 TGCTACTCCCAGCACATCTC CTACCCACCCCCTCTTTGTA
M 135-A 07 A I1 7 3 0 0 1 AGGGGCGGTTAGGTTTAGTT CTTCATTTCTTCGAGCTCCC
M 141-B 07 A I4 2 5 9 7  0 TGTTTTTAGCTGTGCTTGCC TTTGTGGGACATTTCCTTCC
M 142-H 01 A I 4 2 9 5 3 5 TGTGGGCCATCTTAGTAGCA CTCTGAAGCATGGCAAAATC
M151-C02
M -1 5 3 -A 0 3 M 32460 GGTCTCCTTTCATCACACCG AAATTCGGTAAATGCCCAAA
M -15 6 -D 1 1 U 96700 GTTGCTGTTTTTGCAGAGGA GGAGCCAGTAGAAGCCAAAG
M 161-G 05 A F 050666 CAACCCACCTCCTTTTCTGT GCCACCACTACCAAGGATTT
M176-C02
M 199-H 07 A I3 2 5 9 8 3 TCTGACCTTGGATTTCGTCA AAAGAGAAGGGCAACAGTGG
M 203-B 05 A I3 2 5 9 8 3 CTGGGGCTTCACTTAATGGT GCATCAGCCATGCTAGAAGA
M 203-D 06 A I3 2 5 9 8 3 TCAGTCCAGGGTTATGTTTCC TCTTGACTGGCACCTACTGC
M 211-E 01 A I3 2 5 9 8 3 AAAACAATGTCCAAGAGGGG TTGTATGCCTCTGGAAACCA
M212-E04
M 220-E 01 A I 8 4 1 8 7 5 AAGTTGCTGGAGGCATTCTT GTTCTAGAGTCTGGGGCAGC
M 237-F 06 A I6 4 8 1 9 9 GAGTGAAGTGCAACAGAGGC TTGCGCAGTAGAGTCAGGTC
M 239-C 02 A V 290867 GC C CAT CAAAACAAC T GC TA AAAAGAAACCAATTGCACCC
M 253-H 12 A I 3 8 5 5 8 7 AGCAAAATCCATGGCCTATC ATCTCTGGCTTCGAGCTCAT
M 257-E 09 A I5 2 8  624 ACCAAGCCTACAACTTGCTGG TGATCGTGAACTGGAGCTGC
M 265-G 02 A I 8 7 5 5 0 5 TCACTGGTGAACTCGTAGGC CTTGGTTGTGTACCCATTGC
M 275-F 01 AW 261723 AGAGTCCTGGCTGAGGAAAA TCATGGGAACATCAAGAGGA
M 280-D 05 AW4 92 955 GCAC T CAT C TAC C CACAG GA TGATCAAATTATGGTAGGTGGC
405
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M 284-F 11 AW 538719 TTCCTCCTCTTCCTGTTTGG GAGCGGTGTCATTCTTCTGA
M 285-C 08 AW 540195 AGCATGACTTTTGCATGGAG TAGTTTGGGAACAGGTGCAG
M 289-B 08 AW 546347 CATGTACTGCACGTGCTCAG TACGAAGCGCTGAAAGAGAA
M 301-H 08 A F 011385 TGCCTACGCGTTGATATATTCTT AACATACAAAT GCAT T CAAAAGC TA
BAC End Sequence Markers Used to probe the RPCI-23 BAC Libraries
Sequence ID Forward Reverse
1 1 2 o l 6 t 7 AAATAGAGCGAGCCCTTAGC CAATGGCAATGGCTATGATG
H F l 7 s p 6 AAAACCGTGTGGTCTGGAAG ACCACCACTAGAGTGCAGCC
1 2 2 c 3 s p 6 CAAAAGAAAAGAT T T T GGGC T TAC AGATTCTCTTCTCCCCACACC
1 2 F 1 5 t7 TTGCCTCTAGACCACCCTTC TGCATGCGAAATAGATGTGG
1 4 8 F 2 1 t7 AACAACACTGCTTTTCATTACCC TCTTCTCGACTGTACCTCTTGG
1 6 F 1 2 sp 6 CAAGTCTCGTTTCTGGAGGG TACCTGGTGATCCAAAAGGG
1 6 F l2 t 7 CGGGATATAGTAGAGCCTCGG T CACACAGT C CAC T CAT C C C
1 8F 15  t 7 GCCCCAGTGTCTTGTGTTAG AAGAGGGGCAGGCACTAAAG
1 8 F l5 s p 6 AGGAAAGCCCTGGGTATTTG TCTCTGGGTGTTTCTGGGAG
2 4 1 e 2 4 s p 6 TCAGCTTCCCCAAAATCATC CAGAGC C C CAC T C T GATAG G
2 5 4 H 1 2 sp 6 TGCCTTGATATTTGGATTTGC CAGACTATGCAAACACAT GGAG
2 6 6 F 1 0 t7 GCCTGTGAGATGCTGTGTTG AAGTTCCTTCCAGCAGGTTG
2 7 1 B 1 0 s p 6 TCCCAAATCAGGAAAACTGC CCCTTTCTTCACCTGAGAGG
2 7 8 e l 6 s p 6 ACACAAAGATAAC C GCAGGG CAAAGTTCTCCAGCTCAGGG
2 7 8 e l 6 t 7 TTCAGAGACACACAGGTGGC ACACTCCGGGAACTTCAATG
2 7 E 3 sp 6 TTCCCATCCACAGAGGCTAC TGAAACTCTGGGAGCAGATG
2 9 0 i 8 t 7 TGTAGTGACACCGCCAGAAG TGGCAAGAGTCACCTTCTCC
2 9 8 j 1 2 s p 6 CCTGTAGCGCTGTGAGAGTG CTGTCCTACTCCCCTCCCTC
3 1 0 c 7 s p 6 TCTTCCCCTTCCCAGATAGC CTTGGTTAGGCGAGGAAATG
3 1 0 c 7 t 7 AATGGTGGGTGTCAGAAAGC GGGCTGTACACACACTGAGC
3 1 2 d 2 1 s p 6 AGATCCTGCACTCCCAGTTG CCTTTGAGATGTGGCAATTATG
3 2 6 c 2 4 s p 6 AAGC CAT C T GGACACAAAC C GGAGCTCCATTCTCATACCG
3 3 5 h 9 t7 AGTGAGGTGGGGAGACATTG CCTCAGTACTGGCTGAAGGG
3 4 9 k 3 s p 6 GTCCTTCCTTCCCAGTGTTG CAAATGACCCTTGGAAGTCG
34M 15sp6 CGCTACTTCGCTTTTATCCG TGGAGTCTGGGAAGGAACAG
34M 15t7 T GGCAAGCAC T TAACCACT G ACTCCATTTGCCTTTTGTGG
3 9 2 L 1 5 sp 6 AGGGACTGGCCTTCTTTCTC GCAGAAAACTGGGGTAGCAG
39M 12sp6 TTTAACAGGATCAGGCCACC TCAGCTGTTTGACCTGCTTG
4 0 4 N 1 0 t7 ATTGAGGGACATCTGCGTTC TCCATCCTTCCTGTTTCCAG
4 0 8 j 2 2 t 7 TCACATTAATGCCTGCCATC TGAGTCGCCTGTGTTGACTC
4 1 4 k l3 s p 6 CAAATGGCCAGGAAGTATGG C C CAAGAAGAAGACAG C CAG
4 3 9 F 1 4 sp 6 ACATGAGCTGTTGGAGGAGC CAAACCTCCCACCACTGAAC
4 6 7 F 1 2 t7 AGGTGGGGCATCCAAAGTAG AGACTTCCAACCCAGTGCAG
468M 24sp6 TCCATGATGTTTGGGTGATG TTGAAGCGTCTTCCACACTG
406
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5 0 9 H 1 7 t7 GCTCCAACTTCCTGCTCAAG AGGAGAGTACTCAGCCCATGTC
5 1 a l l s p 6 ATTTCGGCAACATTAGCTCG AGGAACCTAGGCTCTGGGAG
5 8 4 b l6 t 7 GCCTACTTCTGTCACATGGC CAGAAACATGGACATGGTGG
7 1 F 1 8 t7 TGCCTCATTTGCTGTCTGTC ATTGAGTACGTGGGTCCTGG
7 2 c l 3 t 7 GGCTGCAGTATTTAGTTTGGC TCCCCATCCTTTGTCTTCAG
8 0 c l 8 s p 6 GAAAAGTGCTAGGTGCTCGC AAAGTGAAGGGGAAAATGAATG
8 0 c l 8 t 7 TAGTCTGTGGGAGGGGTTTG GGCCATGTGAGTGTTGTGAG
8 7 c l 0 s p 6 TGCTGCTAAGACATCCATGC ACCCAAAACCAACCAACAAG
9 2 g l3 s p 6 CCCCAGTGATACCCAGTGAC TTCCATGGGCGTTAAGTTTC
9 2 g l3 t 7 TGCACAGAAGCCAGAGAAAG GTCTGGGGCTTTTGAGACTG
9 4 b l0 t 7 TCTGTGCTAGTGTTGGCTGG GCGAAGCTCCTAGATGGTTG
Appendix 3.11
PAC End Sequence Markers Used to probe the RPCI-23 BAC Libraries
Sequence
ID Forward Reverse
3 4 3 e l 2 s p 6 CAGCACCCAACTACCATAGG AAAC CAT GAAAC C AAAAGAGAT G
3 6 6 h 7 t7 CCGGTAGCAGCATAAACCTC GCATGTGGATGTGGTCTGTC
4 2 3 H 1 8 sp 6 AATCACAATGACGCCTCCTC GAATCATGCTGGGATGGAAG
490 K 5 sp 6 TTGGCTACATTAGTTTTCATGAGG GTGGAAAGTTGTAGCCCTGC
5 2 5 F 1 8 t7 ACTTCTTCAGGCCTGTGTGC CTTCCCAAATGGTGTGTGTG
407
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Appendix 3.12
Primers Used to Screen For SNPs within the Del36 Region
Primer ID Forward Primer Reverse Primer
c l 3 s n p l TGGTGACCCATTGATTTTCC AGACCACGAGAGGATTGAGC
c l 3 s n p 2 TTCCTTCAAACGTGGTTTCC AAGAACACCCCAACCCTTTC
c l 3 s n p 3 GCAGGCTGAATTTCCCTTATC GACTCCCCGAGAAGAAGAGG
c l 3 s n p 4 TAGCAATGCACATGGCAAC CAGCAGGTCACATGATGAGG
c l 3 s n p 5 GTGCCTTTCCCCTTCTTAGG ATTGCCTTGCTGGTGGTATC
c l 3 s n p 6 GCAACCTCAAAGAGGCAGAG TTTTAAGCCTGCGTCTACAGC
c l 3 s n p 7 ATGCAACAGAGCCACATAGC GGCTCTGACTGATGGTTTCC
c l 3 s n p 8 TTAAGGCCTTCCATGCTTTG TCATGTTCACTTGCCCAAAC
c l 3 s n p 9 ACACCAAAAGGAGCATCAGG GCCAAGCTGTCTATCCAAGG
c l 3 s n p l 0 GGGCTTCAGCTCTACAATGC GGTGTCAGGGACAGCAGAAC
c l 3 s n p l l GAAAGCTCGTCCTTGCAAAC ACAAGAGCAGAGGTGGCATC
c l 3 s n p l 2 GGAACAGCTACCCACTGAGC TGGTGAAAAGCTCCTGGTTG
s n p lb - R TGGTGACCCATTGATTTTCC TCATGCAGCATCGTCTAAGC
sn p 2 b -R TTCCTTCAAACGTGGTTTCC AAAATTCTGCGCAACCTGAG
sn p 3 b -R GCAGGCTGAATTTCCCTTATC GGAAGAGTAAGTCCCGCCTAAG
sn p 4 b -R TAGCAATGCACATGGCAAC GGGGATTCTCCGTCAAGTTC
sn p 5 b -R GTGCCTTTCCCCTTCTTAGG GTGACCTTCTCCCTGGTTCC
sn p 6 b -R GCAACCTCAAAGAGGCAGAG TGTAAGGTAGGAGAGAGTGGTAAGC
sn p 7 b -R ATGCAACAGAGCCACATAGC TGGAAACTCACCAAAACCTTTC
sn p 8 b -R TTAAGGCCTTCCATGCTTTG TCTGAGCGCAGCTTTCTATG
sn p 9 b -R ACACCAAAAGGAGCATCAGG CTGCAAAGTGATTGCTCTTCC
sn p lO b -R GGGCTTCAGCTCTACAATGC GTCTCGATGTGGCTCAGGAC
s n p l l b - R GAAAGCTCGTCCTTGCAAAC TTTGAGCAGGGACTCTCAGG
s n p l2 b - R GGAACAGCTACCCACTGAGC AATAAAGGCCATCCAAGTCG
s n p lc - L CATCTCCCACAGTTCCAGTG AGACCACGAGAGGATTGAGC
s n p 2 c -L GAAGAGACTGGCCTCTGAGC AAGAACACCCCAACCCTTTC
s n p 3 c -L AACCCCAAAATGGTTGGAAG GACTCCCCGAGAAGAAGAGG
s n p 4 c -L ATCTGGCCTGAATTGGTTTG CAGCAGGTCACATGATGAGG
s n p 5 c -L GAGGCACAAGAGCAGAATGG ATTGCCTTGCTGGTGGTATC
s n p 6 c -L GC C T G T GAC CAGCAAGATAT G TTTTAAGCCTGCGTCTACAGC
s n p 7 c -L AAGCACAAATGCCACATACAAC GGCTCTGACTGATGGTTTCC
s n p 8 c -L TCGCCTTGCTGAACAGAAC TCATGTTCACTTGCCCAAAC
s n p 9 c -L GACACCAGGTTCTAGCTGACG GCCAAGCTGTCTATCCAAGG
sn p lO c -L AAAGCCAGCCTAGGTCACAC GGTGTCAGGGACAGCAGAAC
s n p l l c - L TCAAAGGTGCTTTTGCAATC a c a a Gagcagaggtggcatc
s n p l2 c - L GTGGCATTTGCCTTCTTTTC TGGTGAAAAGCTCCTGGTTG
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Appendix 3.13
Primers Used for Genotyping
Forward
Primer ID Forward Primer Reverse Primer primerFluorescent
Label
F o x q l F2&R5 GAGATCAACGAGTACCTCATGGG CGAAGGAGCTGGAGAACTTG
D l3 M itll5 (+ F A M ) TGGTGAAGTGTTTGGAAAAGG TTTAACCCATTGATCTACTTCAAGG FAM
d l3 M itl7 (+ F A M ) CACCCCCAAGTTCTCTTGAA CCCACATACACATGTGCACA FAM
D N R 059(+ROX) GTTCTCACGGCCATTTCAG CCATGATGTGAGCAAGAAACC ROX
D N R 0 5 9 ( a lt l ) TTTTGCCCTATCCAGACCAG
D N R 0 5 9 ( a lt 2 ) CGGAAAAGGAAAAGAATAAAAGG
TetNR5(+FAM ) TCTCCTGCATGCTCTGTGTC AACAGCCTGGTCTATAATGCAAG FAM
TetNRlO(+FAM ) GCTGATGCTAGGGCTTTCTC CCCTAGGGCACATTTCACTG FAM
D N R 037(+ROX) AACTGCTGGGGAAAGGTAGG CACGGGGACCATTACTTCC ROX
DNR024(+HEX) AGCCCACTTCAACTCCTCAG CCCTCAGGGGTACCTCAATC HEX
D N R 0 2 4 (a lt l ) T CAC T CAACAC T TACAT CATAGGC
D N R 0 2 4 ( a lt 2 ) GGGGTACCTCAATCACTCAAC
DNR003(+HEX) AAGTCAAACATGGCTGCTAGTG GGAGAAAACAGAC T T CAT T CAGG HEX
D N R 0 0 3 ( a lt l ) ATAAGGCATTGGCGAGAATC
D N R 0 0 3 ( a lt 2 ) TAAAGGGCATTTCCTTGGTC
DNR016(+ROX) GGAGAATTGTGAGGGAATGC CAGC CAT CACATAC CACAC C ROX
D N R 0 1 6 (a lt l ) TCCTAAGCCACACCCAAGAG
D N R 0 1 6 ( a lt 2 ) ATCCCTGGAACCTCAAATCC
d l3 M itl3 6 (+ F A M ) TTTTATCTATTGAGTAGATTCATGGTG TATGCCTGGAGGAAAACAGG FAM
d n rl23(+ F A M ) GAGGAGTGTATGGCCTGATTTC ACAGGAGCAGCTTGTCATTG FAM
DNR123 R i CGGCAGGATGCCTATTATATTG
DNR123 R i i TGATAAGTAGTTCCAGGCCTTAGC
DNR123 R i i i CCACAGATCATCTAGCTTGTGC
d l3 M itl5 (+ F A M ) AGGAACAGCAAGCTCTAAGGG GGC C T C C CAAGATAT CAT CA FAM
d l3 M it l5  R i C CG T T TAGG T T T T TAAGT TACAGG
d l3 M it l3 3 (+ H E X ) TAGACACTTAATTCTGTGATGAAATGG AGCAAAAGCCCCAGTTAGTG HEX
d nr48(+H E X ) CATGCAGTCAAAACATGCTG CCCTACACACAAGGTTCAGG HEX
DNR048 R i GCAGATTCAGGTGTCTGAGG
DNR048 R i i GGGTTACTTGTATCACCCTACCC
DNR048 R i i i GAGGGTTATTGAGATCTTGATGG
d n r7  6(+FAM) CATTAAGCTCCACCCATTCC ACAGGAGCAGCTTGTCATTG FAM
DNR07 6 R i ACAAAGAAGT GC T C C CAAC C
DNR07 6 R i i CCCAGCTTAGCAAACCAATAC
DNR07 6 R i i i ACAGGTGTGCATCAACAGAAC
d n rlO l(+ H E X ) GCAAT TAGCAGGAAGGTGAT G CAAAACACCCGAAGGAACAG HEX
DNR101 R i TTTCTTCCGCTTCCATTAGG
DNR101 R i i CTTCCAACTGGGCCAAAAC
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DNR101 R i i i TCCATTAGGCAGATCAAATGTC
d l3 M itl9 8 (+ R O X ) TTCATGAGTCCCTAACCAATAGTC TCTTAAATAGTCCATGCATTGGC ROX
D N R 111(+ROX) ATTGGCACTTGCCTGGTAAC T GAC T G T CAT GC C TACAC CAG ROX
DNR111 R i AACAGAGACCCTTTGTGAGAGC
D N R lll R i i GACTCCTGAGTGGTTGTGAGC
DNR111 R i i i AAGCACAGCAGGAAAACTAACAG
D N R 201(+ROX) ACACACACGGCAAGTGCTC TTCATGGCTCCACTGTTCTG ROX
Appendices for Chapter 5 
Appendix 5.1
Table of Results from all urinalysis tests
Urinalysis
ID Genotype Sex Date
Bi
lir
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Ur
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Bl
oo
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XQ. Ni
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te
8.1g +/- M 18/06/04 neg norm neg/+ ++ neg + neg 6 n
8.1h +/- M 18/06/04 neg norm neg/+ ++ neg + neg 6 n
8.1 j +/- M 18/06/04 neg norm neg/+ ++ neg +/++ neg 6/7 n
8.11 +/- M 18/06/04 neg norm neg/+ ++ neg +/++ neg 6 n
10.1 d +/- M 18/06/04 neg norm neg/+ ++ neg + neg 6 n
10.1e +/- M 18/06/04 neg norm neg/+ ++ neg + neg 6 n
6.1f +/+ M 18/06/04 neg norm neg/+ +/++ neg Neg/+ neg 6 n
6.1h +/+ M 18/06/04 neg norm neg/+ ++ neg Neg/+ neg 6 n
7.1 e +/+ M 18/06/04 neg norm neg/+ + / + + neg Neg/+ neg 6 n
8.1k +/+ M 18/06/04 neg norm neg/+ + / + + neg + / + + neg 6 n
9.1g +/+ M 18/06/04 neg norm neg/+ + + neg Neg/+ neg 6 n
9.1h +/+ M 18/06/04 neg norm neg/+ + + neg + neg 6 n
9.1 i +/+ M 18/06/04 neg norm neg/+ +/++ neg Neg/+ neg 6 n
11.1e +/+ M 18/06/04 neg norm Neg ++ neg + neg 6 n
6.1d +/- F 18/06/04 neg norm neg/+ ++ neg neg neg 6 neg
8.1c +/- F 18/06/04 neg norm neg/+ +/++ neg +/++ neg 6 n
8.1e +/- F 18/06/04 neg norm neg/+ +/++ neg + neg 6 n
9.1d +/- F 18/06/04 neg norm neg/+ +/++ neg + neg 6 n
9.1e +/- F 18/06/04 neg norm neg/+ +/++ neg + neg 5/6 n
6.1e +/+ F 18/06/04 neg norm neg/+ ++ neg + neg 6 neg
10.1b +/+ F 18/06/04 neg norm neg/+ ++ neg + neg 6 n
11.1a +/+ F 18/06/04 neg norm neg/+ ++ neg + neg 5 n
11.1c +/+ F 18/06/04 neg norm neg/+ ++ neg + neg 6 n
9.1a +/+ F 18/06/04 neg norm neg/+ +/++ neg + neg 5/6 n
8.1a +/+ F 18/06/04 neg norm neg/+ +/++ neg + neg 6 n
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Appendix 5.2
R Code for Fisher Exact Test.
Fisher Exact Test for Urine Ascorbic Acid in Males
> m a l e s _ a s c o r b i c a c i d  < -  m a t r i x ( 0 ( 0 ,  6 , 4, 2 ) ,  n r = 2 ,
+ d i m n a m e s = l i s t ( c (" + /+ + " , " + + " ) ,  c ( " m u ts " ,  " w t " ) ) )
> f i s h e r . t e s t ( m a l e s _ a s c o r b i c a c i d )
Fisher Exact Test for Urine Ascorbic Acid in Females
> f e m a l e s _ a s c o r b i c a c i d  < -  m a t r i x ( c ( 4 ,  1 ,  2 ,  4 ) ,  n r = 2 ,
+ d i m n a m e s = l i s t ( c (" + /+ + " , " + + " ) ,  c ( " m u ts " ,  " w t " ) ) )
> fisher.test(females_ascorbicacid)
Fisher Exact Test for Urine Protein in Males
> m a l e s _ p r o t e i n  < -  m a t r i x ( c ( 0 ,  4, 2, 5 ,  2, 1 ) ,  n r = 3 ,
+ d i m n a m e s = l i s t ( c ( " n e g /+ " , " + " , " + / + + " ) ,  c (" m u ts " ,  " w t " ) ) )
> f i s h e r . t e s t ( m a l e s _ p r o t e i n )
Fisher Exact Test for Urine Protein in Females
> f e m a l e s _ p r o t e i n  < -  m a t r i x ( c ( l ,  3 ,  1,  0, 6,  0 ) ,  n r = 3 ,
+ d i m n a m e s = l i s t ( c ( " n e g " , "+" , " + / + + " ) ,  c ( " m u t s " ,  " w t " ) ) )
> f i s h e r . t e s t ( f e m a l e s _ p r o t e i n )
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Appendix 5.3
Frequency of Animals Tested for Blood Metabolites.
The number o f animals used in each of the Blood biochemistry tests. Grey boxes indicate that fewer 
than three animals were tested in one of the genotype groups.
Number of Animals used for each 
Metabolism Test.
Test
Test 1 Test 2
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+/
+ 
Fe
m
al
es
 
+/
m
Sodium 8 5 7 4 8 4 6 4
Potassium 8 5 7 4 8 4 6 4
Chloride 8 5 7 4 8 4 6 4
Urea 8 3 7 4 8 4 6 4
Creatinine 8 3 4 4 6 4 6 4
Tot. Calcium 8 3 3 2 5 4 5 4
Phos 3 0 0 1 5 3 3 2
ALP 5 3 1 1 4 4 4 2
ALT 5 3 2 2 3 4 5 4
AST 1 1 0 1 3 4 3 2
Tot. Protein 5 2 0 1 3 4 3 2
Albumin 3 1 0 1 3 4 3 2
Tot. Cholesterol 0 0 0 0 3 4 3 1
Triglycerides 0 0 0 0 2 3 1 1
Glucose 8 3 6 4 7 4 6 4
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Appendix 5.4
Blood Metabolism Data.
Metabolic bleed: Test 1
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6.1f M +/+ 151 5.7 115 13 28 2.38 2.21 83 43 49 59 32 12.8
6.1h M +/+ 151 5.9 115 12 30 2.45 81 49 57 12.1
7.1e M +/+ 154 5.3 114 9 29 2.48 96 14.8
8.1k M +/+ 147 7.5 112 13 32 2.41 2.02 10.0
9.1g M +/+ 152 5.6 115 11 25 2.42 86 158 62 33 10.3
9.1 h M +/+ 149 7.2 114 10 28 2.42 2.00 54 + 30 8.6
9.1 i M +/+ 153 5.6 115 11 27 2.44 26 11.6
11.1e M +/+ 157 6.0 118 11 32 2.49 94 + 63 30 7.7
8.1g M M/+ 154 9.6 121
8.1j M M/+ 154 8.4 120
8.11 M M/+ 151 6.5 115 11 29 2.39 80 60 57 61 31 11.8
10.1 d M M/+ 154 9.2 119 13 33 2.32 28 145 - 7.2
10.1e M M/+ 153 8.0 117 13 36 2.38 83 46 53 11.1
6.1a F +/+ 147 8.5 114 11 32 8.3
6.1e F +/+ 149 8.5 119 12 10.4
8.1a F +/+ 151 5.6 117 12 2.60
9.1a F +/+ 150 7.2 117 11 30 2.57 127 48 9.2
10.1b +/+ 151 6.4 115 10 29 2.51 12.0
11.1a F +/+ 149 5.3 114 12 31 2.45 40 12.4
11.1c F +/+ 150 6.1 116 10 12.0
8.1c F M/+ 149 6.8 115 13 34 2.50 - 117 45 62 60 37 10.4
8.1e F M/+ 148 7.3 117 13 33 2.45 36 11.1
9.1d F M/+ 149 7.2 116 12 31 10.2
9.1e F M/+ 150 8.2 118 12 32 10.4
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Metabolic bleed: Test 2
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6.1f +/+ 150 7.9 113 11 30 2.46 66 42 59 62 32 2.5 1.80 8.9
6.1h +/+ 151 7.2 117 2.16
7.1e +/+ 150 6.9 112 2.49 2.56 106 374 58 28 2.9 1.9 8.5
8.1k +/+ 148 7.7 112 12 29 2.46 1.98 48 10.6
9.1g +/+ 151 7.3 115 10 22 2.35 7.8
9.1h +/+ 151 7.8 116 27 2.43 102 179 133 56 29 2.6 9.2
9.1i +/+ 149 6.5 112 11 26 2.38 11.0
11.1e +/+ 153 7.6 116 10 26 2.54 118 161 7.8
8.1g M/+
8.1j M/+ 151 7.6 116 23 2.33 2.38 107 94 111 56 29 2.7 1.4 9.2
8.11 M/+ 149 6.2 111 27 2.49 1.8 73 45 47 63 34 4.2 3.5 10.5
10.1d M/+ 152 7.7 115 27 2.49 120 173 100 60 31 2.3 6.6
10.1e M/+ 150 7.4 111 10 29 2.49 2.14 65 45 47 64 33 4.5 2.6 9.3
6.1a +/+ 146 6.4 114 28 2.40 1.98 105 31 10.6
6.1e +/+ 144 8.5 111 10 29 9.2
8.1a +/+
9.1a +/+ 149 7.7 114 31 2.59 2.12 113 40 60 64 34 2.8 4.4 8.5
10.1b +/+ 149 7.1 114 26 2.6 42 9.6
11.1a +/+ 147 7.1 111 31 2.53 112 38 54 62 36 2.9 8.7
11.1c +/+ 150 7.1 112 30 2.64 1.99 84 43 58 67 37 2.2 9.3
8.1c M/+ 146 5.6 111 12 28 2.55 1.85 109 42 52 74 34 2.7 3.7 10.3
8.1e M/+ 145 7.7 112 29 2.47 2.17 34 8.8
9.1d M/+ 147 8.2 113 10 32 2.61 40 7.1
9.1e M/+ 145 6.6 114 29 2.40 120 31 49 58 34 9.9
Key: + = Value too high to be real therefore excluded from dataset 
- = Value too low to be real therefore excluded from dataset
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Appendix 5.5
Grip Strength data
Grip Strength
Mouse Details Forelimb Grip Strength (g/cm3) Forelimb & hindlimb grip strength (g/cm3)
M ouse
ID Genotype Sex Date 1 2 3 4 5 Total Ave 1 2 3 4 5 Total Ave
1 0 .1d M / + M 12/5/04 128 90 119 123 114 5 7 4 115 238 221 200 203 233 1095 219
1 0 .1e M / + M 12/5/04 130 107 119 119 128 6 0 3 121 228 216 197 212 209 1062 21 2
6 . 1 g M / + M 12/5/04 82 87 118 100 106 4 9 3 9 9 212 214 221 164 130 9 4 1 188
8 . 1 g M / + M 14/5/04 171 126 136 104 110 6 4 7 129 238 175 240 214 208 1075 215
8 . 1 h M / + M 14/5/04 93 71 100 88 91 4 4 3 8 9 210 195 224 178 228 1035 207
8 . 1 j M / + M 14/5/04 77 121 149 128 139 6 1 4 123 204 224 195 193 193 1009 202
8 . 1 1 M / + M 17/5/04 89 93 102 98 87 4 6 9 9 4 197 192 191 198 187 9 6 5 193
9 . 1 f M / + M 21/5/04 88 130 112 112 89 5 3 1 106 212 233 250 215 222 1132 226
6 . 1 f + / + M 12/5/04 65 7 2 7 7 88 86 3 8 8 7 8 147 138 144 160 162 7 5 1 150
6 . 1 h + / + M 12/5/04 124 127 133 92 156 6 3 2 126 234 142 182 183 188 9 2 9 186
7 .1  e + / + M 14/5/04 99 106 102 98 112 5 1 7 103 175 184 173 188 192 9 1 2 182
8 . 1 k + / + M 17/5/04 95 125 73 89 76 4 5 8 9 2 257 197 193 245 175 1067 213
9 . 1 g + / + M 21/5/04 112 123 145 143 88 6 1 1 122 235 254 216 213 198 1116 223
9 . 1 h + / + M 21/5/04 141 105 137 100 141 6 2 4 125 239 225 193 196 179 1032 206
9 . 1 i + / + M 21/5/04 120 121 154 99 197 6 9 1 138 197 203 224 198 212 1034 207
1 1 . 1 e + / + M 17/5/04 96 10 114 96 111 4 2 7 8 5 199 158 198 157 187 8 9 9 180
1 0 .1 a M / + F 12/5/04 81 97 121 101 95 4 9 5 9 9 140 162 165 150 198 8 1 5 163
6 . 1 c M / + F 12/5/04 97 112 91 109 120 5 2 9 106 155 143 140 124 148 7 1 0 142
6 . 1 d M / + 12/5/04 63 61 134 73 110 4 4  1 8 8 156 145 123 138 158 7 2 0 144
8 . 1 b M / + F 14/5/04 102 104 94 97 102 4 9 9 100 154 157 147 152 145 7 5 5 151
8 . 1 c M / + F 14/5/04 131 127 141 125 137 6 6 1 132 156 145 171 154 162 7 8 8 158
8 . 1 d M / + F 14/5/04 87 87 120 83 85 4 6 2 9 2 141 131 114 143 119 6 4 8 130
9 . 1 d M / + F 17/5/04 58 76 91 92 89 4 0 6 8 1 135 133 140 175 195 7 7 8 156
9 . 1 e M / + F 17/5/04 60 76 78 95 67 3 7 6 7 5 167 157 178 157 146 8 0 5 161
1 0 .1 b + / + F 12/5/04 136 95 111 115 118 5 7 5 115 188 175 156 157 170 8 4 6 169
6 . 1 a + / + F 12/5/04 98 94 95 108 115 5 1 0 102 139 157 140 156 163 7 5 5 151
6 . 1 e + / + F 12/5/04 112 108 105 107 108 5 4 0 108 149 144 171 161 154 7 7 9 156
8 . 1 a + / + F 14/5/04 90 96 103 96 100 4 8 5 9 7 157 162 171 155 162 8 0 7 161
8 . 1 e + / + F 14/5/04 93 70 75 67 75 3 8 0 7 6 164 151 142 152 149 7 5 8 152
9 . 1 a + / + F 17/5/04 82 85 89 91 102 4 4 9 9 0 145 158 165 154 154 7 7 6 155
1 1 .1 a + / + F 17/5/04 101 91 101 112 97 5 0 2 100 155 157 165 177 165 8 1 9 164
1 1 .1 c + / + F 17/5/04 98 97 122 94 102 5 1 3 103 191 181 173 195 187 9 2 7 185
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Appendix 5.6
Spontaneous Alternation data
Foxf21 
S
A/174R Phenotyping Screen: 
pontaneous Alternation
Mouse ID Genotype Sex Date Latency(secs) Alternations
Total
No.
arms
-2
%
Alt
10.1d M/+ M 14/05/2004 9 17 26 65
10.1e M/+ M 14/05/2004 17 12 19 63
6.1g M/+ M 14/05/2004 34 9 11 82
9.1f M/+ M 24/05/2004 90 5 12 42
8.1fl M/+ M 18/05/2004 13 0 2 0
8.1h M/+ M 18/05/2004 149 0 4 0
8.1 j M/+ M 18/05/2004 11 11 15 73
8.11 M/+ M 18/05/2004 18 7 14 50
6.1f +/+ M 14/05/2004 105 5 9 56
6.1h +/+ M 14/05/2004 13 9 17 53
7.1e +/+ M 18/05/2004 300 0 0 0
8.1k +/+ M 18/05/2004 12 10 19 53
9.1g +/+ M 24/05/2004 25 21 12 175
9.1h +/+ M 24/05/2004 12 11 23 48
9.1 i +/+ M 24/05/2004 34 10 15 67
11.1e +/+ M 18/05/2004 123 4 10 40
6.1c M/+ F 14/05/2004 17 11 18 61
6.1d M/+ F 14/05/2004 21 11 21 52
10.1a M/+ F 14/05/2004 46 9 17 53
8.1b M/+ F 18/05/2004 47 2 7 29
8.1c M/+ F 18/05/2004 25 7 15 47
8.1d M/+ F 18/05/2004 300 0 0 0
9.1d M/+ F 18/05/2004 8 6 8 75
9.1e M/+ F 18/05/2004 55 7 14 50
10.1b +/+ F 14/05/2004 7 5 15 33
6.1a +/+ F 14/05/2004 52 19 30 63
6.1e +/+ F 14/05/2004 22 10 17 59
8.1a +/+ F 18/05/2004 17 14 19 74
8.1e +/+ F 18/05/2004 106 13 19 68
9.1a +/+ F 18/05/2004 17 13 23 57
11.1a +/+ F 18/05/2004 284 0 2 0
11.1c +/+ F 18/05/2004 257 0 2 o
Appendix 5.7
Intra-peritoneal Glucose Tolerance Screen Data
Foxf2 W174R Phenotyping Screen: 
IPGTT
ID Sex Transgenic? Date To T60 T-I20
8.1k m +/+ 25/06/04 6.12 9.4 fail
9 .lg m +/+ 25/06/04 5.93 7.83 5.47
9.1h m +/+ 25/06/04 7.46 9.64 6.76
10.1d m M/+ 25/06/04 5.82 7.65 5.54
10.1e m M/+ 25/06/04 7.7 8.92 3.97
8.1g m M/+ 25/06/04 7.17 10.25 7.93
6.1a f +/+ 25/06/04 6.21 6.91 5.19
6.1e f +/+ 25/06/04 7.04 8.02 6.21
9.1a f +/+ 25/06/04 4.23 8.35 5.69
9.1d f M/+ 25/06/04 4.99 7.65 6.13
9.1e M/+ 25/06/04 5.62 7.32 4.99
8.1c f M/+ 25/06/04 4.29 7.76 5.47
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Appendix 5.8
Light-Dark Box Behavioural Data
Foxf2 W174R Phenotyping Screen: Light-dark box
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o>00* M/+ M 14/06/04 23 42 246 499.7 99.9 136 164 5 33 18 23
8.1h M/+ M 14/06/04 19 33 253 759.3 151.8 119 181 10 40 9 19
8.1 j M/+ M 14/06/04 35 48 234 802.1 160.4 107 193 10 60 12 32
10.1d M/+ M 14/06/04 3 24 257 898.9 179.7 136 164 11 53 8 14
10.1e M/+ M 14/06/04 5 26 266 923.3 184.6 171 129 14 56 12 11
8.11 M/+ M 14/06/04 39 39 247 916.2 183.2 124 176 13 53 13 23
6.1f +/+ M 14/06/04 5 28 259 776 155.2 181 119 6 30 16 11
6.1h +/+ M 14/06/04 13 30 262 833.2 166.6 143 157 10 37 10 19
7.1e +/+ M 14/06/04 24 27 263 792.9 158.5 163 137 9 41 14 10
8.1k +/+ M 14/06/04 9 33 252 903.5 180.7 139 161 13 47 14 16
9.1q +/+ M 14/06/04 11 32 253 843 168.6 135 165 11 50 10 21
9.1h +/+ M 14/06/04 48 31 263 979.2 195.8 140 160 10 51 12 16
9.1 i +/+ M 14/06/04 23 31 249 926.5 185.3 109 191 10 56 10 19
11.1e +/+ M 14/06/04 22 33 259 900.5 180.1 120 180 11 58 11 21
6.1d M/+ F 14/06/04 18 33 263 1028.9 205.7 108 192 13 41 10 21
8.1c M/+ 14/06/04 21 31 261 1004.1 200.8 158 142 12 50 13 14
8.1e M/+ F 14/06/04 41 34 261 864.7 172.9 147 153 12 48 15 19
9.Id M/+ F 14/06/04 12 36 246 854.7 170.9 174 126 11 39 19 13
9.1e M/+ F 14/06/04 37 42 242 774.7 154.9 112 188 7 39 11 26
6.1e +/+ F 14/06/04 66 38 253 714.7 142.9 178 122 12 31 18 16
8.1a +/+ F 14/06/04 10 42 251 862.4 172.4 102 198 13 49 9 27
9.1a +/+ F 14/06/04 28 27 268 994.1 198.8 165 135 12 46 10 10
10.1b +/+ F 14/06/04 39 43 240 585.9 117.1 192 108 9 28 31 7
11.1a +/+ F 14/06/04 22 43 239 879.6 175.9 114 186 14 54 10 24
11.1c +/+ F 14/06/04 12 35 250 881.4 176.2 120 180 15 55 11 21
Appendix 5.9
Pre-Pulse Inhibition Behavioural Data
Fo>:f2 W174R Phenotyping Screen: Pre-Pulse Inhibition
ID Genotype Sex Date Box dB % inhibition 12Hz % inhibition 20Hz
10.1 d M/+ M 17/05/04 1 90 81.16 74.66
10.1e M/+ M 17/05/04 2 90 70.26 70.18
6.1g M/+ M 17/05/04 11 90 54.35 64.99
8.1g M/+ M 19/05/04 7 90 52.87 34.77
8.1h M/+ M 19/05/04 8 90 61.13 53.48
8.1 j M/+ M 19/05/04 9 90 73.03 71.72
8.11 M/+ M 19/05/04 12 90 73.49 71.91
9.1f M/+ M 19/05/04 1 90 73.79 78.77
6.1f +/+ M 17/05/04 10 90 N.A. 67.89
6.1h +/+ M 17/05/04 12 90 56.4 52.11
7.1e +/+ M 19/05/04 12 90 49.94 53.92
8.1k +/+ M 19/05/04 11 90 61.26 67.67
9.1g +/+ M 26/05/04 2 90 49.85 54.43
9.1h +/+ M 26/05/04 3 90 58.68 44.97
9.1 i +/+ M 26/05/04 4 90 56.25 49.3
11.1e +/+ M 19/05/04 2 90 39.4 49.94
10.1a M/+ F 17/05/04 3 90 52.18 40.44
6.1c M/+ F 17/05/04 7 90 70.43 73.3
6.1d M/+ F 17/05/04 8 90 67.36 60.76
8.1b M/+ F 19/05/04 2 90 69.63 56.88
8.1c M/+ F 19/05/04 3 90 69.09 58.1
8.1d M/+ F 19/05/04 4 90 66.06 48.43
9.1d M/+ F 19/05/04 7 90 46.15 42.93
9.1e M/+ F 19/05/04 8 90 35.79 18.88
10.1b +/+ F 17/05/04 4 90 31.7 22.36
6.1a +/+ F 17/05/04 5 90 45.79 41.47
6.1e +/+ F 17/05/04 9 90 60.53 57.26
8.1a +/+ F 19/05/04 1 90 73.39 75.71
9.1a +/+ F 19/05/04 3 90 20.22 17.6
8.1e +/+ F 19/05/04 5 90 58.71 45.46
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I 11.1a I +/+ I F I__26/05/04__I____________ 9_|________ 90_|_________________ 62.45_I_________________ 60.43 I
| 11.1c I +/+ I F I 19/05/04 | 11 I 90 I 56.12 | 54.26 |
PPI Re-Tests
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Foxf2/8.1j M/+ 70 110 26.30 80 110 64.46 85 110 58.18 90 110 57.92
Foxf2/8.1l M/+ 70 110 20.15 80 110 69.64 85 110 62.85 90 110 46.43
Foxf2/8.1g M/+ 70 110 11.30 80 110 68.34 85 110 74.96 90 110 60.22
foxf2/8.1h M/+ 70 110 26.57 80 110 66.38 85 110 79.53 90 110 61.73
Foxf2/10.1d M/+ 70 110 7.76 80 110 49.22 85 110 62.85 90 110 56.67
Foxf2/10.1e M/+ 70 110 32.14 80 110 64.67 85 110 60.82 90 110 51.58
Foxf2?6.1g M/+ 70 110 5.25 80 110 46.41 85 110 59.76 90 110 47.23
Foxf2/9.1f M/+ 70 110 12.36 80 110 54.71 85 110 66.72 90 110 56.73
AVERAGE 17.7 60.5 65.7 54.8
STDV 9.3 9.0 7.7 5.8
Foxf2/6.1f +/+ 70 110 1.38 80 110 65.56 85 110 70.67 90 110 55.74
Foxf2/6.1h +/+ 70 110 13.78 80 110 75.11 85 110 70.27 90 110 64.95
Foxf2/11.1e +/+ 70 110 4.65 80 110 71.48 85 110 67.86 90 110 51.71
Foxf2/7.1e +/+ 70 110 26.05 80 110 59.84 85 110 76.73 90 110 70.20
Foxf2/8.1k +/+ 70 110 -12.34 80 110 53.95 85 110 54.94 90 110 50.21
Foxf2/9.1g +/+ 70 110 37.14 80 110 78.42 85 110 79.94 90 110 70.28
Foxf2/9.1h +/+ 70 110 -11.10 80 110 50.34 85 110 41.36 90 110 46.32
Foxf2/9.1i +/+ 70 110 9.06 80 110 59.92 85 110 67.90 90 110 51.68
AVERAGE 8.58 64.33 66.21 57.64
STDV 17.07 10.07 12.45 9.48
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Appendix 5.10
Acoustic Startle Data
Foxf2 W174R Phenotyping Screen: 
Acoustic Startle
Screen Information
Mouse ID Genotype Sex Date Box Whitenoise
12
Hz
20
Hz
10.1d M/+ M 17/05/04 1 677 663 990
10.1e M/+ M 17/05/04 2 1243 1183 1458
6.1g M/+ M 17/05/04 11 889 447 992
8.1g M/+ M 19/05/04 7 529 1071 1076
8.1h M/+ M 19/05/04 8 1225 1255 1062
8.1j M/+ M 19/05/04 9 1558.6 1437 1170
8.11 M/+ M 19/05/04 12 978 848 844.6
9.1f M/+ M 26/05/04 1 1290 1125 1224
6.1f +/+ M 17/05/04 10 705 641 631
6.1h +/+ M 17/05/04 12 1593 1478 1810
7.1e +/+ M 19/05/04 12 611 966 1247
9.1g +/+ M 26/05/04 2 1518 1488 1810
9.1h +/+ M 26/05/04 3 1179 805 853
9.1 i +/+ M 26/05/04 I 1015 1085 1032
11.1e +/+ M 19/05/04 2 869.2 926 1019
8.1k +/+ M 19/05/04 11 804.4 861 820
10.1a M/+ F 17/05/04 3 622 489 990
6.1c M/+ F 17/05/04 7 855 557 698
6.1d M/+ F 17/05/04 8 821 998 1116
8.1b M/+ 19/05/04 2 726 922 1251
8.1c M/+ F 19/05/04 3 635 322 793
8.1d M/+ F 19/05/04 4 493 770 750
9.1d M/+ 19/05/04 7 666 378 949
9.1e M/+ F 19/05/04 8 512 499.2 430.6
10.1b +/+ 17/05/04 4 597 551 597
6.1a +/+ F 17/05/04 5 413 517 663
8.1a +/+ F 19/05/04 1 738 630 627
8.1e +/+ F 19/05/04 5 865 668 752
9.1a +/+ 19/05/04 3 581.2 1012 660
6.1e +/+ 17/05/04 9 920 870 980
11.1a +/+ F 19/05/04 9 676 933 811
11.1c +/+ F 19/05/04 11 271 401 325
419
Richard McKeone PhD Thesis
Appendix 5.11
Correction for Multiple Testing
One possibility requiring consideration is that the observations which indicated a 
significant difference between mutants and wildtype data are caused by random 
events. The only significant difference that was observed in the initial test cohort 
was between mutant and wildtype males at 12 kHz during tests for PPI. These tests 
were only a small fraction of the total number of tests that these mice were subjected 
to. The most severe correction for multiple testing, the Bonferroni correction, would 
multiply the raw p-values by the total number of independent tests [294].
When correcting a dataset with the Bonferroni method, tests that are not independent 
of the test of interest should not be included because the probability that they would 
give the same result when testing a null hypothesis is greater than if the data resulted 
from independent tests. The determination of whether a test is independent however, 
can be difficult. Some tests could mistakenly be considered as independent when 
phenotypic links exist but are not immediately apparent. There is also the issue of 
varying degrees of relatedness between tests and how strong a correlation is required 
before omitting a test from a Bonferroni correction.
One example of a strong correlation is that deaf mice would show an absence of the 
preyer reflex and would also not respond to startle. The Startle test is an inherent 
component of PPI trials, so a healthy hearing range is also required for a normal PPI 
response.
The replicated tests for males and females are obviously correlated and the numbers 
of tests taken into account for a Bonferroni correction are therefore not doubled 
during a correction when both sexes are analysed within separate cohorts.
That anxiety can be tested with acoustic startle is clearly recognised, well 
documented [251, 252,254,295] and should therefore be considered as correlated. 
The numerous anxiety tests that were performed on the Fox£2wl74R mutants therefore 
should all be omitted from a Bonferroni correction for Startle data. These tests were: 
Transfer arousal, Locomotive Activity, positional passivity (2 tests), touch escape, 
and all 9 of the Light/Dark box tests.
The association between PPI and anxiety is not nearly as extensively documented as 
the relationship between the startle response and anxiety. There is evidence to 
suggest that patients with panic disorder and post traumatic stress (both of which are 
regarded as anxiety related conditions) exhibit a reduced PPI [296,297]. However, 
the correlation is not nearly as pervasive as it is with startle and this weaker 
correlation was considered low enough to allow the anxiety tests to remain in the 
PPI Bonferroni corrections.
Links between PPI and Startle with aggression have been identified in mice [298- 
300] and humans [301, 302]. There are therefore potential links between the 
biting/aggression observation with PPI and the acoustic startle test. However, such 
correlations are unlikely to be frequent enough to interfere with most PPI analysis
420
Richard McKeone PhD Thesis
and the link was too weak to warrant losing the test from the correction without 
some evidence of positive correlation within this study.
The majority of the “physical appearance” observations that were required during 
SHIRPA analysis were not applied to any multiple testing correction. Potential 
outcomes of most of these observations were only likely to deviate between 
categories if there was an anomaly in the features of the test animals and therefore, 
for most of the tests every individual produced the same “normal” result (table 5.2). 
These data are not normally distributed and the probability of these tests producing a 
significant result by chance would be very much lower than 0.05%. It therefore did 
not seem reasonable to include these observations in the correction calculations.
This was also the case for the majority of the nominal behavioural observations 
which required a mouse frequency as output of qualitative rather than quantitative 
data (table 5.1), although more of these behavioural tests showed variability than the 
physical appearance observations.
The method that was used to determine whether or not these categorical tests were 
included in a correction for multiple testing was the selection of only those tests 
which demonstrated some variability between the category outputs, including those 
tests where only one individual deviated from the norm. This is because the groups 
that exhibited some level of background variation could realistically produce a 
significant difference by chance.
If this selection procedure is used, the only appearance observation which would 
contribute towards the correction is the “head shape” record. There were seven 
frequency based behavioural tests that resulted in the allocation of mice to more than 
one category; these were: Transfer arousal, Startle Response, Positional Passivity 
(two observations), Wire manoeuvre, Limb grasping and Contact righting reflex. 
These methods would be added to the quantitative tests (including the individual 
metabolic and light/dark box tests) to bring the total number of tests involved in any 
correction to 65
63 of the 65 phenotyping tests were classified as independent of PPI data, the 
exceptions being Startle and the preyer reflex observation. This would mean that 
p=0.009 for the original PPI test would be corrected to p=0.567 with the Bonferroni 
adjustment (or the significance threshold would be adjusted to 0.0008)- and 
therefore the result is not significant. Further PPI tests were not corrected because 
the only other secondary tests performed were the startle tests which are strongly 
correlated to PPI.
The Bonferroni adjustment is considered conservative by many statisticians. One 
alternative is to control the false discovery rate (FDR) [303]. There are many 
alternative methods for the determination of the FDR threshold, but one that seemed 
particularly appropriate was a method designed by Benjamini and Lieu which
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Benjamini states has no requirement for the elimination of non-independent tests 
from the calculation [303, 304].
This method requires that the data is first tabulated with the tests ordered by their 
significance, with the lowest p value first. A threshold is then calculated for each test 
with the following equation:
h = 0.05xm/
(777+ I -7  )2
Where h = the significance threshold for a specific test
m = the total number of tests requiring correction 
i = the rank of the specific test within the table (i.e.: lowest p value is 
ranked 1 , the second lowest = 2  etc).
The threshold for the first test is then compared with it’s p value, and if the p value 
is below the threshold then the result is considered significant and the procedure is 
repeated for the next test listed on the table. This process continues until the first test 
with a higher p value than its threshold is discovered. This is classified as having no 
significant difference between the analysed groups, as are all the subsequent tests 
that follow in the table.
Within the male Foxf2wl74R dataset, the lowest p value was for potassium test 1, 
where p = 0.02. A total of 65 tests were included in the correction which included 
two tests for each metabolite for the blood chemistry analysis. The lowest threshold, 
which is equal to the Bonferroni threshold for all tests, is 0.0008 - well below the 
lowest p value. Even if only 1 test per metabolite contributes to the correction (to 
avoid the inclusion of the repeated tests), the threshold remains significantly lower 
than the lowest observed p value at p=0.0009 for 55 tests. Therefore none of the tests 
are significant with either correction protocol.
Other significant results in the initial cohort of animals included levels of blood 
potassium, calcium and chloride in males and blood urea in females. No obvious 
correlation existed between the potential results of these tests and the other primary 
screen tests, so each of the significant results were corrected by 65.
The significance adjustments from the two different correction methods are equal for 
the sample with the lowest p value. There is an increasingly lenient threshold as the 
p value decreases within the ranked table for the Benjamini and Liu method (Table 
5.10a). However in these data, none of the tests were significant.
Another, more commonly utilised method for the determination of the false 
discovery rate was also designed by Benjamini, alongside a different co-worker, 
Hochberg [305]. This procedure requires that only independent data is applied to the 
correction. The startle test and the preyer observation were excluded from the 
Benjamini & Hochberg correction of PPI significance as with the execution of the
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Bonferroni correction. The results from this method also shifted the significance 
thresholds for each test below their respective p values, meaning that there were no 
significant results in the corrected data as shown in appendix 5.11.
Test p value Rank BL Threshold
Blood Potassium 1 0.002 1 0.0008
Blood Chloride 1 0.008 2 0.0008
PPI. 12khz@90dB 0.009 3 0.0008
Blood Calcium 1 0.017 4 0.0008
Urine Protein *0.049 5 0.0009
Urine Ascorbic acid *0.06 6 0.0009
Blood Creatinine 1 0.068 7 0.0009
PPI. 20khz@90dB 0.070 8 0.0010
Light - Dark Move time 0.140 9 0.0010
Grip strength Fore & Hindlimbs 0.150 10 0.0010
Light - Dark Move episodes 0.190 11 0.0011
PPI retest. WN@70dB 0.210 12 0.0011
Blood AST 2 0.229 13 0.0012
R-Half Horz CNT 0.260 14 0.0012
Urine pH 0.260 15 0.0012
Blood Urea 1 0.263 16 0.0013
Blood Albumin 2 0.263 17 0.0014
Light - Dark Velocity 0.290 18 0.0014
Blood Cholesterol 2 0.297 19 0.0015
Number o f pellets 0.330 20 0.0015
Blood Sodium 1 0.343 21 0.0016
Startle/Preyer reflex 0.350 22 0.0017
Blood ALP 1 0.354 23 0.0018
Blood Phosphate 2 0.364 24 0.0018
Spontaneous Alternation Latency 0.390 25 0.0019
PPI retest. WN@80dB 0.430 26 0.0020
Blood Urea 2 0.433 27 0.0021
Blood Protein 2 0.457 28 0.0023
Startle. 20khz@90dB 0.460 29 0.0024
Light - Dark Distance 0.460 30 0.0025
struggles when scruffed *0.4667 31 0.0027
Light - Dark L-Half time 0.470 32 0.0028
Light - Dark R-Half time 0.470 33 0.0030
PPI retest. WN@90dB 0.480 34 0.0032
Spontaneous Alternation 0.500 35 0.0034
Blood Chloride 2 0.544 36 0.0036
Blood Calcium 2 0.546 37 0.0039
Blood Glucose 1 0.563 38 0.0041
struggles when held by tail *0.5692 39 0.0500
Contact righting reflex *0.5692 40 0.0500
Light - Dark V-plane entries 0.600 41 0.0052
Startle. 12khz@90dB 0.610 42 0.0056
Head shape *0.61 43 0.0500
Weight 0.650 44 0.0067
Blood Potassium 2 0.695 45 0.0074
Locomotive activity 0.700 46 0.0081
Blood ALP 2 0.710 47 0.0090
Blood ALT 2 0.712 48 0.0100
Light - Dark R-Half Entries 0.720 49 0.0112
Blood Protein 1 0.800 50 0.0127
Blood Glucose 2 0.813 51 0.0144
Blood ALT 1 0.820 52 0.0166
Startle. WN@90dB 0.850 53 0.0192
Light - Dark Latency 0.870 54 0.0226
Blood Sodium 2 0.890 55 0.0269
PPI retest. WN@85dB 0.920 56 0.0325
Blood Creatinine 2 0.926 57 0.0401
Light - Dark L-Half Horz CNT 0.940 58 0.0500
Grip Strength: Forelimbs 0.950 59 0.0500
IPGTT 0.970 60 0.0500
Urine Nitrite *1.000 61 0.0500
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Transfer arousal *1.000 62 0.0500
Wire manoeuvre *1.000 63 0.0500
Limb Grasping *1.000 64 0.0500
Urine Ketones *1.000 65 0.0500
The False Discovery Rate calculated for the male cohort using the Benjamini & Liu method [304]. 
This procedure incorporates the full range of tests on which Foxf2wl74R mice were tested. Benjamini 
claims that there are no inherent assumptions regarding the independence of tests with this method 
[303, 304]. This would make the correction ideal for these data in which there is a range of complex 
relationships between potential test outputs. However an increase in the number of tests increases the 
lowest p value threshold to the same extent as the Bonferroni method so it is difficult to see how this 
test is not effected by the independence or otherwise o f the tests. This method is less conservative 
than the Bonferroni correction on average, but the removal of the non-independent test data for the 
Bonferroni correction causes an increase in the Bonferroni significance threshold (to p=0.0009). This, 
combined with the fact that none o f the p values come close to approaching either threshold means 
that the Bonferroni threshold is effectively more lenient with these data.
The threshold for the test with the most significant p value will be more conservative in the 
Benjamini and Liu calculation. Asterixes (*) represent those p values that were inferred by the Fisher 
Exact test from frequency data. All other p values were from continuous data calculated with either 
two-tailed student T tests or ANOVA with repeated measures.
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Test p value Rank BL Threshold
Blood Urea 1 0.025 1 0.0010
Grip strength Fore & Hindlimbs 0.070 2 0.0010
Blood Creatinine 1 0.071 3 0.0011
Blood AST 2 0.074 4 0.0011
Number o f pellets 0.080 5 0.0012
Startle. 20khz@90dB 0.100 6 0.0012
Blood Urea 2 0.160 7 0.0013
Urine Protein *0.180 8 0.0013
Blood Sodium 2 0.187 9 0.0014
Urine Ascorbic acid *0.240 10 0.0014
PPI. 12khz@90dB 0.290 11 0.0015
Light - Dark Distance 0.300 12 0.0016
IPGTT 0.300 13 0.0017
Locomotive activity 0.340 14 0.0018
Light - Dark Velocity 0.360 15 0.0019
Light - Dark Move episodes 0.420 16 0.0020
Blood Potassium 1 0.435 17 0.0021
Spontaneous Alternation 
Latency 0.440 18 0.0022
Blood Sodium 1 0.479 19 0.0023
Light - Dark Move time 0.490 20 0.0025
Urine pH 0.490 21 0.0027
Startle. 12khz@90dB 0.500 22 0.0028
Blood Calcium 2 0.514 23 0.0030
Blood ALT 2 0.554 24 0.0033
struggles when held by tail *0.569 25 0.0035
Weight 0.570 26 0.0038
Blood Potassium 2 0.632 27 0.0041
Blood Chloride 1 0.644 28 0.0044
Blood Glucose 2 0.680 29 0.0048
Startle. WN@90dB 0.710 30 0.0053
Light - Dark Latency 0.740 31 0.0058
Light - Dark L-Half Horz CNT 0.770 32 0.0064
Grip Strength: Forelimbs 0.780 33 0.0071
Blood Creatinine 2 0.789 34 0.0079
R-Half Horz CNT 0.798 35 0.0088
Light - Dark L-Half time 0.800 36 0.0100
Light - Dark R-Half time 0.800 37 0.0113
Blood Glucose 1 0.833 38 0.0130
Blood Chloride 2 0.861 39 0.0151
PPL 20khz@90dB 0.910 40 0.0177
Light - Dark V-plane entries 0.940 41 0.0211
Spontaneous Alternation 0.980 42 0.0255
Head shape *1.000 43 0.0315
Wire manoeuvre *1.000 44 0.0398
Limb Grasping *1.000 45 0.0500
Urine Ketones *1.000 46 0.0500
Transfer arousal *1.000 47 0.0500
Startle/Preyer reflex *1.000 48 0.0500
struggles when scruffed *1.000 49 0.0500
Contact righting reflex *1.000 50 0.0500
Urine Nitrite *1.000 51 0.0500
Table 5.10b: The False Discovery Rate calculated for the female cohort using the Benjamini & Liu 
method [304]. * = tests for which the p value was determined from frequency data - with the Fisher 
Exact test. Other tests using cumulative data were performed with either ANOVA & repeated 
measures or two-tailed T-tests. As was seen in the male cohort, no tests showed a significant 
difference between mutants and wildtypes following correction for multiple testing.
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The False Discovery Rate for the significant PPI result using the method 
described by Benjamini & Hochberg [305].
All tests that were not independent o f PPI at 12kHz/90dB were removed from the calculation o f the 
Benjamini & Hochberg correction because tests are assumed to have no correlation with the measure 
to be corrected [303]. The tests that were removed from the correction were all other PPI tests, all 
startle tests and the preyer reflex test.____________________________
Test p value Rank BH Threshold
Blood Potassium 1 0.002 1 0.0009
Blood Chloride 1 0.008 2 0.0009
PPI. 12khz@90dB 0.009 3 0.0010
Blood Calcium 1 0.017 4 0.0010
Urine Protein *0.049 5 0.0010
Urine Ascorbic acid *0.060 6 0.0011
Blood Creatinine 1 0.068 7 0.0011
Light -  Dark Move time 0.140 8 0.0012
Grip strength Fore & Hindlimbs 0.150 9 0.0012
Light -  Dark Move episodes 0.190 10 0.0013
Blood AST 2 0.229 11 0.0013
R-Half Horz CNT 0.260 12 0.0014
Urine pH 0.260 13 0.0014
Blood Urea 1 0.263 14 0.0015
Blood Albumin 2 0.263 15 0.0016
Light -  Dark Velocity 0.290 16 0.0017
Blood Cholesterol 2 0.297 17 0.0018
Number o f pellets 0.330 18 0.0018
Blood Sodium 1 0.343 19 0.0019
Blood ALP 1 0.354 20 0.0020
Blood Phosphate 2 0.364 21 0.0022
Spontaneous Alternation 
Latency 0.390 22 0.0023
Blood Urea 2 0.433 23 0.0024
Blood Protein 2 0.457 24 0.0026
Light -  Dark Distance 0.460 25 0.0027
struggles when scruffed *0.4667 26 0.0029
Light -  Dark L-Half time 0.470 27 0.0031
Light -  Dark R-Half time 0.470 28 0.0033
Spontaneous Alternation 0.500 29 0.0036
Blood Chloride 2 0.544 30 0.0038
Blood Calcium 2 0.546 31 0.0041
Blood Glucose 1 0.563 32 0.0045
struggles when held by tail *0.5692 33 0.0049
Contact righting reflex *0.5692 34 0.0053
Light -  Dark V-plane entries 0.600 35 0.0058
Head shape *0.61 36 0.0063
Weight 0.650 37 0.0070
Blood Potassium 2 0.695 38 0.0078
Locomotive activity 0.700 39 0.0086
Blood ALP 2 0.710 40 0.0097
Blood ALT 2 0.712 41 0.0109
Light -  Dark R-Half Entries 0.720 42 0.0124
Blood Protein 1 0.800 43 0.0143
Blood Glucose 2 0.813 44 0.0166
Blood ALT 1 0.820 45 0.0194
Light -  Dark Latency 0.870 46 0.0231
Blood Sodium 2 0.890 47 0.0280
Blood Creatinine 2 0.926 48 0.0346
Light -  Dark L-Half Horz CNT 0.940 49 0.0438
Grip Strength: Forelimbs 0.950 50 0.0500
IPGTT 0.970 51 0.0500
Urine Nitrite *1.000 52 0.0500
Transfer arousal *1.000 53 0.0500
Wire manoeuvre *1.000 54 0.0500
Limb Grasping *1.000 55 0.0500
Urine Ketones *1.000 56 0.0500
The False Discovery Rate as calculated by the Benjamini &Hochberg method [305]. Tests that 
correlated with PPI at 12kHz/90dB were removed from the calculation of the Benjamini & Hochberg 
correction because tests are assumed to have no correlation with the measure to be corrected [303].
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The tests that were removed from the correction were all other PPI tests, all startle tests and the 
preyer reflex test.
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Appendices for Chapter 6 
Appendix 6.1
Standard Curve Is RMSEAP1 and RMSEAP2
Transfection Optimisation of EGFP with Genejuice
Total Cell %
Genejuice to Count Transfected Cell Transfected % Transfected
DNA Ratio View Field (DAPI) Count (EGFP) Cells Cells Average
a 142 19 13.4
3ul genejuice: b 128 22 17.2 15.3
1ug DNA c - - -
a 137 13 9.5
6ul genejuice: b 84 8 9.5 11.2
1ug DNA c 136 20 14.7
a 106 24 22.6
3ul genejuice: b 119 15 12.6 17.6
2ug DNA c - - -
Appendix 6.2
SEAP Concentration 
(pg/ml)
Transfection A: RLU 
(Relative Light Units)
Transfection B: RLU 
(Relative Light Units)
4000000 310.7 390.3
2000000 179.2 278
1000000 107.8 186.1
500000 59.34 114.2
100000 12.37 27.82
20000 2.704 6.377
4000 0.5313 1.661
800 0.1248 0.5489
160 0.1035 0.335
0 - 0.273
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Appendix 6.3_____________
SEAP Standard Curve For Transfection A
y = -8E-12x2 + O.OOOIx + 1.7097
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Figure 6.26: Standard SEAP Curves for the two transfections of the FOXF2/pEVRFO constructs that 
were co-transfected using pTAL-SEAP as a transfection control. Each data set was entered into an 
excel table, from which a polynomial trend-line was added. The top two graphs represent the data in 
the usual format for a standard curve, the bottom two graphs are in a format which enabled the 
generated equation to be used to calculate SEAP concentrations from RLU output. The trend-line 
equation for transfection A was: y = 15.691x2 + 8061.3x - 6438.7. The trend-line equation for 
transfection B was y = 23.638x2 + 883.13x + 16301.
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Appendix 6.4
Cell Counts of DAPI Stained Cells and EGFP Transfected Cells
Reprter View
Empty
pEVRFO
V410F
FOXF2
W174R
FOXF2
Wildtype
FOXF2
Vector Transfection Field DAPI EGFP DAPI EGFP DAPI EGFP DAPI EGFP
0)
1 a 347 53 227 53 218 91 262 51
b 309 66 188 47 372 74 133 18
55
O)c
c 282 69 240 48 265 63 116 17
d 129 19
■Oc e 136 34
ffl
CM
U_
2 a 331 67 101 12 242 76 229 40
b 304 69 114 17 299 83 144 24Ao c 271 49 123 32 246 67 137 20u_
06
CL
d 129 21 155 21
e 138 16 130 11
<LU 3 a 371 86 114 25 207 74 161 35
(/>1 b 289 60 111 23 266 60 153 9J
< c 278 63 97 12 340 65 135 231-Q. d 185 23 130 26
e 165 25
1 a 281 32 319 60 264 54 297 30
Q.
< b 321 43 335 60 324 69 242 38
UJV) c 256 37 282 51 246 59 323 401_l 2 a 276 49 213 44 261 49 350 33
2 b 267 42 317 45 298 50 196 51Q.
>» c 294 74 319 39 284 73 250 33■*->o. 3 a 304 45 285 43 243 63 264 39
E
LU b 289 50 219 43 288 54 305 46
c 147 56 195 51 212 44 214 50
Cell counts under different lighting conditions which allow for a total cell count because each mount 
was DAPI-stained, and a count o f the EGFP transfected cells. The percentage of cells which had been 
transfected by EGFP provided a ratio with which to normalise the SEAP data. Cell counts in black 
were taken on a Zeiss Axioplan 2 Microscope with the associated imaging software Axiovision v4.5. 
Cell counts in green text were performed on an Olympus BX40 Microscope. Green and blue 
wavelengths were filtered electronically from this microscope with Smartcapture (Digitalscientific 
UK Ltd). This microscope had a smaller field o f view at identical magnification, so a larger number 
of view fields were counted to compensate for this.
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Appendix 6.5
pEVRFO
C onstruct
SEAP Production  
after T ransfection  
A (pg/ml)
SEAP Production  
after Transfection  
B (pg/ml)
0 1.06 X 1 0 5 4.75 X 1 0 4
WR 9.58 X 1 0 4 4.82 X 1 0 4
VF 6.18 X 106 1 .5 7 X 1 0 6
WT 1.29 X 1 0 6 7.05 X 1 0 5
PG 6.08 X 1 0 6 4.29 X 1 0 5
NT -1 .8 2 X 1 0 3 1.67 X 1 0 4
EMSA SEAP data.
Appendix 6 .6
Transactivation Data for Each Sam ple at 24hrs Post-T ransfection
SfcAr Norm alisation norm alised did
Sam ple No. RLU pg/ml figure SEAP/GFP Average Deviation Std error
1 18.74 317528.2 12.7 24945.0
WT & 0 2 18.98 321659.0 16.2 19835.5
3 20.1 340510.3 17.7 19194.8 21325.1 3151.3 1819.4
1 12.1 205278.7 17.5 11745.9
W T& BS 2 12.1 205933.2 14.1 14555.2
3 10.6 181201.7 16.2 11209.8 12503.6 1796.8 1037.4
1 9.4 162313.5 21.9 7407.7
W-R&O 2 9.9 170649.5 20.4 8357.4
3 9.7 167706.3 21.8 7689.3 7818.2 487.8 281.6
1 5.3 97302.6 28.5 3417.8
N-R & Bi 2 5.6 102724.7 28.8 3566.8
3 5.7 104172.1 25.8 4036.5 3673.7 322.9 186.4
1 14.4 243238.9 18.3 13314.9
V-F&O 2 16.8 284910.5 15.7 18155.4
3 17.1 290173.5 20.3 14299.8 15256.7 2558.2 1477.0
1 10.2 175063.9 22.8 7684.1
V-F & BS 2 10.5 179584.7 16.1 11129.0
3 11.1 189954.8 16.5 11497.7 10103.6 2103.5 1214.4
1 5.3 98000.9 13.1 7493.1
eP& O 2 6.7 119254.7 19.6 6099.6
3 7.2 126705.8 23.4 5414.9 6335.8 1059.1 611.4
1 4.9 90859.5 20.4 4461.1
eP & B S 2 6.5 116573.5 20.3 5731.2
3 6.2 111534.7 22.2 5023.8 5072.0 636.4 367.4
The Mean percentage of EGFP transfected cells within each Transactivation assay. These figures 
were used to normalise SEAP levels. EGFP was the co-transfectant control which was used to 
provide information regarding the relative transfection efficiency in each sample. DAPI stained cells 
were counted to give the total cell count and this was compared with the number o f green cells that 
were associated with EGFP transfection.
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Appendix 6.7
Transactivation Data for Each Sam ple at 48hrs Post-Transfection
bcAK norm alisation Norm ansea ota
Sam ple No. RLU pg/ml figure SEAP/GFP Average Deviation Std Error
1 44.3 720532.8 12.7 56605.0
WT & 0 2 40.34 651697.5 16.2 40187.7
3 47.7 780004.2 17.7 43969.3 46920.7 8597.4 4963.7
1 25.4 399844.9 17.5 22878.8
W T& BS 2 25.7 404932.3 14.1 28620.2
3 26.5 417922.2 16.2 25854.1 25784.4 2871.3 1657.8
1 30.4 483246.6 21.9 22054.4
W-R&O 2 31.8 506003.7 20.4 24781.1
3 31.1 494946.5 21.8 22693.3 23176.3 1426.1 823.3
1 27.6 436069.6 28.5 15317.0
N-R & Bi 2 20.9 327267.2 28.8 11363.5
3 21.5 337125.8 25.8 13063.0 13247.8 1983.2 1145.0
1 35.0 560820.2 18.3 30699.4
V-F&O 2 38.6 622253.8 15.7 39652.0
3 40.2 649453.1 20.3 32005.2 34118.9 4836.1 2792.1
1 22.7 355770.2 22.8 15615.8
V-F & BS 2 24.1 378571.1 16.1 23460.4
3 24.0 376612.2 16.5 22795.8 20624.0 4349.9 2511.4
1 18.0 280853.0 13.1 21473.8
e P&O 2 20.4 319524.8 19.6 16342.9
3 19.9 310830.5 23.4 13283.6 17033.4 4138.5 2389.4
1 16.5 255682.1 20.4 12553.7
e P & B S 2 23.3 366505.0 20.3 18018.9
3 22.4 351385.9 22.2 15827.3 15466.6 2750.4 1587.9
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Appendix 6 .8
Transactivation Data for Each Sam ple at 72hrs Post-T ransfection
K L U s t a r Norm alisation Norm ansea b i d
Sam ple No. (X3) pg/ml figure SEAP/GFP Average Deviation Std Error
1 132.9 3659267.1 12.7 287471.9
WT&O 2 121 3389129.5 16.2 208994.9
3 143.0 3880460.7 17.7 218744.1 238403.6 42773.0 137642.4
1 76.1 2261614.4 17.5 129407.6
WT &B S 2 77.1 2286695.4 14.1 161621.3
3 79.4 2350283.2 16.2 145396.7 145475.2 16107.0 83990.2
1 91.3 2660372.1 21.9 121414.3
W-R&O 2 95.3 2764683.1 20.4 135398.3
3 93.4 2714236.2 21.8 124447.9 127086.8 7356.0 73373.6
1 82.7 2438037.1 28.5 85636.1
N-R & BS 2 62.8 1892728.8 28.8 65719.8
3 64.6 1944069.6 25.8 75329.3 75561.7 9960.2 43625.6
1 105.1 3008292.1 18.3 164674.5
V-F&O 2 115.9 3268814.0 15.7 208299.5
3 120.6 3380060.3 20.3 166570.3 179848.1 24657.9 103835.4
1 68.0 2040094.4 22.8 89545.9
V-F & BS 2 72.2 2155644.6 16.1 133587.3
3 71.9 2145798.3 16.5 129882.1 117671.8 24428.1 67937.8
1 54.1 1645667.9 13.1 125826.3
e P &O 2 61.3 1852131.8 19.6 94731.7
3 59.7 1806251.9 23.4 77191.5 99249.8 24630.2 57301.9
1 49.4 1507926.8 20.4 74037.6
e P & B S 2 70.0 2094752.7 20.3 102986.4
3 67.2 2017639.2 22.2 90879.6 89301.2 14538.8 51558.1
Full Dataset for the transactivation Assay. The RLU at 75 hours are multiplied by 3 because samples 
were diluted 3X to stay within the optimum SEAP concentrations for measurement reliability.
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Appendix 6.9
Time after 
Transfection
Transfected
Plasm ids WR& 0
VF
& 0
EP&
0
WT&
BS
WR 
& BS
VF & 
BS
EP&
BS
24 hrs
WT&O 12.98 5.83 14.40 8.48 16.96 10.78 15.62
WR&O 7.15 1.42 4.50 3.98 2.20 2.64
VF&O 8.57 2.65 11.13 4.95 9.79
EP&O 5.93 2.56 3.62 1.21
W T & B S 8.48 2.31 7.14
W R & B S 6.18 1.34
V F & B S 4.83
48 hrs
WT&O 9.34 5.04 11.76 8.31 13.24 10.34 12.37
WR&O 4.30 2.42 1.03 3.91 1.00 3.03
VF&O 6.72 3.28 8.21 5.31 7.34
EP&O 3.44 1.49 1.41 0.62
W T & B S 4.93 2.03 4.06
W R & B S 2.90 0.87
V F & B S 2.03
72 hrs
WT&O 8.35 4.39 10.44 6.97 12.22 9.06 11.18
WR&O 3.96 2.09 1.38 3.87 0.71 2.83
VF&O 6.05 2.58 7.82 4.66 6.79
EP&O 3.47 1.78 1.38 0.75
W T & B S 5.24 2.09 4.21
W R & B S 3.16 1.03
V F & B S 2.13
Tukey test for the two-factor ANOVA with replication of normalised SEAP data from 
three time points (24,48 and 72 hours). Each data-point is a q-value determined with 
the equation shown below, as described at 
http://web.mst.edu/~psyworld/tukeyssteps.htm:
M.-M,
Mi = the larger of the treatment/group means. M2 = the smaller of the two means, n 
= number per treatment/group. MSW = Mean square within groups.
The two reporters and four expression plasmids meant that 16 degrees of freedom
were applied to this comparison. This was used to determine the significance
434
Richard McKeone PhD Thesis
threshold (determined from the Tukey critical value table at 
http://web.mst.edu/~psyworld/virtualstat/tukeys/criticaltable.html). The q 
thresholds were 4.9 for p=0.05 and 6.08 for p=0.01. q values have an inverse 
relationship with the p value and therefore significance increases with a 
higher number. Red figures represent all q values above 4.9 and therefore 
p<0.05.
Appendix 6.10
Transfection Parameter
Transactivation A ssa y EMSA
Transactivation
A ssa y
Transactivation  
A ssay  
(per cm2)
EMSA
EMSA
(Pe/
cm 2)
Surface area (cm2) 9.60 1.00 175 1.00
Expression vector m ass (ng) 450.00 46.88 15750 90.00
SEAP vector m ass (ng) 450.00 46.88 1750 10.00
GFP vector m ass (ng) 100.00 10.42 NA NA
Volume Genejuice (ul) 3.00 0.31 56 0.32
Serum free media (ul) 97.00 10.10 2200 12.57
Total volume (ul) 2104.00 219.17 45126 257.86
Total cells 175000.00 18229.17 5250000 30000.00
Comparison of relative constituent ratios in the transfections for the transactivation assay and the 
EMS A. The conditions were not to scale because different sources were used to determine initial 
conditions for each experiment. The amounts o f genejuice and serum free media were added to each 
transfection at similar levels. The pTAL-SEAP vector was present in the transactivation assay at ~5 
times the level used in the EMSA. GFP was not added to the EMSA. Cells were seeded at 
approximately double the density in the EMSA. The expression vector was also added at 
approximately double the volume per cm2.
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